[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"_public_publisher_byId_591637e0-fd04-43ea-8c76-34d492ca99e7":3,"_public_publication_all{\"sortAscending\":false,\"sortField\":\"updateTime\",\"page\":0,\"size\":10,\"facet\":true,\"searchKey\":\"publisherId:591637e0-fd04-43ea-8c76-34d492ca99e7,\"}":162},{"code":4,"data":5,"meta":24},"SUCCESS",{"id":6,"createTime":7,"updateTime":8,"relativeEntities":9,"slug":10,"properties":11,"entityType":22,"verifyStatus":23,"verifyTime":24,"verifyNote":24,"syncStatus":23,"languages":24,"translateLanguages":24,"viewCount":25,"subjectFields":26,"manageAffiliations":43,"indexDatabases":66,"url":106,"thumbnailPath":24,"statistic":107,"gsStatistic":24,"type":24,"analyzePriority":24},"591637e0-fd04-43ea-8c76-34d492ca99e7","2023-05-29T11:07:44.472+00:00","2025-11-21T10:02:14.823+00:00",[],"Nature-Reviews-Gastroenterology-and-Hepatology",{"country":12,"issn":14,"introduce":16,"eissn":18,"title":20},{"VOID":13},"GB",{"VOID":15},"17595045",{"EN":17},"The basic, translational and clinical content in Nature Reviews Gastroenterology & Hepatology is written by internationally renowned basic and clinical academics and researchers and targeted towards readers in the biological and medical sciences, from postgraduate level upwards. While intended to be read by practising doctors, researchers and academics within a specialty, we aim to make all our articles accessible to readers working in any biological or medical discipline. In-depth Reviews present authoritative, up-to-date information on a topic, placing it in the context of a field's history and development. Consensus Statements provide evidence-based or eminence-based recommendations and present a balanced review put together by a task force of experts. Topical discussion and opinions are proffered in Perspectives, Comment and News & Views articles, and in the Research Highlights section we filter primary research from a range of specialty and general medical and scientific journals. Subjects Covered: -Cancer -Diagnosis and screening -Endoscopy (including imaging) -Epidemiology -Gall bladder and biliary tract -Gastro-oesophageal reflux disease -Gastrointestinal bleeding -Genetics -Geriatric medicine -Gut microbiota -Hepatitis -Infection (including bacterial, viral, parasitic) -Inflammatory bowel disease -Large intestine (including anus) -Liver (including cirrhosis and fibrosis) -Motility (including irritable bowel syndrome) -Nutrition (including digestion, intolerance, allergies, therapy, obesity) -Pancreas -Paediatrics -Small intestine -Stomach -Surgery (including transplantation) -Therapy (including pharmacotherapy, radiotherapy, nutrition, alternative) -Translational medicine -Ulcers -Upper gastrointestinal tract (including mouth, oesophagus, ingestion)",{"VOID":19},"17595053",{"EN":21},"Nature Reviews Gastroenterology and Hepatology","PUBLISHER","PENDING",null,0,[27,35],{"id":28,"createTime":29,"updateTime":30,"relativeEntities":31,"label":32,"description":34,"parentId":24,"standard":24,"scholarHubFieldId":24},"a520f91c-9c10-4000-96b1-c80ea7776e25","2023-05-29T10:24:12.053+00:00","2023-11-21T07:53:13.948+00:00",[],{"EN":33},"Gastroenterology",{},{"id":36,"createTime":37,"updateTime":38,"relativeEntities":39,"label":40,"description":42,"parentId":24,"standard":24,"scholarHubFieldId":24},"01203b2d-e9ba-432d-a4b0-d0f3ced5dfa6","2023-05-29T10:24:07.274+00:00","2023-11-21T07:04:43.214+00:00",[],{"EN":41},"Hepatology",{},[44,55],{"id":45,"createTime":46,"updateTime":47,"relativeEntities":48,"slug":49,"properties":50,"entityType":53,"verifyStatus":23,"verifyTime":24,"verifyNote":24,"syncStatus":23,"languages":24,"translateLanguages":24,"viewCount":25,"url":24,"parentIds":54,"statistic":24},"b134a19f-d595-49fa-bd59-70d90fa3a3b3","2023-05-29T12:35:12.827+00:00","2024-02-20T05:01:33.021+00:00",[],"NATURE-PORTFOLIO",{"title":51},{"EN":52},"NATURE PORTFOLIO","AFFILIATION",[],{"id":56,"createTime":57,"updateTime":58,"relativeEntities":59,"slug":60,"properties":61,"entityType":53,"verifyStatus":23,"verifyTime":24,"verifyNote":24,"syncStatus":23,"languages":24,"translateLanguages":24,"viewCount":64,"url":24,"parentIds":65,"statistic":24},"ae54b068-a7dd-4746-b752-b7b24439de47","2023-05-29T10:24:12.391+00:00","2025-11-21T09:53:50.486+00:00",[],"Nature-Publishing-Group",{"title":62},{"EN":63},"Nature Publishing Group",6,[],[67,87],{"id":68,"indexDatabase":69,"url":81,"indexYears":82,"academicFieldIds":83,"indexDatabaseRanking":86},"f7653d24-c751-4d20-a7b9-913862d89fe4",{"id":70,"createTime":71,"updateTime":72,"relativeEntities":73,"label":74,"description":76,"key":78,"publicationTags":79,"standard":24},"3c7051d4-eb7d-4c57-a56b-36fc74c5d1e9","2023-05-22T09:57:18.509+00:00","2025-11-21T10:07:52.274+00:00",[],{"EN":75,"VI":75},"Scopus - Elsevier",{"EN":75,"VI":77},"Cơ sở dữ liệu Scopus thuộc Elsevier","scopus",[80],"SCOPUS","https:\u002F\u002Fwww.scopus.com\u002Fsourceid\u002F17700156208","2009-2025",[84,85],"34ca0c58-3b99-4064-9bf3-a754a6e2e9a7","d39aa686-8d5d-45f0-81c4-13c21a0f2f39","SCOPUS__Q1",{"id":88,"indexDatabase":89,"url":103,"indexYears":24,"academicFieldIds":104,"indexDatabaseRanking":24},"427a9c31-7c72-4c70-a6f4-a9b95a7df13a",{"id":90,"createTime":91,"updateTime":92,"relativeEntities":93,"label":94,"description":96,"key":99,"publicationTags":100,"standard":24},"a4921856-b128-4d9f-8f1f-e80813d3bbd4","2023-05-22T09:59:31.026+00:00","2025-11-21T10:07:52.153+00:00",[],{"EN":95,"VI":95},"ISI\u002FSCIE - Science Citation Index Expanded",{"VI":97,"EN":98},"Cơ sở dữ liệu SCIE","SCIE database","scie",[101,102],"SCIE","ISI","https:\u002F\u002Fmjl.clarivate.com\u002Fsearch-results?issn=1759-5045",[105],"4b2c1694-c69d-4b20-b2eb-9687848dfb30","http:\u002F\u002Fwww.nature.com\u002Fnrgastro\u002Findex.html",{"impactFactor":25,"impactFactorByYear":108,"i10Index":121,"i10IndexLast5Year":122,"totalPublication":121,"totalPublicationByYear":123,"totalCitation":129,"totalCitationByYear":130,"totalCitationPerPublication":145,"totalCitationPerPublicationByYear":146,"hindexLast5Year":161,"hindex":161},{"2012":109,"2013":110,"2014":111,"2015":112,"2016":113,"2017":114,"2018":115,"2019":116,"2020":117,"2021":118,"2022":119,"2023":120},29.75,23.71,23.67,48.86,56.88,41.22,50.09,109.45,178,169.17,129.86,178.57,53,13,{"2009":124,"2010":124,"2011":125,"2012":126,"2013":127,"2014":124,"2015":125,"2016":127,"2017":128,"2018":127,"2019":127,"2020":126,"2021":125,"2022":126},3,5,2,4,7,40142,{"2009":131,"2010":132,"2011":133,"2012":134,"2013":135,"2014":136,"2015":137,"2016":138,"2017":139,"2018":140,"2019":141,"2020":142,"2021":143,"2022":144},789,1769,2446,371,1975,7104,2913,1563,6437,6132,4865,469,2852,457,757.4,{"2009":147,"2010":148,"2011":149,"2012":150,"2013":151,"2014":152,"2015":153,"2016":154,"2017":155,"2018":156,"2019":157,"2020":158,"2021":159,"2022":160},263,589.67,489.2,185.5,493.75,2368,582.6,390.75,919.57,1533,1216.25,234.5,570.4,228.5,49,{"meta":163,"data":165},{"total":164},"69",[166,596,1363,2115,2992,3309,4110,5320,6478,7467],{"id":167,"createTime":168,"updateTime":168,"relativeEntities":169,"slug":170,"properties":171,"entityType":184,"verifyStatus":185,"verifyTime":168,"verifyNote":186,"syncStatus":23,"languages":187,"translateLanguages":24,"viewCount":25,"primaryUrl":189,"fullTextUrl":24,"authors":190,"publicationType":310,"publisherRelationship":311,"citationCount":349,"citationInfo":350,"publishDate":362,"publishYear":363,"citationAnalyzeStatus":23,"lastCitationAnalyze":24,"indexDatabases":24,"openAccess":24,"references":364,"isForceReanalyzing":595},"8e7d1bb3-8eb0-4fd0-b7ce-52f987b58980","2024-10-09T23:50:21.760+00:00",[],"Pancreatic-cancer-understanding-and-overcoming-chemoresistance",{"mag":172,"keywords":174,"openalex":175,"abstract":177,"title":178,"pm":180,"doi":182},{"VOID":173},"1979342940",{},{"VOID":176},"W1979342940",{},{"EN":179},"Pancreatic cancer: understanding and overcoming chemoresistance",{"VOID":181},"21102532",{"VOID":183},"10.1038\u002Fnrgastro.2010.188","PUBLICATION","VERIFIED","Auto Verify",[188],"EN","https:\u002F\u002Fwww.nature.com\u002Farticles\u002Fnrgastro.2010.188",[191,213,231,246,261,278,293],{"id":192,"sortIndex":25,"researcher":24,"roles":193,"affiliations":194,"properties":206},"71dbb1cd-f136-4c46-8722-30ce5bcad527",[],[195],{"id":196,"sortIndex":25,"affiliation":197,"properties":24},"9d625193-12b5-433a-ac95-f38dc15f8ccd",{"id":198,"createTime":199,"updateTime":200,"relativeEntities":201,"slug":202,"properties":203,"entityType":53,"verifyStatus":23,"verifyTime":24,"verifyNote":24,"syncStatus":23,"languages":24,"translateLanguages":24,"viewCount":25},"2eb6c19c-f4ac-42e6-88d9-77e7d8cb3760","2024-01-13T00:32:18.641+00:00","2024-10-09T23:50:21.779+00:00",[],"Department-of-Pathology-Karmanos-Cancer-Institute-Wayne-State-University-School-of-Medicine-Detroit-USA",{"title":204},{"VI":205},"Department of Pathology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, USA",{"openalex":207,"orcid":209,"title":211},{"VOID":208},"A5100449964",{"VOID":210},"https:\u002F\u002Forcid.org\u002F0000-0002-6465-7779",{"EN":212},"Zhiwei Wang",{"id":214,"sortIndex":215,"researcher":24,"roles":216,"affiliations":217,"properties":224},"bf85af96-9121-45e4-9087-135bd6a67675",1,[],[218],{"id":219,"sortIndex":25,"affiliation":220,"properties":24},"54b1c3c0-c0eb-4c75-9155-4d71c7cd6c4d",{"id":198,"createTime":199,"updateTime":200,"relativeEntities":221,"slug":202,"properties":222,"entityType":53,"verifyStatus":23,"verifyTime":24,"verifyNote":24,"syncStatus":23,"languages":24,"translateLanguages":24,"viewCount":25},[],{"title":223},{"VI":205},{"openalex":225,"orcid":227,"title":229},{"VOID":226},"A5100633410",{"VOID":228},"https:\u002F\u002Forcid.org\u002F0000-0003-2389-3203",{"EN":230},"Yiwei Li",{"id":232,"sortIndex":124,"researcher":24,"roles":233,"affiliations":234,"properties":241},"73c4b54a-155a-44f7-a9b3-f3868c29be91",[],[235],{"id":236,"sortIndex":25,"affiliation":237,"properties":24},"ee0d4257-6e3f-4ca7-91ad-f82a223eb80c",{"id":198,"createTime":199,"updateTime":200,"relativeEntities":238,"slug":202,"properties":239,"entityType":53,"verifyStatus":23,"verifyTime":24,"verifyNote":24,"syncStatus":23,"languages":24,"translateLanguages":24,"viewCount":25},[],{"title":240},{"VI":205},{"openalex":242,"title":244},{"VOID":243},"A5054504867",{"EN":245},"Sanjeev Banerjee",{"id":247,"sortIndex":64,"researcher":24,"roles":248,"affiliations":249,"properties":256},"9b1ca247-ed29-47a0-bcb1-52d21205fe48",[],[250],{"id":251,"sortIndex":25,"affiliation":252,"properties":24},"46142ed8-794f-465d-9ddc-159ac1401af2",{"id":198,"createTime":199,"updateTime":200,"relativeEntities":253,"slug":202,"properties":254,"entityType":53,"verifyStatus":23,"verifyTime":24,"verifyNote":24,"syncStatus":23,"languages":24,"translateLanguages":24,"viewCount":25},[],{"title":255},{"VI":205},{"openalex":257,"title":259},{"VOID":258},"A5042547707",{"EN":260},"Fazlul H. Sarkar",{"id":262,"sortIndex":127,"researcher":24,"roles":263,"affiliations":264,"properties":271},"32ca0714-5aa6-45e2-b97c-a862dde4468e",[],[265],{"id":266,"sortIndex":25,"affiliation":267,"properties":24},"0734b207-a1ca-46a0-9544-53819745a2df",{"id":198,"createTime":199,"updateTime":200,"relativeEntities":268,"slug":202,"properties":269,"entityType":53,"verifyStatus":23,"verifyTime":24,"verifyNote":24,"syncStatus":23,"languages":24,"translateLanguages":24,"viewCount":25},[],{"title":270},{"VI":205},{"openalex":272,"orcid":274,"title":276},{"VOID":273},"A5026049304",{"VOID":275},"https:\u002F\u002Forcid.org\u002F0000-0003-1178-9505",{"EN":277},"Asfar S. Azmi",{"id":279,"sortIndex":125,"researcher":24,"roles":280,"affiliations":281,"properties":288},"38423033-e8a0-4d04-9211-0c483adb382b",[],[282],{"id":283,"sortIndex":25,"affiliation":284,"properties":24},"fbb570eb-ebfc-41e6-b1d7-b80011cda850",{"id":198,"createTime":199,"updateTime":200,"relativeEntities":285,"slug":202,"properties":286,"entityType":53,"verifyStatus":23,"verifyTime":24,"verifyNote":24,"syncStatus":23,"languages":24,"translateLanguages":24,"viewCount":25},[],{"title":287},{"VI":205},{"openalex":289,"title":291},{"VOID":290},"A5070316994",{"EN":292},"Dejuan Kong",{"id":294,"sortIndex":126,"researcher":24,"roles":295,"affiliations":296,"properties":303},"accc4a06-bfe7-4e25-9cfe-eb33b4e312a3",[],[297],{"id":298,"sortIndex":25,"affiliation":299,"properties":24},"046a75ad-e6af-49a0-9021-0bfd2c2e21f3",{"id":198,"createTime":199,"updateTime":200,"relativeEntities":300,"slug":202,"properties":301,"entityType":53,"verifyStatus":23,"verifyTime":24,"verifyNote":24,"syncStatus":23,"languages":24,"translateLanguages":24,"viewCount":25},[],{"title":302},{"VI":205},{"openalex":304,"orcid":306,"title":308},{"VOID":305},"A5072765154",{"VOID":307},"https:\u002F\u002Forcid.org\u002F0000-0003-1784-5723",{"EN":309},"Aamir Ahmad","ARTICLE",{"url":24,"publisher":312,"properties":342},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":313,"slug":10,"properties":314,"entityType":22,"verifyStatus":23,"verifyTime":24,"verifyNote":24,"syncStatus":23,"languages":24,"translateLanguages":24,"viewCount":25,"subjectFields":320,"manageAffiliations":321,"indexDatabases":322,"url":106,"thumbnailPath":24,"statistic":337,"gsStatistic":24,"type":24,"analyzePriority":24},[],{"country":315,"issn":316,"introduce":317,"eissn":318,"title":319},{"VOID":13},{"VOID":15},{"EN":17},{"VOID":19},{"EN":21},[],[],[323,330],{"id":88,"indexDatabase":324,"url":103,"indexYears":24,"academicFieldIds":329,"indexDatabaseRanking":24},{"id":90,"createTime":91,"updateTime":92,"relativeEntities":325,"label":326,"description":327,"key":99,"publicationTags":328,"standard":24},[],{"EN":95,"VI":95},{"VI":97,"EN":98},[101,102],[105],{"id":68,"indexDatabase":331,"url":81,"indexYears":82,"academicFieldIds":336,"indexDatabaseRanking":86},{"id":70,"createTime":71,"updateTime":72,"relativeEntities":332,"label":333,"description":334,"key":78,"publicationTags":335,"standard":24},[],{"EN":75,"VI":75},{"EN":75,"VI":77},[80],[84,85],{"impactFactor":25,"impactFactorByYear":338,"i10Index":121,"i10IndexLast5Year":122,"totalPublication":121,"totalPublicationByYear":339,"totalCitation":129,"totalCitationByYear":340,"totalCitationPerPublication":145,"totalCitationPerPublicationByYear":341,"hindexLast5Year":161,"hindex":161},{"2012":109,"2013":110,"2014":111,"2015":112,"2016":113,"2017":114,"2018":115,"2019":116,"2020":117,"2021":118,"2022":119,"2023":120},{"2009":124,"2010":124,"2011":125,"2012":126,"2013":127,"2014":124,"2015":125,"2016":127,"2017":128,"2018":127,"2019":127,"2020":126,"2021":125,"2022":126},{"2009":131,"2010":132,"2011":133,"2012":134,"2013":135,"2014":136,"2015":137,"2016":138,"2017":139,"2018":140,"2019":141,"2020":142,"2021":143,"2022":144},{"2009":147,"2010":148,"2011":149,"2012":150,"2013":151,"2014":152,"2015":153,"2016":154,"2017":155,"2018":156,"2019":157,"2020":158,"2021":159,"2022":160},{"volume":343,"pages":345,"issue":347},{"VOID":344},"8",{"VOID":346},"27-33",{"VOID":348},"1",328,{"total":349,"publishYear":24,"statisticByYear":351},{"2012":352,"2013":353,"2014":354,"2015":355,"2016":356,"2017":356,"2018":357,"2019":358,"2020":358,"2021":359,"2022":360,"2023":361,"2024":361},42,20,29,35,24,21,19,17,25,16,"2011-01-01",2011,[365,369,373,377,381,385,388,392,395,399,403,407,410,414,418,422,426,430,434,438,442,446,450,454,458,462,466,469,473,477,481,485,489,493,497,501,505,509,512,516,520,524,528,532,536,540,544,548,552,556,560,564,568,572,576,580,584,587,591],{"id":24,"text":366,"url":24,"identifiers":367},"Jemal, A., Siegel, R., Xu, J. & Ward, E. Cancer statistics, 2010. CA Cancer J. Clin. 60, 277–300 (2010).",{"doi":368},"10.3322\u002Fcaac.20073",{"id":24,"text":370,"url":24,"identifiers":371},"Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C. & Gottesman, M. M. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 5, 219–234 (2006).",{"doi":372},"10.1038\u002Fnrd1984",{"id":24,"text":374,"url":24,"identifiers":375},"Gottesman, M. M. Mechanisms of cancer drug resistance. Annu. Rev. Med. 53, 615–627 (2002).",{"doi":376},"10.1146\u002Fannurev.med.53.082901.103929",{"id":24,"text":378,"url":24,"identifiers":379},"Damiano, J. S. Integrins as novel drug targets for overcoming innate drug resistance. Curr. Cancer Drug Targets 2, 37–43 (2002).",{"doi":380},"10.2174\u002F1568009023334033",{"id":24,"text":382,"url":24,"identifiers":383},"Jiang, B. H. & Liu, L. Z. Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment. Drug Resist. Updat. 11, 63–76 (2008).",{"doi":384},"10.1016\u002Fj.drup.2008.03.001",{"id":24,"text":386,"url":24,"identifiers":387},"Lopez-Chavez, A., Carter, C. A. & Giaccone, G. The role of KRAS mutations in resistance to EGFR inhibition in the treatment of cancer. Curr. Opin. Investig. Drugs 10, 1305–1314 (2009).",{},{"id":24,"text":389,"url":24,"identifiers":390},"LoPiccolo, J., Blumenthal, G. M., Bernstein, W. B. & Dennis, P. A. Targeting the PI3K\u002FAkt\u002FmTOR pathway: effective combinations and clinical considerations. Drug Resist. Updat. 11, 32–50 (2008).",{"doi":391},"10.1016\u002Fj.drup.2007.11.003",{"id":24,"text":393,"url":24,"identifiers":394},"Wang, Z.  et al. Emerging roles of PDGF-D signaling pathway in tumor development and progression. Biochim. Biophys. Acta 1806, 122–130 (2010).",{},{"id":24,"text":396,"url":24,"identifiers":397},"Wang, Z.  et al. Targeting Notch signaling pathway to overcome drug resistance for cancer therapy. Biochim. Biophys. Acta doi: 10.1016\u002Fj.bbcan.2010.06.001.",{"doi":398},"10.1016\u002Fj.bbcan.2010.06.001",{"id":24,"text":400,"url":24,"identifiers":401},"Singh, A. & Settleman, J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29, 4741–4751 (2010).",{"doi":402},"10.1038\u002Fonc.2010.215",{"id":24,"text":404,"url":24,"identifiers":405},"Hermann, P. C.  et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1, 313–323 (2007).",{"doi":406},"10.1016\u002Fj.stem.2007.06.002",{"id":24,"text":408,"url":24,"identifiers":409},"Voulgari, A. & Pintzas, A. Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim. Biophys. Acta 1796, 75–90 (2009).",{},{"id":24,"text":411,"url":24,"identifiers":412},"Sarkar, F. H., Li, Y., Wang, Z., Kong, D. & Ali, S. Implication of microRNAs in drug resistance for designing novel cancer therapy. Drug Resist. Updat. 13, 57–66 (2010).",{"doi":413},"10.1016\u002Fj.drup.2010.02.001",{"id":24,"text":415,"url":24,"identifiers":416},"Thiery, J. P., Acloque, H., Huang, R. Y. & Nieto, M. A. Epithelial-mesenchymal transitions in development and disease. Cell 139, 871–890 (2009).",{"doi":417},"10.1016\u002Fj.cell.2009.11.007",{"id":24,"text":419,"url":24,"identifiers":420},"Wang, Z.  et al. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res. 69, 2400–2407 (2009).",{"doi":421},"10.1158\u002F0008-5472.CAN-08-4312",{"id":24,"text":423,"url":24,"identifiers":424},"Shah, A. N.  et al. Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann. Surg. Oncol. 14, 3629–3637 (2007).",{"doi":425},"10.1245\u002Fs10434-007-9583-5",{"id":24,"text":427,"url":24,"identifiers":428},"Arumugam, T.  et al. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res. 69, 5820–5828 (2009).",{"doi":429},"10.1158\u002F0008-5472.CAN-08-2819",{"id":24,"text":431,"url":24,"identifiers":432},"Li, Y.  et al. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res. 69, 6704–6712 (2009).",{"doi":433},"10.1158\u002F0008-5472.CAN-09-1298",{"id":24,"text":435,"url":24,"identifiers":436},"Rückert, F., Joensson, P., Saeger, H. D., Grützmann, R. & Pilarsky, C. Functional analysis of LOXL2 in pancreatic carcinoma. Int. J. Colorectal Dis. 25, 303–311 (2010).",{"doi":437},"10.1007\u002Fs00384-009-0853-5",{"id":24,"text":439,"url":24,"identifiers":440},"Frank, N. Y., Schatton, T. & Frank, M. H. The therapeutic promise of the cancer stem cell concept. J. Clin. Invest. 120, 41–50 (2010).",{"doi":441},"10.1172\u002FJCI41004",{"id":24,"text":443,"url":24,"identifiers":444},"Clarke, M. F.  et al. Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 66, 9339–9344 (2006).",{"doi":445},"10.1158\u002F0008-5472.CAN-06-3126",{"id":24,"text":447,"url":24,"identifiers":448},"Lee, C. J., Dosch, J. & Simeone, D. M. Pancreatic cancer stem cells. J. Clin. Oncol. 26, 2806–2812 (2008).",{"doi":449},"10.1200\u002FJCO.2008.16.6702",{"id":24,"text":451,"url":24,"identifiers":452},"Li, C.  et al. Identification of pancreatic cancer stem cells. Cancer Res. 67, 1030–1037 (2007).",{"doi":453},"10.1158\u002F0008-5472.CAN-06-2030",{"id":24,"text":455,"url":24,"identifiers":456},"Rasheed, Z. A.  et al. Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J. Natl Cancer Inst. 102, 340–351 (2010).",{"doi":457},"10.1093\u002Fjnci\u002Fdjp535",{"id":24,"text":459,"url":24,"identifiers":460},"Jimeno, A.  et al. A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development. Mol. Cancer Ther. 8, 310–314 (2009).",{"doi":461},"10.1158\u002F1535-7163.MCT-08-0924",{"id":24,"text":463,"url":24,"identifiers":464},"Mimeault, M.  et al. MUC4 down-regulation reverses chemoresistance of pancreatic cancer stem\u002Fprogenitor cells and their progenies. Cancer Lett. 295, 69–84 (2010).",{"doi":465},"10.1016\u002Fj.canlet.2010.02.015",{"id":24,"text":467,"url":24,"identifiers":468},"Yao, J.  et al. Side population in the pancreatic cancer cell lines SW1990 and CFPAC-1 is enriched with cancer stem-like cells. Oncol. Rep. 23, 1375–1382 (2010).",{},{"id":24,"text":470,"url":24,"identifiers":471},"Hong, S. P., Wen, J., Bang, S., Park, S. & Song, S. Y. CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells. Int. J. Cancer 125, 2323–2331 (2009).",{"doi":472},"10.1002\u002Fijc.24573",{"id":24,"text":474,"url":24,"identifiers":475},"Wang, Y. H.  et al. A side population of cells from a human pancreatic carcinoma cell line harbors cancer stem cell characteristics. Neoplasma 56, 371–378 (2009).",{"doi":476},"10.4149\u002Fneo_2009_05_371",{"id":24,"text":478,"url":24,"identifiers":479},"Mani, S. A.  et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133, 704–715 (2008).",{"doi":480},"10.1016\u002Fj.cell.2008.03.027",{"id":24,"text":482,"url":24,"identifiers":483},"Kong, D.  et al. Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells. PLoS ONE 5, e12445 (2010).",{"doi":484},"10.1371\u002Fjournal.pone.0012445",{"id":24,"text":486,"url":24,"identifiers":487},"Dembinski, J. L. & Krauss, S. Characterization and functional analysis of a slow cycling stem cell-like subpopulation in pancreas adenocarcinoma. Clin. Exp. Metastasis 26, 611–623 (2009).",{"doi":488},"10.1007\u002Fs10585-009-9260-0",{"id":24,"text":490,"url":24,"identifiers":491},"Kabashima, A.  et al. Side population of pancreatic cancer cells predominates in TGF-β-mediated epithelial to mesenchymal transition and invasion. Int. J. Cancer 124, 2771–2779 (2009).",{"doi":492},"10.1002\u002Fijc.24349",{"id":24,"text":494,"url":24,"identifiers":495},"Du, Z.  et al. Pancreatic cancer cells resistant to chemoradiotherapy rich in “stem-cell-like” tumor cells. Dig. Dis. Sci. doi: 10.1007\u002Fs10620-010-1340-0.",{"doi":496},"10.1007\u002Fs10620-010-1340-0",{"id":24,"text":498,"url":24,"identifiers":499},"Garzon, R., Marcucci, G. & Croce, C. M. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat. Rev. Drug Discov. 9, 775–789 (2010).",{"doi":500},"10.1038\u002Fnrd3179",{"id":24,"text":502,"url":24,"identifiers":503},"Brown, B. D. & Naldini, L. Exploiting and antagonizing microRNA regulation for therapeutic and experimental applications. Nat. Rev. Genet. 10, 578–585 (2009).",{"doi":504},"10.1038\u002Fnrg2628",{"id":24,"text":506,"url":24,"identifiers":507},"Ryan, B. M., Robles, A. I. & Harris, C. C. Genetic variation in microRNA networks: the implications for cancer research. Nat. Rev. Cancer 10, 389–402 (2010).",{"doi":508},"10.1038\u002Fnrc2867",{"id":24,"text":510,"url":24,"identifiers":511},"Xia, Q. S., Ishigaki, Y., Sun, L., Chen, R. & Motoo, Y. Effect of anti-cancer drugs on the expression of BIC\u002FmiR-155 in human pancreatic cancer PANC-1 cells [Chinese]. Zhonghua Yi Xue Za Zhi 90, 123–127 (2010).",{},{"id":24,"text":513,"url":24,"identifiers":514},"Hwang, J. H.  et al. Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS ONE 5, e10630 (2010).",{"doi":515},"10.1371\u002Fjournal.pone.0010630",{"id":24,"text":517,"url":24,"identifiers":518},"Giovannetti, E.  et al. MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res. 70, 4528–4538 (2010).",{"doi":519},"10.1158\u002F0008-5472.CAN-09-4467",{"id":24,"text":521,"url":24,"identifiers":522},"Wang, F.  et al. hsa-miR-520h downregulates ABCG2 in pancreatic cancer cells to inhibit migration, invasion, and side populations. Br. J. Cancer 103, 567–574 (2010).",{"doi":523},"10.1038\u002Fsj.bjc.6605724",{"id":24,"text":525,"url":24,"identifiers":526},"Ji, Q.  et al. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS ONE 4, e6816 (2009).",{"doi":527},"10.1371\u002Fjournal.pone.0006816",{"id":24,"text":529,"url":24,"identifiers":530},"Gregory, P. A., Bracken, C. P., Bert, A. G. & Goodall, G. J. MicroRNAs as regulators of epithelial-mesenchymal transition. Cell Cycle 7, 3112–3118 (2008).",{"doi":531},"10.4161\u002Fcc.7.20.6851",{"id":24,"text":533,"url":24,"identifiers":534},"Wellner, U.  et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat. Cell Biol. 11, 1487–1495 (2009).",{"doi":535},"10.1038\u002Fncb1998",{"id":24,"text":537,"url":24,"identifiers":538},"Li, Y.  et al. miR-146a suppresses invasion of pancreatic cancer cells. Cancer Res. 70, 1486–1495 (2010).",{"doi":539},"10.1158\u002F0008-5472.CAN-09-2792",{"id":24,"text":541,"url":24,"identifiers":542},"Li, Y., Kong, D., Wang, Z. & Sarkar, F. H. Regulation of microRNAs by natural agents: an emerging field in chemoprevention and chemotherapy research. Pharm. Res. 27, 1027–1041 (2010).",{"doi":543},"10.1007\u002Fs11095-010-0105-y",{"id":24,"text":545,"url":24,"identifiers":546},"Melkamu, T., Zhang, X., Tan, J., Zeng, Y. & Kassie, F. Alteration of microRNA expression in vinyl carbamate-induced mouse lung tumors and modulation by the chemopreventive agent indole-3-carbinol. Carcinogenesis 31, 252–258 (2010).",{"doi":547},"10.1093\u002Fcarcin\u002Fbgp208",{"id":24,"text":549,"url":24,"identifiers":550},"Sun, M.  et al. Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Mol. Cancer Ther. 7, 464–473 (2008).",{"doi":551},"10.1158\u002F1535-7163.MCT-07-2272",{"id":24,"text":553,"url":24,"identifiers":554},"Park, J. K., Lee, E. J., Esau, C. & Schmittgen, T. D. Antisense inhibition of microRNA-21 or -221 arrests cell cycle, induces apoptosis, and sensitizes the effects of gemcitabine in pancreatic adenocarcinoma. Pancreas 38, e190–e199 (2009).",{"doi":555},"10.1097\u002FMPA.0b013e3181ba82e1",{"id":24,"text":557,"url":24,"identifiers":558},"Ali, S.  et al. Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Res. 70, 3606–3617 (2010).",{"doi":559},"10.1158\u002F0008-5472.CAN-09-4598",{"id":24,"text":561,"url":24,"identifiers":562},"Moriyama, T.  et al. MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance. Mol. Cancer Ther. 8, 1067–1074 (2009).",{"doi":563},"10.1158\u002F1535-7163.MCT-08-0592",{"id":24,"text":565,"url":24,"identifiers":566},"Thiery, J. P. & Sleeman, J. P. Complex networks orchestrate epithelial-mesenchymal transitions. Nat. Rev. Mol. Cell Biol. 7, 131–142 (2006).",{"doi":567},"10.1038\u002Fnrm1835",{"id":24,"text":569,"url":24,"identifiers":570},"Gupta, P. B.  et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138, 645–659 (2009).",{"doi":571},"10.1016\u002Fj.cell.2009.06.034",{"id":24,"text":573,"url":24,"identifiers":574},"Hirsch, H. A., Iliopoulos, D., Tsichlis, P. N. & Struhl, K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 69, 7507–7511 (2009).",{"doi":575},"10.1158\u002F0008-5472.CAN-09-2994",{"id":24,"text":577,"url":24,"identifiers":578},"Rausch, V.  et al. Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer stem cell characteristics. Cancer Res. 70, 5004–5013 (2010).",{"doi":579},"10.1158\u002F0008-5472.CAN-10-0066",{"id":24,"text":581,"url":24,"identifiers":582},"Kallifatidis, G.  et al. Sulforaphane increases drug-mediated cytotoxicity toward cancer stem-like cells of pancreas and prostate. Mol. Ther. doi: 10.1038\u002Fmt.2010.216.",{"doi":583},"10.1038\u002Fmt.2010.216",{"id":24,"text":585,"url":24,"identifiers":586},"Zhou, W.  et al. Dietary polyphenol quercetin targets pancreatic cancer stem cells. Int. J. Oncol. 37, 551–561 (2010).",{},{"id":24,"text":588,"url":24,"identifiers":589},"Thomson, S.  et al. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res. 65, 9455–9462 (2005).",{"doi":590},"10.1158\u002F0008-5472.CAN-05-1058",{"id":24,"text":592,"url":24,"identifiers":593},"Buck, E.  et al. Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition. Mol. Cancer Ther. 6, 532–541 (2007).",{"doi":594},"10.1158\u002F1535-7163.MCT-06-0462",false,{"id":597,"createTime":598,"updateTime":598,"relativeEntities":599,"slug":600,"properties":601,"entityType":184,"verifyStatus":185,"verifyTime":598,"verifyNote":186,"syncStatus":23,"languages":614,"translateLanguages":24,"viewCount":25,"primaryUrl":615,"fullTextUrl":24,"authors":616,"publicationType":310,"publisherRelationship":739,"citationCount":777,"citationInfo":778,"publishDate":786,"publishYear":787,"citationAnalyzeStatus":23,"lastCitationAnalyze":24,"indexDatabases":24,"openAccess":24,"references":788,"isForceReanalyzing":595},"520e3094-bc2f-4397-81e3-9a3d127b63d6","2024-10-09T23:50:19.195+00:00",[],"Therapeutic-developments-in-pancreatic-cancer-current-and-future-perspectives",{"mag":602,"keywords":604,"openalex":605,"abstract":607,"title":608,"pm":610,"doi":612},{"VOID":603},"2800389517",{},{"VOID":606},"W2800389517",{},{"EN":609},"Therapeutic developments in pancreatic cancer: current and future perspectives",{"VOID":611},"29717230",{"VOID":613},"10.1038\u002Fs41575-018-0005-x",[188],"https:\u002F\u002Fwww.nature.com\u002Farticles\u002Fs41575-018-0005-x",[617,639,661,683,700,717],{"id":618,"sortIndex":215,"researcher":24,"roles":619,"affiliations":620,"properties":632},"65061d2a-8431-4992-bb1a-94949b3c6fb1",[],[621],{"id":622,"sortIndex":25,"affiliation":623,"properties":24},"3b029121-42f8-4374-9e3b-b74b6b801422",{"id":624,"createTime":625,"updateTime":626,"relativeEntities":627,"slug":628,"properties":629,"entityType":53,"verifyStatus":23,"verifyTime":24,"verifyNote":24,"syncStatus":23,"languages":24,"translateLanguages":24,"viewCount":25},"cd679da9-771e-4198-bb5e-45c04cb5b933","2024-01-04T06:44:02.572+00:00","2024-10-09T23:50:19.220+00:00",[],"Department-of-Visceral-Vascular-and-Endocrine-Surgery-Martin-Luther-University-Halle-Wittenberg-Halle-Saale-Germany",{"title":630},{"VI":631},"Department of Visceral, Vascular and Endocrine Surgery, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany",{"openalex":633,"orcid":635,"title":637},{"VOID":634},"A5031667128",{"VOID":636},"https:\u002F\u002Forcid.org\u002F0000-0003-3432-6669",{"EN":638},"Jörg Kleeff",{"id":640,"sortIndex":125,"researcher":24,"roles":641,"affiliations":642,"properties":654},"c7ee42c3-ee29-4282-b4e1-78c89d20dab0",[],[643],{"id":644,"sortIndex":25,"affiliation":645,"properties":24},"7766e52f-63f6-4197-97b0-a7d77546b4ad",{"id":646,"createTime":647,"updateTime":648,"relativeEntities":649,"slug":650,"properties":651,"entityType":53,"verifyStatus":23,"verifyTime":24,"verifyNote":24,"syncStatus":23,"languages":24,"translateLanguages":24,"viewCount":25},"1df51844-a56c-4602-825c-58174d88b5a5","2024-01-24T08:50:47.400+00:00","2024-10-09T23:50:19.239+00:00",[],"Department-of-Molecular-and-Clinical-Cancer-Medicine-Institute-of-Translational-Medicine-University-of-Liverpool-Liverpool-UK",{"title":652},{"VI":653},"Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, UK",{"openalex":655,"orcid":657,"title":659},{"VOID":656},"A5025272654",{"VOID":658},"https:\u002F\u002Forcid.org\u002F0000-0002-5766-9990",{"EN":660},"Daniel H. Palmer",{"id":662,"sortIndex":126,"researcher":24,"roles":663,"affiliations":664,"properties":676},"4b4eb98f-5826-421c-87df-0691e82fdba7",[],[665],{"id":666,"sortIndex":25,"affiliation":667,"properties":24},"937f943d-da1f-47a7-b5f0-9fd214f2ca49",{"id":668,"createTime":669,"updateTime":670,"relativeEntities":671,"slug":672,"properties":673,"entityType":53,"verifyStatus":23,"verifyTime":24,"verifyNote":24,"syncStatus":23,"languages":24,"translateLanguages":24,"viewCount":25},"60e316ad-89f3-4958-a517-6ab6f0df5ab2","2023-12-24T16:00:31.646+00:00","2024-10-09T23:50:19.229+00:00",[],"Department-of-Internal-Medicine-I-Martin-Luther-University-Halle-Wittenberg-Halle-Saale-Germany",{"title":674},{"VI":675},"Department of Internal Medicine I, Martin-Luther-University Halle-Wittenberg, Halle, Saale, Germany",{"openalex":677,"orcid":679,"title":681},{"VOID":678},"A5023460203",{"VOID":680},"https:\u002F\u002Forcid.org\u002F0000-0002-0401-5600",{"EN":682},"Patrick Michl",{"id":684,"sortIndex":127,"researcher":24,"roles":685,"affiliations":686,"properties":693},"2af88069-82c5-4521-b0b4-fdafbf5b0628",[],[687],{"id":688,"sortIndex":25,"affiliation":689,"properties":24},"1933a38e-7715-4107-a3f0-d937123f7991",{"id":646,"createTime":647,"updateTime":648,"relativeEntities":690,"slug":650,"properties":691,"entityType":53,"verifyStatus":23,"verifyTime":24,"verifyNote":24,"syncStatus":23,"languages":24,"translateLanguages":24,"viewCount":25},[],{"title":692},{"VI":653},{"openalex":694,"orcid":696,"title":698},{"VOID":695},"A5030627781",{"VOID":697},"https:\u002F\u002Forcid.org\u002F0000-0002-1865-3195",{"EN":699},"William Greenhalf",{"id":701,"sortIndex":124,"researcher":24,"roles":702,"affiliations":703,"properties":710},"657779b5-04b5-4ea9-bbbe-e09522894326",[],[704],{"id":705,"sortIndex":25,"affiliation":706,"properties":24},"427a8dc8-d43d-4cd4-bdb7-743b20fc3ae2",{"id":646,"createTime":647,"updateTime":648,"relativeEntities":707,"slug":650,"properties":708,"entityType":53,"verifyStatus":23,"verifyTime":24,"verifyNote":24,"syncStatus":23,"languages":24,"translateLanguages":24,"viewCount":25},[],{"title":709},{"VI":653},{"openalex":711,"orcid":713,"title":715},{"VOID":712},"A5007485514",{"VOID":714},"https:\u002F\u002Forcid.org\u002F0000-0002-0104-8992",{"EN":716},"Eithne Costello",{"id":718,"sortIndex":25,"researcher":24,"roles":719,"affiliations":720,"properties":732},"82cb1a72-eaee-4cfa-9295-9c8fb589d4c3",[],[721],{"id":722,"sortIndex":25,"affiliation":723,"properties":24},"1287b800-52bc-46a4-84a7-d54fb4dfa76a",{"id":724,"createTime":725,"updateTime":726,"relativeEntities":727,"slug":728,"properties":729,"entityType":53,"verifyStatus":23,"verifyTime":24,"verifyNote":24,"syncStatus":23,"languages":24,"translateLanguages":24,"viewCount":25},"14f64c62-fa99-4521-81e8-b42b25c32d1a","2023-12-07T05:15:16.104+00:00","2024-10-09T23:50:19.210+00:00",[],"Department-of-General-Surgery-University-of-Heidelberg-Heidelberg-Germany",{"title":730},{"VI":731},"Department of General Surgery, University of Heidelberg, Heidelberg, Germany",{"openalex":733,"orcid":735,"title":737},{"VOID":734},"A5052825850",{"VOID":736},"https:\u002F\u002Forcid.org\u002F0000-0002-6201-7399",{"EN":738},"John P. Neoptolemos",{"url":24,"publisher":740,"properties":770},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":741,"slug":10,"properties":742,"entityType":22,"verifyStatus":23,"verifyTime":24,"verifyNote":24,"syncStatus":23,"languages":24,"translateLanguages":24,"viewCount":25,"subjectFields":748,"manageAffiliations":749,"indexDatabases":750,"url":106,"thumbnailPath":24,"statistic":765,"gsStatistic":24,"type":24,"analyzePriority":24},[],{"country":743,"issn":744,"introduce":745,"eissn":746,"title":747},{"VOID":13},{"VOID":15},{"EN":17},{"VOID":19},{"EN":21},[],[],[751,758],{"id":88,"indexDatabase":752,"url":103,"indexYears":24,"academicFieldIds":757,"indexDatabaseRanking":24},{"id":90,"createTime":91,"updateTime":92,"relativeEntities":753,"label":754,"description":755,"key":99,"publicationTags":756,"standard":24},[],{"EN":95,"VI":95},{"VI":97,"EN":98},[101,102],[105],{"id":68,"indexDatabase":759,"url":81,"indexYears":82,"academicFieldIds":764,"indexDatabaseRanking":86},{"id":70,"createTime":71,"updateTime":72,"relativeEntities":760,"label":761,"description":762,"key":78,"publicationTags":763,"standard":24},[],{"EN":75,"VI":75},{"EN":75,"VI":77},[80],[84,85],{"impactFactor":25,"impactFactorByYear":766,"i10Index":121,"i10IndexLast5Year":122,"totalPublication":121,"totalPublicationByYear":767,"totalCitation":129,"totalCitationByYear":768,"totalCitationPerPublication":145,"totalCitationPerPublicationByYear":769,"hindexLast5Year":161,"hindex":161},{"2012":109,"2013":110,"2014":111,"2015":112,"2016":113,"2017":114,"2018":115,"2019":116,"2020":117,"2021":118,"2022":119,"2023":120},{"2009":124,"2010":124,"2011":125,"2012":126,"2013":127,"2014":124,"2015":125,"2016":127,"2017":128,"2018":127,"2019":127,"2020":126,"2021":125,"2022":126},{"2009":131,"2010":132,"2011":133,"2012":134,"2013":135,"2014":136,"2015":137,"2016":138,"2017":139,"2018":140,"2019":141,"2020":142,"2021":143,"2022":144},{"2009":147,"2010":148,"2011":149,"2012":150,"2013":151,"2014":152,"2015":153,"2016":154,"2017":155,"2018":156,"2019":157,"2020":158,"2021":159,"2022":160},{"volume":771,"pages":773,"issue":775},{"VOID":772},"15",{"VOID":774},"333-348",{"VOID":776},"6",862,{"total":777,"publishYear":24,"statisticByYear":779},{"2018":361,"2019":780,"2020":781,"2021":782,"2022":783,"2023":784,"2024":785},69,134,197,184,163,95,"2018-06-01",2018,[789,793,797,801,805,809,813,817,821,825,829,833,837,841,845,848,852,856,860,864,868,872,876,880,884,888,892,896,899,902,906,910,914,918,922,926,930,934,938,942,946,950,954,958,962,966,970,974,978,982,986,990,994,998,1002,1006,1010,1014,1018,1022,1026,1030,1034,1038,1042,1046,1050,1054,1058,1062,1066,1070,1074,1078,1082,1086,1090,1094,1098,1102,1106,1110,1114,1118,1122,1126,1130,1134,1138,1142,1146,1150,1154,1158,1162,1166,1170,1174,1178,1182,1186,1190,1194,1198,1202,1206,1210,1214,1218,1222,1225,1229,1233,1237,1241,1245,1249,1253,1257,1261,1265,1269,1273,1277,1281,1285,1289,1293,1297,1301,1304,1308,1312,1316,1320,1324,1328,1332,1336,1340,1343,1347,1351,1355,1359],{"id":24,"text":790,"url":24,"identifiers":791},"Rahib, L. et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 74, 2913–2921 (2014).",{"doi":792},"10.1158\u002F0008-5472.CAN-14-0155",{"id":24,"text":794,"url":24,"identifiers":795},"Ferlay, J. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136, E359–E386 (2015).",{"doi":796},"10.1002\u002Fijc.29210",{"id":24,"text":798,"url":24,"identifiers":799},"Kleeff, J. et al. Pancreatic cancer. Nat. Rev. Dis. Primers 2, 16022 (2016).",{"doi":800},"10.1038\u002Fnrdp.2016.22",{"id":24,"text":802,"url":24,"identifiers":803},"Hartwig, W., Werner, J., Jager, D., Debus, J. & Buchler, M. W. Improvement of surgical results for pancreatic cancer. Lancet Oncol. 14, e476–e485 (2013).",{"doi":804},"10.1016\u002FS1470-2045(13)70172-4",{"id":24,"text":806,"url":24,"identifiers":807},"Kalser, M. H. & Ellenberg, S. S. Pancreatic cancer. adjuvant combined radiation and chemotherapy following curative resection. Arch. Surg. 120, 899–903 (1985).",{"doi":808},"10.1001\u002Farchsurg.1985.01390320023003",{"id":24,"text":810,"url":24,"identifiers":811},"Klinkenbijl, J. H. et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann. Surg. 230, 776–782; discussion 782–784 (1999).",{"doi":812},"10.1097\u002F00000658-199912000-00006",{"id":24,"text":814,"url":24,"identifiers":815},"Neoptolemos, J. P. et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 358, 1576–1585 (2001).",{"doi":816},"10.1016\u002FS0140-6736(01)06651-X",{"id":24,"text":818,"url":24,"identifiers":819},"Neoptolemos, J. P. et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N. Engl. J. Med. 350, 1200–1210 (2004).",{"doi":820},"10.1056\u002FNEJMoa032295",{"id":24,"text":822,"url":24,"identifiers":823},"Regine, W. F. et al. Fluorouracil versus gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 299, 1019–1026 (2008).",{"doi":824},"10.1001\u002Fjama.299.9.1019",{"id":24,"text":826,"url":24,"identifiers":827},"Oettle, H. et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA 310, 1473–1481 (2013).",{"doi":828},"10.1001\u002Fjama.2013.279201",{"id":24,"text":830,"url":24,"identifiers":831},"Oettle, H. et al. Adjuvant chemotherapy with gemcitabine versus observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297, 267–277 (2007).",{"doi":832},"10.1001\u002Fjama.297.3.267",{"id":24,"text":834,"url":24,"identifiers":835},"Neoptolemos, J. P. et al. Adjuvant chemotherapy with fluorouracil plus folinic acid versus gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 304, 1073–1081 (2010).",{"doi":836},"10.1001\u002Fjama.2010.1275",{"id":24,"text":838,"url":24,"identifiers":839},"Greenhalf, W. et al. Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. J. Natl Cancer Inst. 106, djt347 (2014).",{"doi":840},"10.1093\u002Fjnci\u002Fdjt347",{"id":24,"text":842,"url":24,"identifiers":843},"Serdjebi, C., Milano, G. & Ciccolini, J. Role of cytidine deaminase in toxicity and efficacy of nucleosidic analogs. Expert Opin. Drug Metab. Toxicol. 11, 665–672 (2015).",{"doi":844},"10.1517\u002F17425255.2015.985648",{"id":24,"text":846,"url":24,"identifiers":847},"Dean, L. in Medical Genetics Summaries (ed. Pratt, V. et al.) (National Center for Biotechnology Information, Bethesda, 2012).",{},{"id":24,"text":849,"url":24,"identifiers":850},"Valle, J. W. et al. Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. J. Clin. Oncol. 32, 504–512 (2014).",{"doi":851},"10.1200\u002FJCO.2013.50.7657",{"id":24,"text":853,"url":24,"identifiers":854},"Sinn, M. et al. CONKO-005: adjuvant chemotherapy with gemcitabine plus erlotinib versus gemcitabine alone in patients after r0 resection of pancreatic cancer: a multicenter randomized phase iii trial. J. Clin. Oncol. 35, 3330–3337 (2017).",{"doi":855},"10.1200\u002FJCO.2017.72.6463",{"id":24,"text":857,"url":24,"identifiers":858},"Uesaka, K. et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet 388, 248–257 (2016).",{"doi":859},"10.1016\u002FS0140-6736(16)30583-9",{"id":24,"text":861,"url":24,"identifiers":862},"Neoptolemos, J. P. et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet 389, 1011–1024 (2017).",{"doi":863},"10.1016\u002FS0140-6736(16)32409-6",{"id":24,"text":865,"url":24,"identifiers":866},"Cunningham, D. et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J. Clin. Oncol. 27, 5513–5518 (2009).",{"doi":867},"10.1200\u002FJCO.2009.24.2446",{"id":24,"text":869,"url":24,"identifiers":870},"Khorana, A. A. et al. Potentially curable pancreatic cancer: American Society of Clinical Oncology clinical practice guideline update. J. Clin. Oncol. 35, 2324–2328 (2017).",{"doi":871},"10.1200\u002FJCO.2017.72.4948",{"id":24,"text":873,"url":24,"identifiers":874},"Bockhorn, M. et al. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Surgery 155, 977–988 (2014).",{"doi":875},"10.1016\u002Fj.surg.2014.02.001",{"id":24,"text":877,"url":24,"identifiers":878},"Gillen, S., Schuster, T., Meyer Zum Buschenfelde, C., Friess, H. & Kleeff, J. Preoperative\u002Fneoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 7, e1000267 (2010).",{"doi":879},"10.1371\u002Fjournal.pmed.1000267",{"id":24,"text":881,"url":24,"identifiers":882},"Golcher, H. et al. Neoadjuvant chemoradiation therapy with gemcitabine\u002Fcisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial. Strahlenther. Onkol. 191, 7–16 (2015).",{"doi":883},"10.1007\u002Fs00066-014-0737-7",{"id":24,"text":885,"url":24,"identifiers":886},"Heinrich, S. et al. Adjuvant gemcitabine versus NEOadjuvant gemcitabine\u002Foxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study). BMC Cancer 11, 346 (2011).",{"doi":887},"10.1186\u002F1471-2407-11-346",{"id":24,"text":889,"url":24,"identifiers":890},"Tachezy, M. et al. Sequential neoadjuvant chemoradiotherapy (CRT) followed by curative surgery versus primary surgery alone for resectable, non-metastasized pancreatic adenocarcinoma: NEOPA- a randomized multicenter phase III study (NCT01900327, DRKS00003893, ISRCTN82191749). BMC Cancer 14, 411 (2014).",{"doi":891},"10.1186\u002F1471-2407-14-411",{"id":24,"text":893,"url":24,"identifiers":894},"Versteijne, E. et al. Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multicentre randomized controlled trial. Trials 17, 127 (2016).",{"doi":895},"10.1186\u002Fs13063-016-1262-z",{"id":24,"text":897,"url":24,"identifiers":898},"ISCRTN registry. ESPAC-5F: European Study group for Pancreatic Cancer - Trial 5F. BMC www.isrctn.com\u002FISRCTN89500674 (2014).",{},{"id":24,"text":900,"url":24,"identifiers":901},"Kwon, W. et al. in 51st Annual Meeting of The Pancreas Club S008 (Chicago, 2017).",{},{"id":24,"text":903,"url":24,"identifiers":904},"Hackert, T. et al. Locally advanced pancreatic cancer: neoadjuvant therapy with Folfirinox results in resectability in 60% of the patients. Ann. Surg. 264, 457–463 (2016).",{"doi":905},"10.1097\u002FSLA.0000000000001850",{"id":24,"text":907,"url":24,"identifiers":908},"Conroy, T. et al. Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer — a groupe tumeurs digestives of the federation nationale des centres de lutte contre le cancer study. J. Clin. Oncol. 23, 1228–1236 (2005).",{"doi":909},"10.1200\u002FJCO.2005.06.050",{"id":24,"text":911,"url":24,"identifiers":912},"Rombouts, S. J. et al. Systematic review of resection rates and clinical outcomes after folfirinox-based treatment in patients with locally advanced pancreatic cancer. Ann. Surg. Oncol. 23, 4352–4360 (2016).",{"doi":913},"10.1245\u002Fs10434-016-5373-2",{"id":24,"text":915,"url":24,"identifiers":916},"Ferrone, C. R. et al. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann. Surg. 261, 12–17 (2015).",{"doi":917},"10.1097\u002FSLA.0000000000000867",{"id":24,"text":919,"url":24,"identifiers":920},"Nitsche, U. et al. Resectability after first-line folfirinox in initially unresectable locally advanced pancreatic cancer: a single-center experience. Ann. Surg. Oncol. 22(Suppl. 3), 1212–1220 (2015).",{"doi":921},"10.1245\u002Fs10434-015-4851-2",{"id":24,"text":923,"url":24,"identifiers":924},"Petrelli, F. et al. FOLFIRINOX-based neoadjuvant therapy in borderline resectable or unresectable pancreatic cancer: a meta-analytical review of published studies. Pancreas 44, 515–521 (2015).",{"doi":925},"10.1097\u002FMPA.0000000000000314",{"id":24,"text":927,"url":24,"identifiers":928},"Katz, M. H. et al. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer 118, 5749–5756 (2012).",{"doi":929},"10.1002\u002Fcncr.27636",{"id":24,"text":931,"url":24,"identifiers":932},"Balaban, E. P., Mangu, P. B. & Yee, N. S. Locally advanced unresectable pancreatic cancer: American Society of Clinical Oncology clinical practice guideline summary. J. Oncol. Pract. 13, 265–269 (2017).",{"doi":933},"10.1200\u002FJOP.2016.017376",{"id":24,"text":935,"url":24,"identifiers":936},"Hurt, C. N. et al. Long-term results and recurrence patterns from SCALOP: a phase II randomised trial of gemcitabine- or capecitabine-based chemoradiation for locally advanced pancreatic cancer. Br. J. Cancer 116, 1264–1270 (2017).",{"doi":937},"10.1038\u002Fbjc.2017.95",{"id":24,"text":939,"url":24,"identifiers":940},"Linecker, M., Pfammatter, T., Kambakamba, P. & DeOliveira, M. L. Ablation strategies for locally advanced pancreatic cancer. Dig. Surg. 33, 351–359 (2016).",{"doi":941},"10.1159\u002F000445021",{"id":24,"text":943,"url":24,"identifiers":944},"Paiella, S. et al. Local ablative strategies for ductal pancreatic cancer (radiofrequency ablation, irreversible electroporation): a review. Gastroenterol. Res. Pract. 2016, 4508376 (2016).",{"doi":945},"10.1155\u002F2016\u002F4508376",{"id":24,"text":947,"url":24,"identifiers":948},"Rombouts, S. J. et al. Systematic review of innovative ablative therapies for the treatment of locally advanced pancreatic cancer. Br. J. Surg. 102, 182–193 (2015).",{"doi":949},"10.1002\u002Fbjs.9716",{"id":24,"text":951,"url":24,"identifiers":952},"Sofuni, A. et al. Safety trial of high-intensity focused ultrasound therapy for pancreatic cancer. World J. Gastroenterol. 20, 9570–9577 (2014).",{"doi":953},"10.3748\u002Fwjg.v20.i28.9570",{"id":24,"text":955,"url":24,"identifiers":956},"Sung, H. Y. et al. Long-term outcome of high-intensity focused ultrasound in advanced pancreatic cancer. Pancreas 40, 1080–1086 (2011).",{"doi":957},"10.1097\u002FMPA.0b013e31821fde24",{"id":24,"text":959,"url":24,"identifiers":960},"Burris, H. A. 3rd et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 15, 2403–2413 (1997).",{"doi":961},"10.1200\u002FJCO.1997.15.6.2403",{"id":24,"text":963,"url":24,"identifiers":964},"Conroy, T. et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 364, 1817–1825 (2011).",{"doi":965},"10.1056\u002FNEJMoa1011923",{"id":24,"text":967,"url":24,"identifiers":968},"Von Hoff, D. D. et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I\u002FII trial. J. Clin. Oncol. 29, 4548–4554 (2011).",{"doi":969},"10.1200\u002FJCO.2011.36.5742",{"id":24,"text":971,"url":24,"identifiers":972},"Neesse, A., Michl, P. & Tuveson, D. A. and Ellenrieder, V. nab-Paclitaxel: novel clinical and experimental evidence in pancreatic cancer. Z. Gastroenterol. 52, 360–366 (2014).",{"doi":973},"10.1055\u002Fs-0034-1366002",{"id":24,"text":975,"url":24,"identifiers":976},"Von Hoff, D. D. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 369, 1691–1703 (2013).",{"doi":977},"10.1056\u002FNEJMoa1304369",{"id":24,"text":979,"url":24,"identifiers":980},"Goldstein, D. et al. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. J. Natl Cancer Inst. 107, dju413 (2015).",{"doi":981},"10.1093\u002Fjnci\u002Fdju413",{"id":24,"text":983,"url":24,"identifiers":984},"Sohal, D. P. et al. Metastatic pancreatic cancer: American Society of Clinical Oncology clinical practice guideline. J. Clin. Oncol. 34, 2784–2796 (2016).",{"doi":985},"10.1200\u002FJCO.2016.67.1412",{"id":24,"text":987,"url":24,"identifiers":988},"Hammel, P. et al. Effect of chemoradiotherapy versus chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the lap07 randomized clinical trial. JAMA 315, 1844–1853 (2016).",{"doi":989},"10.1001\u002Fjama.2016.4324",{"id":24,"text":991,"url":24,"identifiers":992},"Nagrial, A. M. et al. Second-line treatment in inoperable pancreatic adenocarcinoma: a systematic review and synthesis of all clinical trials. Crit. Rev. Oncol. Hematol. 96, 483–497 (2015).",{"doi":993},"10.1016\u002Fj.critrevonc.2015.07.007",{"id":24,"text":995,"url":24,"identifiers":996},"Pelzer, U. et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur. J. Cancer 47, 1676–1681 (2011).",{"doi":997},"10.1016\u002Fj.ejca.2011.04.011",{"id":24,"text":999,"url":24,"identifiers":1000},"Oettle, H. et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J. Clin. Oncol. 32, 2423–2429 (2014).",{"doi":1001},"10.1200\u002FJCO.2013.53.6995",{"id":24,"text":1003,"url":24,"identifiers":1004},"Gill, S. et al. PANCREOX: A randomized phase III study of fluorouracil\u002Fleucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapy. J. Clin. Oncol. 34, 3914–3920 (2016).",{"doi":1005},"10.1200\u002FJCO.2016.68.5776",{"id":24,"text":1007,"url":24,"identifiers":1008},"Wang-Gillam, A. et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet 387, 545–557 (2016).",{"doi":1009},"10.1016\u002FS0140-6736(15)00986-1",{"id":24,"text":1011,"url":24,"identifiers":1012},"Portal, A. et al. Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort. Br. J. Cancer 113, 989–995 (2015).",{"doi":1013},"10.1038\u002Fbjc.2015.328",{"id":24,"text":1015,"url":24,"identifiers":1016},"Tempero, M. A. et al. Pancreatic adenocarcinoma, version 2.2017, nccn clinical practice guidelines in oncology. J. Natl Compr. Canc. Netw. 15, 1028–1061 (2017).",{"doi":1017},"10.6004\u002Fjnccn.2017.0131",{"id":24,"text":1019,"url":24,"identifiers":1020},"Kindler, H. L. et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J. Clin. Oncol. 28, 3617–3622 (2010).",{"doi":1021},"10.1200\u002FJCO.2010.28.1386",{"id":24,"text":1023,"url":24,"identifiers":1024},"Rougier, P. et al. Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer. Eur. J. Cancer 49, 2633–2642 (2013).",{"doi":1025},"10.1016\u002Fj.ejca.2013.04.002",{"id":24,"text":1027,"url":24,"identifiers":1028},"Kindler, H. L. et al. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncol. 12, 256–262 (2011).",{"doi":1029},"10.1016\u002FS1470-2045(11)70004-3",{"id":24,"text":1031,"url":24,"identifiers":1032},"Kindler, H. L. et al. Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium. Invest. New Drugs 30, 382–386 (2012).",{"doi":1033},"10.1007\u002Fs10637-010-9526-z",{"id":24,"text":1035,"url":24,"identifiers":1036},"Michl, P. & Gress, T. M. Current concepts and novel targets in advanced pancreatic cancer. Gut 62, 317–326 (2013).",{"doi":1037},"10.1136\u002Fgutjnl-2012-303588",{"id":24,"text":1039,"url":24,"identifiers":1040},"O’Reilly, E. M. et al. A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603). Oncologist 15, 1310–1319 (2010).",{"doi":1041},"10.1634\u002Ftheoncologist.2010-0152",{"id":24,"text":1043,"url":24,"identifiers":1044},"Fuchs, C. S. et al. A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial. Ann. Oncol. 26, 921–927 (2015).",{"doi":1045},"10.1093\u002Fannonc\u002Fmdv027",{"id":24,"text":1047,"url":24,"identifiers":1048},"Philip, P. A. et al. Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727). Cancer 120, 2980–2985 (2014).",{"doi":1049},"10.1002\u002Fcncr.28744",{"id":24,"text":1051,"url":24,"identifiers":1052},"Deplanque, G. et al. A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer. Ann. Oncol. 26, 1194–1200 (2015).",{"doi":1053},"10.1093\u002Fannonc\u002Fmdv133",{"id":24,"text":1055,"url":24,"identifiers":1056},"O’Neil, B. H. et al. A phase II\u002FIII randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer. Ann. Oncol. 26, 1923–1929 (2015).",{"doi":1057},"10.1093\u002Fannonc\u002Fmdv264",{"id":24,"text":1059,"url":24,"identifiers":1060},"Ottaiano, A. et al. Gemcitabine mono-therapy versus gemcitabine plus targeted therapy in advanced pancreatic cancer: a meta-analysis of randomized phase III trials. Acta Oncol. 56, 377–383 (2017).",{"doi":1061},"10.1080\u002F0284186X.2017.1288922",{"id":24,"text":1063,"url":24,"identifiers":1064},"Moore, M. J. et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 25, 1960–1966 (2007).",{"doi":1065},"10.1200\u002FJCO.2006.07.9525",{"id":24,"text":1067,"url":24,"identifiers":1068},"Potthoff, K. et al. Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion. Ann. Oncol. 22, 524–535 (2011).",{"doi":1069},"10.1093\u002Fannonc\u002Fmdq387",{"id":24,"text":1071,"url":24,"identifiers":1072},"Wacker, B. et al. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin. Cancer Res. 13, 3913–3921 (2007).",{"doi":1073},"10.1158\u002F1078-0432.CCR-06-2610",{"id":24,"text":1075,"url":24,"identifiers":1076},"Kleeff, J. et al. Pancreatic cancer microenvironment. Int. J. Cancer 121, 699–705 (2007).",{"doi":1077},"10.1002\u002Fijc.22871",{"id":24,"text":1079,"url":24,"identifiers":1080},"Hidalgo, M. et al. SPARC expression did not predict efficacy of nab-paclitaxel plus gemcitabine or gemcitabine alone for metastatic pancreatic cancer in an exploratory analysis of the phase III MPACT Trial. Clin. Cancer Res. 21, 4811–4818 (2015).",{"doi":1081},"10.1158\u002F1078-0432.CCR-14-3222",{"id":24,"text":1083,"url":24,"identifiers":1084},"Provenzano, P. P. et al. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 21, 418–429 (2012).",{"doi":1085},"10.1016\u002Fj.ccr.2012.01.007",{"id":24,"text":1087,"url":24,"identifiers":1088},"Jacobetz, M. A. et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut 62, 112–120 (2013).",{"doi":1089},"10.1136\u002Fgutjnl-2012-302529",{"id":24,"text":1091,"url":24,"identifiers":1092},"Hingorani, S. R. et al. High response rate and PFS with PEGPH20 added to nab-paclitaxel\u002Fgemcitabine in stage IV previously untreated pancreatic cancer patients with high-HA tumors: Interim results of a randomized phase II study. J. Clin. Oncol. 33, 4006 (2015).",{"doi":1093},"10.1200\u002Fjco.2015.33.15_suppl.4006",{"id":24,"text":1095,"url":24,"identifiers":1096},"Erkan, M. et al. StellaTUM: current consensus and discussion on pancreatic stellate cell research. Gut 61, 172–178 (2012).",{"doi":1097},"10.1136\u002Fgutjnl-2011-301220",{"id":24,"text":1099,"url":24,"identifiers":1100},"Sherman, M. H. et al. Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell 159, 80–93 (2014).",{"doi":1101},"10.1016\u002Fj.cell.2014.08.007",{"id":24,"text":1103,"url":24,"identifiers":1104},"Roberts, K. J., Kershner, A. M. & Beachy, P. A. The stromal niche for epithelial stem cells: a template for regeneration and a brake on malignancy. Cancer Cell 32, 404–410 (2017).",{"doi":1105},"10.1016\u002Fj.ccell.2017.08.007",{"id":24,"text":1107,"url":24,"identifiers":1108},"Olive, K. P. et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324, 1457–1461 (2009).",{"doi":1109},"10.1126\u002Fscience.1171362",{"id":24,"text":1111,"url":24,"identifiers":1112},"Rhim, A. D. et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell 25, 735–747 (2014).",{"doi":1113},"10.1016\u002Fj.ccr.2014.04.021",{"id":24,"text":1115,"url":24,"identifiers":1116},"Ozdemir, B. C. et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 25, 719–734 (2014).",{"doi":1117},"10.1016\u002Fj.ccr.2014.04.005",{"id":24,"text":1119,"url":24,"identifiers":1120},"Van Cutsem, E. et al. MAESTRO: a randomized, double-blind phase III study of evofosfamide (Evo) in combination with gemcitabine (Gem) in previously untreated patients (pts) with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC). J. Clin. Oncol. 34, 4007 (2016).",{"doi":1121},"10.1200\u002FJCO.2016.34.15_suppl.4007",{"id":24,"text":1123,"url":24,"identifiers":1124},"Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).",{"doi":1125},"10.1016\u002Fj.cell.2011.02.013",{"id":24,"text":1127,"url":24,"identifiers":1128},"Farren, M. R. et al. Systemic immune activity predicts overall survival in treatment naive patients with metastatic pancreatic cancer. Clin. Cancer Res. 22, 2565–2574 (2015).",{"doi":1129},"10.1158\u002F1078-0432.CCR-15-1732",{"id":24,"text":1131,"url":24,"identifiers":1132},"Silva, I. P. & Long, G. V. Systemic therapy in advanced melanoma: integrating targeted therapy and immunotherapy into clinical practice. Curr. Opin. Oncol. 29, 484–492 (2017).",{"doi":1133},"10.1097\u002FCCO.0000000000000405",{"id":24,"text":1135,"url":24,"identifiers":1136},"Tang, H., Qiao, J. & Fu, Y. X. Immunotherapy and tumor microenvironment. Cancer Lett. 370, 85–90 (2016).",{"doi":1137},"10.1016\u002Fj.canlet.2015.10.009",{"id":24,"text":1139,"url":24,"identifiers":1140},"Limagne, E. et al. Accumulation of MDSC and Th17 cells in patients with metastatic colorectal cancer predict the efficacy of a FOLFOX-bevacizumab drug treatment regimen. Cancer Res. 76, 5241–5252 (2016).",{"doi":1141},"10.1158\u002F0008-5472.CAN-15-3164",{"id":24,"text":1143,"url":24,"identifiers":1144},"Lepique, A. P., Daghastanli, K. R., Cuccovia, I. M. & Villa, L. L. HPV16 tumor associated macrophages suppress antitumor T cell responses. Clin. Cancer Res. 15, 4391–4400 (2009).",{"doi":1145},"10.1158\u002F1078-0432.CCR-09-0489",{"id":24,"text":1147,"url":24,"identifiers":1148},"Carmi, Y. et al. Allogeneic IgG combined with dendritic cell stimuli induce antitumour T-cell immunity. Nature 521, 99–104 (2015).",{"doi":1149},"10.1038\u002Fnature14424",{"id":24,"text":1151,"url":24,"identifiers":1152},"Mills, C. D., Lenz, L. L. & Harris, R. A. A. Breakthrough: macrophage-directed cancer immunotherapy. Cancer Res. 76, 513–516 (2016).",{"doi":1153},"10.1158\u002F0008-5472.CAN-15-1737",{"id":24,"text":1155,"url":24,"identifiers":1156},"Feig, C. et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc. Natl Acad. Sci. USA 110, 20212–20217 (2013).",{"doi":1157},"10.1073\u002Fpnas.1320318110",{"id":24,"text":1159,"url":24,"identifiers":1160},"Spadi, R. et al. Current therapeutic strategies for advanced pancreatic cancer: a review for clinicians. World J. Clin. Oncol. 7, 27–43 (2016).",{"doi":1161},"10.5306\u002Fwjco.v7.i1.27",{"id":24,"text":1163,"url":24,"identifiers":1164},"Melero, I. et al. Therapeutic vaccines for cancer: an overview of clinical trials. Nat. Rev. Clin. Oncol. 11, 509–524 (2014).",{"doi":1165},"10.1038\u002Fnrclinonc.2014.111",{"id":24,"text":1167,"url":24,"identifiers":1168},"Middleton, G. et al. Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. Lancet Oncol. 15, 829–840 (2014).",{"doi":1169},"10.1016\u002FS1470-2045(14)70236-0",{"id":24,"text":1171,"url":24,"identifiers":1172},"Palmer, D. H. et al. A prospective, single-arm, phase I\u002FII trial of RAS peptide vaccine TG01\u002FGM-CSF and gemcitabine as adjuvant therapy for patients with resected pancreatic adenocarcinoma [abstract]. J. Clin. Oncol. 35, 4119 (2015).",{"doi":1173},"10.1200\u002FJCO.2017.35.15_suppl.4119",{"id":24,"text":1175,"url":24,"identifiers":1176},"Dueland, S. et al. 669PTG01\u002FGM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas. Ann. Oncol. https:\u002F\u002Fdoi.org\u002F10.1093\u002Fannonc\u002Fmdx369.053 (2017).",{"doi":1177},"10.1093\u002Fannonc\u002Fmdx369.053",{"id":24,"text":1179,"url":24,"identifiers":1180},"Meng, Q. et al. Expansion of tumor-reactive T cells from patients with pancreatic cancer. J. Immunother. 39, 81–89 (2016).",{"doi":1181},"10.1097\u002FCJI.0000000000000111",{"id":24,"text":1183,"url":24,"identifiers":1184},"Byrne, K. T., Vonderheide, R. H., Jaffee, E. M. & Armstrong, T. D. Special conference on tumor immunology and immunotherapy: a new chapter. Cancer Immunol. Res. https:\u002F\u002Fdoi.org\u002F10.1158\u002F2326-6066.CIR-15-0106 (2015).",{"doi":1185},"10.1158\u002F2326-6066.CIR-15-0106",{"id":24,"text":1187,"url":24,"identifiers":1188},"Starck, L., Popp, K., Pircher, H. & Uckert, W. Immunotherapy with TCR-redirected T cells: comparison of TCR-transduced and TCR-engineered hematopoietic stem cell-derived T cells. J. Immunol. 192, 206–213 (2014).",{"doi":1189},"10.4049\u002Fjimmunol.1202591",{"id":24,"text":1191,"url":24,"identifiers":1192},"Morgan, R. A. et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J. Immunother. 36, 133–151 (2013).",{"doi":1193},"10.1097\u002FCJI.0b013e3182829903",{"id":24,"text":1195,"url":24,"identifiers":1196},"Maus, M. V. & June, C. H. Making better chimeric antigen receptors for adoptive t-cell therapy. Clin. Cancer Res. 22, 1875–1884 (2016).",{"doi":1197},"10.1158\u002F1078-0432.CCR-15-1433",{"id":24,"text":1199,"url":24,"identifiers":1200},"Sathyanarayanan, V. & Neelapu, S. S. Cancer immunotherapy: strategies for personalization and combinatorial approaches. Mol. Oncol. 9, 2043–2053 (2015).",{"doi":1201},"10.1016\u002Fj.molonc.2015.10.009",{"id":24,"text":1203,"url":24,"identifiers":1204},"Alrifai, D., Sarker, D. & Maher, J. Prospects for adoptive immunotherapy of pancreatic cancer using chimeric antigen receptor-engineered T-cells. Immunopharmacol. Immunotoxicol. 38, 50–60 (2016).",{"doi":1205},"10.3109\u002F08923973.2015.1100204",{"id":24,"text":1207,"url":24,"identifiers":1208},"David, J. M., Dominguez, C., Hamilton, D. H. & Palena, C. The IL-8\u002FIL-8R axis: a double agent in tumor immune resistance. Vaccines 4, E22 (2016).",{"doi":1209},"10.3390\u002Fvaccines4030022",{"id":24,"text":1211,"url":24,"identifiers":1212},"Weed, D. T. et al. Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma. Clin. Cancer Res. 21, 39–48 (2015).",{"doi":1213},"10.1158\u002F1078-0432.CCR-14-1711",{"id":24,"text":1215,"url":24,"identifiers":1216},"Wesolowski, R., Markowitz, J. & Carson, W. E. 3rd. Myeloid derived suppressor cells - a new therapeutic target in the treatment of cancer. J. Immunother. Cancer 1, 10 (2013).",{"doi":1217},"10.1186\u002F2051-1426-1-10",{"id":24,"text":1219,"url":24,"identifiers":1220},"Noman, M. Z. et al. Tumor-promoting effects of myeloid-derived suppressor cells are potentiated by hypoxia-induced expression of miR-210. Cancer Res. 75, 3771–3787 (2015).",{"doi":1221},"10.1158\u002F0008-5472.CAN-15-0405",{"id":24,"text":1223,"url":24,"identifiers":1224},"Bigelow, E. et al. Immunohistochemical staining of B7-H1 (PD-L1) on paraffin-embedded slides of pancreatic adenocarcinoma tissue. J. Vis. Exp. 71, 4059 (2013).",{},{"id":24,"text":1226,"url":24,"identifiers":1227},"Noy, R. & Pollard, J. W. Tumor-associated macrophages: from mechanisms to therapy. Immunity 41, 49–61 (2014).",{"doi":1228},"10.1016\u002Fj.immuni.2014.06.010",{"id":24,"text":1230,"url":24,"identifiers":1231},"Wolchok, J. D. & Saenger, Y. The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. Oncologist 13 (Suppl. 4), 2–9 (2008).",{"doi":1232},"10.1634\u002Ftheoncologist.13-S4-2",{"id":24,"text":1234,"url":24,"identifiers":1235},"Yeung, A. W., Terentis, A. C., King, N. J. & Thomas, S. R. Role of indoleamine 2,3-dioxygenase in health and disease. Clin. Sci. 129, 601–672 (2015).",{"doi":1236},"10.1042\u002FCS20140392",{"id":24,"text":1238,"url":24,"identifiers":1239},"Bessede, A. et al. Aryl hydrocarbon receptor control of a disease tolerance defence pathway. Nature 511, 184–190 (2014).",{"doi":1240},"10.1038\u002Fnature13323",{"id":24,"text":1242,"url":24,"identifiers":1243},"Wolchok, J. D. et al. Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann. NY Acad. Sci. 1291, 1–13 (2013).",{"doi":1244},"10.1111\u002Fnyas.12180",{"id":24,"text":1246,"url":24,"identifiers":1247},"Zhai, L. et al. Molecular pathways: targeting ido1 and other tryptophan dioxygenases for cancer immunotherapy. Clin. Cancer Res. 21, 5427–5433 (2015).",{"doi":1248},"10.1158\u002F1078-0432.CCR-15-0420",{"id":24,"text":1250,"url":24,"identifiers":1251},"Voo, K. S. et al. Antibodies targeting human OX40 expand effector T cells and block inducible and natural regulatory T cell function. J. Immunol. 191, 3641–3650 (2013).",{"doi":1252},"10.4049\u002Fjimmunol.1202752",{"id":24,"text":1254,"url":24,"identifiers":1255},"Bauer, C. et al. Prevailing over T cell exhaustion: new developments in the immunotherapy of pancreatic cancer. Cancer Lett. 381, 259–268 (2016).",{"doi":1256},"10.1016\u002Fj.canlet.2016.02.057",{"id":24,"text":1258,"url":24,"identifiers":1259},"Beatty, G. L. et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331, 1612–1616 (2011).",{"doi":1260},"10.1126\u002Fscience.1198443",{"id":24,"text":1262,"url":24,"identifiers":1263},"Ryter, S. W. & Choi, A. M. Targeting heme oxygenase-1 and carbon monoxide for therapeutic modulation of inflammation. Transl Res. 167, 7–34 (2016).",{"doi":1264},"10.1016\u002Fj.trsl.2015.06.011",{"id":24,"text":1266,"url":24,"identifiers":1267},"Manrique, S. Z. et al. Definitive activation of endogenous antitumor immunity by repetitive cycles of cyclophosphamide with interspersed Toll-like receptor agonists. Oncotarget 7, 42919–42942 (2016).",{"doi":1268},"10.18632\u002Foncotarget.10190",{"id":24,"text":1270,"url":24,"identifiers":1271},"Vaz, J. & Andersson, R. Intervention on toll-like receptors in pancreatic cancer. World J. Gastroenterol. 20, 5808–5817 (2014).",{"doi":1272},"10.3748\u002Fwjg.v20.i19.5808",{"id":24,"text":1274,"url":24,"identifiers":1275},"Fearon, D. T. The carcinoma-associated fibroblast expressing fibroblast activation protein and escape from immune surveillance. Cancer Immunol. Res. 2, 187–193 (2014).",{"doi":1276},"10.1158\u002F2326-6066.CIR-14-0002",{"id":24,"text":1278,"url":24,"identifiers":1279},"Overman, M. J. et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet. Oncol. 18, 1182–1191 (2017).",{"doi":1280},"10.1016\u002FS1470-2045(17)30422-9",{"id":24,"text":1282,"url":24,"identifiers":1283},"Hofmann, L. et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur. J. Cancer 60, 190–209 (2016).",{"doi":1284},"10.1016\u002Fj.ejca.2016.02.025",{"id":24,"text":1286,"url":24,"identifiers":1287},"Brunet, L. R., Hagemann, T., Andrew, G., Mudan, S. & Marabelle, A. Have lessons from past failures brought us closer to the success of immunotherapy in metastatic pancreatic cancer? Oncoimmunology 5, e1112942 (2016).",{"doi":1288},"10.1080\u002F2162402X.2015.1112942",{"id":24,"text":1290,"url":24,"identifiers":1291},"Mackall, C. L. et al. Distinctions between CD8 + and CD4 + T-cell regenerative pathways result in prolonged T-cell subset imbalance after intensive chemotherapy. Blood 89, 3700–3707 (1997).",{"doi":1292},"10.1182\u002Fblood.V89.10.3700",{"id":24,"text":1294,"url":24,"identifiers":1295},"Schiavoni, G. et al. Cyclophosphamide induces type I interferon and augments the number of CD44(hi) T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer. Blood 95, 2024–2030 (2000).",{"doi":1296},"10.1182\u002Fblood.V95.6.2024",{"id":24,"text":1298,"url":24,"identifiers":1299},"Middleton, G. et al. Immunobiological effects of gemcitabine and capecitabine combination chemotherapy in advanced pancreatic ductal adenocarcinoma. Br. J. Cancer 114, 510–518 (2016).",{"doi":1300},"10.1038\u002Fbjc.2015.468",{"id":24,"text":1302,"url":24,"identifiers":1303},"Prasanna, A., Ahmed, M. M., Mohiuddin, M. & Coleman, C. N. Exploiting sensitization windows of opportunity in hyper and hypo-fractionated radiation therapy. J. Thorac. Dis. 6, 287–302 (2014).",{},{"id":24,"text":1305,"url":24,"identifiers":1306},"Biankin, A. V., Piantadosi, S. & Hollingsworth, S. J. Patient-centric trials for therapeutic development in precision oncology. Nature 526, 361–370 (2015).",{"doi":1307},"10.1038\u002Fnature15819",{"id":24,"text":1309,"url":24,"identifiers":1310},"Boj, S. F. et al. Organoid models of human and mouse ductal pancreatic cancer. Cell 160, 324–338 (2015).",{"doi":1311},"10.1016\u002Fj.cell.2014.12.021",{"id":24,"text":1313,"url":24,"identifiers":1314},"Chantrill, L. A. et al. Precision medicine for advanced pancreas cancer: the individualized molecular pancreatic cancer therapy (IMPaCT) trial. Clin. Cancer Res. 21, 2029–2037 (2015).",{"doi":1315},"10.1158\u002F1078-0432.CCR-15-0426",{"id":24,"text":1317,"url":24,"identifiers":1318},"Hurwitz, H. I. et al. Randomized, double-blind, phase II study of Ruxolitinib or placebo in combination with capecitabine in patients with metastatic pancreatic cancer for whom therapy with gemcitabine has failed. J. Clin. Oncol. 33, 4039–4047 (2015).",{"doi":1319},"10.1200\u002FJCO.2015.61.4578",{"id":24,"text":1321,"url":24,"identifiers":1322},"Waddell, N. et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 518, 495–501 (2015).",{"doi":1323},"10.1038\u002Fnature14169",{"id":24,"text":1325,"url":24,"identifiers":1326},"Bendell, J. et al. Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced\u002Fmetastatic pancreatic cancer. Ann. Oncol. 26, 804–811 (2015).",{"doi":1327},"10.1093\u002Fannonc\u002Fmdu581",{"id":24,"text":1329,"url":24,"identifiers":1330},"Kaufman, B. et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\u002F2 mutation. J. Clin. Oncol. 33, 244–250 (2015).",{"doi":1331},"10.1200\u002FJCO.2014.56.2728",{"id":24,"text":1333,"url":24,"identifiers":1334},"Witkiewicz, A. K. et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat. Commun. 6, 6744 (2015).",{"doi":1335},"10.1038\u002Fncomms7744",{"id":24,"text":1337,"url":24,"identifiers":1338},"Bailey, P. et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 531, 47–52 (2016).",{"doi":1339},"10.1038\u002Fnature16965",{"id":24,"text":1341,"url":24,"identifiers":1342},"Chung, V. M. et al. SWOG S1115: randomized phase ii trial of selumetinib (AZD6244; ARRY 142886) hydrogen sulfate (NSC-748727) and MK-2206 (NSC-749607) versus mFOLFOX in pretreated patients (Pts) with metastatic pancreatic cancer [abstract]. ASCO Meet. Abstr. 33, 4119 (2015).",{},{"id":24,"text":1344,"url":24,"identifiers":1345},"Ge, F. et al. S-1 as monotherapy or in combination with leucovorin as second-line treatment in gemcitabine-refractory advanced pancreatic cancer: a randomized, open-label, multicenter, phase II study. Oncologist 19, 1133–1134 (2014).",{"doi":1346},"10.1634\u002Ftheoncologist.2014-0223",{"id":24,"text":1348,"url":24,"identifiers":1349},"Wu, Z. et al. Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer. Cancer Chemother. Pharmacol. 76, 1309–1314 (2015).",{"doi":1350},"10.1007\u002Fs00280-015-2855-z",{"id":24,"text":1352,"url":24,"identifiers":1353},"Dragovich, T. et al. Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001). Cancer Chemother. Pharmacol. 74, 379–387 (2014).",{"doi":1354},"10.1007\u002Fs00280-014-2499-4",{"id":24,"text":1356,"url":24,"identifiers":1357},"Soares, H. P. et al. A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere. Cancer Chemother. Pharmacol. 73, 839–845 (2014).",{"doi":1358},"10.1007\u002Fs00280-014-2414-z",{"id":24,"text":1360,"url":24,"identifiers":1361},"Saif, M. W. et al. First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancer. Cancer Chemother. Pharmacol. 73, 373–380 (2014).",{"doi":1362},"10.1007\u002Fs00280-013-2359-7",{"id":1364,"createTime":1365,"updateTime":1365,"relativeEntities":1366,"slug":1367,"properties":1368,"entityType":184,"verifyStatus":185,"verifyTime":1383,"verifyNote":186,"syncStatus":23,"languages":1384,"translateLanguages":24,"viewCount":25,"primaryUrl":1385,"fullTextUrl":24,"authors":1386,"publicationType":310,"publisherRelationship":1474,"citationCount":1511,"citationInfo":1512,"publishDate":1521,"publishYear":1522,"citationAnalyzeStatus":23,"lastCitationAnalyze":24,"indexDatabases":24,"openAccess":24,"references":1523,"isForceReanalyzing":595},"39b2d8cb-eb86-4ba9-a9fa-12f81c65047e","2024-10-09T23:50:08.807+00:00",[],"Mucins-in-pancreatic-cancer-and-its-microenvironment",{"mag":1369,"keywords":1371,"pmc":1372,"openalex":1374,"abstract":1376,"title":1377,"pm":1379,"doi":1381},{"VOID":1370},"2076211055",{},{"VOID":1373},"3934431",{"VOID":1375},"W2076211055",{},{"EN":1378},"Mucins in pancreatic cancer and its microenvironment",{"VOID":1380},"23856888",{"VOID":1382},"10.1038\u002Fnrgastro.2013.120","2024-10-09T23:50:08.806+00:00",[188],"https:\u002F\u002Fwww.nature.com\u002Farticles\u002Fnrgastro.2013.120",[1387,1406,1427,1442,1459],{"id":1388,"sortIndex":124,"researcher":24,"roles":1389,"affiliations":1390,"properties":1401},"8e804c0d-e3f9-41b3-b9e2-0d13a668905c",[],[1391],{"id":1392,"sortIndex":25,"affiliation":1393,"properties":24},"8a12fca3-78fa-41e6-bb01-dcb57237188b",{"id":1394,"createTime":1395,"updateTime":1395,"relativeEntities":1396,"slug":1397,"properties":1398,"entityType":53,"verifyStatus":23,"verifyTime":24,"verifyNote":24,"syncStatus":23,"languages":24,"translateLanguages":24,"viewCount":25},"cb3ec358-9354-4507-9e67-be14f1f45420","2024-10-09T23:50:08.853+00:00",[],"Department-of-Surgery-University-of-Nebraska-Medical-Centre-985870-Nebraska-Medical-Centre-Omaha-68198-5870-NE-USA",{"title":1399},{"EN":1400},"Department of Surgery, University of Nebraska Medical Centre, 985870 Nebraska Medical Centre, Omaha, 68198-5870, NE, USA",{"openalex":1402,"title":1404},{"VOID":1403},"A5090025086",{"EN":1405},"Aaron R. Sasson",{"id":1407,"sortIndex":215,"researcher":24,"roles":1408,"affiliations":1409,"properties":1420},"d8018ce4-2f3b-4e2a-8080-bffc84585b8f",[],[1410],{"id":1411,"sortIndex":25,"affiliation":1412,"properties":24},"59d40844-1c44-4c02-b7c6-2c0c5578f38a",{"id":1413,"createTime":1414,"updateTime":1414,"relativeEntities":1415,"slug":1416,"properties":1417,"entityType":53,"verifyStatus":23,"verifyTime":24,"verifyNote":24,"syncStatus":23,"languages":24,"translateLanguages":24,"viewCount":25},"c45aae13-bf29-4fd9-b8a7-955a3302d072","2024-10-09T23:50:08.824+00:00",[],"Department-of-Biochemistry-and-Molecular-Biology-985870-Nebraska-Medical-Centre-Omaha-68198-5870-NE-USA",{"title":1418},{"EN":1419},"Department of Biochemistry and Molecular Biology, 985870 Nebraska Medical Centre, Omaha, 68198-5870, NE, USA",{"openalex":1421,"orcid":1423,"title":1425},{"VOID":1422},"A5086534465",{"VOID":1424},"https:\u002F\u002Forcid.org\u002F0000-0002-2155-3443",{"EN":1426},"Sushil Kumar",{"id":1428,"sortIndex":25,"researcher":24,"roles":1429,"affiliations":1430,"properties":1437},"7a4e2356-1344-4638-a381-1d577c7fbe0e",[],[1431],{"id":1432,"sortIndex":25,"affiliation":1433,"properties":24},"ac9e9c78-ba6d-4d7b-b3c8-b8214e81cea3",{"id":1413,"createTime":1414,"updateTime":1414,"relativeEntities":1434,"slug":1416,"properties":1435,"entityType":53,"verifyStatus":23,"verifyTime":24,"verifyNote":24,"syncStatus":23,"languages":24,"translateLanguages":24,"viewCount":25},[],{"title":1436},{"EN":1419},{"openalex":1438,"title":1440},{"VOID":1439},"A5103999569",{"EN":1441},"Sukhwinder Kaur",{"id":1443,"sortIndex":127,"researcher":24,"roles":1444,"affiliations":1445,"properties":1452},"1977462b-40dd-403e-91f0-a7ec76636c92",[],[1446],{"id":1447,"sortIndex":25,"affiliation":1448,"properties":24},"61369e43-ca01-4009-a10a-cad80c839cec",{"id":1413,"createTime":1414,"updateTime":1414,"relativeEntities":1449,"slug":1416,"properties":1450,"entityType":53,"verifyStatus":23,"verifyTime":24,"verifyNote":24,"syncStatus":23,"languages":24,"translateLanguages":24,"viewCount":25},[],{"title":1451},{"EN":1419},{"openalex":1453,"orcid":1455,"title":1457},{"VOID":1454},"A5085256777",{"VOID":1456},"https:\u002F\u002Forcid.org\u002F0000-0001-9470-9317",{"EN":1458},"Surinder K. Batra",{"id":1460,"sortIndex":126,"researcher":24,"roles":1461,"affiliations":1462,"properties":1469},"65cf1aaf-853f-4829-b21e-922298516303",[],[1463],{"id":1464,"sortIndex":25,"affiliation":1465,"properties":24},"b9ab9b7f-db7a-4253-bbe1-c0ea7372e94e",{"id":1413,"createTime":1414,"updateTime":1414,"relativeEntities":1466,"slug":1416,"properties":1467,"entityType":53,"verifyStatus":23,"verifyTime":24,"verifyNote":24,"syncStatus":23,"languages":24,"translateLanguages":24,"viewCount":25},[],{"title":1468},{"EN":1419},{"openalex":1470,"title":1472},{"VOID":1471},"A5043100736",{"EN":1473},"Navneet Momi",{"url":24,"publisher":1475,"properties":1505},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1476,"slug":10,"properties":1477,"entityType":22,"verifyStatus":23,"verifyTime":24,"verifyNote":24,"syncStatus":23,"languages":24,"translateLanguages":24,"viewCount":25,"subjectFields":1483,"manageAffiliations":1484,"indexDatabases":1485,"url":106,"thumbnailPath":24,"statistic":1500,"gsStatistic":24,"type":24,"analyzePriority":24},[],{"country":1478,"issn":1479,"introduce":1480,"eissn":1481,"title":1482},{"VOID":13},{"VOID":15},{"EN":17},{"VOID":19},{"EN":21},[],[],[1486,1493],{"id":88,"indexDatabase":1487,"url":103,"indexYears":24,"academicFieldIds":1492,"indexDatabaseRanking":24},{"id":90,"createTime":91,"updateTime":92,"relativeEntities":1488,"label":1489,"description":1490,"key":99,"publicationTags":1491,"standard":24},[],{"EN":95,"VI":95},{"VI":97,"EN":98},[101,102],[105],{"id":68,"indexDatabase":1494,"url":81,"indexYears":82,"academicFieldIds":1499,"indexDatabaseRanking":86},{"id":70,"createTime":71,"updateTime":72,"relativeEntities":1495,"label":1496,"description":1497,"key":78,"publicationTags":1498,"standard":24},[],{"EN":75,"VI":75},{"EN":75,"VI":77},[80],[84,85],{"impactFactor":25,"impactFactorByYear":1501,"i10Index":121,"i10IndexLast5Year":122,"totalPublication":121,"totalPublicationByYear":1502,"totalCitation":129,"totalCitationByYear":1503,"totalCitationPerPublication":145,"totalCitationPerPublicationByYear":1504,"hindexLast5Year":161,"hindex":161},{"2012":109,"2013":110,"2014":111,"2015":112,"2016":113,"2017":114,"2018":115,"2019":116,"2020":117,"2021":118,"2022":119,"2023":120},{"2009":124,"2010":124,"2011":125,"2012":126,"2013":127,"2014":124,"2015":125,"2016":127,"2017":128,"2018":127,"2019":127,"2020":126,"2021":125,"2022":126},{"2009":131,"2010":132,"2011":133,"2012":134,"2013":135,"2014":136,"2015":137,"2016":138,"2017":139,"2018":140,"2019":141,"2020":142,"2021":143,"2022":144},{"2009":147,"2010":148,"2011":149,"2012":150,"2013":151,"2014":152,"2015":153,"2016":154,"2017":155,"2018":156,"2019":157,"2020":158,"2021":159,"2022":160},{"volume":1506,"pages":1508,"issue":1510},{"VOID":1507},"10",{"VOID":1509},"607-620",{"VOID":1507},256,{"total":1511,"publishYear":24,"statisticByYear":1513},{"2013":126,"2014":1514,"2015":359,"2016":1515,"2017":1516,"2018":1517,"2019":353,"2020":1518,"2021":1515,"2022":1515,"2023":1519,"2024":1520},11,28,14,26,39,27,15,"2013-10-01",2013,[1524,1527,1531,1535,1538,1542,1546,1549,1553,1557,1561,1565,1569,1573,1577,1580,1584,1588,1592,1596,1600,1604,1608,1612,1616,1620,1624,1628,1632,1636,1639,1643,1647,1651,1655,1659,1663,1667,1671,1675,1679,1683,1687,1691,1695,1699,1703,1707,1711,1715,1719,1723,1727,1730,1733,1737,1740,1744,1748,1752,1756,1760,1762,1764,1768,1772,1776,1780,1783,1787,1791,1794,1798,1802,1806,1810,1814,1818,1822,1826,1830,1834,1838,1842,1846,1850,1854,1858,1861,1865,1869,1873,1877,1881,1885,1889,1893,1897,1901,1905,1908,1912,1916,1919,1923,1927,1931,1934,1938,1941,1944,1947,1951,1955,1959,1963,1967,1971,1975,1979,1983,1987,1991,1995,1999,2003,2007,2011,2015,2019,2023,2026,2030,2034,2038,2042,2046,2050,2054,2058,2062,2065,2069,2073,2076,2080,2084,2088,2091,2095,2099,2103,2107,2111],{"id":24,"text":1525,"url":24,"identifiers":1526},"Cancer Facts and Statistics. American Cancer Society [online], (2013).",{},{"id":24,"text":1528,"url":24,"identifiers":1529},"Kufe, D. W. Mucins in cancer: function, prognosis and therapy. Nat. Rev. Cancer 9, 874–885 (2009).",{"doi":1530},"10.1038\u002Fnrc2761",{"id":24,"text":1532,"url":24,"identifiers":1533},"Hollingsworth, M. A. & Swanson, B. J. Mucins in cancer: protection and control of the cell surface. Nat. Rev. Cancer 4, 45–60 (2004).",{"doi":1534},"10.1038\u002Fnrc1251",{"id":24,"text":1536,"url":24,"identifiers":1537},"Pflugfelder, S. C. et al. Detection of sialomucin complex (MUC4) in human ocular surface epithelium and tear fluid. Invest. Ophthalmol. Vis. Sci. 41, 1316–1326 (2000).",{},{"id":24,"text":1539,"url":24,"identifiers":1540},"Moniaux, N., Escande, F., Porchet, N., Aubert, J. P. & Batra, S. K. Structural organization and classification of the human mucin genes. Front. Biosci. 6, D1192–D1206 (2001).",{"doi":1541},"10.2741\u002FMoniaux",{"id":24,"text":1543,"url":24,"identifiers":1544},"Bafna, S., Kaur, S. & Batra, S. K. Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells. Oncogene 29, 2893–2904 (2010).",{"doi":1545},"10.1038\u002Fonc.2010.87",{"id":24,"text":1547,"url":24,"identifiers":1548},"Senapati, S., Sharma, P., Bafna, S., Roy, H. K. & Batra, S. K. The MUC gene family: their role in the diagnosis and prognosis of gastric cancer. Histol. Histopathol. 23, 1541–1552 (2008).",{},{"id":24,"text":1550,"url":24,"identifiers":1551},"Singh, A. P. et al. Clinical potential of mucins in diagnosis, prognosis, and therapy of ovarian cancer. Lancet Oncol. 9, 1076–1085 (2008).",{"doi":1552},"10.1016\u002FS1470-2045(08)70277-8",{"id":24,"text":1554,"url":24,"identifiers":1555},"Nagata, K. et al. Mucin expression profile in pancreatic cancer and the precursor lesions. J. Hepatobiliary Pancreat. Surg. 14, 243–254 (2007).",{"doi":1556},"10.1007\u002Fs00534-006-1169-2",{"id":24,"text":1558,"url":24,"identifiers":1559},"Yonezawa, S., Higashi, M., Yamada, N., Yokoyama, S. & Goto, M. Significance of mucin expression in pancreatobiliary neoplasms. J. Hepatobiliary Pancreat. Sci. 17, 108–124 (2010).",{"doi":1560},"10.1007\u002Fs00534-009-0174-7",{"id":24,"text":1562,"url":24,"identifiers":1563},"Yonezawa, S. et al. MUC-1 mucin expression in invasive areas of intraductal papillary mucinous tumors of the pancreas. Pathol. Int. 48, 319–322 (1998).",{"doi":1564},"10.1111\u002Fj.1440-1827.1998.tb03913.x",{"id":24,"text":1566,"url":24,"identifiers":1567},"Swartz, M. J. et al. MUC4 expression increases progressively in pancreatic intraepithelial neoplasia. Am. J. Clin. Pathol. 117, 791–796 (2002).",{"doi":1568},"10.1309\u002F7Y7N-M1WM-R0YK-M2VA",{"id":24,"text":1570,"url":24,"identifiers":1571},"Saitou, M. et al. MUC4 expression is a novel prognostic factor in patients with invasive ductal carcinoma of the pancreas. J. Clin. Pathol. 58, 845–852 (2005).",{"doi":1572},"10.1136\u002Fjcp.2004.023572",{"id":24,"text":1574,"url":24,"identifiers":1575},"Takikita, M. et al. Associations between selected biomarkers and prognosis in a population-based pancreatic cancer tissue microarray. Cancer Res. 69, 2950–2955 (2009).",{"doi":1576},"10.1158\u002F0008-5472.CAN-08-3879",{"id":24,"text":1578,"url":24,"identifiers":1579},"Yamasaki, H. et al. Expression and localization of MUC1, MUC2, MUC5AC and small intestinal mucin antigen in pancreatic tumors. Int. J. Oncol. 24, 107–113 (2004).",{},{"id":24,"text":1581,"url":24,"identifiers":1582},"Moniaux, N., Junker, W. M., Singh, A. P., Jones, A. M. & Batra, S. K. Characterization of human mucin MUC17. Complete coding sequence and organization. J. Biol. Chem. 281, 23676–23685 (2006).",{"doi":1583},"10.1074\u002Fjbc.M600302200",{"id":24,"text":1585,"url":24,"identifiers":1586},"Haridas, D. et al. Pathobiological implications of MUC16 expression in pancreatic cancer. PLoS ONE 6, e26839 (2011).",{"doi":1587},"10.1371\u002Fjournal.pone.0026839",{"id":24,"text":1589,"url":24,"identifiers":1590},"Chauhan, S. C. et al. MUC13 mucin augments pancreatic tumorigenesis. Mol. Cancer Ther. 11, 24–33 (2012).",{"doi":1591},"10.1158\u002F1535-7163.MCT-11-0598",{"id":24,"text":1593,"url":24,"identifiers":1594},"Nissim, S., Idos, G. E. & Wu, B. Genetic markers of malignant transformation in intraductal papillary mucinous neoplasm of the pancreas: a meta-analysis. Pancreas 41, 1195–1205 (2012).",{"doi":1595},"10.1097\u002FMPA.0b013e3182580fb4",{"id":24,"text":1597,"url":24,"identifiers":1598},"Shimamoto, T. et al. MUC1 is a useful molecular marker for malignant intraductal papillary mucinous neoplasms in pancreatic juice obtained from endoscopic retrograde pancreatography. Pancreas 39, 879–883 (2010).",{"doi":1599},"10.1097\u002FMPA.0b013e3181d6ba04",{"id":24,"text":1601,"url":24,"identifiers":1602},"Maker, A. V. et al. Pancreatic cyst fluid and serum mucin levels predict dysplasia in intraductal papillary mucinous neoplasms of the pancreas. Ann. Surg. Oncol. 18, 199–206 (2011).",{"doi":1603},"10.1245\u002Fs10434-010-1225-7",{"id":24,"text":1605,"url":24,"identifiers":1606},"Choudhury, A. et al. Alternate splicing at the 3′-end of the human pancreatic tumor-associated mucin MUC4 cDNA. Teratog. Carcinog. Mutagen. 21, 83–96 (2001).",{"doi":1607},"10.1002\u002F1520-6866(2001)21:1\u003C83::AID-TCM8>3.0.CO;2-3",{"id":24,"text":1609,"url":24,"identifiers":1610},"Escande, F. et al. Genomic organization of MUC4 mucin gene. Towards the characterization of splice variants. Eur. J. Biochem. 269, 3637–3644 (2002).",{"doi":1611},"10.1046\u002Fj.1432-1033.2002.03032.x",{"id":24,"text":1613,"url":24,"identifiers":1614},"Singh, P. K. & Hollingsworth, M. A. Cell surface-associated mucins in signal transduction. Trends Cell Biol. 16, 467–476 (2006).",{"doi":1615},"10.1016\u002Fj.tcb.2006.07.006",{"id":24,"text":1617,"url":24,"identifiers":1618},"Singh, A. P., Moniaux, N., Chauhan, S. C., Meza, J. L. & Batra, S. K. Inhibition of MUC4 expression suppresses pancreatic tumor cell growth and metastasis. Cancer Res. 64, 622–630 (2004).",{"doi":1619},"10.1158\u002F0008-5472.CAN-03-2636",{"id":24,"text":1621,"url":24,"identifiers":1622},"Pochampalli, M. R., el Bejjani, R. M. & Schroeder, J. A. MUC1 is a novel regulator of ErbB1 receptor trafficking. Oncogene 26, 1693–1701 (2007).",{"doi":1623},"10.1038\u002Fsj.onc.1209976",{"id":24,"text":1625,"url":24,"identifiers":1626},"Pochampalli, M. R., Bitler, B. G. & Schroeder, J. A. Transforming growth factor α dependent cancer progression is modulated by Muc1. Cancer Res. 67, 6591–6598 (2007).",{"doi":1627},"10.1158\u002F0008-5472.CAN-06-4518",{"id":24,"text":1629,"url":24,"identifiers":1630},"Li, X., Wang, L., Nunes, D. P., Troxler, R. F. & Offner, G. D. Suppression of MUC1 synthesis downregulates expression of the epidermal growth factor receptor. Cancer Biol. Ther. 4, 968–973 (2005).",{"doi":1631},"10.4161\u002Fcbt.4.9.1913",{"id":24,"text":1633,"url":24,"identifiers":1634},"Hisatsune, A. et al. Anti-MUC1 antibody inhibits EGF receptor signaling in cancer cells. Biochem. Biophys. Res. Commun. 405, 377–381 (2011).",{"doi":1635},"10.1016\u002Fj.bbrc.2011.01.029",{"id":24,"text":1637,"url":24,"identifiers":1638},"Li, Y. et al. Heregulin targets γ-catenin to the nucleolus by a mechanism dependent on the DF3\u002FMUC1 oncoprotein. Mol. Cancer Res. 1, 765–775 (2003).",{},{"id":24,"text":1640,"url":24,"identifiers":1641},"Chaturvedi, P. et al. MUC4 mucin interacts with and stabilizes the HER2 oncoprotein in human pancreatic cancer cells. Cancer Res. 68, 2065–2070 (2008).",{"doi":1642},"10.1158\u002F0008-5472.CAN-07-6041",{"id":24,"text":1644,"url":24,"identifiers":1645},"Funes, M., Miller, J. K., Lai, C., Carraway, K. L. & Sweeney, C. The mucin Muc4 potentiates neuregulin signaling by increasing the cell-surface populations of ErbB2 and ErbB3. J. Biol. Chem. 281, 19310–19319 (2006).",{"doi":1646},"10.1074\u002Fjbc.M603225200",{"id":24,"text":1648,"url":24,"identifiers":1649},"Price-Schiavi, S. A. et al. Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance. Int. J. Cancer 99, 783–791 (2002).",{"doi":1650},"10.1002\u002Fijc.10410",{"id":24,"text":1652,"url":24,"identifiers":1653},"Chaturvedi, P. et al. MUC4 mucin potentiates pancreatic tumor cell proliferation, survival, and invasive properties and interferes with its interaction to extracellular matrix proteins. Mol. Cancer Res. 5, 309–320 (2007).",{"doi":1654},"10.1158\u002F1541-7786.MCR-06-0353",{"id":24,"text":1656,"url":24,"identifiers":1657},"Jonckheere, N. et al. The mucin MUC4 and its membrane partner ErbB2 regulate biological properties of human CAPAN-2 pancreatic cancer cells via different signalling pathways. PLoS ONE 7, e32232 (2012).",{"doi":1658},"10.1371\u002Fjournal.pone.0032232",{"id":24,"text":1660,"url":24,"identifiers":1661},"Gupta, B. K. et al. Increased expression and aberrant localization of mucin 13 in metastatic colon cancer. J. Histochem. Cytochem. 60, 822–831 (2012).",{"doi":1662},"10.1369\u002F0022155412460678",{"id":24,"text":1664,"url":24,"identifiers":1665},"Xu, H. et al. Expression of KL-6\u002FMUC1 in pancreatic ductal carcinoma and its potential relationship with β-catenin in tumor progression. Life Sci. 88, 1063–1069 (2011).",{"doi":1666},"10.1016\u002Fj.lfs.2011.03.021",{"id":24,"text":1668,"url":24,"identifiers":1669},"Singh, P. K. et al. Phosphorylation of MUC1 by Met modulates interaction with p53 and MMP1 expression. J. Biol. Chem. 283, 26985–26995 (2008).",{"doi":1670},"10.1074\u002Fjbc.M805036200",{"id":24,"text":1672,"url":24,"identifiers":1673},"Lau, S. K. et al. EGFR-mediated carcinoma cell metastasis mediated by integrin αvβ5 depends on activation of c-Src and cleavage of MUC1. PLoS ONE 7, e36753 (2012).",{"doi":1674},"10.1371\u002Fjournal.pone.0036753",{"id":24,"text":1676,"url":24,"identifiers":1677},"Bitler, B. G., Goverdhan, A. & Schroeder, J. A. MUC1 regulates nuclear localization and function of the epidermal growth factor receptor. J. Cell Sci. 123, 1716–1723 (2010).",{"doi":1678},"10.1242\u002Fjcs.062661",{"id":24,"text":1680,"url":24,"identifiers":1681},"Inaguma, S., Kasai, K. & Ikeda, H. GLI1 facilitates the migration and invasion of pancreatic cancer cells through MUC5AC-mediated attenuation of E-cadherin. Oncogene 30, 714–723 (2011).",{"doi":1682},"10.1038\u002Fonc.2010.459",{"id":24,"text":1684,"url":24,"identifiers":1685},"Kondo, A. et al. From glycomics to functional glycomics of sugar chains: Identification of target proteins with functional changes using gene targeting mice and knock down cells of FUT8 as examples. Biochim. Biophys. Acta 1764, 1881–1889 (2006).",{"doi":1686},"10.1016\u002Fj.bbapap.2006.10.011",{"id":24,"text":1688,"url":24,"identifiers":1689},"Remmers, N. et al. Aberrant expression of mucin core proteins and O-linked glycans associated with progression of pancreatic cancer. Clin. Cancer Res. 19, 1981–1993 (2013).",{"doi":1690},"10.1158\u002F1078-0432.CCR-12-2662",{"id":24,"text":1692,"url":24,"identifiers":1693},"Park, H. U. et al. Aberrant expression of MUC3 and MUC4 membrane-associated mucins and sialyl Lex antigen in pancreatic intraepithelial neoplasia. Pancreas 26, e48–e54 (2003).",{"doi":1694},"10.1097\u002F00006676-200304000-00022",{"id":24,"text":1696,"url":24,"identifiers":1697},"Yue, T. et al. The prevalence and nature of glycan alterations on specific proteins in pancreatic cancer patients revealed using antibody-lectin sandwich arrays. Mol. Cell. Proteomics 8, 1697–1707 (2009).",{"doi":1698},"10.1074\u002Fmcp.M900135-MCP200",{"id":24,"text":1700,"url":24,"identifiers":1701},"Kui, W. N. et al. Characterization of the oligosaccharides associated with the human ovarian tumor marker CA125. J. Biol. Chem. 278, 28619–28634 (2003).",{"doi":1702},"10.1074\u002Fjbc.M302741200",{"id":24,"text":1704,"url":24,"identifiers":1705},"Tu, L. & Banfield, D. K. Localization of Golgi-resident glycosyltransferases. Cell. Mol. Life Sci. 67, 29–41 (2010).",{"doi":1706},"10.1007\u002Fs00018-009-0126-z",{"id":24,"text":1708,"url":24,"identifiers":1709},"Colley, K. J. Golgi localization of glycosyltransferases: more questions than answers. Glycobiology 7, 1–13 (1997).",{"doi":1710},"10.1093\u002Fglycob\u002F7.1.1-b",{"id":24,"text":1712,"url":24,"identifiers":1713},"Varki, A. Selectin ligands. Proc. Natl Acad. Sci. USA 91, 7390–7397 (1994).",{"doi":1714},"10.1073\u002Fpnas.91.16.7390",{"id":24,"text":1716,"url":24,"identifiers":1717},"Yu, C. J. et al. Sialyl Lewis antigens: association with MUC5AC protein and correlation with post-operative recurrence of non-small cell lung cancer. Lung Cancer 47, 59–67 (2005).",{"doi":1718},"10.1016\u002Fj.lungcan.2004.05.018",{"id":24,"text":1720,"url":24,"identifiers":1721},"Geng, Y., Marshall, J. R. & King, M. R. Glycomechanics of the metastatic cascade: tumor cell-endothelial cell interactions in the circulation. Ann. Biomed. Eng. 40, 790–805 (2012).",{"doi":1722},"10.1007\u002Fs10439-011-0463-6",{"id":24,"text":1724,"url":24,"identifiers":1725},"Chen, S. H., Dallas, M. R., Balzer, E. M. & Konstantopoulos, K. Mucin 16 is a functional selectin ligand on pancreatic cancer cells. FASEB J. 26, 1349–1359 (2012).",{"doi":1726},"10.1096\u002Ffj.11-195669",{"id":24,"text":1728,"url":24,"identifiers":1729},"Komatsu, M., Yee, L. & Carraway, K. L. Overexpression of sialomucin complex, a rat homologue of MUC4, inhibits tumor killing by lymphokine-activated killer cells. Cancer Res. 59, 2229–2236 (1999).",{},{"id":24,"text":1731,"url":24,"identifiers":1732},"Komatsu, M., Tatum, L., Altman, N. H., Carothers Carraway, C. A. & Carraway, K. L. Potentiation of metastasis by cell surface sialomucin complex (rat MUC4), a multifunctional anti-adhesive glycoprotein. Int. J. Cancer. 87, 480–486 (2000).",{},{"id":24,"text":1734,"url":24,"identifiers":1735},"Besmer, D. M. et al. Pancreatic ductal adenocarcinoma mice lacking mucin 1 have a profound defect in tumor growth and metastasis. Cancer Res. 71, 4432–4442 (2011).",{"doi":1736},"10.1158\u002F0008-5472.CAN-10-4439",{"id":24,"text":1738,"url":24,"identifiers":1739},"Kohlgraf, K. G. et al. Contribution of the MUC1 tandem repeat and cytoplasmic tail to invasive and metastatic properties of a pancreatic cancer cell line. Cancer Res. 63, 5011–5020 (2003).",{},{"id":24,"text":1741,"url":24,"identifiers":1742},"Tinder, T. L. et al. MUC1 enhances tumor progression and contributes toward immunosuppression in a mouse model of spontaneous pancreatic adenocarcinoma. J. Immunol. 181, 3116–3125 (2008).",{"doi":1743},"10.4049\u002Fjimmunol.181.5.3116",{"id":24,"text":1745,"url":24,"identifiers":1746},"Zhao, Q. et al. Interaction between circulating galectin-3 and cancer-associated MUC1 enhances tumour cell homotypic aggregation and prevents anoikis. Mol. Cancer 9, 154 (2010).",{"doi":1747},"10.1186\u002F1476-4598-9-154",{"id":24,"text":1749,"url":24,"identifiers":1750},"Sanders, W. J., Katsumoto, T. R., Bertozzi, C. R., Rosen, S. D. & Kiessling, L. L. L-selectin-carbohydrate interactions: relevant modifications of the Lewis x trisaccharide. Biochemistry 35, 14862–14867 (1996).",{"doi":1751},"10.1021\u002Fbi9613640",{"id":24,"text":1753,"url":24,"identifiers":1754},"Cadron, I. et al. The impact of enzastaurin (LY317615.HCl) on CA125 biosynthesis and shedding in ovarian cancer cells. Gynecol. Oncol. 118, 64–68 (2010).",{"doi":1755},"10.1016\u002Fj.ygyno.2010.03.008",{"id":24,"text":1757,"url":24,"identifiers":1758},"Agrawal, B., Gendler, S. J. & Longenecker, B. M. The biological role of mucins in cellular interactions and immune regulation: prospects for cancer immunotherapy. Mol. Med. Today 4, 397–403 (1998).",{"doi":1759},"10.1016\u002FS1357-4310(98)01322-7",{"id":24,"text":1532,"url":24,"identifiers":1761},{"doi":1534},{"id":24,"text":1075,"url":24,"identifiers":1763},{"doi":1077},{"id":24,"text":1765,"url":24,"identifiers":1766},"Tsuboi, S. et al. A novel strategy for evasion of NK cell immunity by tumours expressing core2 O-glycans. EMBO J. 30, 3173–3185 (2011).",{"doi":1767},"10.1038\u002Femboj.2011.215",{"id":24,"text":1769,"url":24,"identifiers":1770},"Senapati, S. et al. Novel INTeraction of MUC4 and galectin: potential pathobiological implications for metastasis in lethal pancreatic cancer. Clin. Cancer Res. 17, 267–274 (2011).",{"doi":1771},"10.1158\u002F1078-0432.CCR-10-1937",{"id":24,"text":1773,"url":24,"identifiers":1774},"Gaida, M. M. et al. Expression of galectin-3 in pancreatic ductal adenocarcinoma. Pathol. Oncol. Res. 18, 299–307 (2012).",{"doi":1775},"10.1007\u002Fs12253-011-9444-1",{"id":24,"text":1777,"url":24,"identifiers":1778},"Okamoto, T. et al. Core2 O-glycan-expressing prostate cancer cells are resistant to NK cell immunity. Mol. Med. Report 7, 359–364 (2013).",{"doi":1779},"10.3892\u002Fmmr.2012.1189",{"id":24,"text":1781,"url":24,"identifiers":1782},"Suzuki, Y. et al. MUC1 carrying core 2 O-glycans functions as a molecular shield against NK cell attack, promoting bladder tumor metastasis. Int. J. Oncol. 40, 1831–1838 (2012).",{},{"id":24,"text":1784,"url":24,"identifiers":1785},"Swanson, B. J. et al. MUC1 is a counter-receptor for myelin-associated glycoprotein (Siglec-4a) and their interaction contributes to adhesion in pancreatic cancer perineural invasion. Cancer Res. 67, 10222–10229 (2007).",{"doi":1786},"10.1158\u002F0008-5472.CAN-06-2483",{"id":24,"text":1788,"url":24,"identifiers":1789},"Konowalchuk, J. D. & Agrawal, B. MUC1 is a novel costimulatory molecule of human T cells and functions in an AP-1-dependent manner. Hum. Immunol. 73, 448–455 (2012).",{"doi":1790},"10.1016\u002Fj.humimm.2012.02.024",{"id":24,"text":1792,"url":24,"identifiers":1793},"Ohno, S. et al. Expression of Tn and sialyl-Tn antigens in endometrial cancer: its relationship with tumor-produced cyclooxygenase-2, tumor-infiltrated lymphocytes and patient prognosis. Anticancer Res. 26, 4047–4053 (2006).",{},{"id":24,"text":1795,"url":24,"identifiers":1796},"Feig, C. et al. The pancreas cancer microenvironment. Clin. Cancer Res. 18, 4266–4276 (2012).",{"doi":1797},"10.1158\u002F1078-0432.CCR-11-3114",{"id":24,"text":1799,"url":24,"identifiers":1800},"Nath, D. et al. Macrophage-tumour cell interactions: identification of MUC1 on breast cancer cells as a potential counter-receptor for the macrophage-restricted receptor, sialoadhesin. Immunology 98, 213–219 (1999).",{"doi":1801},"10.1046\u002Fj.1365-2567.1999.00827.x",{"id":24,"text":1803,"url":24,"identifiers":1804},"Allavena, P. et al. Engagement of the mannose receptor by tumoral mucins activates an immune suppressive phenotype in human tumor-associated macrophages. Clin. Dev. Immunol. 2010, 547179 (2010).",{"doi":1805},"10.1155\u002F2010\u002F547179",{"id":24,"text":1807,"url":24,"identifiers":1808},"Kitamoto, S. et al. MUC1 enhances hypoxia-driven angiogenesis through the regulation of multiple proangiogenic factors, Oncogene http:\u002F\u002Fdx.doi.org\u002F10.1038\u002Fonc.2012.478.",{"doi":1809},"10.1038\u002Fonc.2012.478",{"id":24,"text":1811,"url":24,"identifiers":1812},"Chaika, N. V. et al. MUC1 mucin stabilizes and activates hypoxia-inducible factor 1 α to regulate metabolism in pancreatic cancer. Proc. Natl Acad. Sci. USA 109, 13787–13792 (2012).",{"doi":1813},"10.1073\u002Fpnas.1203339109",{"id":24,"text":1815,"url":24,"identifiers":1816},"Tsutsumida, H. et al. RNA interference suppression of MUC1 reduces the growth rate and metastatic phenotype of human pancreatic cancer cells. Clin. Cancer Res. 12, 2976–2987 (2006).",{"doi":1817},"10.1158\u002F1078-0432.CCR-05-1197",{"id":24,"text":1819,"url":24,"identifiers":1820},"Sawada, T. et al. Biphasic effect of cell surface sialic acids on pancreatic cancer cell adhesiveness. Biochem. Biophys. Res. Commun. 195, 1096–1103 (1993).",{"doi":1821},"10.1006\u002Fbbrc.1993.2157",{"id":24,"text":1823,"url":24,"identifiers":1824},"Senapati, S., Gnanapragassam, V. S., Moniaux, N., Momi, N. & Batra, S. K. Role of MUC4-NIDO domain in the MUC4-mediated metastasis of pancreatic cancer cells. Oncogene 31, 3346–5610 (2011).",{"doi":1825},"10.1038\u002Fonc.2011.505",{"id":24,"text":1827,"url":24,"identifiers":1828},"Paszek, M. J., Boettiger, D., Weaver, V. M. & Hammer, D. A. Integrin clustering is driven by mechanical resistance from the glycocalyx and the substrate. PLoS Comput. Biol. 5, e1000604 (2009).",{"doi":1829},"10.1371\u002Fjournal.pcbi.1000604",{"id":24,"text":1831,"url":24,"identifiers":1832},"Levental, K. R. et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 139, 891–906 (2009).",{"doi":1833},"10.1016\u002Fj.cell.2009.10.027",{"id":24,"text":1835,"url":24,"identifiers":1836},"Wang, Y. et al. Diagnostic value of mucins (MUC1, MUC2 and MUC5AC) expression profile in endoscopic ultrasound-guided fine-needle aspiration specimens of the pancreas. Int. J. Cancer. 121, 2716–2722 (2007).",{"doi":1837},"10.1002\u002Fijc.22997",{"id":24,"text":1839,"url":24,"identifiers":1840},"Carrara, S. et al. Mucin expression pattern in pancreatic diseases: findings from EUS-guided fine-needle aspiration biopsies. Am. J. Gastroenterol. 106, 1359–1363 (2011).",{"doi":1841},"10.1038\u002Fajg.2011.22",{"id":24,"text":1843,"url":24,"identifiers":1844},"Jhala, N. et al. Biomarkers in diagnosis of pancreatic carcinoma in fine-needle aspirates. Am. J. Clin. Pathol. 126, 572–579 (2006).",{"doi":1845},"10.1309\u002FCEV30BE088CBDQD9",{"id":24,"text":1847,"url":24,"identifiers":1848},"Horn, A. et al. Immunocytochemistry for MUC4 and MUC16 is a useful adjunct in the diagnosis of pancreatic adenocarcinoma on fine-needle aspiration cytology. Arch. Pathol. Lab. Med. 137, 546–551 (2013).",{"doi":1849},"10.5858\u002Farpa.2011-0229-OA",{"id":24,"text":1851,"url":24,"identifiers":1852},"Tewes, M. et al. Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies. Breast Cancer Res. Treat. 115, 581–590 (2009).",{"doi":1853},"10.1007\u002Fs10549-008-0143-x",{"id":24,"text":1855,"url":24,"identifiers":1856},"Kaur, S., Baine, M. J., Jain, M., Sasson, A. R. & Batra, S. K. Early diagnosis of pancreatic cancer: challenges and new developments. Biomark. Med. 6, 597–612 (2012).",{"doi":1857},"10.2217\u002Fbmm.12.69",{"id":24,"text":1859,"url":24,"identifiers":1860},"Ballehaninna, U. K. & Chamberlain, R. S. The clinical utility of serum CA 19–9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J. Gastrointest. Oncol. 3, 105–119 (2012).",{},{"id":24,"text":1862,"url":24,"identifiers":1863},"Goggins, M. Molecular markers of early pancreatic cancer. J. Clin. Oncol. 23, 4524–4531 (2005).",{"doi":1864},"10.1200\u002FJCO.2005.19.711",{"id":24,"text":1866,"url":24,"identifiers":1867},"Goonetilleke, K. S. & Siriwardena, A. K. Systematic review of carbohydrate antigen (CA 19–9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur. J. Surg. Oncol. 33, 266–270 (2007).",{"doi":1868},"10.1016\u002Fj.ejso.2006.10.004",{"id":24,"text":1870,"url":24,"identifiers":1871},"Yue, T. et al. Enhanced discrimination of malignant from benign pancreatic disease by measuring the CA 19–9 antigen on specific protein carriers. PLoS ONE 6, e29180 (2011).",{"doi":1872},"10.1371\u002Fjournal.pone.0029180",{"id":24,"text":1874,"url":24,"identifiers":1875},"Shiozaki, K., Yamaguchi, K., Takahashi, K., Moriya, S. & Miyagi, T. Regulation of sialyl Lewis antigen expression in colon cancer cells by sialidase NEU4. J. Biol. Chem. 286, 21052–21061 (2011).",{"doi":1876},"10.1074\u002Fjbc.M111.231191",{"id":24,"text":1878,"url":24,"identifiers":1879},"Qiu, J. et al. Occurrence of autoantibodies to annexin I, 14-3-3 τ and LAMR1 in prediagnostic lung cancer sera. J. Clin. Oncol. 26, 5060–5066 (2008).",{"doi":1880},"10.1200\u002FJCO.2008.16.2388",{"id":24,"text":1882,"url":24,"identifiers":1883},"Zhong, L. et al. Profiling tumor-associated antibodies for early detection of non-small cell lung cancer. J. Thorac. Oncol. 1, 513–519 (2006).",{"doi":1884},"10.1097\u002F01243894-200607000-00003",{"id":24,"text":1886,"url":24,"identifiers":1887},"Pedersen, J. W. et al. Early detection of cancer in the general population: a blinded case–control study of p53 autoantibodies in colorectal cancer. Br. J. Cancer 108, 107–114 (2013).",{"doi":1888},"10.1038\u002Fbjc.2012.517",{"id":24,"text":1890,"url":24,"identifiers":1891},"Pedersen, J. W. et al. Seromic profiling of colorectal cancer patients with novel glycopeptide microarray. Int. J. Cancer 128, 1860–1871 (2011).",{"doi":1892},"10.1002\u002Fijc.25778",{"id":24,"text":1894,"url":24,"identifiers":1895},"Bafna, S., Kaur, S., Momi, N. & Batra, S. K. Pancreatic cancer cells resistance to gemcitabine: the role of MUC4 mucin. Br. J. Cancer 101, 1155–1161 (2009).",{"doi":1896},"10.1038\u002Fsj.bjc.6605285",{"id":24,"text":1898,"url":24,"identifiers":1899},"Karanikas, V. et al. Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. J. Clin. Invest. 100, 2783–2792 (1997).",{"doi":1900},"10.1172\u002FJCI119825",{"id":24,"text":1902,"url":24,"identifiers":1903},"Ioannides, C. G. et al. Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. J. Immunol. 151, 3693–3703 (1993).",{"doi":1904},"10.4049\u002Fjimmunol.151.7.3693",{"id":24,"text":1906,"url":24,"identifiers":1907},"Rowse, G. J., Tempero, R. M., VanLith, M. L., Hollingsworth, M. A. & Gendler, S. J. Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model. Cancer Res. 58, 315–321 (1998).",{},{"id":24,"text":1909,"url":24,"identifiers":1910},"Turner, M. S., Cohen, P. A. & Finn, O. J. Lack of effective MUC1 tumor antigen-specific immunity in MUC1-transgenic mice results from a Th\u002FT regulatory cell imbalance that can be corrected by adoptive transfer of wild-type Th cells. J. Immunol. 178, 2787–2793 (2007).",{"doi":1911},"10.4049\u002Fjimmunol.178.5.2787",{"id":24,"text":1913,"url":24,"identifiers":1914},"Tempero, R. M. et al. CD4+ lymphocytes provide MUC1-specific tumor immunity in vivo that is undetectable in vitro and is absent in MUC1 transgenic mice. J. Immunol. 161, 5500–5506 (1998).",{"doi":1915},"10.4049\u002Fjimmunol.161.10.5500",{"id":24,"text":1917,"url":24,"identifiers":1918},"Barratt-Boyes, S. M., Vlad, A. & Finn, O. J. Immunization of chimpanzees with tumor antigen MUC1 mucin tandem repeat peptide elicits both helper and cytotoxic T-cell responses. Clin. Cancer Res. 5, 1918–1924 (1999).",{},{"id":24,"text":1920,"url":24,"identifiers":1921},"Soares, M. M., Mehta, V. & Finn, O. J. Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection. J. Immunol. 166, 6555–6563 (2001).",{"doi":1922},"10.4049\u002Fjimmunol.166.11.6555",{"id":24,"text":1924,"url":24,"identifiers":1925},"Goydos, J. S., Elder, E., Whiteside, T. L., Finn, O. J. & Lotze, M. T. A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. J. Surg. Res. 63, 298–304 (1996).",{"doi":1926},"10.1006\u002Fjsre.1996.0264",{"id":24,"text":1928,"url":24,"identifiers":1929},"Ramanathan, R. K. et al. Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer. Cancer Immunol. Immunother. 54, 254–264 (2005).",{"doi":1930},"10.1007\u002Fs00262-004-0581-1",{"id":24,"text":1932,"url":24,"identifiers":1933},"Yamamoto, K. et al. MUC1 peptide vaccination in patients with advanced pancreas or biliary tract cancer. Anticancer Res. 25, 3575–3579 (2005).",{},{"id":24,"text":1935,"url":24,"identifiers":1936},"Kaufman, H. L. et al. Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer. J. Transl. Med. 5, 60 (2007).",{"doi":1937},"10.1186\u002F1479-5876-5-60",{"id":24,"text":1939,"url":24,"identifiers":1940},"Kawaoka, T. et al. Adoptive immunotherapy for pancreatic cancer: cytotoxic T lymphocytes stimulated by the MUC1-expressing human pancreatic cancer cell line YPK-1. Oncol. Rep. 20, 155–163 (2008).",{},{"id":24,"text":1942,"url":24,"identifiers":1943},"Kawaoka, T., Takashima, M., Yamamoto, K., Ueno, T. & Oka, M. Adoptive immunotherapy using MUC1--specific CTLs for unresectable pancreatic cancer [Japanese]. Nihon Rinsho 64 (Suppl. 1), 279–282 (2006).",{},{"id":24,"text":1945,"url":24,"identifiers":1946},"Kondo, H. et al. Adoptive immunotherapy for pancreatic cancer using MUC1 peptide-pulsed dendritic cells and activated T lymphocytes. Anticancer Res. 28, 379–387 (2008).",{},{"id":24,"text":1948,"url":24,"identifiers":1949},"Wu, J. et al. Identification of an HLA-A*0201-restrictive CTL epitope from MUC4 for applicable vaccine therapy. Immunopharmacol. Immunotoxicol. 31, 468–476 (2009).",{"doi":1950},"10.1080\u002F08923970902795203",{"id":24,"text":1952,"url":24,"identifiers":1953},"Fan, X. N., Karsten, U., Goletz, S. & Cao, Y. Reactivity of a humanized antibody (hPankoMab) towards a tumor-related MUC1 epitope (TA-MUC1) with various human carcinomas. Pathol. Res. Pract. 206, 585–589 (2010).",{"doi":1954},"10.1016\u002Fj.prp.2010.03.006",{"id":24,"text":1956,"url":24,"identifiers":1957},"Berek, J. et al. Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. J. Clin. Oncol. 27, 418–425 (2009).",{"doi":1958},"10.1200\u002FJCO.2008.17.8400",{"id":24,"text":1960,"url":24,"identifiers":1961},"Bitler, B. G. et al. Intracellular MUC1 peptides inhibit cancer progression. Clin. Cancer Res. 15, 100–109 (2009).",{"doi":1962},"10.1158\u002F1078-0432.CCR-08-1745",{"id":24,"text":1964,"url":24,"identifiers":1965},"Raina, D. et al. Direct targeting of the mucin 1 oncoprotein blocks survival and tumorigenicity of human breast carcinoma cells. Cancer Res. 69, 5133–5141 (2009).",{"doi":1966},"10.1158\u002F0008-5472.CAN-09-0854",{"id":24,"text":1968,"url":24,"identifiers":1969},"Savla, R., Taratula, O., Garbuzenko, O. & Minko, T. Tumor targeted quantum dot-mucin 1 aptamer-doxorubicin conjugate for imaging and treatment of cancer. J. Control Release 153, 16–22 (2011).",{"doi":1970},"10.1016\u002Fj.jconrel.2011.02.015",{"id":24,"text":1972,"url":24,"identifiers":1973},"Andrianifahanana, M. et al. MUC4-expressing pancreatic adenocarcinomas show elevated levels of both T1 and T2 cytokines: potential pathobiologic implications. Am. J. Gastroenterol. 101, 2319–2329 (2006).",{"doi":1974},"10.1111\u002Fj.1572-0241.2006.00871.x",{"id":24,"text":1976,"url":24,"identifiers":1977},"Ren, J. et al. MUC1 oncoprotein functions in activation of fibroblast growth factor receptor signaling. Mol. Cancer Res. 4, 873–883 (2006).",{"doi":1978},"10.1158\u002F1541-7786.MCR-06-0204",{"id":24,"text":1980,"url":24,"identifiers":1981},"Choudhury, A. et al. Retinoic acid-dependent transforming growth factor-β 2-mediated induction of MUC4 mucin expression in human pancreatic tumor cells follows retinoic acid receptor-α signaling pathway. J. Biol. Chem. 275, 33929–33936 (2000).",{"doi":1982},"10.1074\u002Fjbc.M005115200",{"id":24,"text":1984,"url":24,"identifiers":1985},"Strobel, O. et al. Pancreatic duct glands are distinct ductal compartments that react to chronic injury and mediate Shh-induced metaplasia. Gastroenterology 138, 1166–1177 (2010).",{"doi":1986},"10.1053\u002Fj.gastro.2009.12.005",{"id":24,"text":1988,"url":24,"identifiers":1989},"Colomb, F. et al. TNF regulates sialyl-Lewisx and 6-sulfo-sialyl-Lewisx expression in human lung through up-regulation of ST3GAL4 transcript isoform BX. Biochimie 94, 2045–2053 (2012).",{"doi":1990},"10.1016\u002Fj.biochi.2012.05.030",{"id":24,"text":1992,"url":24,"identifiers":1993},"Springer, G. F. T and Tn, general carcinoma autoantigens. Science 224, 1198–1206 (1984).",{"doi":1994},"10.1126\u002Fscience.6729450",{"id":24,"text":1996,"url":24,"identifiers":1997},"Nanashima, A. et al. High serum concentrations of sialyl Tn antigen in carcinomas of the biliary tract and pancreas. J. Hepatobiliary Pancreat. Surg. 6, 391–395 (1999).",{"doi":1998},"10.1007\u002Fs005340050137",{"id":24,"text":2000,"url":24,"identifiers":2001},"Yu, L. G. et al. Galectin-3 interaction with Thomsen-Friedenreich disaccharide on cancer-associated MUC1 causes increased cancer cell endothelial adhesion. J. Biol. Chem. 282, 773–781 (2007).",{"doi":2002},"10.1074\u002Fjbc.M606862200",{"id":24,"text":2004,"url":24,"identifiers":2005},"Tsuboi, S. Hatakeyama, S., Ohyama, C. & Fukuda, M. Two opposing roles of O-glycans in tumor metastasis. Trends Mol. Med. 18, 224–232 (2012).",{"doi":2006},"10.1016\u002Fj.molmed.2012.02.001",{"id":24,"text":2008,"url":24,"identifiers":2009},"Lee, S. H. et al. Core3 O-glycan synthase suppresses tumor formation and metastasis of prostate carcinoma PC3 and LNCaP cells through down-regulation of α2β1 integrin complex. J. Biol. Chem. 284, 17157–17169 (2009).",{"doi":2010},"10.1074\u002Fjbc.M109.010934",{"id":24,"text":2012,"url":24,"identifiers":2013},"Terris, B. et al. Mucin gene expression in intraductal papillary-mucinous pancreatic tumours and related lesions. J. Pathol. 197, 632–637 (2002).",{"doi":2014},"10.1002\u002Fpath.1146",{"id":24,"text":2016,"url":24,"identifiers":2017},"Yonezawa, S. et al. MUC2 gene expression is found in noninvasive tumors but not in invasive tumors of the pancreas and liver: its close relationship with prognosis of the patients. Hum. Pathol. 28, 344–352 (1997).",{"doi":2018},"10.1016\u002FS0046-8177(97)90134-9",{"id":24,"text":2020,"url":24,"identifiers":2021},"Yonezawa, S. et al. Gene expression of gastric type mucin (MUC5AC) in pancreatic tumors: its relationship with the biological behavior of the tumor. Pathol. Int. 49, 45–54 (1999).",{"doi":2022},"10.1046\u002Fj.1440-1827.1999.00823.x",{"id":24,"text":2024,"url":24,"identifiers":2025},"Andrianifahanana, M. et al. Mucin (MUC) gene expression in human pancreatic adenocarcinoma and chronic pancreatitis: a potential role of MUC4 as a tumor marker of diagnostic significance. Clin. Cancer Res. 7, 4033–4040 (2001).",{},{"id":24,"text":2027,"url":24,"identifiers":2028},"Shimizu, A. et al. Coexpression of MUC16 and mesothelin is related to the invasion process in pancreatic ductal adenocarcinoma. Cancer Sci. 103, 739–746 (2012).",{"doi":2029},"10.1111\u002Fj.1349-7006.2012.02214.x",{"id":24,"text":2031,"url":24,"identifiers":2032},"Higuchi, T. et al. Molecular cloning, genomic structure, and expression analysis of MUC20, a novel mucin protein, up-regulated in injured kidney. J. Biol. Chem. 279, 1968–1979 (2004).",{"doi":2033},"10.1074\u002Fjbc.M304558200",{"id":24,"text":2035,"url":24,"identifiers":2036},"Itoh, Y. et al. Identification and expression of human epiglycanin\u002FMUC21: a novel transmembrane mucin. Glycobiology 18, 74–83 (2008).",{"doi":2037},"10.1093\u002Fglycob\u002Fcwm118",{"id":24,"text":2039,"url":24,"identifiers":2040},"Rückert, F., Pilarsky, C. & Grützmann, R. Serum tumor markers in pancreatic cancer—recent discoveries. Cancer 2, 1107 (2010).",{"doi":2041},"10.3390\u002Fcancers2021107",{"id":24,"text":2043,"url":24,"identifiers":2044},"Ni, X. G. et al. The clinical value of serum CEA, CA19–9, and CA242 in the diagnosis and prognosis of pancreatic cancer. Eur. J. Surg. Oncol. 31, 164–169 (2005).",{"doi":2045},"10.1016\u002Fj.ejso.2004.09.007",{"id":24,"text":2047,"url":24,"identifiers":2048},"Tsutsumi, K. et al. Monitoring of CA19–9 and SPan-1 can facilitate the earlier confirmation of progressing pancreatic cancer during chemotherapy. Pancreatology 12, 409–416 (2012).",{"doi":2049},"10.1016\u002Fj.pan.2012.07.009",{"id":24,"text":2051,"url":24,"identifiers":2052},"Bunger, S., Laubert, T., Roblick, U. J. & Habermann, J. K. Serum biomarkers for improved diagnostic of pancreatic cancer: a current overview. J. Cancer Res. Clin. Oncol. 137, 375–389 (2011).",{"doi":2053},"10.1007\u002Fs00432-010-0965-x",{"id":24,"text":2055,"url":24,"identifiers":2056},"Yonezawa, S., Higashi, M., Yamada, N. & Goto, M. Precursor lesions of pancreatic cancer. Gut Liver 2, 137–154 (2008).",{"doi":2057},"10.5009\u002Fgnl.2008.2.3.137",{"id":24,"text":2059,"url":24,"identifiers":2060},"Gold, D. V. et al. PAM4 enzyme immunoassay alone and in combination with CA 19–9 for the detection of pancreatic adenocarcinoma. Cancer 119, 522–528 (2013).",{"doi":2061},"10.1002\u002Fcncr.27762",{"id":24,"text":2063,"url":24,"identifiers":2064},"Lepisto, A. J. et al. A phase I\u002FII study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors. Cancer Ther. 6, 955–964 (2008).",{},{"id":24,"text":2066,"url":24,"identifiers":2067},"Pecher, G., Haring, A., Kaiser, L. & Thiel, E. Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a phase I\u002FII clinical trial. Cancer Immunol. Immunother. 51, 669–673 (2002).",{"doi":2068},"10.1007\u002Fs00262-002-0317-z",{"id":24,"text":2070,"url":24,"identifiers":2071},"Gulec, S. A. et al. Treatment of advanced pancreatic carcinoma with 90Y-clivatuzumab tetraxetan: a phase I single-dose escalation trial, Clin. Cancer Res. 17, 4091–4100 (2011).",{"doi":2072},"10.1158\u002F1078-0432.CCR-10-2579",{"id":24,"text":2074,"url":24,"identifiers":2075},"Cardillo, T. M., Ying, Z. & Gold, D. V. Therapeutic advantage of 90yttrium versus 131iodine-labeled PAM4 antibody in experimental pancreatic cancer. Clin. Cancer Res. 7, 3186–3192 (2001).",{},{"id":24,"text":2077,"url":24,"identifiers":2078},"Gold, D. V., Cardillo, T., Vardi, Y. & Blumenthal, R. Radioimmunotherapy of experimental pancreatic cancer with 131I-labeled monoclonal antibody PAM4. Int. J. Cancer 71, 660–667 (1997).",{"doi":2079},"10.1002\u002F(SICI)1097-0215(19970516)71:4\u003C660::AID-IJC24>3.0.CO;2-E",{"id":24,"text":2081,"url":24,"identifiers":2082},"Gold, D. V., Cardillo, T., Goldenberg, D. M. & Sharkey, R. M. Localization of pancreatic cancer with radiolabeled monoclonal antibody PAM4. Crit. Rev. Oncol. Hematol. 39, 147–154 (2001).",{"doi":2083},"10.1016\u002FS1040-8428(01)00114-7",{"id":24,"text":2085,"url":24,"identifiers":2086},"Joshi, M. D. et al. MUC1 oncoprotein is a druggable target in human prostate cancer cells. Mol. Cancer Ther. 8, 3056–3065 (2009).",{"doi":2087},"10.1158\u002F1535-7163.MCT-09-0646",{"id":24,"text":2089,"url":24,"identifiers":2090},"Brockhausen, I., Schachter, H. & Stanley, P. in Essentials of Glycobiology. 2nd edn Ch. 9 (Cold Spring Harbor, 2009).",{},{"id":24,"text":2092,"url":24,"identifiers":2093},"Lang, T., Hansson, G. C. & Samuelsson, T. Gel-forming mucins appeared early in metazoan evolution. Proc. Natl Acad. Sci. USA 104, 16209–16214 (2007).",{"doi":2094},"10.1073\u002Fpnas.0705984104",{"id":24,"text":2096,"url":24,"identifiers":2097},"Chaturvedi, P., Singh, A. P. & Batra, S. K. Structure, evolution, and biology of the MUC4 mucin. FASEB J. 22, 966–981 (2008).",{"doi":2098},"10.1096\u002Ffj.07-9673rev",{"id":24,"text":2100,"url":24,"identifiers":2101},"Duraisamy, S., Ramasamy, S., Kharbanda, S. & Kufe, D. Distinct evolution of the human carcinoma-associated transmembrane mucins, MUC1, MUC4 AND MUC16. Gene 373, 28–34 (2006).",{"doi":2102},"10.1016\u002Fj.gene.2005.12.021",{"id":24,"text":2104,"url":24,"identifiers":2105},"Pelaseyed, T. et al. Unfolding dynamics of the mucin SEA domain probed by force spectroscopy suggest that it acts as a cell protective device. FEBS J. 280, 1491–1501 (2013).",{"doi":2106},"10.1111\u002Ffebs.12144",{"id":24,"text":2108,"url":24,"identifiers":2109},"Ho, S. B. et al. Activity of recombinant cysteine-rich domain proteins derived from the membrane-bound MUC17\u002FMuc3 family mucins. Biochim. Biophys. Acta 1800, 629–638 (2010).",{"doi":2110},"10.1016\u002Fj.bbagen.2010.03.010",{"id":24,"text":2112,"url":24,"identifiers":2113},"Ciccarelli, F. D., Doerks, T. & Bork, P. AMOP, a protein module alternatively spliced in cancer cells. Trends Biochem. Sci. 27, 113–115 (2002).",{"doi":2114},"10.1016\u002FS0968-0004(01)02049-7",{"id":2116,"createTime":2117,"updateTime":2117,"relativeEntities":2118,"slug":2119,"properties":2120,"entityType":184,"verifyStatus":185,"verifyTime":2117,"verifyNote":186,"syncStatus":23,"languages":2133,"translateLanguages":24,"viewCount":25,"primaryUrl":2134,"fullTextUrl":24,"authors":2135,"publicationType":310,"publisherRelationship":2175,"citationCount":2213,"citationInfo":2214,"publishDate":2221,"publishYear":2222,"citationAnalyzeStatus":23,"lastCitationAnalyze":24,"indexDatabases":24,"openAccess":24,"references":2223,"isForceReanalyzing":595},"5f55adc2-b5b3-49f3-b2a8-645f7f836245","2024-09-30T23:43:27.417+00:00",[],"Acute-on-chronic-liver-failure-terminology-mechanisms-and-management",{"mag":2121,"keywords":2123,"openalex":2124,"abstract":2126,"title":2127,"pm":2129,"doi":2131},{"VOID":2122},"2254417733",{},{"VOID":2125},"W2254417733",{},{"EN":2128},"Acute-on-chronic liver failure: terminology, mechanisms and management",{"VOID":2130},"26837712",{"VOID":2132},"10.1038\u002Fnrgastro.2015.219",[188],"https:\u002F\u002Fwww.nature.com\u002Farticles\u002Fnrgastro.2015.219",[2136,2158],{"id":2137,"sortIndex":25,"researcher":24,"roles":2138,"affiliations":2139,"properties":2151},"e170da1e-24da-4887-a48d-c59845fa8b64",[],[2140],{"id":2141,"sortIndex":25,"affiliation":2142,"properties":24},"8a67aaaa-1c53-44ec-bcdf-6ee1d775ed45",{"id":2143,"createTime":2144,"updateTime":2145,"relativeEntities":2146,"slug":2147,"properties":2148,"entityType":53,"verifyStatus":23,"verifyTime":24,"verifyNote":24,"syncStatus":23,"languages":24,"translateLanguages":24,"viewCount":25},"8552b9c2-0979-4720-a37b-9a5f4bb437e2","2023-12-06T23:48:28.509+00:00","2024-09-30T23:43:27.436+00:00",[],"Department-of-Hepatology-Institute-of-Liver-and-Biliary-Sciences-D-1-Vasant-Kunj-New-Delhi-110070-India",{"title":2149},{"VI":2150},"Department of Hepatology, Institute of Liver and Biliary Sciences, D-1, Vasant Kunj, New Delhi 110070, India",{"openalex":2152,"orcid":2154,"title":2156},{"VOID":2153},"A5026415059",{"VOID":2155},"https:\u002F\u002Forcid.org\u002F0000-0002-0544-5610",{"EN":2157},"Shiv Kumar Sarin",{"id":2159,"sortIndex":215,"researcher":24,"roles":2160,"affiliations":2161,"properties":2168},"58e0703d-566c-4112-a6c7-d2291c9714a2",[],[2162],{"id":2163,"sortIndex":25,"affiliation":2164,"properties":24},"14138f5f-bfd4-4f2c-8812-f832f3c7d694",{"id":2143,"createTime":2144,"updateTime":2145,"relativeEntities":2165,"slug":2147,"properties":2166,"entityType":53,"verifyStatus":23,"verifyTime":24,"verifyNote":24,"syncStatus":23,"languages":24,"translateLanguages":24,"viewCount":25},[],{"title":2167},{"VI":2150},{"openalex":2169,"orcid":2171,"title":2173},{"VOID":2170},"A5034157022",{"VOID":2172},"https:\u002F\u002Forcid.org\u002F0000-0001-6540-2623",{"EN":2174},"Ashok Choudhury",{"url":24,"publisher":2176,"properties":2206},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":2177,"slug":10,"properties":2178,"entityType":22,"verifyStatus":23,"verifyTime":24,"verifyNote":24,"syncStatus":23,"languages":24,"translateLanguages":24,"viewCount":25,"subjectFields":2184,"manageAffiliations":2185,"indexDatabases":2186,"url":106,"thumbnailPath":24,"statistic":2201,"gsStatistic":24,"type":24,"analyzePriority":24},[],{"country":2179,"issn":2180,"introduce":2181,"eissn":2182,"title":2183},{"VOID":13},{"VOID":15},{"EN":17},{"VOID":19},{"EN":21},[],[],[2187,2194],{"id":88,"indexDatabase":2188,"url":103,"indexYears":24,"academicFieldIds":2193,"indexDatabaseRanking":24},{"id":90,"createTime":91,"updateTime":92,"relativeEntities":2189,"label":2190,"description":2191,"key":99,"publicationTags":2192,"standard":24},[],{"EN":95,"VI":95},{"VI":97,"EN":98},[101,102],[105],{"id":68,"indexDatabase":2195,"url":81,"indexYears":82,"academicFieldIds":2200,"indexDatabaseRanking":86},{"id":70,"createTime":71,"updateTime":72,"relativeEntities":2196,"label":2197,"description":2198,"key":78,"publicationTags":2199,"standard":24},[],{"EN":75,"VI":75},{"EN":75,"VI":77},[80],[84,85],{"impactFactor":25,"impactFactorByYear":2202,"i10Index":121,"i10IndexLast5Year":122,"totalPublication":121,"totalPublicationByYear":2203,"totalCitation":129,"totalCitationByYear":2204,"totalCitationPerPublication":145,"totalCitationPerPublicationByYear":2205,"hindexLast5Year":161,"hindex":161},{"2012":109,"2013":110,"2014":111,"2015":112,"2016":113,"2017":114,"2018":115,"2019":116,"2020":117,"2021":118,"2022":119,"2023":120},{"2009":124,"2010":124,"2011":125,"2012":126,"2013":127,"2014":124,"2015":125,"2016":127,"2017":128,"2018":127,"2019":127,"2020":126,"2021":125,"2022":126},{"2009":131,"2010":132,"2011":133,"2012":134,"2013":135,"2014":136,"2015":137,"2016":138,"2017":139,"2018":140,"2019":141,"2020":142,"2021":143,"2022":144},{"2009":147,"2010":148,"2011":149,"2012":150,"2013":151,"2014":152,"2015":153,"2016":154,"2017":155,"2018":156,"2019":157,"2020":158,"2021":159,"2022":160},{"volume":2207,"pages":2209,"issue":2211},{"VOID":2208},"13",{"VOID":2210},"131-149",{"VOID":2212},"3",288,{"total":2213,"publishYear":24,"statisticByYear":2215},{"2016":2216,"2017":1515,"2018":1517,"2019":2217,"2020":355,"2021":2218,"2022":2219,"2023":2220,"2024":356},10,30,37,44,48,"2016-03-01",2016,[2224,2228,2232,2236,2240,2244,2248,2252,2256,2260,2264,2268,2272,2276,2280,2284,2288,2292,2294,2298,2302,2306,2310,2314,2318,2322,2326,2330,2334,2338,2342,2346,2350,2354,2358,2362,2366,2370,2374,2378,2382,2386,2390,2394,2398,2402,2406,2410,2414,2417,2421,2425,2429,2433,2437,2441,2445,2449,2453,2457,2461,2464,2467,2471,2475,2479,2483,2487,2491,2495,2499,2503,2507,2511,2515,2519,2523,2527,2531,2535,2539,2543,2547,2551,2555,2558,2562,2566,2570,2574,2578,2582,2586,2590,2594,2598,2602,2606,2610,2614,2618,2621,2624,2628,2632,2636,2639,2643,2647,2650,2653,2657,2661,2665,2669,2673,2677,2680,2684,2688,2692,2696,2700,2704,2708,2712,2716,2720,2724,2728,2732,2736,2740,2744,2748,2752,2755,2759,2763,2767,2771,2775,2779,2783,2787,2791,2795,2799,2803,2807,2811,2815,2819,2823,2827,2831,2835,2838,2841,2845,2849,2853,2857,2861,2865,2869,2873,2877,2881,2885,2889,2893,2897,2901,2905,2909,2913,2917,2921,2925,2929,2933,2937,2941,2944,2948,2952,2956,2960,2964,2968,2972,2976,2980,2984,2988],{"id":24,"text":2225,"url":24,"identifiers":2226},"Byass, P. The global burden of liver disease: a challenge for methods and for public health. BMC Med. 12, 159 (2014).",{"doi":2227},"10.1186\u002Fs12916-014-0159-5",{"id":24,"text":2229,"url":24,"identifiers":2230},"Sarin, S. et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol. Int. 8, 453–471 (2014).",{"doi":2231},"10.1007\u002Fs12072-014-9580-2",{"id":24,"text":2233,"url":24,"identifiers":2234},"Moreau, R. et al. Acute on chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 144, 1426–1437 (2013).",{"doi":2235},"10.1053\u002Fj.gastro.2013.02.042",{"id":24,"text":2237,"url":24,"identifiers":2238},"Sarin, S. et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol. Int. 3, 269–282 (2009).",{"doi":2239},"10.1007\u002Fs12072-008-9106-x",{"id":24,"text":2241,"url":24,"identifiers":2242},"Bernal, W. et al. Lessons from look-back in acute liver failure? A single centre experience of 3300 patients. J. Hepatol. 59, 74–80 (2013).",{"doi":2243},"10.1016\u002Fj.jhep.2013.02.010",{"id":24,"text":2245,"url":24,"identifiers":2246},"Bajaj, J. S. Defining acute-on-chronic liver failure: will East and West ever meet? Gastroenterology 144, 1337–1339 (2013).",{"doi":2247},"10.1053\u002Fj.gastro.2013.04.024",{"id":24,"text":2249,"url":24,"identifiers":2250},"Jalan, R., Gines, P., Arroyo, V. & Kamath, P. S. Acute-on chronic liver failure. J. Hepatol. 57, 1336–1348 (2012).",{"doi":2251},"10.1016\u002Fj.jhep.2012.06.026",{"id":24,"text":2253,"url":24,"identifiers":2254},"Sen, S., Williams, R. & Jalan, R. The pathophysiological basis of acute-on-chronic liver failure. Liver 22 (Suppl. 2), 5–13 (2002).",{"doi":2255},"10.1034\u002Fj.1600-0676.2002.00001.x",{"id":24,"text":2257,"url":24,"identifiers":2258},"Jalan, R. et al. Toward an improved definition of acute-on-chronic liver failure. Gastroenterology 147, 4–10 (2014).",{"doi":2259},"10.1053\u002Fj.gastro.2014.05.005",{"id":24,"text":2261,"url":24,"identifiers":2262},"Shi, Y. et al. Acute-on-chronic liver failure precipitated by hepatic injury is distinct from that precipitated by extrahepatic insults. Hepatology 62, 232–242 (2015).",{"doi":2263},"10.1002\u002Fhep.27795",{"id":24,"text":2265,"url":24,"identifiers":2266},"Bajaj, J. S. et al. Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures. Hepatology 60, 250–256 (2014).",{"doi":2267},"10.1002\u002Fhep.27077",{"id":24,"text":2269,"url":24,"identifiers":2270},"Bernal, W. et al. Acute-on-chronic liver failure. Lancet 386, 1576–1587 (2015).",{"doi":2271},"10.1016\u002FS0140-6736(15)00309-8",{"id":24,"text":2273,"url":24,"identifiers":2274},"Arroyo, V. et al. Acute-on-chronic liver failure: a new syndrome that will re-classify cirrhosis. J. Hepatol. 62, S131–S143 (2015).",{"doi":2275},"10.1016\u002Fj.jhep.2014.11.045",{"id":24,"text":2277,"url":24,"identifiers":2278},"Gustot, T. et al. Clinical course of acute-on-chronic liver failure syndrome and effects on prognosis. Hepatology 62, 243–252 (2015).",{"doi":2279},"10.1002\u002Fhep.27849",{"id":24,"text":2281,"url":24,"identifiers":2282},"Agrawal, S., Duseja, A., Dhiman, R. K. & Chawla, Y. Simple organ failure count versus CANONIC grading system for predicting mortality in acute-on-chronic liver failure. J. Gastroenterol. Hepatol. 30, 575–581 (2015).",{"doi":2283},"10.1111\u002Fjgh.12778",{"id":24,"text":2285,"url":24,"identifiers":2286},"Garg, H., Kumar, A., Sharma, B. C. & Sarin, S. K. Clinical profile and predictors of mortality in patients of acute on chronic liver failure. Dig. Liver Dis. 44, 166–171 (2012).",{"doi":2287},"10.1016\u002Fj.dld.2011.08.029",{"id":24,"text":2289,"url":24,"identifiers":2290},"Silva, P. E. et al. Single-centre validation of the EASL-CLIF consortium definition of acute-on-chronic liver failure and CLIF-SOFA for prediction of mortality in cirrhosis. Liver Int. 35, 1516–1523 (2015).",{"doi":2291},"10.1111\u002Fliv.12597",{"id":24,"text":2289,"url":24,"identifiers":2293},{"doi":2291},{"id":24,"text":2295,"url":24,"identifiers":2296},"Dhiman, R. K., Agrawal, S., Gupta, T., Duseja, A. & Chawla, Y. Chronic liver failure-sequential organ failure assessment is better than the Asia-Pacific Association for the Study of Liver criteria for defining acute-on-chronic liver failure and predicting outcome. World J. Gastroenterol. 20, 14934–14941 (2014).",{"doi":2297},"10.3748\u002Fwjg.v20.i40.14934",{"id":24,"text":2299,"url":24,"identifiers":2300},"Zhang, Q. et al. Comparison of current diagnostic criteria for acute-on-chronic liver failure. PLoS ONE 10, e0122158 (2015).",{"doi":2301},"10.1371\u002Fjournal.pone.0122158",{"id":24,"text":2303,"url":24,"identifiers":2304},"Moreau, R., Jalan, R. & Arroyo, V. Acute-on-chronic liver failure: recent concepts. J. Clin. Exp. Hepatol. 5, 81–85 (2015).",{"doi":2305},"10.1016\u002Fj.jceh.2014.09.003",{"id":24,"text":2307,"url":24,"identifiers":2308},"Sheen, I. S., Liaw, Y. F., Tai, D. I. & Chu, C. M. Hepatic decompensation associated with hepatitis B e antigen clearance in chronic type B hepatitis. Gastroenterology 89, 732–735 (1985).",{"doi":2309},"10.1016\u002F0016-5085(85)90566-9",{"id":24,"text":2311,"url":24,"identifiers":2312},"Yuen, M. F. et al. Difference in T helper responses during hepatitis flares in hepatitis B e antigen (HBeAg)-positive patients with genotypes B and C: implication for early HBeAg seroconversion. J. Viral Hepat. 14, 269–275 (2007).",{"doi":2313},"10.1111\u002Fj.1365-2893.2006.00799.x",{"id":24,"text":2315,"url":24,"identifiers":2316},"Aoki, J., Kowazaki, Y., Okamoto, R. & Kimura, K. Kinetics of peripheral hepatitis B virus-specific CD8+ T cells in patients with onset of viral reactivation. J. Gastroenterol. 48, 728–737 (2013).",{"doi":2317},"10.1007\u002Fs00535-012-0676-y",{"id":24,"text":2319,"url":24,"identifiers":2320},"Zhang, Z., Zhang, J. Y., Wherry, E. J. & Wang, F. S. Dynamic programmed death 1 expression by virus-specific CD8 T cells correlates with the outcome of acutehepatitis B. Gastroenterology 134, 1938–1949.e3 (2008).",{"doi":2321},"10.1053\u002Fj.gastro.2008.03.037",{"id":24,"text":2323,"url":24,"identifiers":2324},"Acharya, S. K. et al. Hepatitis E virus (HEV) infection in patients with cirrhosis is associated with rapid decompensation and death. J. Hepatol. 46, 387–394 (2007).",{"doi":2325},"10.1016\u002Fj.jhep.2006.09.016",{"id":24,"text":2327,"url":24,"identifiers":2328},"Dhiman, R. K. et al. Clinical features and predictors of outcomein acute hepatitis A and hepatitis E virus hepatitis on cirrhosis. Liver Int. 29, 392–398 (2009).",{"doi":2329},"10.1111\u002Fj.1478-3231.2008.01887.x",{"id":24,"text":2331,"url":24,"identifiers":2332},"Kamar, N. et al. Hepatitis E. Lancet 379, 2477–2488 (2012).",{"doi":2333},"10.1016\u002FS0140-6736(11)61849-7",{"id":24,"text":2335,"url":24,"identifiers":2336},"Sayed, I. M. et al. Is HEV an emerging problem in industrialized countries? Hepatology http:\u002F\u002Fdx.doi.org\u002F10.1002\u002Fhep.27990 (2015).",{"doi":2337},"10.1002\u002Fhep.27990",{"id":24,"text":2339,"url":24,"identifiers":2340},"Blasco-Perrin, H. et al. Hepatitis E virus in patients with decompensated chronic liver disease: a prospective UK\u002FFrench study. Aliment. Pharmacol. Ther. 42, 574–581 (2015).",{"doi":2341},"10.1111\u002Fapt.13309",{"id":24,"text":2343,"url":24,"identifiers":2344},"Sehgal, R. et al. Impaired monocyte-macrophage functions and defective TLR signalling in hepatitis E virus infected pregnant women with acute liver failure. Hepatology http:\u002F\u002Fdx.doi.org\u002F10.1002\u002Fhep.28143 (2015).",{"doi":2345},"10.1002\u002Fhep.28143",{"id":24,"text":2347,"url":24,"identifiers":2348},"Saravanabalaji, S. et al. Viral load, antibody titers and recombinant open reading frame 2 protein-induced Th1\u002FTh2 cytokines and cellular immune responses in self-limiting and fulminant hepatitis E. Intervirology 52, 78–85 (2009).",{"doi":2349},"10.1159\u002F000214862",{"id":24,"text":2351,"url":24,"identifiers":2352},"Tripathy, A. S. et al. Peripheral T regulatory cells and cytokines in hepatitis E infection. Eur. J. Clin. Microbiol. Infect. Dis. 31, 179–184 (2012).",{"doi":2353},"10.1007\u002Fs10096-011-1291-1",{"id":24,"text":2355,"url":24,"identifiers":2356},"Kumar, M., Sharma, B. C. & Sarin, S. K. Hepatitis E virus as an etiology of acute exacerbation of previously unrecognized asymptomatic patients with hepatitis B virus-related chronic liver disease. J. Gastroenterol. Hepatol. 23, 883–887 (2008).",{"doi":2357},"10.1111\u002Fj.1440-1746.2007.05243.x",{"id":24,"text":2359,"url":24,"identifiers":2360},"Keeffe, E. B. Acute hepatitis A and B in patients with chronic liver disease: prevention through vaccination. Am. J. Med. 118, 21–27 (2005).",{"doi":2361},"10.1016\u002Fj.amjmed.2005.07.013",{"id":24,"text":2363,"url":24,"identifiers":2364},"Zhang, X., Ke, W., Xie, D. & Gao, Z. Comparison of effects of hepatitis E or A viral superinfection in patients with chronic hepatitis B. Hepatol. Int. 4, 615–620 (2010).",{"doi":2365},"10.1007\u002Fs12072-010-9204-4",{"id":24,"text":2367,"url":24,"identifiers":2368},"Kim, H. Y. et al. A polymorphism in TIM1 is associated with susceptibility to severe hepatitis A virus infection in humans. J. Clin. Invest. 121, 1111–1118 (2011).",{"doi":2369},"10.1172\u002FJCI44182",{"id":24,"text":2371,"url":24,"identifiers":2372},"Choi, Y. S. et al. Liver injury in acute hepatitis A is associated with decreased frequency of regulatory T cells caused by Fas-mediated apoptosis. Gut 64, 1303–1313 (2015).",{"doi":2373},"10.1136\u002Fgutjnl-2013-306213",{"id":24,"text":2375,"url":24,"identifiers":2376},"Rutherford, A. et al. Influence of high body mass index on outcome in acute liver failure. Clin. Gastroenterol. Hepatol. 4, 1544–1549 (2006).",{"doi":2377},"10.1016\u002Fj.cgh.2006.07.014",{"id":24,"text":2379,"url":24,"identifiers":2380},"Gao, B. & Bataller, R. Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology 141, 1572–1585 (2011).",{"doi":2381},"10.1053\u002Fj.gastro.2011.09.002",{"id":24,"text":2383,"url":24,"identifiers":2384},"Malhi, H. & Kaufman, R. J. Endoplasmic reticulum stress in liver disease. J. Hepatol. 54, 795–809 (2011).",{"doi":2385},"10.1016\u002Fj.jhep.2010.11.005",{"id":24,"text":2387,"url":24,"identifiers":2388},"Cederbaum, A. I. Alcohol metabolism. Clin. Liver Dis. 16, 667–685 (2012).",{"doi":2389},"10.1016\u002Fj.cld.2012.08.002",{"id":24,"text":2391,"url":24,"identifiers":2392},"Gustot, T. et al. Differential liver sensitization to toll-like receptor pathways in mice with alcoholic fatty liver. Hepatology 43, 989–1000 (2006).",{"doi":2393},"10.1002\u002Fhep.21138",{"id":24,"text":2395,"url":24,"identifiers":2396},"Tilg, H., Moschen, A. R. & Kaneider, N. C. Pathways of liver injury in alcoholic liver disease. J. Hepatol. 55, 1159–1161 (2011).",{"doi":2397},"10.1016\u002Fj.jhep.2011.05.015",{"id":24,"text":2399,"url":24,"identifiers":2400},"Louvet, A. & Mathurin, P. Alcoholic liver disease: mechanisms of injury and targeted treatment. Nat. Rev. Gastroenterol. Hepatol. 12, 231–242 (2015).",{"doi":2401},"10.1038\u002Fnrgastro.2015.35",{"id":24,"text":2403,"url":24,"identifiers":2404},"Sancho-Bru, P. et al. Liver progenitor cell markers correlate with liver damage and predict short-term mortality in patients with alcoholic hepatitis. Hepatology 55, 1931–1941 (2012).",{"doi":2405},"10.1002\u002Fhep.25614",{"id":24,"text":2407,"url":24,"identifiers":2408},"Dubuquoy, L., Louvet, A., Bataller, R. & Mathurin, P. Progenitor cell expansion and impaired hepatocyte regeneration in explanted livers from alcoholic hepatitis. Gut 64, 1949–1960 (2015).",{"doi":2409},"10.1136\u002Fgutjnl-2014-308410",{"id":24,"text":2411,"url":24,"identifiers":2412},"Devarbhavi, H., Dierkhising, R., Sandeep, M. S. & Adarsh, C. K. Single-center experience with drug-induced liver injury from India: causes, outcome, prognosis, and predictors of mortality. Am. J. Gastroenterol. 105, 2396–2404 (2010).",{"doi":2413},"10.1038\u002Fajg.2010.287",{"id":24,"text":2415,"url":24,"identifiers":2416},"Kedarisetty, C. K. et al. Liver failure determines the extra-hepatic organ failure and outcome in patients with acute-on-chronic liver failure: analysis of 1363 patients of AARC Data Base [abstract 733]. Hepatology 60 (Suppl. 1), 553A (2014).",{},{"id":24,"text":2418,"url":24,"identifiers":2419},"Chalasani, N. P. et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am. J. Gastroenterol. 109, 950–966 (2014).",{"doi":2420},"10.1038\u002Fajg.2014.131",{"id":24,"text":2422,"url":24,"identifiers":2423},"Reuben, A., Koch, D. G. & Lee, W. M. Drug-induced acute liver failure: results of a US multicenter, prospective study. Hepatology 52, 2065–2076 (2010).",{"doi":2424},"10.1002\u002Fhep.23937",{"id":24,"text":2426,"url":24,"identifiers":2427},"Sargenti, K., Prytz, H., Nilsson, E. & Kalaitzakis, E. Predictors of mortality among patients with compensated and decompensated liver cirrhosis: the role of bacterial infections and infection-related acute-on-chronic liver failure. Scand. J. Gastroenterol. 50, 875–883 (2015).",{"doi":2428},"10.3109\u002F00365521.2015.1017834",{"id":24,"text":2430,"url":24,"identifiers":2431},"Garg, H. et al. Hepatic and systemic hemodynamic derangements predict early mortality and recovery in patients with acute-on-chronic liver failure. J. Gastroenterol. Hepatol. 28, 1361–1367 (2013).",{"doi":2432},"10.1111\u002Fjgh.12191",{"id":24,"text":2434,"url":24,"identifiers":2435},"Bruns, T., Zimmermann, H. W. & Stallmach, A. Risk factors and outcome of bacterial infections in cirrhosis. World J. Gastroenterol. 20, 2542–2554 (2014).",{"doi":2436},"10.3748\u002Fwjg.v20.i10.2542",{"id":24,"text":2438,"url":24,"identifiers":2439},"Albillos, A., Lario, M. & Álvarez-Mon, M. Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance. J. Hepatol. 61, 1385–1396 (2014).",{"doi":2440},"10.1016\u002Fj.jhep.2014.08.010",{"id":24,"text":2442,"url":24,"identifiers":2443},"Berry, P. A. et al. Severity of the compensatory anti-inflammatory response determined by monocyte HLA-DR expression may assist outcome prediction in cirrhosis. Intensive Care Med. 37, 453–460 (2011).",{"doi":2444},"10.1007\u002Fs00134-010-2099-7",{"id":24,"text":2446,"url":24,"identifiers":2447},"Khanam, A., Trehanpati, N., Sharma, B. C. & Sarin, S. K. Altered frequencies of dendritic cells and IFN-gamma-secreting T cells with granulocyte colony-stimulating factor (G-CSF) therapy in acute-on- chronic liver failure. Liver Int. 34, 505–513 (2014).",{"doi":2448},"10.1111\u002Fliv.12415",{"id":24,"text":2450,"url":24,"identifiers":2451},"Mookerjee, R. P. et al. Neutrophil dysfunction in alcoholic hepatitis superimposed on cirrhosis is reversible and predicts outcome. Hepatology 46, 831–840 (2007).",{"doi":2452},"10.1002\u002Fhep.21737",{"id":24,"text":2454,"url":24,"identifiers":2455},"Nischalke, H. D. et al. Toll-like receptor (TLR) 2 promoter and intron 2 polymorphisms are associated with increased risk for spontaneous bacterial peritonitis in liver cirrhosis. J. Hepatol. 55, 1010–1016 (2011).",{"doi":2456},"10.1016\u002Fj.jhep.2011.02.022",{"id":24,"text":2458,"url":24,"identifiers":2459},"Jalan, R., Stadlbauer, V., Sen, S. & Mookerjee, R. Role of predisposition, injury, response and organ failure in the prognosis of patients with acute-on chronic liver failure: a prospective cohort study. Crit. Care 16, R227 (2012).",{"doi":2460},"10.1186\u002Fcc11882",{"id":24,"text":2462,"url":24,"identifiers":2463},"Choudhury, A. K., Vashishtha, C., Kedarisetty, C. K. & Sarin, S. K. Systemic inflammatory response syndrome (SIRS) — a potential clinical marker for early sepsis and survival in acute on chronic liver failure (ACLF) [abstract 580]. Hepatology 60 (Suppl. 1), A476A (2014).",{},{"id":24,"text":2465,"url":24,"identifiers":2466},"Jeon, S. H. et al. Incidence and risk factors of acute hepatic failure after transcatheter arterial chemoembolization for hepatocellular carcinoma. Korean J. Gastroenterol. 50, 176–182 (in Korean) (2007).",{},{"id":24,"text":2468,"url":24,"identifiers":2469},"Huang, Y. S., Chiang, J. H. & Lee, S. D. Risk of hepatic failure after transcatheter arterial chemoembolization for hepatocellular carcinoma: predictive value of the monoethylglycinexylidide test. Am. J. Gastroenterol. 97, 1223–1227 (2002).",{"doi":2470},"10.1111\u002Fj.1572-0241.2002.05709.x",{"id":24,"text":2472,"url":24,"identifiers":2473},"Min, Y. W., Kim, J., Paik, S. W., Yoo, B. C. & Lee, J. H. Risk factors and a predictive model for acute hepatic failure after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. Liver Int. 33, 197–202 (2013).",{"doi":2474},"10.1111\u002Fliv.12023",{"id":24,"text":2476,"url":24,"identifiers":2477},"Olson, J. C. & Kamath, P. S. Acute-on-chronic liver failure: concept, natural history, and prognosis. Curr. Opin. Crit. Care 17, 165–169 (2011).",{"doi":2478},"10.1097\u002FMCC.0b013e328344b42d",{"id":24,"text":2480,"url":24,"identifiers":2481},"Laleman, W. et al. Acute-on-chronic liver failure: current concepts on definition pathogenesis, clinical manifestations and potential therapeutic interventions. Expert Rev. Gastroenterol. Hepatol. 5, 523–537 (2011).",{"doi":2482},"10.1586\u002Fegh.11.47",{"id":24,"text":2484,"url":24,"identifiers":2485},"Rastogi, A. et al. Liver histology as predictor of outcome in patients with acute-on-chronic liver failure (ACLF). Virchows Arch. 459, 121–127 (2011).",{"doi":2486},"10.1007\u002Fs00428-011-1115-9",{"id":24,"text":2488,"url":24,"identifiers":2489},"Loomba, R. & Sanyal, A. The global NAFLD epidemic. Nat. Rev. Gastroenterol. Hepatol. 10, 686–690 (2013).",{"doi":2490},"10.1038\u002Fnrgastro.2013.171",{"id":24,"text":2492,"url":24,"identifiers":2493},"Medzhitov, R. Inflammation 2010: new adventures of an old flame. Cell 140, 771–776 (2010).",{"doi":2494},"10.1016\u002Fj.cell.2010.03.006",{"id":24,"text":2496,"url":24,"identifiers":2497},"Chovatiya, R. & Medzhitov, R. Stress, inflammation, and defense of homeostasis. Mol. Cell. 54, 281–288 (2014).",{"doi":2498},"10.1016\u002Fj.molcel.2014.03.030",{"id":24,"text":2500,"url":24,"identifiers":2501},"Bone, R. C. Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: what we do and do not know about cytokine regulation. Crit. Care Med. 24, 163–172 (1996).",{"doi":2502},"10.1097\u002F00003246-199601000-00026",{"id":24,"text":2504,"url":24,"identifiers":2505},"Malik, R., Mookerjee, R. & Jalan, R. Infection and inflammation in liver failure: two sides of the same coin. J. Hepatol. 51, 426–429 (2009).",{"doi":2506},"10.1016\u002Fj.jhep.2009.06.013",{"id":24,"text":2508,"url":24,"identifiers":2509},"Chen, Y., Guo, J., Shi, D. & Li, L. Gut dysbiosis in acute-on-chronic liver failure and its predictive value for mortality. J. Gastroenterol. Hepatol. 30, 1429–1437 (2015).",{"doi":2510},"10.1111\u002Fjgh.12932",{"id":24,"text":2512,"url":24,"identifiers":2513},"Cirera, I. et al. Bacterial translocation of enteric organisms in patients with cirrhosis. J. Hepatol. 34, 32–37 (2001).",{"doi":2514},"10.1016\u002FS0168-8278(00)00013-1",{"id":24,"text":2516,"url":24,"identifiers":2517},"Cariello, R. et al. Intestinal permeability in patients with chronic liver diseases: its relationship with the aetiology and the entity of liver damage. Dig. Liver Dis. 42, 200–204 (2010).",{"doi":2518},"10.1016\u002Fj.dld.2009.05.001",{"id":24,"text":2520,"url":24,"identifiers":2521},"Bellot, P. et al. Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis. Hepatology 52, 2044–2052 (2010).",{"doi":2522},"10.1002\u002Fhep.23918",{"id":24,"text":2524,"url":24,"identifiers":2525},"Wan, J. et al. M2 Kupffer cells promote M1 Kupffer cell apoptosis: a protective mechanism against alcoholic and nonalcoholic fatty liver disease. Hepatology 59, 130–142 (2014).",{"doi":2526},"10.1002\u002Fhep.26607",{"id":24,"text":2528,"url":24,"identifiers":2529},"Seki, E. & Brenner, D. A. Toll-like receptors and adaptor molecules in liver disease: update. Hepatology 48, 322–335 (2008).",{"doi":2530},"10.1002\u002Fhep.22306",{"id":24,"text":2532,"url":24,"identifiers":2533},"Desmots, F. et al. Pro-inflammatory cytokines tumor necrosis factor and interleukin-6 and survival factor epidermal growth factor positively regulate the murine GSTA4 enzyme in hepatocytes. J. Biol. Chem. 277, 17892–17900 (2002).",{"doi":2534},"10.1074\u002Fjbc.M112351200",{"id":24,"text":2536,"url":24,"identifiers":2537},"Spahr, L. et al. Soluble TNF R1, but not tumor necrosis factor alpha, predicts the 3 month mortality in patients with alcoholic hepatitis. J. Hepatol. 41, 229–234 (2004).",{"doi":2538},"10.1016\u002Fj.jhep.2004.04.028",{"id":24,"text":2540,"url":24,"identifiers":2541},"Wasmuth, H. E. et al. Patients with acute on chronic liver failure display 'sepsis-like' immune paralysis. J. Hepatol. 42, 195–201 (2005).",{"doi":2542},"10.1016\u002Fj.jhep.2004.10.019",{"id":24,"text":2544,"url":24,"identifiers":2545},"Rockey, D. C. et al. Cellular localization of endothelin-1 and increased production in liver injury in the rat: potential for autocrine and paracrine effects on stellate cells. Hepatology 27, 472–480 (1998).",{"doi":2546},"10.1002\u002Fhep.510270222",{"id":24,"text":2548,"url":24,"identifiers":2549},"Yan, A. W. et al. Enteric dysbiosis associated with a mouse model of alcoholic liver disease. Hepatology 53, 96–105 (2011).",{"doi":2550},"10.1002\u002Fhep.24018",{"id":24,"text":2552,"url":24,"identifiers":2553},"Keshavarzian, A. et al. Leaky gut in alcoholic cirrhosis: a possible mechanism for alcohol-induced liver damage. Am. J. Gastroenterol. 94, 200–207 (1999).",{"doi":2554},"10.1111\u002Fj.1572-0241.1999.00797.x",{"id":24,"text":2556,"url":24,"identifiers":2557},"Khanam, A. et al. Impaired neutrophil function aggravates liver injury and correlates with clinical severity indices in acute on-chronic liver failure [abstract 733]. Hepatology 60 (Suppl. 1), 553A (2014).",{},{"id":24,"text":2559,"url":24,"identifiers":2560},"Xing, T., Li, L., Cao, H. & Huang, J. Altered immune function of monocytes in different stages of patients with acute on chronic liver failure. Clin. Exp. Immunol. 147, 184–188 (2007).",{"doi":2561},"10.1111\u002Fj.1365-2249.2006.03259.x",{"id":24,"text":2563,"url":24,"identifiers":2564},"Zhang, Z. et al. Severe dendritic cell perturbation is actively involved in the pathogenesis of acute-on-chronic hepatitis B liver failure. J. Hepatol. 49, 396–406 (2008).",{"doi":2565},"10.1016\u002Fj.jhep.2008.05.017",{"id":24,"text":2567,"url":24,"identifiers":2568},"Zhao, J. et al. Improved survival ratios correlate with myeloid dendritic cell restoration in acute-on-chronic liver failure patients receiving methylprednisolone therapy. Cell. Mol. Immunol. 9, 417–422 (2012).",{"doi":2569},"10.1038\u002Fcmi.2011.51",{"id":24,"text":2571,"url":24,"identifiers":2572},"Bernsmeier, C. et al. Patients with acute-on-chronic liver failure have increased numbers of regulatory immune cells expressing the receptor tyrosine kinase MERTK. Gastroenterology 148, 603–615.e14 (2015).",{"doi":2573},"10.1053\u002Fj.gastro.2014.11.045",{"id":24,"text":2575,"url":24,"identifiers":2576},"Guignant, C. et al. Increased MerTK expression in circulating innate immune cells of patients with septic shock. Intensive Care Med. 39, 1556–1564 (2013).",{"doi":2577},"10.1007\u002Fs00134-013-3006-9",{"id":24,"text":2579,"url":24,"identifiers":2580},"Zhai, S. et al. The ratio of Th-17 to Treg cells is associated with survival of patients with acute-on-chronic hepatitis B liver failure. Viral Immunol. 24, 303–310 (2011).",{"doi":2581},"10.1089\u002Fvim.2010.0135",{"id":24,"text":2583,"url":24,"identifiers":2584},"Kumar, A., Das, K., Sharma, B. C. & Sarin, S. K. Hemodynamic studies in acute-on-chronic liver failure. Dig. Dis. Sci. 54, 869–878 (2009).",{"doi":2585},"10.1007\u002Fs10620-008-0421-9",{"id":24,"text":2587,"url":24,"identifiers":2588},"Kalambokis, G., Manousou, P., Patch, D. & Burroughs, A. K. Transjugular liver biopsy — indications, adequacy, quality of specimens, and complications — a systematic review. J. Hepatol. 47, 284–294 (2007).",{"doi":2589},"10.1016\u002Fj.jhep.2007.05.001",{"id":24,"text":2591,"url":24,"identifiers":2592},"Katoonizadeh, A. et al. Early features of acute-on-chronic alcoholic liver failure: a prospective cohort study. Gut 59, 1561–1569 (2010).",{"doi":2593},"10.1136\u002Fgut.2009.189639",{"id":24,"text":2595,"url":24,"identifiers":2596},"Li, H. et al. Submassive hepatic necrosis distinguishes HBV-associated acute on chronic liver failure from cirrhotic patients with acute decompensation. J. Hepatol. 63, 50–59 (2015).",{"doi":2597},"10.1016\u002Fj.jhep.2015.01.029",{"id":24,"text":2599,"url":24,"identifiers":2600},"Altamirano, J. et al. A histologic scoring system for prognosis of patients with alcoholic hepatitis. Gastroenterology 146, 1231–1239.e6 (2014).",{"doi":2601},"10.1053\u002Fj.gastro.2014.01.018",{"id":24,"text":2603,"url":24,"identifiers":2604},"Mookerjee, R. P. et al. The role of liver biopsy in the diagnosis and prognosis of patients with acute deterioration of alcoholic cirrhosis. J. Hepatol. 55, 1103–1111 (2011).",{"doi":2605},"10.1016\u002Fj.jhep.2011.02.021",{"id":24,"text":2607,"url":24,"identifiers":2608},"Louvet, A. et al. Infection in patients with severe alcoholic hepatitis treated with steroids: early response to therapy is the key factor. Gastroenterology 137, 541–548 (2009).",{"doi":2609},"10.1053\u002Fj.gastro.2009.04.062",{"id":24,"text":2611,"url":24,"identifiers":2612},"Jalan, R. & Mookerjee, R. P. Acute-on-chronic liver failure: an early biopsy is essential? Gut 59, 1455–1456 (2010).",{"doi":2613},"10.1136\u002Fgut.2010.214627",{"id":24,"text":2615,"url":24,"identifiers":2616},"Shasthry, S. et al. Baseline liver biopsy can predict response to steroids in patients with severe alcoholic hepatitis. J. Hepatol. 60, S67–S214 (2014).",{"doi":2617},"10.1016\u002FS0168-8278(14)60491-8",{"id":24,"text":2619,"url":24,"identifiers":2620},"Krenitsky, J. Nutrition for patients with hepatic failure. Pract. Gastroenterol. 6, 23–42 (2003).",{},{"id":24,"text":2622,"url":24,"identifiers":2623},"Canbay, A. et al. Overweight patients are more susceptible for acute liver failure. Hepatogastroenterology 52, 1516–1520 (2005).",{},{"id":24,"text":2625,"url":24,"identifiers":2626},"Tsien, C. D., McCullough, A. J. & Dasarathy, S. Late-evening snack: exploiting a period of anabolic opportunity in cirrhosis. J. Gastroenterol. Hepatol. 27, 430–441 (2012).",{"doi":2627},"10.1111\u002Fj.1440-1746.2011.06951.x",{"id":24,"text":2629,"url":24,"identifiers":2630},"Hou, W., Li, J., Wang, J. H. & Meng, Q. H. Carbohydrate-predominant LES is associated with increases in fasting carbohydrate oxidation, REE and reductions in fat oxidation in adults with ACLF. Therapeutic strategies utilizing LES may promote improved nutritional status in adults with ACLF. Eur. J. Clin. Nutr. 67, 1251–1256 (2013).",{"doi":2631},"10.1038\u002Fejcn.2013.163",{"id":24,"text":2633,"url":24,"identifiers":2634},"Morgan, T. et al. Protein consumption and hepatic encephalopathy in alcoholic hepatitis. J. Am. Coll. Nutr. 14, 152–158 (1995).",{"doi":2635},"10.1080\u002F07315724.1995.10718487",{"id":24,"text":2637,"url":24,"identifiers":2638},"Choudhury, A. K., Vasistha, C., Kumar, S. & Sarin, S. K. A prospective open label randomized noninferiority trial to compare the efficacy and safety of monotherapy with noradrenaline and terlipressin in patients of cirrhosis with septic shock admitted to the intensive care unit [abstract 131]. Hepatology 60 (Suppl. 1), A252A (2014).",{},{"id":24,"text":2640,"url":24,"identifiers":2641},"O'Brien, A. J. et al. Immunosuppression in acutely decompensated cirrhosis is mediated by prostaglandin E2 . Nat. Med. 20, 518–523 (2014).",{"doi":2642},"10.1038\u002Fnm.3516",{"id":24,"text":2644,"url":24,"identifiers":2645},"Bernardi, M., Ricci, C. S. & Zaccherini, G. Role of human albumin in the management of complications of liver cirrhosis. J. Clin. Exp. Hepatol. 4, 302–311 (2014).",{"doi":2646},"10.1016\u002Fj.jceh.2014.08.007",{"id":24,"text":2648,"url":24,"identifiers":2649},"Maiwall, R. et al. Utility of a modified PIRO (predisposition, injury, response, organ failure) model for predicting kidney failure in patients with ACLF — a multinational cohort study [abstract 578]. Hepatology 60 (Suppl. 1), 476A (2014).",{},{"id":24,"text":2651,"url":24,"identifiers":2652},"Nayak, S. et al. Bile pigment nephropathy and acute tubular necrosis in decompensated cirrhotics and acute on chronic liver failure [abstract 248]. Hepatology 60 (Suppl. 1), 325A (2014).",{},{"id":24,"text":2654,"url":24,"identifiers":2655},"Jindal, A., Bhadoria, A. S., Maiwall, R. & Sarin, S. K. Evaluation of acute kidney injury and its response to terlipressin in patients with acute-on-chronic liver failure. Liver Int. http:\u002F\u002Fdx.doi.org\u002F10.1111\u002Fliv.12895 (2015).",{"doi":2656},"10.1111\u002Fliv.12895",{"id":24,"text":2658,"url":24,"identifiers":2659},"Slack, A. J. et al. Ammonia clearance with haemofiltration in adults with liver disease. Liver Int. 34, 42–48 (2014).",{"doi":2660},"10.1111\u002Fliv.12221",{"id":24,"text":2662,"url":24,"identifiers":2663},"Gonwa, T. A. & Wadei, H. M. The challenges of providing renal replacement therapy in decompensated liver cirrhosis. Blood Purif. 33, 144–148 (2012).",{"doi":2664},"10.1159\u002F000334149",{"id":24,"text":2666,"url":24,"identifiers":2667},"Davenport, A. Continuous renal replacement therapies in patients with liver disease. Semin. Dial. 22, 169–172 (2009).",{"doi":2668},"10.1111\u002Fj.1525-139X.2008.00539.x",{"id":24,"text":2670,"url":24,"identifiers":2671},"Sun, L. J. et al. Influential factors of prognosis in lamivudine treatment for patients with acute-onchronic hepatitis B liver failure. J. Gastroenterol. Hepatol 25, 583–590 (2010).",{"doi":2672},"10.1111\u002Fj.1440-1746.2009.06089.x",{"id":24,"text":2674,"url":24,"identifiers":2675},"Garg, H., Sarin, S. K., Sharma, B. C. & Kumar, A. Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure. Hepatology 53, 774–780 (2011).",{"doi":2676},"10.1002\u002Fhep.24109",{"id":24,"text":2678,"url":24,"identifiers":2679},"Jindal, A., Kumar, M. & Sarin, S. K. A randomized comparative open label trial of tenofovir monotherapy versus tenofovir plus telbuvidine dual therapy in spontaneous reactivation of hepatitis B. J. Viral Hepat. 22 (Suppl. 2), 1–18 (2015).",{},{"id":24,"text":2681,"url":24,"identifiers":2682},"Addolorato, G., Leggio, L., Haber, P. S. & Gasbarrini, G. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet 370, 1915–1922 (2007).",{"doi":2683},"10.1016\u002FS0140-6736(07)61814-5",{"id":24,"text":2685,"url":24,"identifiers":2686},"Cabré, E., Rodríguez-Iglesias, P., Caballería, J., R. & Gassull, M. A. Short- and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition: a multicenter randomized trial. Hepatology 32, 36–42 (2000).",{"doi":2687},"10.1053\u002Fjhep.2000.8627",{"id":24,"text":2689,"url":24,"identifiers":2690},"Yeoman, A. D., O'Grady, J. G. & Heneghan, M. A. Prognosis of acute severe autoimmune hepatitis (AS-AIH): the role of corticosteroids in modifying outcome. J. Hepatol. 61, 876–882 (2014).",{"doi":2691},"10.1016\u002Fj.jhep.2014.05.021",{"id":24,"text":2693,"url":24,"identifiers":2694},"Karkhanis, J. et al. Steroid use in acute liver failure. Hepatology 59, 612–621 (2014).",{"doi":2695},"10.1002\u002Fhep.26678",{"id":24,"text":2697,"url":24,"identifiers":2698},"Mendizabal, M. et al. Fulminant presentation of autoimmune hepatitis: clinical features and early predictors of corticosteroid treatment failure. Eur. J. Gastroenterol. Hepatol. 27, 644–648 (2015).",{"doi":2699},"10.1097\u002FMEG.0000000000000353",{"id":24,"text":2701,"url":24,"identifiers":2702},"Yeoman, A. D. et al. Early predictors corticosteroid treatment fail in icteric presentations of autoimmune hepatitis. Hepatology 53, 926–934 (2011).",{"doi":2703},"10.1002\u002Fhep.24141",{"id":24,"text":2705,"url":24,"identifiers":2706},"Larsen, F. S., Vainer, B., Bjerring, P. N. & Hansen, B. A. Low-dose tacrolimus ameliorates liver inflammation and fibrosis in steroid refractory autoimmune hepatitis. World J. Gastroenterol. 13, 3232–3236 (2007).",{"doi":2707},"10.3748\u002Fwjg.v13.i23.3232",{"id":24,"text":2709,"url":24,"identifiers":2710},"Hennes, E. M. et al. Mycophenolate mofetil as second line therapy in autoimmune hepatitis? Am. J. Gastroenterol. 103, 3063–3070 (2008).",{"doi":2711},"10.1111\u002Fj.1572-0241.2008.02180.x",{"id":24,"text":2713,"url":24,"identifiers":2714},"Mathurin, P. et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut 60, 255–260 (2011).",{"doi":2715},"10.1136\u002Fgut.2010.224097",{"id":24,"text":2717,"url":24,"identifiers":2718},"Lucey, M. R., Mathurin, P. & Morgan, T. R. Alcoholic hepatitis. N. Engl. J. Med. 360, 2758–2769 (2009).",{"doi":2719},"10.1056\u002FNEJMra0805786",{"id":24,"text":2721,"url":24,"identifiers":2722},"di Mambro, A. J. et al. In vitro steroid resistance correlates with outcome in severe alcoholic hepatitis. Hepatology 53, 1316–1322 (2011).",{"doi":2723},"10.1002\u002Fhep.24159",{"id":24,"text":2725,"url":24,"identifiers":2726},"Akriviadis, E., Botla, R., Reynolds, T. & Shakil, O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 119, 1637–1648 (2000).",{"doi":2727},"10.1053\u002Fgast.2000.20189",{"id":24,"text":2729,"url":24,"identifiers":2730},"Sidhu, S. S. et al. Corticosteroid plus pentoxifylline is not better than corticosteroid alone for improving survival in severe alcoholic hepatitis (COPE trial). Dig. Dis. Sci. 57, 1664–1671 (2012).",{"doi":2731},"10.1007\u002Fs10620-012-2097-4",{"id":24,"text":2733,"url":24,"identifiers":2734},"De, B. K. et al. Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial. World J. Gastroenterol. 15, 1613–1619 (2009).",{"doi":2735},"10.3748\u002Fwjg.15.1613",{"id":24,"text":2737,"url":24,"identifiers":2738},"Lebrec, D. et al. Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis. Gastroenterology 138, 1755–1762 (2010).",{"doi":2739},"10.1053\u002Fj.gastro.2010.01.040",{"id":24,"text":2741,"url":24,"identifiers":2742},"Park, S. H. et al. Pentoxifylline versus corticosteroid to treat severe alcoholic hepatitis: a randomised, non-inferiority, open trial. J. Hepatol. 61, 792–798 (2014).",{"doi":2743},"10.1016\u002Fj.jhep.2014.05.014",{"id":24,"text":2745,"url":24,"identifiers":2746},"Thursz, M. R. et al. Prednisolone or pentoxifylline for alcoholic hepatitis. N. Engl. J. Med. 372, 1619–1628 (2015).",{"doi":2747},"10.1056\u002FNEJMoa1412278",{"id":24,"text":2749,"url":24,"identifiers":2750},"Tilg, H. et al. Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J. Hepatol. 38, 419–425 (2003).",{"doi":2751},"10.1016\u002FS0168-8278(02)00442-7",{"id":24,"text":2753,"url":24,"identifiers":2754},"US National Library of Medicine. ClinicalTrials.gov [online] , (2015).",{},{"id":24,"text":2756,"url":24,"identifiers":2757},"Hong, M., Kim, S. W., Baik, S. K. & Ham, Y. L. Probiotics (Lactobacillus rhamnosus R0011 and acidophilus R0052) reduce the expression of toll-like receptor 4 in mice with alcoholic liver disease. PLoS ONE 10, e0117451 (2015).",{"doi":2758},"10.1371\u002Fjournal.pone.0117451",{"id":24,"text":2760,"url":24,"identifiers":2761},"Enomoto, N. et al. Thalidomide prevents alcoholi liver injury in rats through suppression of Kupffer cell sensitization and TNF-α production. Gastroenterology 123, 291–300 (2002).",{"doi":2762},"10.1053\u002Fgast.2002.34161",{"id":24,"text":2764,"url":24,"identifiers":2765},"Nyberg, S. L. Bridging the gap: advances in artificial liver support. Liver Transpl. 18, S10–S14 (2012).",{"doi":2766},"10.1002\u002Flt.23506",{"id":24,"text":2768,"url":24,"identifiers":2769},"Maiwall, R., Maras, J. S., Nayak, S. L. & Sarin, S. K. Liver dialysis in acute-on-chronic liver failure: current and future perspectives. Hepatol. Int. 8, S505–S513 (2014).",{"doi":2770},"10.1007\u002Fs12072-014-9534-8",{"id":24,"text":2772,"url":24,"identifiers":2773},"Catalina, M. V. et al. Hepatic and systemic haemodynamic changes after MARS in patients with acute on chronic liver failure. Liver Int. 23 (Suppl. 3), 39–43 (2003).",{"doi":2774},"10.1034\u002Fj.1478-3231.23.s.3.10.x",{"id":24,"text":2776,"url":24,"identifiers":2777},"Nevens, F. & Laleman, W. Artificial liver support devices as treatment option for liver failure. Best Pract. Res. Clin. Gastroenterol. 26, 17–26 (2012).",{"doi":2778},"10.1016\u002Fj.bpg.2012.01.002",{"id":24,"text":2780,"url":24,"identifiers":2781},"Tritto, G., Davies, N. A. & Jalan, R. Liver replacement therapy. Semin. Respir. Crit. Care Med. 33, 70–79 (2012).",{"doi":2782},"10.1055\u002Fs-0032-1301736",{"id":24,"text":2784,"url":24,"identifiers":2785},"Banares, R. et al. Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial. Hepatology 57, 1153–1162 (2013).",{"doi":2786},"10.1002\u002Fhep.26185",{"id":24,"text":2788,"url":24,"identifiers":2789},"Kribben, A. et al. Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure. Gastroenterology 142, 782–789.e3 (2012).",{"doi":2790},"10.1053\u002Fj.gastro.2011.12.056",{"id":24,"text":2792,"url":24,"identifiers":2793},"Zheng, Z. et al. Artificial and bioartificial liver support systems for acute and acute-on-chronic hepatic failure: a meta-analysis and meta-regression. Exp. Ther. Med. 6, 929–936 (2013).",{"doi":2794},"10.3892\u002Fetm.2013.1241",{"id":24,"text":2796,"url":24,"identifiers":2797},"Ling, Q. et al. Downgrading MELD improves the outcomes after liver transplantation in patients with acute-on-chronic hepatitis B liver failure. PLoS ONE 7, e30322 (2012).",{"doi":2798},"10.1371\u002Fjournal.pone.0030322",{"id":24,"text":2800,"url":24,"identifiers":2801},"Finkenstedt, A., Nachbaur, K., Graziadei, W. & Vogel, W. Acute-on-chronic liver failure: excellent outcomes after liver transplantation but high mortality on the wait list. Liver Transpl. 19, 879–886 (2013).",{"doi":2802},"10.1002\u002Flt.23678",{"id":24,"text":2804,"url":24,"identifiers":2805},"Pamecha, V., Kumar, S. & Bharathy, K. G. Liver transplantation in acute on chronic liver failure: challenges and an algorithm for patient selection and management. Hepatol. Int. 9, 534–542 (2015).",{"doi":2806},"10.1007\u002Fs12072-015-9646-9",{"id":24,"text":2808,"url":24,"identifiers":2809},"Xing, T. et al. Experience of combined liver-kidney transplantation for acute-on-chronic liver failure patients with renal dysfunction. Transplant. Proc. 45, 2307–2313 (2013).",{"doi":2810},"10.1016\u002Fj.transproceed.2013.02.127",{"id":24,"text":2812,"url":24,"identifiers":2813},"Kumar, R. et al. Change in model for end-stage liver disease score at two weeks, as an indicator of mortality or liver transplantation at 60 days in acute-on-chronic liver failure. Gastroenterol. Rep. 3, 122–127 (2015).",{"doi":2814},"10.1093\u002Fgastro\u002Fgou075",{"id":24,"text":2816,"url":24,"identifiers":2817},"Duan, B. W. et al. Liver transplantation in acute-on-chronic liver failure patients with high model for end-stage liver disease (MELD) scores: a single center experience of 100 consecutive cases. J. Surg. Res. 183, 936–943 (2013).",{"doi":2818},"10.1016\u002Fj.jss.2013.03.008",{"id":24,"text":2820,"url":24,"identifiers":2821},"Chan, A. C. et al. Liver transplantation for acute-on-chronic liver failure. Hepatol. Int. 3, 571–581 (2009).",{"doi":2822},"10.1007\u002Fs12072-009-9148-8",{"id":24,"text":2824,"url":24,"identifiers":2825},"Mathurin, P., Moreno, C., Pruvot, F. R. & Vallée, J. C. Early liver transplantation for severe alcoholic hepatitis. N. Engl. J. Med. 365, 1790–1800 (2011).",{"doi":2826},"10.1056\u002FNEJMoa1105703",{"id":24,"text":2828,"url":24,"identifiers":2829},"Stroh, G., Rosell, T., Dong, F. & Forster, J. Early liver transplantation for patients with acute alcoholic hepatitis: public views and the effects on organ donation. Am. J. Transplant. 15, 1598–1604 (2015).",{"doi":2830},"10.1111\u002Fajt.13176",{"id":24,"text":2832,"url":24,"identifiers":2833},"Fausto, N. Liver regeneration and repair: hepatocytes, progenitor cells, and stem cells. Hepatology 39, 1477–1487 (2004).",{"doi":2834},"10.1002\u002Fhep.20214",{"id":24,"text":2836,"url":24,"identifiers":2837},"Shubham, S., Maras, J. S., Kumar, A. & Sarin, S. K. Altered hepatic microenvironment governs the nature of hepatic regenerative response to acute hepatic insult [abstract 297]. Hepatology 58 (Suppl. 1), 92A (2013).",{},{"id":24,"text":2839,"url":24,"identifiers":2840},"Kumar, D., Rooge, S., Kumar, A. & Sarin, S. K. Alternatively activated M2 macrophages promotes hepatocyte differentiation in hepatic progenitor cell mediated liver regeneration in acute on chronic liver failure patients [abstract 423]. Hepatology 60 (Suppl. 1), 102A (2014).",{},{"id":24,"text":2842,"url":24,"identifiers":2843},"Karaca, G. et al. TWEAK\u002FFn14 signaling is required for liver regeneration after partial hepatectomy in mice. PLoS ONE 9, e83987 (2014).",{"doi":2844},"10.1371\u002Fjournal.pone.0083987",{"id":24,"text":2846,"url":24,"identifiers":2847},"Boulter, L. et al. Macrophage-derived Wnt opposes Notch signaling to specify hepatic progenitor cell fate in chronic liver disease. Nat. Med. 18, 572–579 (2012).",{"doi":2848},"10.1038\u002Fnm.2667",{"id":24,"text":2850,"url":24,"identifiers":2851},"Burgada, J. et al. Hybrid periportal hepatocytes regenerate the injured liver without giving rise to cancer. Cell 162, 766–779 (2015).",{"doi":2852},"10.1016\u002Fj.cell.2015.07.026",{"id":24,"text":2854,"url":24,"identifiers":2855},"Lu, W. Y. et al. Hepatic progenitor cells of biliary origin with liver repopulation capacity. Nat. Cell Biol. 17, 971–983 (2015).",{"doi":2856},"10.1038\u002Fncb3203",{"id":24,"text":2858,"url":24,"identifiers":2859},"Rastogi, A., Bihari, C., Kumar, A. & Sarin, S. K. Hepatic stellate cells are involved in the pathogenesis of acute-on-chronic liver failure (ACLF). Virchows Arch. 461, 393–398 (2012).",{"doi":2860},"10.1007\u002Fs00428-012-1291-2",{"id":24,"text":2862,"url":24,"identifiers":2863},"Kordes, C. et al. Hepatic stellate cells contribute to progenitor cells and liver regeneration. J. Clin. Invest. 124, 5503–5515 (2014).",{"doi":2864},"10.1172\u002FJCI74119",{"id":24,"text":2866,"url":24,"identifiers":2867},"Maiwal, R., Kumar, A. & Sarin, S. K. Liver regeneration during acute-on-chronic liver failure using growth factors: in vivo or ex vivo indulgence of bone marrow? Gastroenterology 145, 901–904 (2013).",{"doi":2868},"10.1053\u002Fj.gastro.2013.08.031",{"id":24,"text":2870,"url":24,"identifiers":2871},"Gilchrist, E. S. & Plevris, J. N. Bone marrow-derived stem cells in liver repair: 10 years down the line. Liver Transpl. 16, 118–129 (2010).",{"doi":2872},"10.1002\u002Flt.21965",{"id":24,"text":2874,"url":24,"identifiers":2875},"Uda, Y., Hirano, T. & Fujimoto, J. Angiogenesis is crucial for liver regeneration after partial hepatectomy. Surgery 153, 70–77 (2013).",{"doi":2876},"10.1016\u002Fj.surg.2012.06.021",{"id":24,"text":2878,"url":24,"identifiers":2879},"Kaur, S., Tripathi, D., Sakhuja, P. & Sarin, S. K. Increased number and function of endothelial progenitor cells stimulate angiogenesis by resident liver sinusoidal endothelial cells (SECs) in cirrhosis through paracrine factors. J. Hepatol. 57, 1193–1198 (2012).",{"doi":2880},"10.1016\u002Fj.jhep.2012.07.016",{"id":24,"text":2882,"url":24,"identifiers":2883},"Wiemann, S. U. et al. Hepatocyte telomere shortening and senescence are general markers of human liver cirrhosis. FASEB J. 16, 935–942 (2002).",{"doi":2884},"10.1096\u002Ffj.01-0977com",{"id":24,"text":2886,"url":24,"identifiers":2887},"Di Campli, C. et al. Safety and efficacy profile of G-CSF therapy in patients with acute on chronic liver failure. Dig. Liver Dis. 39, 1071–1076 (2007).",{"doi":2888},"10.1016\u002Fj.dld.2007.08.006",{"id":24,"text":2890,"url":24,"identifiers":2891},"Garg, V. et al. Granulocyte-colony stimulating factor mobilizes CD34+ cells and improves survival of patients with acute on chronic liver failure. Gastroenterology 142, 505–512 (2012).",{"doi":2892},"10.1053\u002Fj.gastro.2011.11.027",{"id":24,"text":2894,"url":24,"identifiers":2895},"Kedarisetty, C. K., Anand, L., Bhatia, V. & Sarin, S. K. Combination of granulocyte colony-stimulating factor and erythropoietin improves outcomes of patients with decompensated cirrhosis. Gastroenterology 148, 1362–1370.e7 (2015).",{"doi":2896},"10.1053\u002Fj.gastro.2015.02.054",{"id":24,"text":2898,"url":24,"identifiers":2899},"Meng, F., Francis, H., Glaser, S. & Alpini, G. Role of stem cell factor and granulocyte colony-stimulating factor in remodeling during liver regeneration. Hepatology 55, 209–221 (2012).",{"doi":2900},"10.1002\u002Fhep.24673",{"id":24,"text":2902,"url":24,"identifiers":2903},"Petit, I., Szyper-Kravitz, M., Zipori, D. & Lapidot, T. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat. Immunol. 3, 687–694 (2002).",{"doi":2904},"10.1038\u002Fni813",{"id":24,"text":2906,"url":24,"identifiers":2907},"Roilides, E. et al. Granulocyte colony-stimulating factor enhances the phagocytic and bactericidal activity of normal and defective human neutrophils. J. Infect. Dis. 163, 579–583 (1991).",{"doi":2908},"10.1093\u002Finfdis\u002F163.3.579",{"id":24,"text":2910,"url":24,"identifiers":2911},"Urao, N. et al. Erythropoietin-mobilized endothelial progenitors enhance reendothelialization via Akt-endothelial nitric oxide synthase activation and prevent neointimal hyperplasia. Circ. Res. 98, 1405–1413 (2006).",{"doi":2912},"10.1161\u002F01.RES.0000224117.59417.f3",{"id":24,"text":2914,"url":24,"identifiers":2915},"Egrie, J. C. & Browne, J. K. Development and characterization of erythropoiesis stimulating protein (NESP). Br. J. Cancer 84, 3–10 (2001).",{"doi":2916},"10.1054\u002Fbjoc.2001.1746",{"id":24,"text":2918,"url":24,"identifiers":2919},"Pusic, I. & Di Persio, J. F. Update on clinical experience with amd3100, an sdf-1\u002Fcxcl12–cxcr4 inhibitor, in mobilization of hematopoietic stem and progenitor cells. Curr. Opin. Hematol. 17, 319–326 (2010).",{"doi":2920},"10.1097\u002FMOH.0b013e328338b7d5",{"id":24,"text":2922,"url":24,"identifiers":2923},"Cui, Y. L. et al. Recombinant human hepatocyte growth factor for liver failure. Contemp. Clin. Trials 29, 696–704 (2008).",{"doi":2924},"10.1016\u002Fj.cct.2008.04.006",{"id":24,"text":2926,"url":24,"identifiers":2927},"Kallis, Y. N., Alison, M. R. & Forbes, J. S. Bone marrow stem cells and liver disease. Gut 56, 716–724 (2007).",{"doi":2928},"10.1136\u002Fgut.2006.098442",{"id":24,"text":2930,"url":24,"identifiers":2931},"Duan, X. Z. et al. Granulocyte-colony stimulating factor therapy improves survival in patients with hepatitis B virus-associated acute on- chronic liver failure. World J. Gastroenterol. 19, 1104–1110 (2013).",{"doi":2932},"10.3748\u002Fwjg.v19.i7.1104",{"id":24,"text":2934,"url":24,"identifiers":2935},"Singh, V. et al. Granulocyte colony-stimulating factor in severe alcoholic hepatitis: a randomized pilot study. Am. J. Gastroenterol. 109, 1417–1423 (2014).",{"doi":2936},"10.1038\u002Fajg.2014.154",{"id":24,"text":2938,"url":24,"identifiers":2939},"Meier, R. P., Müller, Y. D., Morel, P. & Bühler, L. H. Transplantation of mesenchymal stem cells for the treatment of liver diseases, is there enough evidence? Stem Cell Res. 11, 1348–1364 (2013).",{"doi":2940},"10.1016\u002Fj.scr.2013.08.011",{"id":24,"text":2942,"url":24,"identifiers":2943},"Ma, X. R., Tang, Y. L., Xuan, M. & Liang, X. H. Transplantation of autologous mesenchymal stem cells for end-stage liver cirrhosis: a meta-analysis based on seven controlled trials. Gastroenterol. Res. Pract. 2015, 908275 (2015).",{},{"id":24,"text":2945,"url":24,"identifiers":2946},"Shi, M., Zhang, Z., Jin, L., Liu, Z. & Wang, F. S. Human mesenchymal stem cell transfusion is safe and improves liver function in acute-on-chronic liver failure patients. Stem Cells Transl. Med. 1, 725–731 (2012).",{"doi":2947},"10.5966\u002Fsctm.2012-0034",{"id":24,"text":2949,"url":24,"identifiers":2950},"Hwang, J. P. & Lok, A. S. Management of patients with hepatitis B who require immunosuppressive therapy. Nat. Rev. Gastroenterol. Hepatol. 11, 209–219 (2014).",{"doi":2951},"10.1038\u002Fnrgastro.2013.216",{"id":24,"text":2953,"url":24,"identifiers":2954},"Roche, B. & Samuel, D. The difficulties of managing severe hepatitis B virus reactivation. Liver Int. 31 (Suppl. 1), 104–110 (2011).",{"doi":2955},"10.1111\u002Fj.1478-3231.2010.02396.x",{"id":24,"text":2957,"url":24,"identifiers":2958},"Fukui, H. Gut–liver axis in liver cirrhosis: how to manage leaky gut & endotoxemia. World J. Hepatol. 7, 425–442 (2015).",{"doi":2959},"10.4254\u002Fwjh.v7.i3.425",{"id":24,"text":2961,"url":24,"identifiers":2962},"Verma, S. & Kaplowitz, N. Diagnosis, management and prevention of drug-induced liver injury. Gut 58, 1555–1564 (2009).",{"doi":2963},"10.1136\u002Fgut.2008.163675",{"id":24,"text":2965,"url":24,"identifiers":2966},"Ash, S. R. Hemodiabsorption in treatment of acute hepatic failure and chronic cirrhosis with ascites. Artif. Organs 18, 355–362 (1994).",{"doi":2967},"10.1111\u002Fj.1525-1594.1994.tb02216.x",{"id":24,"text":2969,"url":24,"identifiers":2970},"Sen, S. et al. Pathophysiological effects of albumin dialysis in acute-on-chronic liver failure: a randomized controlled study. Liver Transpl. 10, 1109–1119 (2004).",{"doi":2971},"10.1002\u002Flt.20236",{"id":24,"text":2973,"url":24,"identifiers":2974},"Laleman, W. et al. Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure. Crit. Care 10, R108 (2006).",{"doi":2975},"10.1186\u002Fcc4985",{"id":24,"text":2977,"url":24,"identifiers":2978},"Lin, K.-H. et al. Impacts of pretransplant infections on clinical outcomes of patients with acute-on-chronic liver failure who received living-donor liver transplantation. PLoS ONE 8, e72893 (2013).",{"doi":2979},"10.1371\u002Fjournal.pone.0072893",{"id":24,"text":2981,"url":24,"identifiers":2982},"Liu, C. L. et al. Live-donor liver transplantation for acute-on-chronic hepatitis B liver failure. Transplantation 76, 1174–1179 (2003).",{"doi":2983},"10.1097\u002F01.TP.0000087341.88471.E5",{"id":24,"text":2985,"url":24,"identifiers":2986},"Bahirwani, R., Shaked, O., Bewtra, M. & Reddy, R. K. Acute-on-chronic liver failure before liver transplantation: impact on posttransplant outcomes. Transplantation 92, 952–957 (2011).",{"doi":2987},"10.1097\u002FTP.0b013e31822e6eda",{"id":24,"text":2989,"url":24,"identifiers":2990},"Wang, Z. X. et al. Impact of pretransplant MELD score on posttransplant outcome in orthotopic liver transplantation for patients with acute-on-chronic hepatitis B liver failure. Transplant. Proc. 39, 1501–1504 (2007).",{"doi":2991},"10.1016\u002Fj.transproceed.2007.02.070",{"id":2993,"createTime":2994,"updateTime":2994,"relativeEntities":2995,"slug":2996,"properties":2997,"entityType":184,"verifyStatus":185,"verifyTime":3009,"verifyNote":186,"syncStatus":23,"languages":3010,"translateLanguages":24,"viewCount":25,"primaryUrl":3011,"fullTextUrl":24,"authors":3012,"publicationType":310,"publisherRelationship":3056,"citationCount":3093,"citationInfo":3094,"publishDate":3105,"publishYear":1522,"citationAnalyzeStatus":23,"lastCitationAnalyze":24,"indexDatabases":24,"openAccess":24,"references":3106,"isForceReanalyzing":595},"3ea7076e-2406-48f0-b32c-4aa038d93391","2024-10-15T22:53:33.350+00:00",[],"The-global-NAFLD-epidemic",{"mag":2998,"keywords":3000,"openalex":3001,"abstract":3003,"title":3004,"pm":3006,"doi":3008},{"VOID":2999},"2002349285",{},{"VOID":3002},"W2002349285",{},{"EN":3005},"The global NAFLD epidemic",{"VOID":3007},"24042449",{"VOID":2490},"2024-10-15T22:53:33.349+00:00",[188],"https:\u002F\u002Fwww.nature.com\u002Farticles\u002Fnrgastro.2013.171",[3013,3034],{"id":3014,"sortIndex":25,"researcher":24,"roles":3015,"affiliations":3016,"properties":3027},"78da9887-2249-4ea6-8ed2-d42a193cf4ea",[],[3017],{"id":3018,"sortIndex":25,"affiliation":3019,"properties":24},"1834093f-b1cb-469a-b233-97ac34fdcee1",{"id":3020,"createTime":3021,"updateTime":3021,"relativeEntities":3022,"slug":3023,"properties":3024,"entityType":53,"verifyStatus":23,"verifyTime":24,"verifyNote":24,"syncStatus":23,"languages":24,"translateLanguages":24,"viewCount":25},"e114d29b-b13a-4e7d-9d46-16a6bacf5eb0","2024-10-15T22:53:33.374+00:00",[],"Division-of-Gastroenterology-Department-of-Medicine-and-Division-of-Epidemiology-Department-of-Family-and-Preventive-Medicine-University-of-California-at-San-Diego-9500-Gilman-Drive-La-Jolla-CA-92093-0063-USA-",{"title":3025},{"EN":3026},"Division of Gastroenterology, Department of Medicine and Division of Epidemiology, Department of Family and Preventive Medicine, University of California at San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0063, USA,",{"openalex":3028,"orcid":3030,"title":3032},{"VOID":3029},"A5052059601",{"VOID":3031},"https:\u002F\u002Forcid.org\u002F0000-0002-4845-9991",{"EN":3033},"Rohit Loomba",{"id":3035,"sortIndex":215,"researcher":24,"roles":3036,"affiliations":3037,"properties":3049},"e50885b9-9ebc-4538-bb00-ec30d4c9fd9e",[],[3038],{"id":3039,"sortIndex":25,"affiliation":3040,"properties":24},"ca5cae83-6c25-4ae5-9d8a-1ff430600b2d",{"id":3041,"createTime":3042,"updateTime":3043,"relativeEntities":3044,"slug":3045,"properties":3046,"entityType":53,"verifyStatus":23,"verifyTime":24,"verifyNote":24,"syncStatus":23,"languages":24,"translateLanguages":24,"viewCount":25},"8f6f2184-96c2-4a03-94d6-9107f7da55e4","2024-01-26T18:04:36.535+00:00","2024-10-15T22:53:33.386+00:00",[],"Division-of-Gastroenterology-Hepatology-and-Nutrition-Virginia-Commonwealth-University-Richmond-USA",{"title":3047},{"VI":3048},"Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University, Richmond, USA",{"openalex":3050,"orcid":3052,"title":3054},{"VOID":3051},"A5070639714",{"VOID":3053},"https:\u002F\u002Forcid.org\u002F0000-0001-8682-5748",{"EN":3055},"Arun J. Sanyal",{"url":24,"publisher":3057,"properties":3087},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":3058,"slug":10,"properties":3059,"entityType":22,"verifyStatus":23,"verifyTime":24,"verifyNote":24,"syncStatus":23,"languages":24,"translateLanguages":24,"viewCount":25,"subjectFields":3065,"manageAffiliations":3066,"indexDatabases":3067,"url":106,"thumbnailPath":24,"statistic":3082,"gsStatistic":24,"type":24,"analyzePriority":24},[],{"country":3060,"issn":3061,"introduce":3062,"eissn":3063,"title":3064},{"VOID":13},{"VOID":15},{"EN":17},{"VOID":19},{"EN":21},[],[],[3068,3075],{"id":88,"indexDatabase":3069,"url":103,"indexYears":24,"academicFieldIds":3074,"indexDatabaseRanking":24},{"id":90,"createTime":91,"updateTime":92,"relativeEntities":3070,"label":3071,"description":3072,"key":99,"publicationTags":3073,"standard":24},[],{"EN":95,"VI":95},{"VI":97,"EN":98},[101,102],[105],{"id":68,"indexDatabase":3076,"url":81,"indexYears":82,"academicFieldIds":3081,"indexDatabaseRanking":86},{"id":70,"createTime":71,"updateTime":72,"relativeEntities":3077,"label":3078,"description":3079,"key":78,"publicationTags":3080,"standard":24},[],{"EN":75,"VI":75},{"EN":75,"VI":77},[80],[84,85],{"impactFactor":25,"impactFactorByYear":3083,"i10Index":121,"i10IndexLast5Year":122,"totalPublication":121,"totalPublicationByYear":3084,"totalCitation":129,"totalCitationByYear":3085,"totalCitationPerPublication":145,"totalCitationPerPublicationByYear":3086,"hindexLast5Year":161,"hindex":161},{"2012":109,"2013":110,"2014":111,"2015":112,"2016":113,"2017":114,"2018":115,"2019":116,"2020":117,"2021":118,"2022":119,"2023":120},{"2009":124,"2010":124,"2011":125,"2012":126,"2013":127,"2014":124,"2015":125,"2016":127,"2017":128,"2018":127,"2019":127,"2020":126,"2021":125,"2022":126},{"2009":131,"2010":132,"2011":133,"2012":134,"2013":135,"2014":136,"2015":137,"2016":138,"2017":139,"2018":140,"2019":141,"2020":142,"2021":143,"2022":144},{"2009":147,"2010":148,"2011":149,"2012":150,"2013":151,"2014":152,"2015":153,"2016":154,"2017":155,"2018":156,"2019":157,"2020":158,"2021":159,"2022":160},{"volume":3088,"pages":3089,"issue":3091},{"VOID":1507},{"VOID":3090},"686-690",{"VOID":3092},"11",1475,{"total":3093,"publishYear":24,"statisticByYear":3095},{"2014":3096,"2015":3097,"2016":3098,"2017":3099,"2018":3100,"2019":3101,"2020":3101,"2021":783,"2022":3102,"2023":3103,"2024":3104},47,88,120,155,176,168,156,132,79,"2013-11-01",[3107,3111,3115,3119,3123,3127,3131,3135,3139,3143,3146,3150,3154,3158,3162,3166,3170,3174,3178,3181,3185,3189,3193,3197,3201,3205,3209,3212,3215,3219,3223,3227,3231,3234,3237,3241,3245,3249,3253,3257,3261,3265,3269,3273,3277,3281,3285,3289,3293,3297,3301,3305],{"id":24,"text":3108,"url":24,"identifiers":3109},"Chalasani, N. et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55, 2005–2023 (2012).",{"doi":3110},"10.1002\u002Fhep.25762",{"id":24,"text":3112,"url":24,"identifiers":3113},"Adams, L. A. et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 129, 113–121 (2005).",{"doi":3114},"10.1053\u002Fj.gastro.2005.04.014",{"id":24,"text":3116,"url":24,"identifiers":3117},"Matteoni, C. A. et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116, 1413–1419 (1999).",{"doi":3118},"10.1016\u002FS0016-5085(99)70506-8",{"id":24,"text":3120,"url":24,"identifiers":3121},"Clark, J. M., Brancati, F. L. & Diehl, A. M. The prevalence and etiology of elevated aminotransferase levels in the United States. Am. J. Gastroenterol. 98, 960–967 (2003).",{"doi":3122},"10.1111\u002Fj.1572-0241.2003.07486.x",{"id":24,"text":3124,"url":24,"identifiers":3125},"Welsh, J. A., Karpen, S. & Vos, M. B. Increasing prevalence of nonalcoholic fatty liver disease among United States adolescents, 1988–1994 to 2007–2010. J. Pediatr. 162, 496–500 (2013).",{"doi":3126},"10.1016\u002Fj.jpeds.2012.08.043",{"id":24,"text":3128,"url":24,"identifiers":3129},"Eguchi, Y. et al. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J. Gastroenterol. 47, 586–595 (2012).",{"doi":3130},"10.1007\u002Fs00535-012-0533-z",{"id":24,"text":3132,"url":24,"identifiers":3133},"Williams, C. D. et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 140, 124–131 (2011).",{"doi":3134},"10.1053\u002Fj.gastro.2010.09.038",{"id":24,"text":3136,"url":24,"identifiers":3137},"Loomba, R. et al. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology 56, 943–951 (2012).",{"doi":3138},"10.1002\u002Fhep.25772",{"id":24,"text":3140,"url":24,"identifiers":3141},"Browning, J. D. et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40, 1387–1395 (2004).",{"doi":3142},"10.1002\u002Fhep.20466",{"id":24,"text":3144,"url":24,"identifiers":3145},"Centers for Disease Control and Prevention Overweight and Obesity [online] , (2012).",{},{"id":24,"text":3147,"url":24,"identifiers":3148},"Babusik, P., Bilal, M. & Duris, I. Nonalcoholic fatty liver disease of two ethnic groups in Kuwait: comparison of prevalence and risk factors. Med. Princ. Pract. 21, 56–62 (2012).",{"doi":3149},"10.1159\u002F000331591",{"id":24,"text":3151,"url":24,"identifiers":3152},"Caballeria, L. et al. Prevalence and factors associated with the presence of nonalcoholic fatty liver disease in an adult population in Spain. Eur. J. Gastroenterol. Hepatol. 22, 24–32 (2010).",{"doi":3153},"10.1097\u002FMEG.0b013e32832fcdf0",{"id":24,"text":3155,"url":24,"identifiers":3156},"Bedogni, G. et al. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 42, 44–52 (2005).",{"doi":3157},"10.1002\u002Fhep.20734",{"id":24,"text":3159,"url":24,"identifiers":3160},"Ratziu, V., Bellentani, S., Cortez-Pinto, H., Day, C. & Marchesini, G. A position statement on NAFLD\u002FNASH based on the EASL 2009 special conference. J. Hepatol. 53, 372–384 (2010).",{"doi":3161},"10.1016\u002Fj.jhep.2010.04.008",{"id":24,"text":3163,"url":24,"identifiers":3164},"Fan, J. G. et al. Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: update 2010: (published in Chinese on Chinese Journal of Hepatology 2010; 18, 163–166). J. Dig. Dis. 12, 38–44 (2011).",{"doi":3165},"10.1111\u002Fj.1751-2980.2010.00476.x",{"id":24,"text":3167,"url":24,"identifiers":3168},"Farrell, G. C., Wong, V. W. & Chitturi, S. NAFLD in Asia—as common and important as in the West. Nat. Rev. Gastroenterol. Hepatol. 10, 307–318 (2013).",{"doi":3169},"10.1038\u002Fnrgastro.2013.34",{"id":24,"text":3171,"url":24,"identifiers":3172},"Das, K. et al. Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease. Hepatology 51, 1593–1602 (2010).",{"doi":3173},"10.1002\u002Fhep.23567",{"id":24,"text":3175,"url":24,"identifiers":3176},"Amarapurkar, D. et al. Prevalence of non-alcoholic fatty liver disease: population based study. Ann. Hepatol. 6, 161–163 (2007).",{"doi":3177},"10.1016\u002FS1665-2681(19)31922-2",{"id":24,"text":3179,"url":24,"identifiers":3180},"Singh, S. P. et al. Prevalence of nonalcoholic fatty liver disease in coastal eastern India: a preliminary ultrasonographic survey. Trop. Gastroenterol. 25, 76–79 (2004).",{},{"id":24,"text":3182,"url":24,"identifiers":3183},"Amarapurkar, D. N. et al. How common is non-alcoholic fatty liver disease in the Asia–Pacific region and are there local differences? J. Gastroenterol. Hepatol. 22, 788–793 (2007).",{"doi":3184},"10.1111\u002Fj.1440-1746.2007.05042.x",{"id":24,"text":3186,"url":24,"identifiers":3187},"Onyekwere, C. A., Ogbera, A. O. & Balogun, B. O. Non-alcoholic fatty liver disease and the metabolic syndrome in an urban hospital serving an African community. Ann. Hepatol. 10, 119–124 (2011).",{"doi":3188},"10.1016\u002FS1665-2681(19)31559-5",{"id":24,"text":3190,"url":24,"identifiers":3191},"Mendez-Sanchez, N. Non alcoholic fatty liver disease. Ann. Hepatol. 8 (Suppl. 1), S3 (2009).",{"doi":3192},"10.1016\u002FS1665-2681(19)31819-8",{"id":24,"text":3194,"url":24,"identifiers":3195},"Chitturi, S. et al. Non-alcoholic fatty liver disease in the Asia–Pacific region: definitions and overview of proposed guidelines. J. Gastroenterol. Hepatol. 22, 778–787 (2007).",{"doi":3196},"10.1111\u002Fj.1440-1746.2007.05001.x",{"id":24,"text":3198,"url":24,"identifiers":3199},"Farrell, G. C., Chitturi, S., Lau, G. K., Sollano, J. D. & Asia–Pacific Working Party on NAFLD. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia–Pacific region: executive summary. J. Gastroenterol. Hepatol. 22, 775–777 (2007).",{"doi":3200},"10.1111\u002Fj.1440-1746.2007.05002.x",{"id":24,"text":3202,"url":24,"identifiers":3203},"Larrain, S. & Rinella, M. E. A myriad of pathways to NASH. Clin. Liver Dis. 16, 525–548 (2012).",{"doi":3204},"10.1016\u002Fj.cld.2012.05.009",{"id":24,"text":3206,"url":24,"identifiers":3207},"Pratt, D. S., Knox, T. A. & Erban, J. Tamoxifen-induced steatohepatitis. Ann. Intern. Med. 123, 236 (1995).",{"doi":3208},"10.7326\u002F0003-4819-123-3-199508010-00018",{"id":24,"text":3210,"url":24,"identifiers":3211},"McLaren, D. S., Bitar, J. G. & Nassar, V. H. Protein–calorie malnutrition and the liver. Prog. Liver Dis. 4, 527–536 (1972).",{},{"id":24,"text":3213,"url":24,"identifiers":3214},"Misra, A. et al. Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic syndrome for Asian Indians and recommendations for physical activity, medical and surgical management. J. Assoc. Physicians India 57, 163–170 (2009).",{},{"id":24,"text":3216,"url":24,"identifiers":3217},"Doycheva, I., Patel, N., Peterson, M. & Loomba, R. Prognostic implication of liver histology in patients with nonalcoholic fatty liver disease in diabetes. J. Diabetes Complications 27, 293–300 (2013).",{"doi":3218},"10.1016\u002Fj.jdiacomp.2012.10.008",{"id":24,"text":3220,"url":24,"identifiers":3221},"Loomba, R. et al. Genetic covariance between γ-glutamyl transpeptidase and fatty liver risk factors: role of β2-adrenergic receptor genetic variation in twins. Gastroenterology 139, 836–845 (2010).",{"doi":3222},"10.1053\u002Fj.gastro.2010.06.009",{"id":24,"text":3224,"url":24,"identifiers":3225},"Petersen, K. F. et al. Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men. Proc. Natl Acad. Sci. USA 103, 18273–18277 (2006).",{"doi":3226},"10.1073\u002Fpnas.0608537103",{"id":24,"text":3228,"url":24,"identifiers":3229},"Fan, J. G. et al. Effects of nonalcoholic fatty liver disease on the development of metabolic disorders. J. Gastroenterol. Hepatol. 22, 1086–1091 (2007).",{"doi":3230},"10.1111\u002Fj.1440-1746.2006.04781.x",{"id":24,"text":3232,"url":24,"identifiers":3233},"Prashanth, M. et al. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. J. Assoc. Physicians India 57, 205–210 (2009).",{},{"id":24,"text":3235,"url":24,"identifiers":3236},"Fan, J. G. & Peng, Y. D. Metabolic syndrome and non-alcoholic fatty liver disease: Asian definitions and Asian studies. Hepatobiliary Pancreat. Dis. Int. 6, 572–578 (2007).",{},{"id":24,"text":3238,"url":24,"identifiers":3239},"Romeo, S. et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 40, 1461–1465 (2008).",{"doi":3240},"10.1038\u002Fng.257",{"id":24,"text":3242,"url":24,"identifiers":3243},"Rotman, Y. et al. The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology 52, 894–903 (2010).",{"doi":3244},"10.1002\u002Fhep.23759",{"id":24,"text":3246,"url":24,"identifiers":3247},"Chalasani, N. et al. Genome-wide association study identifies variants associated with histologic features of nonalcoholic fatty liver disease. Gastroenterology 139, 1567–1576 (2010).",{"doi":3248},"10.1053\u002Fj.gastro.2010.07.057",{"id":24,"text":3250,"url":24,"identifiers":3251},"Speliotes, E. K. et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet. 7, e1001324 (2011).",{"doi":3252},"10.1371\u002Fjournal.pgen.1001324",{"id":24,"text":3254,"url":24,"identifiers":3255},"Miele, L. et al. The Kruppel-like factor 6 genotype is associated with fibrosis in nonalcoholic fatty liver disease. Gastroenterology 135, 282–291 (2008).",{"doi":3256},"10.1053\u002Fj.gastro.2008.04.004",{"id":24,"text":3258,"url":24,"identifiers":3259},"Bechmann, L. P. et al. Glucokinase links Kruppel-like factor 6 to the regulation of hepatic insulin sensitivity in nonalcoholic fatty liver disease. Hepatology 55, 1083–1093 (2012).",{"doi":3260},"10.1002\u002Fhep.24793",{"id":24,"text":3262,"url":24,"identifiers":3263},"Anstee, Q. M. & Day, C. P. The genetics of NAFLD. Nat. Rev. Gastroenterol. Hepatol. http:\u002F\u002Fdx.doi.org\u002F10.1038\u002Fnrgastro.2013.183 .",{"doi":3264},"10.1038\u002Fnrgastro.2013.183",{"id":24,"text":3266,"url":24,"identifiers":3267},"Petersen, K. F. et al. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N. Engl. J. Med. 362, 1082–1089 (2010).",{"doi":3268},"10.1056\u002FNEJMoa0907295",{"id":24,"text":3270,"url":24,"identifiers":3271},"Ekstedt, M. et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44, 865–873 (2006).",{"doi":3272},"10.1002\u002Fhep.21327",{"id":24,"text":3274,"url":24,"identifiers":3275},"Rafiq, N. et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin. Gastroenterol. Hepatol. 7, 234–238 (2009).",{"doi":3276},"10.1016\u002Fj.cgh.2008.11.005",{"id":24,"text":3278,"url":24,"identifiers":3279},"Noureddin, M. et al. Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients. Hepatology http:\u002F\u002Fdx.doi.org\u002F10.1002\u002Fhep.26465 .",{"doi":3280},"10.1002\u002Fhep.26465",{"id":24,"text":3282,"url":24,"identifiers":3283},"Sanyal, A. J. et al. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology 43, 682–689 (2006).",{"doi":3284},"10.1002\u002Fhep.21103",{"id":24,"text":3286,"url":24,"identifiers":3287},"Ascha, M. S. et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 51, 1972–1978 (2010).",{"doi":3288},"10.1002\u002Fhep.23527",{"id":24,"text":3290,"url":24,"identifiers":3291},"White, D. L., Kanwal, F. & El-Serag, H. B. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin. Gastroenterol. Hepatol. 10, 1342–1359 (2012).",{"doi":3292},"10.1016\u002Fj.cgh.2012.10.001",{"id":24,"text":3294,"url":24,"identifiers":3295},"Sanyal, A., Poklepovic, A., Moyneur, E. & Barghout, V. Population-based risk factors and resource utilization for HCC: US perspective. Curr. Med. Res. Opin. 26, 2183–2191 (2010).",{"doi":3296},"10.1185\u002F03007995.2010.506375",{"id":24,"text":3298,"url":24,"identifiers":3299},"Charlton, M. R. et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 141, 1249–1253 (2011).",{"doi":3300},"10.1053\u002Fj.gastro.2011.06.061",{"id":24,"text":3302,"url":24,"identifiers":3303},"Finucane, M. M. et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet 377, 557–567 (2011).",{"doi":3304},"10.1016\u002FS0140-6736(10)62037-5",{"id":24,"text":3306,"url":24,"identifiers":3307},"WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 363, 157–163 (2004).",{"doi":3308},"10.1016\u002FS0140-6736(03)15268-3",{"id":3310,"createTime":3311,"updateTime":3311,"relativeEntities":3312,"slug":3313,"properties":3314,"entityType":184,"verifyStatus":185,"verifyTime":3311,"verifyNote":186,"syncStatus":23,"languages":3327,"translateLanguages":24,"viewCount":25,"primaryUrl":3328,"fullTextUrl":24,"authors":3329,"publicationType":310,"publisherRelationship":3412,"citationCount":3449,"citationInfo":3450,"publishDate":3456,"publishYear":787,"citationAnalyzeStatus":23,"lastCitationAnalyze":24,"indexDatabases":24,"openAccess":24,"references":3457,"isForceReanalyzing":595},"ecba478e-1762-46bd-b7ef-7988e640046b","2024-10-15T22:53:24.502+00:00",[],"Risk-of-cardiomyopathy-and-cardiac-arrhythmias-in-patients-with-nonalcoholic-fatty-liver-disease",{"mag":3315,"keywords":3317,"openalex":3318,"abstract":3320,"title":3321,"pm":3323,"doi":3325},{"VOID":3316},"2799787792",{},{"VOID":3319},"W2799787792",{},{"EN":3322},"Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease",{"VOID":3324},"29713021",{"VOID":3326},"10.1038\u002Fs41575-018-0010-0",[188],"https:\u002F\u002Fwww.nature.com\u002Farticles\u002Fs41575-018-0010-0",[3330,3352,3373,3395],{"id":3331,"sortIndex":124,"researcher":24,"roles":3332,"affiliations":3333,"properties":3345},"29d4dc43-f8c3-45d0-9f11-c6a813b8a0d4",[],[3334],{"id":3335,"sortIndex":25,"affiliation":3336,"properties":24},"910391f1-3a3a-42dd-85f1-e82b20995745",{"id":3337,"createTime":3338,"updateTime":3339,"relativeEntities":3340,"slug":3341,"properties":3342,"entityType":53,"verifyStatus":23,"verifyTime":24,"verifyNote":24,"syncStatus":23,"languages":24,"translateLanguages":24,"viewCount":25},"ea1cf459-9a53-4376-a033-b114ade25099","2023-12-11T06:29:39.416+00:00","2024-10-15T22:53:24.531+00:00",[],"Department-of-Medicine-Section-of-Endocrinology-Diabetes-and-Metabolism-University-and-Azienda-Ospedaliera-Universitaria-Integrata-of-Verona-Verona-Italy",{"title":3343},{"VI":3344},"Department of Medicine, Section of Endocrinology, Diabetes and Metabolism, University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy",{"openalex":3346,"orcid":3348,"title":3350},{"VOID":3347},"A5071075382",{"VOID":3349},"https:\u002F\u002Forcid.org\u002F0000-0002-4325-3900",{"EN":3351},"Giovanni Targher",{"id":3353,"sortIndex":126,"researcher":24,"roles":3354,"affiliations":3355,"properties":3366},"bdd6c7e2-bf82-47e0-87aa-2aca5b291cbd",[],[3356],{"id":3357,"sortIndex":25,"affiliation":3358,"properties":24},"ba0287db-d23b-435d-8e69-f7807bb8e6ef",{"id":3359,"createTime":3360,"updateTime":3360,"relativeEntities":3361,"slug":3362,"properties":3363,"entityType":53,"verifyStatus":23,"verifyTime":24,"verifyNote":24,"syncStatus":23,"languages":24,"translateLanguages":24,"viewCount":25},"75ac2ed4-7331-4b19-b07e-4ae9835c2f4f","2024-10-15T22:53:24.539+00:00",[],"Department-of-Internal-Medicine-I-Gastroenterology-Hepatology-and-Metabolism-Medical-University-Innsbruck-Innsbruck-Austria",{"title":3364},{"EN":3365},"Department of Internal Medicine I, Gastroenterology, Hepatology and Metabolism, Medical University Innsbruck, Innsbruck, Austria",{"openalex":3367,"orcid":3369,"title":3371},{"VOID":3368},"A5050626665",{"VOID":3370},"https:\u002F\u002Forcid.org\u002F0000-0002-4235-2579",{"EN":3372},"Herbert Tilg",{"id":3374,"sortIndex":25,"researcher":24,"roles":3375,"affiliations":3376,"properties":3388},"07e08a75-5568-4022-8f86-57ab79445f74",[],[3377],{"id":3378,"sortIndex":25,"affiliation":3379,"properties":24},"dd5df363-741a-498c-bf97-4992a5c89206",{"id":3380,"createTime":3381,"updateTime":3382,"relativeEntities":3383,"slug":3384,"properties":3385,"entityType":53,"verifyStatus":23,"verifyTime":24,"verifyNote":24,"syncStatus":23,"languages":24,"translateLanguages":24,"viewCount":25},"a1e6d8e6-0454-41fa-a379-c367fce057cd","2024-01-10T04:14:18.746+00:00","2024-12-11T01:52:49.262+00:00",[],"Institute-of-Cellular-Medicine-Faculty-of-Medical-Sciences-Newcastle-University-Newcastle-upon-Tyne-UK",{"title":3386},{"VI":3387},"Institute of Cellular Medicine–Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK",{"openalex":3389,"orcid":3391,"title":3393},{"VOID":3390},"A5059068278",{"VOID":3392},"https:\u002F\u002Forcid.org\u002F0000-0002-9518-0088",{"EN":3394},"Quentin M. Anstee",{"id":3396,"sortIndex":215,"researcher":24,"roles":3397,"affiliations":3398,"properties":3405},"d517a650-539c-4726-999f-9cfeff63f79e",[],[3399],{"id":3400,"sortIndex":25,"affiliation":3401,"properties":24},"dc7bc3ac-c435-4707-9e07-de03410ff39f",{"id":3337,"createTime":3338,"updateTime":3339,"relativeEntities":3402,"slug":3341,"properties":3403,"entityType":53,"verifyStatus":23,"verifyTime":24,"verifyNote":24,"syncStatus":23,"languages":24,"translateLanguages":24,"viewCount":25},[],{"title":3404},{"VI":3344},{"openalex":3406,"orcid":3408,"title":3410},{"VOID":3407},"A5036950034",{"VOID":3409},"https:\u002F\u002Forcid.org\u002F0000-0002-7271-6329",{"EN":3411},"Alessandro Mantovani",{"url":24,"publisher":3413,"properties":3443},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":3414,"slug":10,"properties":3415,"entityType":22,"verifyStatus":23,"verifyTime":24,"verifyNote":24,"syncStatus":23,"languages":24,"translateLanguages":24,"viewCount":25,"subjectFields":3421,"manageAffiliations":3422,"indexDatabases":3423,"url":106,"thumbnailPath":24,"statistic":3438,"gsStatistic":24,"type":24,"analyzePriority":24},[],{"country":3416,"issn":3417,"introduce":3418,"eissn":3419,"title":3420},{"VOID":13},{"VOID":15},{"EN":17},{"VOID":19},{"EN":21},[],[],[3424,3431],{"id":88,"indexDatabase":3425,"url":103,"indexYears":24,"academicFieldIds":3430,"indexDatabaseRanking":24},{"id":90,"createTime":91,"updateTime":92,"relativeEntities":3426,"label":3427,"description":3428,"key":99,"publicationTags":3429,"standard":24},[],{"EN":95,"VI":95},{"VI":97,"EN":98},[101,102],[105],{"id":68,"indexDatabase":3432,"url":81,"indexYears":82,"academicFieldIds":3437,"indexDatabaseRanking":86},{"id":70,"createTime":71,"updateTime":72,"relativeEntities":3433,"label":3434,"description":3435,"key":78,"publicationTags":3436,"standard":24},[],{"EN":75,"VI":75},{"EN":75,"VI":77},[80],[84,85],{"impactFactor":25,"impactFactorByYear":3439,"i10Index":121,"i10IndexLast5Year":122,"totalPublication":121,"totalPublicationByYear":3440,"totalCitation":129,"totalCitationByYear":3441,"totalCitationPerPublication":145,"totalCitationPerPublicationByYear":3442,"hindexLast5Year":161,"hindex":161},{"2012":109,"2013":110,"2014":111,"2015":112,"2016":113,"2017":114,"2018":115,"2019":116,"2020":117,"2021":118,"2022":119,"2023":120},{"2009":124,"2010":124,"2011":125,"2012":126,"2013":127,"2014":124,"2015":125,"2016":127,"2017":128,"2018":127,"2019":127,"2020":126,"2021":125,"2022":126},{"2009":131,"2010":132,"2011":133,"2012":134,"2013":135,"2014":136,"2015":137,"2016":138,"2017":139,"2018":140,"2019":141,"2020":142,"2021":143,"2022":144},{"2009":147,"2010":148,"2011":149,"2012":150,"2013":151,"2014":152,"2015":153,"2016":154,"2017":155,"2018":156,"2019":157,"2020":158,"2021":159,"2022":160},{"volume":3444,"pages":3445,"issue":3447},{"VOID":772},{"VOID":3446},"425-439",{"VOID":3448},"7",238,{"total":3449,"publishYear":24,"statisticByYear":3451},{"2018":3452,"2019":353,"2020":3453,"2021":3454,"2022":3455,"2023":3096,"2024":360},12,41,55,36,"2018-07-01",[3458,3461,3465,3469,3473,3477,3481,3485,3489,3493,3497,3501,3505,3509,3512,3516,3520,3524,3528,3532,3536,3540,3544,3548,3552,3556,3560,3564,3568,3572,3576,3580,3584,3588,3592,3596,3600,3604,3608,3612,3616,3620,3624,3628,3632,3636,3640,3644,3648,3652,3656,3660,3664,3668,3672,3676,3680,3684,3688,3692,3696,3700,3704,3708,3711,3715,3719,3722,3726,3729,3733,3737,3741,3745,3749,3753,3757,3761,3765,3769,3773,3777,3781,3785,3789,3793,3796,3800,3804,3808,3812,3816,3820,3824,3828,3832,3836,3840,3844,3848,3851,3855,3859,3863,3867,3871,3875,3879,3883,3887,3891,3895,3899,3903,3907,3911,3915,3919,3923,3927,3931,3935,3939,3943,3947,3951,3955,3959,3963,3967,3971,3975,3979,3983,3987,3991,3995,3998,4002,4006,4010,4014,4018,4022,4026,4030,4034,4038,4042,4046,4050,4054,4058,4062,4066,4070,4074,4078,4082,4086,4090,4094,4098,4102,4106],{"id":24,"text":3459,"url":24,"identifiers":3460},"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) & European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 64, 1388–1402 (2016).",{},{"id":24,"text":3462,"url":24,"identifiers":3463},"Lonardo, A. et al. Epidemiological modifiers of non-alcoholic fatty liver disease: focus on high-risk groups. Dig. Liver Dis. 47, 997–1006 (2015).",{"doi":3464},"10.1016\u002Fj.dld.2015.08.004",{"id":24,"text":3466,"url":24,"identifiers":3467},"Younossi, Z. M. et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64, 73–84 (2016).",{"doi":3468},"10.1002\u002Fhep.28431",{"id":24,"text":3470,"url":24,"identifiers":3471},"Tilg, H., Moschen, A. R. & Roden, M. NAFLD and diabetes mellitus. Nat. Rev. Gastroenterol. Hepatol. 14, 32–42 (2017).",{"doi":3472},"10.1038\u002Fnrgastro.2016.147",{"id":24,"text":3474,"url":24,"identifiers":3475},"Targher, G., Day, C. P. & Bonora, E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N. Engl. J. Med. 363, 1341–1350 (2010).",{"doi":3476},"10.1056\u002FNEJMra0912063",{"id":24,"text":3478,"url":24,"identifiers":3479},"Byrne, C. D. & Targher, G. NAFLD: a multisystem disease. J. Hepatol. 62, S47–64 (2015).",{"doi":3480},"10.1016\u002Fj.jhep.2014.12.012",{"id":24,"text":3482,"url":24,"identifiers":3483},"Adams, L. A., Anstee, Q. M., Tilg, H. & Targher, G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut 66, 1138–1153 (2017).",{"doi":3484},"10.1136\u002Fgutjnl-2017-313884",{"id":24,"text":3486,"url":24,"identifiers":3487},"Younossi, Z. M. et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology 64, 1577–1586 (2016).",{"doi":3488},"10.1002\u002Fhep.28785",{"id":24,"text":3490,"url":24,"identifiers":3491},"Perseghin, G. et al. Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver. Hepatology 47, 51–58 (2008).",{"doi":3492},"10.1002\u002Fhep.21983",{"id":24,"text":3494,"url":24,"identifiers":3495},"Rijzewijk, L. J. et al. Effects of hepatic triglyceride content on myocardial metabolism in type 2 diabetes. J. Am. Coll. Cardiol. 56, 225–233 (2010).",{"doi":3496},"10.1016\u002Fj.jacc.2010.02.049",{"id":24,"text":3498,"url":24,"identifiers":3499},"Lautamaki, R. et al. Liver steatosis coexists with myocardial insulin resistance and coronary dysfunction in patients with type 2 diabetes. Am. J. Physiol. Endocrinol. Metab. 291, E282–E290 (2006).",{"doi":3500},"10.1152\u002Fajpendo.00604.2005",{"id":24,"text":3502,"url":24,"identifiers":3503},"Goland, S. et al. Cardiac abnormalities as a new manifestation of nonalcoholic fatty liver disease: echocardiographic and tissue Doppler imaging assessment. J. Clin. Gastroenterol. 40, 949–955 (2006).",{"doi":3504},"10.1097\u002F01.mcg.0000225668.53673.e6",{"id":24,"text":3506,"url":24,"identifiers":3507},"Fallo, F. et al. Non-alcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in essential hypertension. Nutr. Metab. Cardiovasc. Dis. 19, 646–653 (2009).",{"doi":3508},"10.1016\u002Fj.numecd.2008.12.007",{"id":24,"text":3510,"url":24,"identifiers":3511},"Fotbolcu, H. et al. Impairment of the left ventricular systolic and diastolic function in patients with non-alcoholic fatty liver disease. Cardiol. J. 17, 457–463 (2010).",{},{"id":24,"text":3513,"url":24,"identifiers":3514},"Mantovani, A., Zoppini, G., Targher, G., Golia, G. & Bonora, E. Non-alcoholic fatty liver disease is independently associated with left ventricular hypertrophy in hypertensive Type 2 diabetic individuals. J. Endocrinol. Invest. 35, 215–218 (2012).",{"doi":3515},"10.1007\u002FBF03345421",{"id":24,"text":3517,"url":24,"identifiers":3518},"Bonapace, S. et al. Nonalcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in patients with type 2 diabetes. Diabetes Care 35, 389–395 (2012).",{"doi":3519},"10.2337\u002Fdc11-1820",{"id":24,"text":3521,"url":24,"identifiers":3522},"Hallsworth, K. et al. Cardiac structure and function are altered in adults with non-alcoholic fatty liver disease. J. Hepatol. 58, 757–762 (2013).",{"doi":3523},"10.1016\u002Fj.jhep.2012.11.015",{"id":24,"text":3525,"url":24,"identifiers":3526},"Kim, N. H. et al. Non-alcoholic fatty liver disease, metabolic syndrome and subclinical cardiovascular changes in the general population. Heart 100, 938–943 (2014).",{"doi":3527},"10.1136\u002Fheartjnl-2013-305099",{"id":24,"text":3529,"url":24,"identifiers":3530},"Karabay, C. Y. et al. Impaired left ventricular mechanics in nonalcoholic fatty liver disease: a speckle-tracking echocardiography study. Eur. J. Gastroenterol. Hepatol. 26, 325–331 (2014).",{"doi":3531},"10.1097\u002FMEG.0000000000000008",{"id":24,"text":3533,"url":24,"identifiers":3534},"VanWagner, L. B. et al. Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: a population-based study. Hepatology 62, 773–783 (2015).",{"doi":3535},"10.1002\u002Fhep.27869",{"id":24,"text":3537,"url":24,"identifiers":3538},"Cassidy, S. et al. Cardiac structure and function are altered in type 2 diabetes and non-alcoholic fatty liver disease and associate with glycemic control. Cardiovasc. Diabetol. 14, 23 (2015).",{"doi":3539},"10.1186\u002Fs12933-015-0187-2",{"id":24,"text":3541,"url":24,"identifiers":3542},"Kocabay, G. et al. Left atrial deformation parameters in patients with non-alcoholic fatty liver disease: a 2D speckle tracking imaging study. Clin. Sci. 126, 297–304 (2014).",{"doi":3543},"10.1042\u002FCS20130298",{"id":24,"text":3545,"url":24,"identifiers":3546},"Graner, M. et al. Ectopic fat depots and left ventricular function in nondiabetic men with nonalcoholic fatty liver disease. Circ. Cardiovasc. Imag. 8, e001979 (2015).",{"doi":3547},"10.1161\u002FCIRCIMAGING.114.001979",{"id":24,"text":3549,"url":24,"identifiers":3550},"Mantovani, A. et al. Nonalcoholic fatty liver disease is independently associated with early left ventricular diastolic dysfunction in patients with type 2 diabetes. PLoS ONE 10, e0135329 (2015).",{"doi":3551},"10.1371\u002Fjournal.pone.0135329",{"id":24,"text":3553,"url":24,"identifiers":3554},"Petta, S. et al. Epicardial fat, cardiac geometry and cardiac function in patients with non-alcoholic fatty liver disease: association with the severity of liver disease. J. Hepatol. 62, 928–933 (2015).",{"doi":3555},"10.1016\u002Fj.jhep.2014.11.030",{"id":24,"text":3557,"url":24,"identifiers":3558},"Sunbul, M. et al. Nonalcoholic steatohepatitis score is an independent predictor of right ventricular dysfunction in patients with nonalcoholic fatty liver disease. Cardiovasc. Ther. 33, 294–299 (2015).",{"doi":3559},"10.1111\u002F1755-5922.12145",{"id":24,"text":3561,"url":24,"identifiers":3562},"Psychari, S. N. et al. Epicardial fat in nonalcoholic fatty liver disease: properties and relationships with metabolic factors, cardiac structure, and cardiac function. Angiology 67, 41–48 (2016).",{"doi":3563},"10.1177\u002F0003319715576672",{"id":24,"text":3565,"url":24,"identifiers":3566},"Ozveren, O. et al. Doppler tissue evaluation of atrial conduction properties in patients with non-alcoholic fatty-liver disease. Ultrason. Imag. 38, 225–235 (2016).",{"doi":3567},"10.1177\u002F0161734615595015",{"id":24,"text":3569,"url":24,"identifiers":3570},"Widya, R. L. et al. Association between hepatic triglyceride content and left ventricular diastolic function in a population-based cohort: the Netherlands epidemiology of obesity study. Radiology 279, 443–450 (2016).",{"doi":3571},"10.1148\u002Fradiol.2015150035",{"id":24,"text":3573,"url":24,"identifiers":3574},"Trovato, F. M. et al. Echocardiography and NAFLD (non-alcoholic fatty liver disease). Int. J. Cardiol. 221, 275–279 (2016).",{"doi":3575},"10.1016\u002Fj.ijcard.2016.06.180",{"id":24,"text":3577,"url":24,"identifiers":3578},"Jung, J. Y. et al. Effect of non-alcoholic fatty liver disease on left ventricular diastolic function and geometry in the Korean general population. Hepatol. Res. 47, 522–532 (2017).",{"doi":3579},"10.1111\u002Fhepr.12770",{"id":24,"text":3581,"url":24,"identifiers":3582},"Simon, T. G., Bamira, D. G., Chung, R. T., Weiner, R. B. & Corey, K. E. Nonalcoholic steatohepatitis is associated with cardiac remodeling and dysfunction. Obesity 25, 1313–1316 (2017).",{"doi":3583},"10.1002\u002Foby.21879",{"id":24,"text":3585,"url":24,"identifiers":3586},"Lee, Y. H. et al. Association of nonalcoholic steatohepatitis with subclinical myocardial dysfunction in non-cirrhotic patients. J. Hepatol. 68, 764–772 (2018).",{"doi":3587},"10.1016\u002Fj.jhep.2017.11.023",{"id":24,"text":3589,"url":24,"identifiers":3590},"Sert, A. et al. Left ventricular function by echocardiography, tissue Doppler imaging, and carotid intima-media thickness in obese adolescents with nonalcoholic fatty liver disease. Am. J. Cardiol. 112, 436–443 (2013).",{"doi":3591},"10.1016\u002Fj.amjcard.2013.03.056",{"id":24,"text":3593,"url":24,"identifiers":3594},"Alp, H. et al. Association between nonalcoholic fatty liver disease and cardiovascular risk in obese children and adolescents. Can. J. Cardiol. 29, 1118–1125 (2013).",{"doi":3595},"10.1016\u002Fj.cjca.2012.07.846",{"id":24,"text":3597,"url":24,"identifiers":3598},"Singh, G. K. et al. Alterations in ventricular structure and function in obese adolescents with nonalcoholic fatty liver disease. J. Pediatr. 162, 1160–1168.e1 (2013).",{"doi":3599},"10.1016\u002Fj.jpeds.2012.11.024",{"id":24,"text":3601,"url":24,"identifiers":3602},"Pacifico, L. et al. Left ventricular dysfunction in obese children and adolescents with nonalcoholic fatty liver disease. Hepatology 59, 461–470 (2014).",{"doi":3603},"10.1002\u002Fhep.26610",{"id":24,"text":3605,"url":24,"identifiers":3606},"Bonci, E. et al. Association of nonalcoholic fatty liver disease with subclinical cardiovascular changes: a systematic review and meta-analysis. Biomed. Res. Int. 2015, 213737 (2015).",{"doi":3607},"10.1155\u002F2015\u002F213737",{"id":24,"text":3609,"url":24,"identifiers":3610},"Dhingra, R. et al. Serum gamma-glutamyl transferase and risk of heart failure in the community. Arterioscler. Thromb. Vasc. Biol. 30, 1855–1860 (2010).",{"doi":3611},"10.1161\u002FATVBAHA.110.207340",{"id":24,"text":3613,"url":24,"identifiers":3614},"Wannamethee, S. G., Whincup, P. H., Shaper, A. G., Lennon, L. & Sattar, N. Gamma-glutamyltransferase, hepatic enzymes, and risk of incident heart failure in older men. Arterioscler. Thromb. Vasc. Biol. 32, 830–835 (2012).",{"doi":3615},"10.1161\u002FATVBAHA.111.240457",{"id":24,"text":3617,"url":24,"identifiers":3618},"Wang, Y. et al. Serum gamma-glutamyltransferase and the risk of heart failure in men and women in Finland. Heart 99, 163–167 (2013).",{"doi":3619},"10.1136\u002Fheartjnl-2012-302972",{"id":24,"text":3621,"url":24,"identifiers":3622},"Valbusa, F. et al. Nonalcoholic fatty liver disease is associated with higher 1-year all-cause rehospitalization rates in patients admitted for acute heart failure. Medicine 95, e2760 (2016).",{"doi":3623},"10.1097\u002FMD.0000000000002760",{"id":24,"text":3625,"url":24,"identifiers":3626},"Valbusa, F. et al. Nonalcoholic fatty liver disease and increased risk of 1-year all-cause and cardiac hospital readmissions in elderly patients admitted for acute heart failure. PLoS ONE 12, e0173398 (2017).",{"doi":3627},"10.1371\u002Fjournal.pone.0173398",{"id":24,"text":3629,"url":24,"identifiers":3630},"Sato, Y. et al. Liver stiffness assessed by Fibrosis-4 index predicts mortality in patients with heart failure. Open Heart 4, e000598 (2017).",{"doi":3631},"10.1136\u002Fopenhrt-2017-000598",{"id":24,"text":3633,"url":24,"identifiers":3634},"Otto, C. M. & Prendergast, B. Aortic-valve stenosis — from patients at risk to severe valve obstruction. N. Engl. J. Med. 371, 744–756 (2014).",{"doi":3635},"10.1056\u002FNEJMra1313875",{"id":24,"text":3637,"url":24,"identifiers":3638},"Volzke, H. et al. Heart valve sclerosis predicts all-cause and cardiovascular mortality. Atherosclerosis 209, 606–610 (2010).",{"doi":3639},"10.1016\u002Fj.atherosclerosis.2009.10.030",{"id":24,"text":3641,"url":24,"identifiers":3642},"Rossi, A. et al. Aortic and mitral annular calcifications are predictive of all-cause and cardiovascular mortality in patients with type 2 diabetes. Diabetes Care 35, 1781–1786 (2012).",{"doi":3643},"10.2337\u002Fdc12-0134",{"id":24,"text":3645,"url":24,"identifiers":3646},"O’Neal, W. T. et al. Mitral annular calcification and incident atrial fibrillation in the Multi-Ethnic Study of Atherosclerosis. Europace 17, 358–363 (2015).",{"doi":3647},"10.1093\u002Feuropace\u002Feuu265",{"id":24,"text":3649,"url":24,"identifiers":3650},"Markus, M. R. et al. Hepatic steatosis is associated with aortic valve sclerosis in the general population: the Study of Health in Pomerania (SHIP). Arterioscler. Thromb. Vasc. Biol. 33, 1690–1695 (2013).",{"doi":3651},"10.1161\u002FATVBAHA.112.300556",{"id":24,"text":3653,"url":24,"identifiers":3654},"Bonapace, S. et al. Nonalcoholic fatty liver disease is associated with aortic valve sclerosis in patients with type 2 diabetes mellitus. PLoS ONE 9, e88371 (2014).",{"doi":3655},"10.1371\u002Fjournal.pone.0088371",{"id":24,"text":3657,"url":24,"identifiers":3658},"Mantovani, A. et al. Heart valve calcification in patients with type 2 diabetes and nonalcoholic fatty liver disease. Metabolism 64, 879–887 (2015).",{"doi":3659},"10.1016\u002Fj.metabol.2015.04.003",{"id":24,"text":3661,"url":24,"identifiers":3662},"Newton, J. L. et al. Fatigue in non-alcoholic fatty liver disease (NAFLD) is significant and associates with inactivity and excessive daytime sleepiness but not with liver disease severity or insulin resistance. Gut 57, 807–813 (2008).",{"doi":3663},"10.1136\u002Fgut.2007.139303",{"id":24,"text":3665,"url":24,"identifiers":3666},"Liu, Y. C. et al. Influence of non-alcoholic fatty liver disease on autonomic changes evaluated by the time domain, frequency domain, and symbolic dynamics of heart rate variability. PLoS ONE 8, e61803 (2013).",{"doi":3667},"10.1371\u002Fjournal.pone.0061803",{"id":24,"text":3669,"url":24,"identifiers":3670},"Kumar, M. S. et al. Cardiovascular autonomic dysfunction in patients of nonalcoholic fatty liver disease. Int. J. Hepatol. 2016, 5160754 (2016).",{"doi":3671},"10.1155\u002F2016\u002F5160754",{"id":24,"text":3673,"url":24,"identifiers":3674},"Ozveren, O. et al. Deterioration of heart rate recovery index in patients with non-alcoholic fatty liver disease (NAFLD). Med. Sci. Monit. 20, 1539–1543 (2014).",{"doi":3675},"10.12659\u002FMSM.890741",{"id":24,"text":3677,"url":24,"identifiers":3678},"Cho, K. I., Jo, E. A., Cho, S. H. & Kim, B. H. The influence of epicardial fat and nonalcoholic fatty liver disease on heart rate recovery in metabolic syndrome. Metab. Syndr. Relat. Disord. 15, 226–232 (2017).",{"doi":3679},"10.1089\u002Fmet.2016.0132",{"id":24,"text":3681,"url":24,"identifiers":3682},"Targher, G. et al. Non-alcoholic fatty liver disease is associated with an increased prevalence of atrial fibrillation in hospitalized patients with type 2 diabetes. Clin. Sci. 125, 301–309 (2013).",{"doi":3683},"10.1042\u002FCS20130036",{"id":24,"text":3685,"url":24,"identifiers":3686},"Targher, G. et al. Non-alcoholic fatty liver disease is associated with an increased incidence of atrial fibrillation in patients with type 2 diabetes. PLoS ONE 8, e57183 (2013).",{"doi":3687},"10.1371\u002Fjournal.pone.0057183",{"id":24,"text":3689,"url":24,"identifiers":3690},"Sinner, M. F. et al. Relation of circulating liver transaminase concentrations to risk of new-onset atrial fibrillation. Am. J. Cardiol. 111, 219–224 (2013).",{"doi":3691},"10.1016\u002Fj.amjcard.2012.09.021",{"id":24,"text":3693,"url":24,"identifiers":3694},"Iscen, S. RBBB is associated with an increased risk of NAFLD in young healthy individuals. Int. J. Cardiol. 168, 4056–4057 (2013).",{"doi":3695},"10.1016\u002Fj.ijcard.2013.07.035",{"id":24,"text":3697,"url":24,"identifiers":3698},"Alonso, A. et al. Circulating levels of liver enzymes and incidence of atrial fibrillation: the Atherosclerosis Risk in Communities cohort. Heart 100, 1511–1516 (2014).",{"doi":3699},"10.1136\u002Fheartjnl-2014-305756",{"id":24,"text":3701,"url":24,"identifiers":3702},"Targher, G. et al. Association of nonalcoholic fatty liver disease with QTc interval in patients with type 2 diabetes. Nutr. Metab. Cardiovasc. Dis. 24, 663–669 (2014).",{"doi":3703},"10.1016\u002Fj.numecd.2014.01.005",{"id":24,"text":3705,"url":24,"identifiers":3706},"Karajamaki, A. J. et al. Non-alcoholic fatty liver disease as a predictor of atrial fibrillation in middle-aged population (OPERA Study). PLoS ONE 10, e0142937 (2015).",{"doi":3707},"10.1371\u002Fjournal.pone.0142937",{"id":24,"text":3709,"url":24,"identifiers":3710},"Hung, C. S. et al. Nonalcoholic fatty liver disease is associated with QT prolongation in the general population. J. Am. Heart Assoc. 4, e001820 (2015).",{},{"id":24,"text":3712,"url":24,"identifiers":3713},"Markus, M. R. et al. Association between hepatic steatosis and serum liver enzyme levels with atrial fibrillation in the general population: the Study of Health in Pomerania (SHIP). Atherosclerosis 245, 123–131 (2016).",{"doi":3714},"10.1016\u002Fj.atherosclerosis.2015.12.023",{"id":24,"text":3716,"url":24,"identifiers":3717},"Mantovani, A. et al. Nonalcoholic fatty liver disease is associated with ventricular arrhythmias in patients with type 2 diabetes referred for clinically indicated 24-hour holter monitoring. Diabetes Care 39, 1416–1423 (2016).",{"doi":3718},"10.2337\u002Fdc16-0091",{"id":24,"text":3720,"url":24,"identifiers":3721},"Mangi, M. A. et al. Association of non-alcoholic fatty liver disease with conduction defects on electrocardiogram. Cureus 9, e1107 (2017).",{},{"id":24,"text":3723,"url":24,"identifiers":3724},"Karajamaki, A. J. et al. Presence of atrial fibrillation is associated with liver stiffness in an elderly Finnish population. PLoS ONE 12, e0173855 (2017).",{"doi":3725},"10.1371\u002Fjournal.pone.0173855",{"id":24,"text":3727,"url":24,"identifiers":3728},"Long, M. T. et al. Relations of liver fat with prevalent and incident atrial fibrillation in the Framingham Heart Study. J. Am. Heart Assoc. 6, e005227 (2017).",{},{"id":24,"text":3730,"url":24,"identifiers":3731},"Mantovani, A. et al. Nonalcoholic fatty liver disease is associated with an increased risk of heart block in hospitalized patients with type 2 diabetes mellitus. PLoS ONE 12, e0185459 (2017).",{"doi":3732},"10.1371\u002Fjournal.pone.0185459",{"id":24,"text":3734,"url":24,"identifiers":3735},"Lip, G. Y., Tse, H. F. & Lane, D. A. Atrial fibrillation. Lancet 379, 648–661 (2012).",{"doi":3736},"10.1016\u002FS0140-6736(11)61514-6",{"id":24,"text":3738,"url":24,"identifiers":3739},"Wijarnpreecha, K., Boonpheng, B., Thongprayoon, C., Jaruvongvanich, V. & Ungprasert, P. The association between non-alcoholic fatty liver disease and atrial fibrillation: a meta-analysis. Clin. Res. Hepatol. Gastroenterol. 41, 525–532 (2017).",{"doi":3740},"10.1016\u002Fj.clinre.2017.08.001",{"id":24,"text":3742,"url":24,"identifiers":3743},"Straus, S. M. et al. Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. J. Am. Coll. Cardiol. 47, 362–367 (2006).",{"doi":3744},"10.1016\u002Fj.jacc.2005.08.067",{"id":24,"text":3746,"url":24,"identifiers":3747},"Coumbe, A. G. et al. Long-term follow-up of older patients with Mobitz type I second degree atrioventricular block. Heart 99, 334–338 (2013).",{"doi":3748},"10.1136\u002Fheartjnl-2012-302770",{"id":24,"text":3750,"url":24,"identifiers":3751},"Kwok, C. S. et al. Prolonged PR interval, first-degree heart block and adverse cardiovascular outcomes: a systematic review and meta-analysis. Heart 102, 672–680 (2016).",{"doi":3752},"10.1136\u002Fheartjnl-2015-308956",{"id":24,"text":3754,"url":24,"identifiers":3755},"Gregor, M. F. & Hotamisligil, G. S. Inflammatory mechanisms in obesity. Annu. Rev. Immunol. 29, 415–445 (2011).",{"doi":3756},"10.1146\u002Fannurev-immunol-031210-101322",{"id":24,"text":3758,"url":24,"identifiers":3759},"Tilg, H. & Moschen, A. R. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 52, 1836–1846 (2010).",{"doi":3760},"10.1002\u002Fhep.24001",{"id":24,"text":3762,"url":24,"identifiers":3763},"Liu, Y. L. et al. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nat. Commun. 5, 4309 (2014).",{"doi":3764},"10.1038\u002Fncomms5309",{"id":24,"text":3766,"url":24,"identifiers":3767},"Anstee, Q. M. & Day, C. P. The genetics of nonalcoholic fatty liver disease: spotlight on PNPLA3 and TM6SF2. Semin. Liver Dis. 35, 270–290 (2015).",{"doi":3768},"10.1055\u002Fs-0035-1562947",{"id":24,"text":3770,"url":24,"identifiers":3771},"Kahali, B. et al. TM6SF2: catch-22 in the fight against nonalcoholic fatty liver disease and cardiovascular disease? Gastroenterology 148, 679–684 (2015).",{"doi":3772},"10.1053\u002Fj.gastro.2015.01.038",{"id":24,"text":3774,"url":24,"identifiers":3775},"Anstee, Q. M., Seth, D. & Day, C. P. Genetic factors that affect risk of alcoholic and nonalcoholic fatty liver disease. Gastroenterology 150, 1728–1744.e7 (2016).",{"doi":3776},"10.1053\u002Fj.gastro.2016.01.037",{"id":24,"text":3778,"url":24,"identifiers":3779},"Tilg, H., Moschen, A. R. & Szabo, G. Interleukin-1 and inflammasomes in alcoholic liver disease\u002Facute alcoholic hepatitis and nonalcoholic fatty liver disease\u002Fnonalcoholic steatohepatitis. Hepatology 64, 955–965 (2016).",{"doi":3780},"10.1002\u002Fhep.28456",{"id":24,"text":3782,"url":24,"identifiers":3783},"Cai, D. et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat. Med. 11, 183–190 (2005).",{"doi":3784},"10.1038\u002Fnm1166",{"id":24,"text":3786,"url":24,"identifiers":3787},"Arkan, M. C. et al. IKK-beta links inflammation to obesity-induced insulin resistance. Nat. Med. 11, 191–198 (2005).",{"doi":3788},"10.1038\u002Fnm1185",{"id":24,"text":3790,"url":24,"identifiers":3791},"Kiechl, S. et al. Blockade of receptor activator of nuclear factor-kappaB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus. Nat. Med. 19, 358–363 (2013).",{"doi":3792},"10.1038\u002Fnm.3084",{"id":24,"text":3794,"url":24,"identifiers":3795},"Mohamed-Ali, V. et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J. Clin. Endocrinol. Metab. 82, 4196–4200 (1997).",{},{"id":24,"text":3797,"url":24,"identifiers":3798},"Moschen, A. R. et al. Anti-inflammatory effects of excessive weight loss: potent suppression of adipose interleukin 6 and tumour necrosis factor alpha expression. Gut 59, 1259–1264 (2010).",{"doi":3799},"10.1136\u002Fgut.2010.214577",{"id":24,"text":3801,"url":24,"identifiers":3802},"Byrne, C. D. & Targher, G. Ectopic fat, insulin resistance, and nonalcoholic fatty liver disease: implications for cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 34, 1155–1161 (2014).",{"doi":3803},"10.1161\u002FATVBAHA.114.303034",{"id":24,"text":3805,"url":24,"identifiers":3806},"Katsiki, N., Athyros, V. G. & Mikhailidis, D. P. Abnormal peri-organ or intra-organ fat (APIFat) deposition: an underestimated predictor of vascular risk? Curr. Vasc. Pharmacol. 14, 432–441 (2016).",{"doi":3807},"10.2174\u002F1570161114666160722112738",{"id":24,"text":3809,"url":24,"identifiers":3810},"Kau, A. L., Ahern, P. P., Griffin, N. W., Goodman, A. L. & Gordon, J. I. Human nutrition, the gut microbiome and the immune system. Nature 474, 327–336 (2011).",{"doi":3811},"10.1038\u002Fnature10213",{"id":24,"text":3813,"url":24,"identifiers":3814},"Tilg, H. & Moschen, A. R. Food, immunity, and the microbiome. Gastroenterology 148, 1107–1119 (2015).",{"doi":3815},"10.1053\u002Fj.gastro.2014.12.036",{"id":24,"text":3817,"url":24,"identifiers":3818},"Calder, P. C. Fatty acids and inflammation: the cutting edge between food and pharma. Eur. J. Pharmacol. 668 (Suppl. 1), S50–S58 (2011).",{"doi":3819},"10.1016\u002Fj.ejphar.2011.05.085",{"id":24,"text":3821,"url":24,"identifiers":3822},"Pendyala, S., Walker, J. M. & Holt, P. R. A high-fat diet is associated with endotoxemia that originates from the gut. Gastroenterology 142, 1100–1101.e2 (2012).",{"doi":3823},"10.1053\u002Fj.gastro.2012.01.034",{"id":24,"text":3825,"url":24,"identifiers":3826},"Wang, Z. et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472, 57–63 (2011).",{"doi":3827},"10.1038\u002Fnature09922",{"id":24,"text":3829,"url":24,"identifiers":3830},"Chen, Y. M. et al. Associations of gut-flora-dependent metabolite trimethylamine-N-oxide, betaine and choline with non-alcoholic fatty liver disease in adults. Sci. Rep. 6, 19076 (2016).",{"doi":3831},"10.1038\u002Fsrep19076",{"id":24,"text":3833,"url":24,"identifiers":3834},"Loomba, R. et al. Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease. Cell Metab. 25, 1054–1062.e5 (2017).",{"doi":3835},"10.1016\u002Fj.cmet.2017.04.001",{"id":24,"text":3837,"url":24,"identifiers":3838},"Moschen, A. R., Kaser, S. & Tilg, H. Non-alcoholic steatohepatitis: a microbiota-driven disease. Trends Endocrinol. Metab. 24, 537–545 (2013).",{"doi":3839},"10.1016\u002Fj.tem.2013.05.009",{"id":24,"text":3841,"url":24,"identifiers":3842},"Shanahan, F., van Sinderen, D., O’Toole, P. W. & Stanton, C. Feeding the microbiota: transducer of nutrient signals for the host. Gut 66, 1709–1717 (2017).",{"doi":3843},"10.1136\u002Fgutjnl-2017-313872",{"id":24,"text":3845,"url":24,"identifiers":3846},"Dusi, V., Ghidoni, A., Ravera, A., De Ferrari, G. M. & Calvillo, L. Chemokines and heart disease: a network connecting cardiovascular biology to immune and autonomic nervous systems. Mediators Inflamm. 2016, 5902947 (2016).",{"doi":3847},"10.1155\u002F2016\u002F5902947",{"id":24,"text":3849,"url":24,"identifiers":3850},"Lazzerini, P. E., Capecchi, P. L. & Laghi-Pasini, F. Systemic inflammation and arrhythmic risk: lessons from rheumatoid arthritis. Eur. Heart J. 38, 1717–1727 (2017).",{},{"id":24,"text":3852,"url":24,"identifiers":3853},"Yalta, T. & Yalta, K. Systemic inflammation and arrhythmogenesis: a review of mechanistic and clinical perspectives. Angiology 69, 288–296 (2017).",{"doi":3854},"10.1177\u002F0003319717709380",{"id":24,"text":3856,"url":24,"identifiers":3857},"Duewell, P. et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464, 1357–1361 (2010).",{"doi":3858},"10.1038\u002Fnature08938",{"id":24,"text":3860,"url":24,"identifiers":3861},"Ridker, P. M. et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 377, 1119–1131 (2017).",{"doi":3862},"10.1056\u002FNEJMoa1707914",{"id":24,"text":3864,"url":24,"identifiers":3865},"Monnerat, G. et al. Macrophage-dependent IL-1beta production induces cardiac arrhythmias in diabetic mice. Nat. Commun. 7, 13344 (2016).",{"doi":3866},"10.1038\u002Fncomms13344",{"id":24,"text":3868,"url":24,"identifiers":3869},"Aschar-Sobbi, R. et al. Increased atrial arrhythmia susceptibility induced by intense endurance exercise in mice requires TNFalpha. Nat. Commun. 6, 6018 (2015).",{"doi":3870},"10.1038\u002Fncomms7018",{"id":24,"text":3872,"url":24,"identifiers":3873},"Abramochkin, D. V. et al. TNF-alpha provokes electrical abnormalities in rat atrial myocardium via a NO-dependent mechanism. Pflugers Arch. 465, 1741–1752 (2013).",{"doi":3874},"10.1007\u002Fs00424-013-1320-2",{"id":24,"text":3876,"url":24,"identifiers":3877},"London, B. et al. Calcium-dependent arrhythmias in transgenic mice with heart failure. Am. J. Physiol. Heart Circ. Physiol. 284, H431–H441 (2003).",{"doi":3878},"10.1152\u002Fajpheart.00431.2002",{"id":24,"text":3880,"url":24,"identifiers":3881},"Kawada, H. et al. Tumor necrosis factor-alpha downregulates the voltage gated outward K+ current in cultured neonatal rat cardiomyocytes: a possible cause of electrical remodeling in diseased hearts. Circ. J. 70, 605–609 (2006).",{"doi":3882},"10.1253\u002Fcircj.70.605",{"id":24,"text":3884,"url":24,"identifiers":3885},"Panama, B. K. et al. Nuclear factor kappaB downregulates the transient outward potassium current I(to,f) through control of KChIP2 expression. Circ. Res. 108, 537–543 (2011).",{"doi":3886},"10.1161\u002FCIRCRESAHA.110.229112",{"id":24,"text":3888,"url":24,"identifiers":3889},"Fu, X. X. et al. Interleukin-17A contributes to the development of post-operative atrial fibrillation by regulating inflammation and fibrosis in rats with sterile pericarditis. Int. J. Mol. Med. 36, 83–92 (2015).",{"doi":3890},"10.3892\u002Fijmm.2015.2204",{"id":24,"text":3892,"url":24,"identifiers":3893},"Takahashi, K. et al. High-fat diet increases vulnerability to atrial arrhythmia by conduction disturbance via miR-27b. J. Mol. Cell Cardiol. 90, 38–46 (2016).",{"doi":3894},"10.1016\u002Fj.yjmcc.2015.11.034",{"id":24,"text":3896,"url":24,"identifiers":3897},"Luo, B. et al. NLRP3 gene silencing ameliorates diabetic cardiomyopathy in a type 2 diabetes rat model. PLoS ONE 9, e104771 (2014).",{"doi":3898},"10.1371\u002Fjournal.pone.0104771",{"id":24,"text":3900,"url":24,"identifiers":3901},"Toldo, S. et al. Interleukin-1beta blockade improves left ventricular systolic\u002Fdiastolic function and restores contractility reserve in severe ischemic cardiomyopathy in the mouse. J. Cardiovasc. Pharmacol. 64, 1–6 (2014).",{"doi":3902},"10.1097\u002FFJC.0000000000000106",{"id":24,"text":3904,"url":24,"identifiers":3905},"Van Tassell, B. W., Raleigh, J. M. & Abbate, A. Targeting interleukin-1 in heart failure and inflammatory heart disease. Curr. Heart Fail. Rep. 12, 33–41 (2015).",{"doi":3906},"10.1007\u002Fs11897-014-0231-7",{"id":24,"text":3908,"url":24,"identifiers":3909},"Amdur, R. L. et al. Interleukin-6 is a risk factor for atrial fibrillation in chronic kidney disease: findings from the CRIC study. PLoS ONE 11, e0148189 (2016).",{"doi":3910},"10.1371\u002Fjournal.pone.0148189",{"id":24,"text":3912,"url":24,"identifiers":3913},"Wu, N. et al. Association of inflammatory factors with occurrence and recurrence of atrial fibrillation: a meta-analysis. Int. J. Cardiol. 169, 62–72 (2013).",{"doi":3914},"10.1016\u002Fj.ijcard.2013.08.078",{"id":24,"text":3916,"url":24,"identifiers":3917},"Chalasani, N. et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67, 328–357 (2017).",{"doi":3918},"10.1002\u002Fhep.29367",{"id":24,"text":3920,"url":24,"identifiers":3921},"Zhang, H. J. et al. Effects of moderate and vigorous exercise on nonalcoholic fatty liver disease: a randomized clinical trial. JAMA Intern. Med. 176, 1074–1082 (2016).",{"doi":3922},"10.1001\u002Fjamainternmed.2016.3202",{"id":24,"text":3924,"url":24,"identifiers":3925},"Promrat, K. et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 51, 121–129 (2010).",{"doi":3926},"10.1002\u002Fhep.23276",{"id":24,"text":3928,"url":24,"identifiers":3929},"Vilar-Gomez, E. et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 149, 367–378 (2015).",{"doi":3930},"10.1053\u002Fj.gastro.2015.04.005",{"id":24,"text":3932,"url":24,"identifiers":3933},"Fontana, L., Meyer, T. E., Klein, S. & Holloszy, J. O. Long-term calorie restriction is highly effective in reducing the risk for atherosclerosis in humans. Proc. Natl Acad. Sci. USA 101, 6659–6663 (2004).",{"doi":3934},"10.1073\u002Fpnas.0308291101",{"id":24,"text":3936,"url":24,"identifiers":3937},"Gupta, P. P., Fonarow, G. C. & Horwich, T. B. Obesity and the obesity paradox in heart failure. Can. J. Cardiol. 31, 195–202 (2015).",{"doi":3938},"10.1016\u002Fj.cjca.2014.08.004",{"id":24,"text":3940,"url":24,"identifiers":3941},"Mantovani, A., Ballestri, S., Lonardo, A. & Targher, G. Cardiovascular disease and myocardial abnormalities in nonalcoholic fatty liver disease. Dig. Dis. Sci. 61, 1246–1267 (2016).",{"doi":3942},"10.1007\u002Fs10620-016-4040-6",{"id":24,"text":3944,"url":24,"identifiers":3945},"Karimian, S., Stein, J., Bauer, B. & Teupe, C. Improvement of impaired diastolic left ventricular function after diet-induced weight reduction in severe obesity. Diabetes Metab. Syndr. Obes. 10, 19–25 (2017).",{"doi":3946},"10.2147\u002FDMSO.S124541",{"id":24,"text":3948,"url":24,"identifiers":3949},"Mahajan, R., Lau, D. H. & Sanders, P. Impact of obesity on cardiac metabolism, fibrosis, and function. Trends Cardiovasc. Med. 25, 119–126 (2015).",{"doi":3950},"10.1016\u002Fj.tcm.2014.09.005",{"id":24,"text":3952,"url":24,"identifiers":3953},"Heneghan, H. M., Meron-Eldar, S., Brethauer, S. A., Schauer, P. R. & Young, J. B. Effect of bariatric surgery on cardiovascular risk profile. Am. J. Cardiol. 108, 1499–1507 (2011).",{"doi":3954},"10.1016\u002Fj.amjcard.2011.06.076",{"id":24,"text":3956,"url":24,"identifiers":3957},"Poirier, P. et al. Bariatric surgery and cardiovascular risk factors: a scientific statement from the American Heart Association. Circulation 123, 1683–1701 (2011).",{"doi":3958},"10.1161\u002FCIR.0b013e3182149099",{"id":24,"text":3960,"url":24,"identifiers":3961},"de las Fuentes, L. et al. Effect of moderate diet-induced weight loss and weight regain on cardiovascular structure and function. J. Am. Coll. Cardiol. 54, 2376–2381 (2009).",{"doi":3962},"10.1016\u002Fj.jacc.2009.07.054",{"id":24,"text":3964,"url":24,"identifiers":3965},"Lin, J. S. et al. Behavioral counseling to promote a healthy lifestyle in persons with cardiovascular risk factors: a systematic review for the U.S. Preventive Services Task Force. Ann. Intern. Med. 161, 568–578 (2014).",{"doi":3966},"10.7326\u002FM14-0130",{"id":24,"text":3968,"url":24,"identifiers":3969},"Hallsworth, K. et al. Modified high-intensity interval training reduces liver fat and improves cardiac function in non-alcoholic fatty liver disease: a randomized controlled trial. Clin. Sci. 129, 1097–1105 (2015).",{"doi":3970},"10.1042\u002FCS20150308",{"id":24,"text":3972,"url":24,"identifiers":3973},"Horwich, T. B. et al. The relationship between obesity and mortality in patients with heart failure. J. Am. Coll. Cardiol. 38, 789–795 (2001).",{"doi":3974},"10.1016\u002FS0735-1097(01)01448-6",{"id":24,"text":3976,"url":24,"identifiers":3977},"Bozkurt, B. & Deswal, A. Obesity as a prognostic factor in chronic symptomatic heart failure. Am. Heart J. 150, 1233–1239 (2005).",{"doi":3978},"10.1016\u002Fj.ahj.2005.02.004",{"id":24,"text":3980,"url":24,"identifiers":3981},"Oreopoulos, A. et al. Body mass index and mortality in heart failure: a meta-analysis. Am. Heart J. 156, 13–22 (2008).",{"doi":3982},"10.1016\u002Fj.ahj.2008.02.014",{"id":24,"text":3984,"url":24,"identifiers":3985},"Frith, J. et al. Potential strategies to improve uptake of exercise interventions in non-alcoholic fatty liver disease. J. Hepatol. 52, 112–116 (2010).",{"doi":3986},"10.1016\u002Fj.jhep.2009.10.010",{"id":24,"text":3988,"url":24,"identifiers":3989},"Centis, E. et al. Stage of change and motivation to healthier lifestyle in non-alcoholic fatty liver disease. J. Hepatol. 58, 771–777 (2013).",{"doi":3990},"10.1016\u002Fj.jhep.2012.11.031",{"id":24,"text":3992,"url":24,"identifiers":3993},"Angulo, P. et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 149, 389–397.e10 (2015).",{"doi":3994},"10.1053\u002Fj.gastro.2015.04.043",{"id":24,"text":3996,"url":24,"identifiers":3997},"Taylor, F. et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst. Rev. 1, CD004816 (2013).",{},{"id":24,"text":3999,"url":24,"identifiers":4000},"Keene, D., Price, C., Shun-Shin, M. J. & Francis, D. P. Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients. BMJ 349, g4379 (2014).",{"doi":4001},"10.1136\u002Fbmj.g4379",{"id":24,"text":4003,"url":24,"identifiers":4004},"Gudzune, K. A. et al. Effectiveness of combination therapy with statin and another lipid-modifying agent compared with intensified statin monotherapy: a systematic review. Ann. Intern. Med. 160, 468–476 (2014).",{"doi":4005},"10.7326\u002FM13-2526",{"id":24,"text":4007,"url":24,"identifiers":4008},"Dongiovanni, P. et al. Statin use and non-alcoholic steatohepatitis in at risk individuals. J. Hepatol. 63, 705–712 (2015).",{"doi":4009},"10.1016\u002Fj.jhep.2015.05.006",{"id":24,"text":4011,"url":24,"identifiers":4012},"Lonardo, A. & Loria, P. Potential for statins in the chemoprevention and management of hepatocellular carcinoma. J. Gastroenterol. Hepatol. 27, 1654–1664 (2012).",{"doi":4013},"10.1111\u002Fj.1440-1746.2012.07232.x",{"id":24,"text":4015,"url":24,"identifiers":4016},"Rzouq, F. S. et al. Hepatotoxicity fears contribute to underutilization of statin medications by primary care physicians. Am. J. Med. Sci. 340, 89–93 (2010).",{"doi":4017},"10.1097\u002FMAJ.0b013e3181e15da8",{"id":24,"text":4019,"url":24,"identifiers":4020},"Bays, H., Cohen, D. E., Chalasani, N., Harrison, S. A. & The National Lipid Association’s Statin Safety Task Force. An assessment by the statin liver safety task force: 2014 update. J. Clin. Lipidol. 8, S47–S57 (2014).",{"doi":4021},"10.1016\u002Fj.jacl.2014.02.011",{"id":24,"text":4023,"url":24,"identifiers":4024},"Lewis, J. H. Clinical perspective: statins and the liver — harmful or helpful? Dig. Dis. Sci. 57, 1754–1763 (2012).",{"doi":4025},"10.1007\u002Fs10620-012-2207-3",{"id":24,"text":4027,"url":24,"identifiers":4028},"Athyros, V. G. et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 376, 1916–1922 (2010).",{"doi":4029},"10.1016\u002FS0140-6736(10)61272-X",{"id":24,"text":4031,"url":24,"identifiers":4032},"Tikkanen, M. J. et al. Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels. Int. J. Cardiol. 168, 3846–3852 (2013).",{"doi":4033},"10.1016\u002Fj.ijcard.2013.06.024",{"id":24,"text":4035,"url":24,"identifiers":4036},"Musso, G., Gambino, R., Cassader, M. & Pagano, G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 52, 79–104 (2010).",{"doi":4037},"10.1002\u002Fhep.23623",{"id":24,"text":4039,"url":24,"identifiers":4040},"Hirose, A. et al. Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis. Hepatology 45, 1375–1381 (2007).",{"doi":4041},"10.1002\u002Fhep.21638",{"id":24,"text":4043,"url":24,"identifiers":4044},"Yokohama, S. et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 40, 1222–1225 (2004).",{"doi":4045},"10.1002\u002Fhep.20420",{"id":24,"text":4047,"url":24,"identifiers":4048},"Georgescu, E. F., Ionescu, R., Niculescu, M., Mogoanta, L. & Vancica, L. Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis. World J. Gastroenterol. 15, 942–954 (2009).",{"doi":4049},"10.3748\u002Fwjg.15.942",{"id":24,"text":4051,"url":24,"identifiers":4052},"McPherson, S. et al. A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis. PLoS ONE 12, e0175717 (2017).",{"doi":4053},"10.1371\u002Fjournal.pone.0175717",{"id":24,"text":4055,"url":24,"identifiers":4056},"Sanyal, A. J. et al. No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. Gastroenterology 147, 377–384.e1 (2014).",{"doi":4057},"10.1053\u002Fj.gastro.2014.04.046",{"id":24,"text":4059,"url":24,"identifiers":4060},"Argo, C. K. et al. Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial. J. Hepatol. 62, 190–197 (2015).",{"doi":4061},"10.1016\u002Fj.jhep.2014.08.036",{"id":24,"text":4063,"url":24,"identifiers":4064},"Foretz, M., Guigas, B., Bertrand, L., Pollak, M. & Viollet, B. Metformin: from mechanisms of action to therapies. Cell Metab. 20, 953–966 (2014).",{"doi":4065},"10.1016\u002Fj.cmet.2014.09.018",{"id":24,"text":4067,"url":24,"identifiers":4068},"Chen, H. P. et al. Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. Gut 62, 606–615 (2013).",{"doi":4069},"10.1136\u002Fgutjnl-2011-301708",{"id":24,"text":4071,"url":24,"identifiers":4072},"Zhang, Z. J. et al. Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 97, 2347–2353 (2012).",{"doi":4073},"10.1210\u002Fjc.2012-1267",{"id":24,"text":4075,"url":24,"identifiers":4076},"Sanyal, A. J. et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med. 362, 1675–1685 (2010).",{"doi":4077},"10.1056\u002FNEJMoa0907929",{"id":24,"text":4079,"url":24,"identifiers":4080},"Cusi, K. et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann. Intern. Med. 165, 305–315 (2016).",{"doi":4081},"10.7326\u002FM15-1774",{"id":24,"text":4083,"url":24,"identifiers":4084},"Armstrong, M. J. et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 387, 679–690 (2016).",{"doi":4085},"10.1016\u002FS0140-6736(15)00803-X",{"id":24,"text":4087,"url":24,"identifiers":4088},"Marso, S. P. et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 375, 311–322 (2016).",{"doi":4089},"10.1056\u002FNEJMoa1603827",{"id":24,"text":4091,"url":24,"identifiers":4092},"Perazzo, H. & Dufour, J. F. The therapeutic landscape of non-alcoholic steatohepatitis. Liver Int. 37, 634–647 (2017).",{"doi":4093},"10.1111\u002Fliv.13270",{"id":24,"text":4095,"url":24,"identifiers":4096},"Neuschwander-Tetri, B. A. et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385, 956–965 (2015).",{"doi":4097},"10.1016\u002FS0140-6736(14)61933-4",{"id":24,"text":4099,"url":24,"identifiers":4100},"Ratziu, V. et al. Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and -delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology 150, 1147–1159.e5 (2016).",{"doi":4101},"10.1053\u002Fj.gastro.2016.01.038",{"id":24,"text":4103,"url":24,"identifiers":4104},"Friedman, S. L. et al. A randomized, placebo-ontrolled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. Hepatology \n                    https:\u002F\u002Fdoi.org\u002F10.1002\u002Fhep.29477\n                    \n                   (2018).",{"doi":4105},"10.1002\u002Fhep.29477",{"id":24,"text":4107,"url":24,"identifiers":4108},"Loomba, R. et al. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: a randomized, phase 2 trial. Hepatology 67, 549–559 (2018).",{"doi":4109},"10.1002\u002Fhep.29514",{"id":4111,"createTime":4112,"updateTime":4112,"relativeEntities":4113,"slug":4114,"properties":4115,"entityType":184,"verifyStatus":185,"verifyTime":4128,"verifyNote":186,"syncStatus":23,"languages":4129,"translateLanguages":24,"viewCount":25,"primaryUrl":4130,"fullTextUrl":24,"authors":4131,"publicationType":310,"publisherRelationship":4230,"citationCount":4267,"citationInfo":4268,"publishDate":4272,"publishYear":4273,"citationAnalyzeStatus":23,"lastCitationAnalyze":24,"indexDatabases":24,"openAccess":24,"references":4274,"isForceReanalyzing":595},"93cd1ddb-e2cd-419a-98a6-a87ee7c10ce5","2024-12-30T22:26:29.246+00:00",[],"New-insights-into-IL-6-family-cytokines-in-metabolism-hepatology-and-gastroenterology",{"mag":4116,"keywords":4118,"openalex":4119,"abstract":4121,"title":4122,"pm":4124,"doi":4126},{"VOID":4117},"3176555726",{},{"VOID":4120},"W3176555726",{},{"EN":4123},"New insights into IL-6 family cytokines in metabolism, hepatology and gastroenterology",{"VOID":4125},"34211157",{"VOID":4127},"10.1038\u002Fs41575-021-00473-x","2024-12-30T22:26:29.245+00:00",[188],"https:\u002F\u002Fwww.nature.com\u002Farticles\u002Fs41575-021-00473-x",[4132,4153,4170,4191,4208],{"id":4133,"sortIndex":215,"researcher":24,"roles":4134,"affiliations":4135,"properties":4146},"30da5dfc-640b-468f-be2a-e706c0ba2eb9",[],[4136],{"id":4137,"sortIndex":25,"affiliation":4138,"properties":24},"58d516b6-e09f-4020-9616-49b79ae59ce7",{"id":4139,"createTime":4140,"updateTime":4140,"relativeEntities":4141,"slug":4142,"properties":4143,"entityType":53,"verifyStatus":23,"verifyTime":24,"verifyNote":24,"syncStatus":23,"languages":24,"translateLanguages":24,"viewCount":25},"3a6c1ef5-ec66-4c0c-8ae3-1f8bc147996d","2024-12-30T22:26:29.256+00:00",[],"Institute-of-Biomedicine-of-Seville-IBIS-Spanish-National-Research-Council-CSIC-University-of-Seville-Virgen-del-Rocio-University-Hospital-Seville-Spain",{"title":4144},{"EN":4145},"Institute of Biomedicine of Seville (IBIS), Spanish National Research Council (CSIC), University of Seville, Virgen del Rocio University Hospital, Seville, Spain",{"openalex":4147,"orcid":4149,"title":4151},{"VOID":4148},"A5091090632",{"VOID":4150},"https:\u002F\u002Forcid.org\u002F0000-0001-5124-4708",{"EN":4152},"David Carneros",{"id":4154,"sortIndex":25,"researcher":24,"roles":4155,"affiliations":4156,"properties":4163},"dd54f123-82fc-446d-891e-3cc2d6306e8b",[],[4157],{"id":4158,"sortIndex":25,"affiliation":4159,"properties":24},"f05abe5c-ccb2-4ff5-9270-5c86cca29029",{"id":4139,"createTime":4140,"updateTime":4140,"relativeEntities":4160,"slug":4142,"properties":4161,"entityType":53,"verifyStatus":23,"verifyTime":24,"verifyNote":24,"syncStatus":23,"languages":24,"translateLanguages":24,"viewCount":25},[],{"title":4162},{"EN":4145},{"openalex":4164,"orcid":4166,"title":4168},{"VOID":4165},"A5037781040",{"VOID":4167},"https:\u002F\u002Forcid.org\u002F0000-0001-6829-7603",{"EN":4169},"María D. Giraldez",{"id":4171,"sortIndex":126,"researcher":24,"roles":4172,"affiliations":4173,"properties":4184},"c2003638-8f76-4d4b-bedc-afda92f0fd4e",[],[4174],{"id":4175,"sortIndex":25,"affiliation":4176,"properties":24},"ba4440fc-026b-4a4d-8d85-535cffa81606",{"id":4177,"createTime":4178,"updateTime":4178,"relativeEntities":4179,"slug":4180,"properties":4181,"entityType":53,"verifyStatus":23,"verifyTime":24,"verifyNote":24,"syncStatus":23,"languages":24,"translateLanguages":24,"viewCount":25},"b481adc5-2fb4-4c89-81ba-09de4e311785","2024-12-30T22:26:29.292+00:00",[],"Department-of-Pathology-Medical-Faculty-Otto-von-Guericke-University-Magdeburg-Magdeburg-Germany",{"title":4182},{"EN":4183},"Department of Pathology, Medical Faculty, Otto-von-Guericke-University Magdeburg, Magdeburg, Germany",{"openalex":4185,"orcid":4187,"title":4189},{"VOID":4186},"A5025552082",{"VOID":4188},"https:\u002F\u002Forcid.org\u002F0000-0003-4939-6950",{"EN":4190},"Christoph Garbers",{"id":4192,"sortIndex":127,"researcher":24,"roles":4193,"affiliations":4194,"properties":4201},"f8f1031a-a11b-4e8e-8629-24f4ced9153a",[],[4195],{"id":4196,"sortIndex":25,"affiliation":4197,"properties":24},"ce747fcf-b921-4edf-bf34-22254d943cc0",{"id":4139,"createTime":4140,"updateTime":4140,"relativeEntities":4198,"slug":4142,"properties":4199,"entityType":53,"verifyStatus":23,"verifyTime":24,"verifyNote":24,"syncStatus":23,"languages":24,"translateLanguages":24,"viewCount":25},[],{"title":4200},{"EN":4145},{"openalex":4202,"orcid":4204,"title":4206},{"VOID":4203},"A5041697627",{"VOID":4205},"https:\u002F\u002Forcid.org\u002F0000-0003-2306-9548",{"EN":4207},"Matilde Bustos",{"id":4209,"sortIndex":124,"researcher":24,"roles":4210,"affiliations":4211,"properties":4223},"b94f2e3e-d8fb-41ed-bad7-42f968bb4602",[],[4212],{"id":4213,"sortIndex":25,"affiliation":4214,"properties":24},"c7c946ff-bd24-49c5-a7ce-e1d06175dc7f",{"id":4215,"createTime":4216,"updateTime":4217,"relativeEntities":4218,"slug":4219,"properties":4220,"entityType":53,"verifyStatus":23,"verifyTime":24,"verifyNote":24,"syncStatus":23,"languages":24,"translateLanguages":24,"viewCount":25},"7fba9167-7012-4d71-bfad-14dd1794c25c","2024-01-09T11:05:03.996+00:00","2024-12-30T22:26:29.303+00:00",[],"Institute-of-Biochemistry-Kiel-University-Kiel-Germany",{"title":4221},{"VI":4222},"Institute of Biochemistry, Kiel University, Kiel, Germany",{"openalex":4224,"orcid":4226,"title":4228},{"VOID":4225},"A5089057275",{"VOID":4227},"https:\u002F\u002Forcid.org\u002F0000-0002-7519-3279",{"EN":4229},"Stefan Rose‐John",{"url":24,"publisher":4231,"properties":4261},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":4232,"slug":10,"properties":4233,"entityType":22,"verifyStatus":23,"verifyTime":24,"verifyNote":24,"syncStatus":23,"languages":24,"translateLanguages":24,"viewCount":25,"subjectFields":4239,"manageAffiliations":4240,"indexDatabases":4241,"url":106,"thumbnailPath":24,"statistic":4256,"gsStatistic":24,"type":24,"analyzePriority":24},[],{"country":4234,"issn":4235,"introduce":4236,"eissn":4237,"title":4238},{"VOID":13},{"VOID":15},{"EN":17},{"VOID":19},{"EN":21},[],[],[4242,4249],{"id":88,"indexDatabase":4243,"url":103,"indexYears":24,"academicFieldIds":4248,"indexDatabaseRanking":24},{"id":90,"createTime":91,"updateTime":92,"relativeEntities":4244,"label":4245,"description":4246,"key":99,"publicationTags":4247,"standard":24},[],{"EN":95,"VI":95},{"VI":97,"EN":98},[101,102],[105],{"id":68,"indexDatabase":4250,"url":81,"indexYears":82,"academicFieldIds":4255,"indexDatabaseRanking":86},{"id":70,"createTime":71,"updateTime":72,"relativeEntities":4251,"label":4252,"description":4253,"key":78,"publicationTags":4254,"standard":24},[],{"EN":75,"VI":75},{"EN":75,"VI":77},[80],[84,85],{"impactFactor":25,"impactFactorByYear":4257,"i10Index":121,"i10IndexLast5Year":122,"totalPublication":121,"totalPublicationByYear":4258,"totalCitation":129,"totalCitationByYear":4259,"totalCitationPerPublication":145,"totalCitationPerPublicationByYear":4260,"hindexLast5Year":161,"hindex":161},{"2012":109,"2013":110,"2014":111,"2015":112,"2016":113,"2017":114,"2018":115,"2019":116,"2020":117,"2021":118,"2022":119,"2023":120},{"2009":124,"2010":124,"2011":125,"2012":126,"2013":127,"2014":124,"2015":125,"2016":127,"2017":128,"2018":127,"2019":127,"2020":126,"2021":125,"2022":126},{"2009":131,"2010":132,"2011":133,"2012":134,"2013":135,"2014":136,"2015":137,"2016":138,"2017":139,"2018":140,"2019":141,"2020":142,"2021":143,"2022":144},{"2009":147,"2010":148,"2011":149,"2012":150,"2013":151,"2014":152,"2015":153,"2016":154,"2017":155,"2018":156,"2019":157,"2020":158,"2021":159,"2022":160},{"volume":4262,"pages":4264,"issue":4266},{"VOID":4263},"18",{"VOID":4265},"787-803",{"VOID":3092},97,{"total":4267,"publishYear":24,"statisticByYear":4269},{"2021":4270,"2022":356,"2023":4271,"2024":354},9,34,"2021-11-01",2021,[4275,4279,4283,4287,4291,4295,4298,4302,4306,4310,4314,4318,4322,4326,4330,4334,4338,4342,4346,4350,4354,4358,4362,4366,4370,4373,4377,4381,4385,4389,4393,4397,4400,4404,4408,4412,4416,4420,4424,4428,4432,4436,4440,4444,4448,4452,4456,4460,4464,4468,4472,4476,4480,4484,4488,4492,4496,4500,4504,4508,4512,4516,4520,4523,4527,4531,4535,4539,4543,4547,4551,4555,4559,4563,4567,4571,4575,4579,4583,4587,4591,4595,4599,4603,4607,4611,4615,4619,4623,4627,4631,4635,4639,4643,4647,4651,4655,4659,4663,4667,4671,4674,4678,4682,4686,4690,4694,4697,4701,4704,4708,4712,4716,4720,4724,4728,4732,4736,4740,4743,4747,4751,4755,4759,4763,4767,4771,4775,4779,4783,4787,4791,4795,4799,4803,4807,4811,4815,4819,4823,4827,4831,4835,4839,4843,4847,4851,4855,4859,4863,4867,4871,4875,4879,4883,4887,4891,4895,4899,4903,4907,4911,4915,4919,4923,4927,4931,4935,4939,4943,4946,4949,4953,4957,4961,4964,4968,4972,4976,4980,4984,4988,4992,4995,4999,5003,5007,5011,5015,5019,5023,5026,5030,5034,5038,5042,5046,5050,5054,5058,5062,5066,5070,5073,5077,5081,5085,5089,5093,5096,5099,5103,5106,5110,5114,5118,5122,5125,5129,5132,5135,5139,5143,5147,5150,5154,5158,5162,5166,5170,5173,5177,5181,5185,5188,5191,5195,5198,5201,5204,5207,5210,5213,5216,5219,5222,5226,5229,5232,5235,5238,5241,5244,5248,5251,5255,5258,5261,5264,5268,5272,5276,5280,5284,5288,5292,5296,5300,5304,5308,5312,5316],{"id":24,"text":4276,"url":24,"identifiers":4277},"Rose-John, S., Scheller, J. & Schaper, F. “Family reunion”–A structured view on the composition of the receptor complexes of interleukin-6-type and interleukin-12-type cytokines. Cytokine Growth Factor. Rev. 26, 471–474 (2015).",{"doi":4278},"10.1016\u002Fj.cytogfr.2015.07.011",{"id":24,"text":4280,"url":24,"identifiers":4281},"Johnson, D. E., O’Keefe, R. A. & Grandis, J. R. Targeting the IL-6\u002FJAK\u002FSTAT3 signalling axis in cancer. Nat. Rev. Clin. Oncol. 15, 234–248 (2018).",{"doi":4282},"10.1038\u002Fnrclinonc.2018.8",{"id":24,"text":4284,"url":24,"identifiers":4285},"Hunter, C. A. & Jones, S. A. IL-6 as a keystone cytokine in health and disease. Nat. Immunol. 16, 448–457 (2015).",{"doi":4286},"10.1038\u002Fni.3153",{"id":24,"text":4288,"url":24,"identifiers":4289},"Garbers, C., Heink, S., Korn, T. & Rose-John, S. Interleukin-6: designing specific therapeutics for a complex cytokine. Nat. Rev. Drug Discov. 17, 395–412 (2018).",{"doi":4290},"10.1038\u002Fnrd.2018.45",{"id":24,"text":4292,"url":24,"identifiers":4293},"Findeisen, M. et al. Treatment of type 2 diabetes with the designer cytokine IC7Fc. Nature 574, 63–68 (2019).",{"doi":4294},"10.1038\u002Fs41586-019-1601-9",{"id":24,"text":4296,"url":24,"identifiers":4297},"Mitsuyama, K. et al. Therapeutic strategies for targeting the IL-6\u002FSTAT3 cytokine signaling pathway in inflammatory bowel disease. Anticancer Res. 27, 3749–3756 (2007).",{},{"id":24,"text":4299,"url":24,"identifiers":4300},"Rose-John, S. Cytokines come of age. Biochim. Biophys. Acta 1592, 213–214 (2002).",{"doi":4301},"10.1016\u002FS0167-4889(02)00359-2",{"id":24,"text":4303,"url":24,"identifiers":4304},"Wang, X., Lupardus, P., Laporte, S. L. & Garcia, K. C. Structural biology of shared cytokine receptors. Annu. Rev. Immunol. 27, 29–60 (2009).",{"doi":4305},"10.1146\u002Fannurev.immunol.24.021605.090616",{"id":24,"text":4307,"url":24,"identifiers":4308},"Wilmes, S. et al. Mechanism of homodimeric cytokine receptor activation and dysregulation by oncogenic mutations. Science 367, 643–652 (2020).",{"doi":4309},"10.1126\u002Fscience.aaw3242",{"id":24,"text":4311,"url":24,"identifiers":4312},"Garbers, C. et al. Plasticity and cross-talk of interleukin 6-type cytokines. Cytokine Growth Factor. Rev. 23, 85–97 (2012).",{"doi":4313},"10.1016\u002Fj.cytogfr.2012.04.001",{"id":24,"text":4315,"url":24,"identifiers":4316},"Grötzinger, J., Kurapkat, G., Wollmer, A., Kalai, M. & Rose-John, S. The family of the IL-6-type cytokines: specificity and promiscuity of the receptor complexes. Proteins 27, 96–109 (1997).",{"doi":4317},"10.1002\u002F(SICI)1097-0134(199701)27:1\u003C96::AID-PROT10>3.0.CO;2-D",{"id":24,"text":4319,"url":24,"identifiers":4320},"Wilkinson, A. N. et al. Granulocytes are unresponsive to IL-6 due to an absence of gp130. J. Immunol. 200, 3547–3555 (2018).",{"doi":4321},"10.4049\u002Fjimmunol.1701191",{"id":24,"text":4323,"url":24,"identifiers":4324},"Jones, S. A. & Jenkins, B. J. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat. Rev. Immunol. 18, 773–789 (2018).",{"doi":4325},"10.1038\u002Fs41577-018-0066-7",{"id":24,"text":4327,"url":24,"identifiers":4328},"Lokau, J. & Garbers, C. Biological functions and therapeutic opportunities of soluble cytokine receptors. Cytokine Growth Factor Rev. 55, 94–108 (2020).",{"doi":4329},"10.1016\u002Fj.cytogfr.2020.04.003",{"id":24,"text":4331,"url":24,"identifiers":4332},"Riethmueller, S. et al. Proteolytic origin of the soluble human IL-6R in vivo and a decisive role of N-glycosylation. PLoS Biol. 15, e2000080 (2017).",{"doi":4333},"10.1371\u002Fjournal.pbio.2000080",{"id":24,"text":4335,"url":24,"identifiers":4336},"Müllberg, J. et al. The soluble interleukin-6 receptor is generated by shedding. Eur. J. Immunol. 23, 473–480 (1993).",{"doi":4337},"10.1002\u002Feji.1830230226",{"id":24,"text":4339,"url":24,"identifiers":4340},"Heink, S. et al. Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic T(H)17 cells. Nat. Immunol. 18, 74–85 (2017).",{"doi":4341},"10.1038\u002Fni.3632",{"id":24,"text":4343,"url":24,"identifiers":4344},"Garbers, C. & Scheller, J. Interleukin-6 and interleukin-11: same same but different. Biol. Chem. 394, 1145–1161 (2013).",{"doi":4345},"10.1515\u002Fhsz-2013-0166",{"id":24,"text":4347,"url":24,"identifiers":4348},"Putoczki, T. & Ernst, M. More than a sidekick: the IL-6 family cytokine IL-11 links inflammation to cancer. J. Leukoc. Biol. 88, 1109–1117 (2010).",{"doi":4349},"10.1189\u002Fjlb.0410226",{"id":24,"text":4351,"url":24,"identifiers":4352},"Lokau, J. et al. Proteolytic cleavage governs interleukin-11 trans-signaling. Cell Rep. 14, 1761–1773 (2016).",{"doi":4353},"10.1016\u002Fj.celrep.2016.01.053",{"id":24,"text":4355,"url":24,"identifiers":4356},"Sun, B. B. et al. Genomic atlas of the human plasma proteome. Nature 558, 73–79 (2018).",{"doi":4357},"10.1038\u002Fs41586-018-0175-2",{"id":24,"text":4359,"url":24,"identifiers":4360},"Lamertz, L. et al. Soluble gp130 prevents interleukin-6 and interleukin-11 cluster signaling but not intracellular autocrine responses. Sci. Signal 11, eaar7388 (2018).",{"doi":4361},"10.1126\u002Fscisignal.aar7388",{"id":24,"text":4363,"url":24,"identifiers":4364},"Heinrich, P. C. et al. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 374, 1–20 (2003).",{"doi":4365},"10.1042\u002Fbj20030407",{"id":24,"text":4367,"url":24,"identifiers":4368},"Schaper, F. & Rose-John, S. Interleukin-6: biology, signaling and strategies of blockade. Cytokine Growth Factor. Rev. 26, 475–487 (2015).",{"doi":4369},"10.1016\u002Fj.cytogfr.2015.07.004",{"id":24,"text":4371,"url":24,"identifiers":4372},"Bastard, J. P. et al. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J. Clin. Endocrinol. Metab. 85, 3338–3342 (2000).",{},{"id":24,"text":4374,"url":24,"identifiers":4375},"Steensberg, A. et al. Production of interleukin-6 in contracting human skeletal muscles can account for the exercise-induced increase in plasma interleukin-6. J. Physiol. 529, 237–242 (2000).",{"doi":4376},"10.1111\u002Fj.1469-7793.2000.00237.x",{"id":24,"text":4378,"url":24,"identifiers":4379},"Wojtaszewski, J. F. & Richter, E. A. Effects of acute exercise and training on insulin action and sensitivity: focus on molecular mechanisms in muscle. Essays Biochem. 42, 31–46 (2006).",{"doi":4380},"10.1042\u002Fbse0420031",{"id":24,"text":4382,"url":24,"identifiers":4383},"Wallenius, V. et al. Interleukin-6-deficient mice develop mature-onset obesity. Nat. Med. 8, 75–79 (2002).",{"doi":4384},"10.1038\u002Fnm0102-75",{"id":24,"text":4386,"url":24,"identifiers":4387},"Matthews, V. B. et al. Interleukin-6-deficient mice develop hepatic inflammation and systemic insulin resistance. Diabetologia 53, 2431–2441 (2010).",{"doi":4388},"10.1007\u002Fs00125-010-1865-y",{"id":24,"text":4390,"url":24,"identifiers":4391},"Sadagurski, M. et al. Human IL6 enhances leptin action in mice. Diabetologia 53, 525–535 (2010).",{"doi":4392},"10.1007\u002Fs00125-009-1580-8",{"id":24,"text":4394,"url":24,"identifiers":4395},"Sabio, G. et al. A stress signaling pathway in adipose tissue regulates hepatic insulin resistance. Science 322, 1539–1543 (2008).",{"doi":4396},"10.1126\u002Fscience.1160794",{"id":24,"text":4398,"url":24,"identifiers":4399},"Cai, D. et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-βB. Nat. Med. 11, 183–190 (2005).",{"doi":3784},{"id":24,"text":4401,"url":24,"identifiers":4402},"Ellingsgaard, H. et al. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat. Med. 17, 1481–1489 (2011).",{"doi":4403},"10.1038\u002Fnm.2513",{"id":24,"text":4405,"url":24,"identifiers":4406},"Ellingsgaard, H. et al. GLP-1 secretion is regulated by IL-6 signalling: a randomised, placebo-controlled study. Diabetologia 63, 362–373 (2020).",{"doi":4407},"10.1007\u002Fs00125-019-05045-y",{"id":24,"text":4409,"url":24,"identifiers":4410},"Han, M. S. et al. Regulation of adipose tissue inflammation by interleukin 6. Proc. Natl Acad. Sci. USA 117, 2751–2760 (2020).",{"doi":4411},"10.1073\u002Fpnas.1920004117",{"id":24,"text":4413,"url":24,"identifiers":4414},"Perry, R. J. et al. Hepatic acetyl CoA links adipose tissue inflammation to hepatic insulin resistance and type 2 diabetes. Cell 160, 745–758 (2015).",{"doi":4415},"10.1016\u002Fj.cell.2015.01.012",{"id":24,"text":4417,"url":24,"identifiers":4418},"Yamaguchi, K. et al. Blockade of interleukin 6 signalling ameliorates systemic insulin resistance through upregulation of glucose uptake in skeletal muscle and improves hepatic steatosis in high-fat diet fed mice. Liver Int. 35, 550–561 (2015).",{"doi":4419},"10.1111\u002Fliv.12645",{"id":24,"text":4421,"url":24,"identifiers":4422},"Yamaguchi, K. et al. Blockade of interleukin-6 signaling enhances hepatic steatosis but improves liver injury in methionine choline-deficient diet-fed mice. Lab. Invest. 90, 1169–1178 (2010).",{"doi":4423},"10.1038\u002Flabinvest.2010.75",{"id":24,"text":4425,"url":24,"identifiers":4426},"Wunderlich, F. T. et al. Interleukin-6 signaling in liver-parenchymal cells suppresses hepatic inflammation and improves systemic insulin action. Cell Metab. 12, 237–249 (2010).",{"doi":4427},"10.1016\u002Fj.cmet.2010.06.011",{"id":24,"text":4429,"url":24,"identifiers":4430},"Mauer, J. et al. Signaling by IL-6 promotes alternative activation of macrophages to limit endotoxemia and obesity-associated resistance to insulin. Nat. Immunol. 15, 423–430 (2014).",{"doi":4431},"10.1038\u002Fni.2865",{"id":24,"text":4433,"url":24,"identifiers":4434},"Timper, K. et al. IL-6 improves energy and glucose homeostasis in obesity via enhanced central IL-6 trans-signaling. Cell Rep. 19, 267–280 (2017).",{"doi":4435},"10.1016\u002Fj.celrep.2017.03.043",{"id":24,"text":4437,"url":24,"identifiers":4438},"Masu, Y. et al. Disruption of the CNTF gene results in motor neuron degeneration. Nature 365, 27–32 (1993).",{"doi":4439},"10.1038\u002F365027a0",{"id":24,"text":4441,"url":24,"identifiers":4442},"Pascual-Gamarra, J. M. et al. Association between CNTF polymorphisms and adiposity markers in European adolescents. J. Pediatr. 219, 23–30.e1 (2020).",{"doi":4443},"10.1016\u002Fj.jpeds.2019.12.036",{"id":24,"text":4445,"url":24,"identifiers":4446},"Watt, M. J. et al. CNTF reverses obesity-induced insulin resistance by activating skeletal muscle AMPK. Nat. Med. 12, 541–548 (2006).",{"doi":4447},"10.1038\u002Fnm1383",{"id":24,"text":4449,"url":24,"identifiers":4450},"Zvonic, S., Cornelius, P., Stewart, W. C., Mynatt, R. L. & Stephens, J. M. The regulation and activation of ciliary neurotrophic factor signaling proteins in adipocytes. J. Biol. Chem. 278, 2228–2235 (2003).",{"doi":4451},"10.1074\u002Fjbc.M205871200",{"id":24,"text":4453,"url":24,"identifiers":4454},"Perugini, J. et al. Biological effects of ciliary neurotrophic factor on hMADS adipocytes. Front. Endocrinol. 10, 768 (2019).",{"doi":4455},"10.3389\u002Ffendo.2019.00768",{"id":24,"text":4457,"url":24,"identifiers":4458},"Sleeman, M. W. et al. Ciliary neurotrophic factor improves diabetic parameters and hepatic steatosis and increases basal metabolic rate in db\u002Fdb mice. Proc. Natl Acad. Sci. USA 100, 14297–14302 (2003).",{"doi":4459},"10.1073\u002Fpnas.2335926100",{"id":24,"text":4461,"url":24,"identifiers":4462},"Cui, M. X. et al. Alleviative effect of ciliary neurotrophic factor analogue on high fat-induced hepatic steatosis is partially independent of the central regulation. Clin. Exp. Pharmacol. Physiol. 44, 395–402 (2017).",{"doi":4463},"10.1111\u002F1440-1681.12709",{"id":24,"text":4465,"url":24,"identifiers":4466},"López-Yoldi, M., Moreno-Aliaga, M. J. & Bustos, M. Cardiotrophin-1: a multifaceted cytokine. Cytokine Growth Factor. Rev. 26, 523–532 (2015).",{"doi":4467},"10.1016\u002Fj.cytogfr.2015.07.009",{"id":24,"text":4469,"url":24,"identifiers":4470},"Castaño, D. et al. Cardiotrophin-1 eliminates hepatic steatosis in obese mice by mechanisms involving AMPK activation. J. Hepatol. 60, 1017–1025 (2014).",{"doi":4471},"10.1016\u002Fj.jhep.2013.12.012",{"id":24,"text":4473,"url":24,"identifiers":4474},"Carneros, D. et al. Cardiotrophin-1 is an anti-inflammatory cytokine and promotes IL-4-induced M2 macrophage polarization. FASEB J. 33, 7578–7587 (2019).",{"doi":4475},"10.1096\u002Ffj.201801563R",{"id":24,"text":4477,"url":24,"identifiers":4478},"Lutz, S. Z. et al. Common genetic variation in the human CTF1 locus, encoding cardiotrophin-1, determines insulin sensitivity. PLoS ONE 9, e100391 (2014).",{"doi":4479},"10.1371\u002Fjournal.pone.0100391",{"id":24,"text":4481,"url":24,"identifiers":4482},"Rosado-Olivieri, E. A., Aigha, I. I., Kenty, J. H. & Melton, D. A. Identification of a LIF-responsive, replication-competent subpopulation of human β cells. Cell Metab. 31, 327–338.e6 (2020).",{"doi":4483},"10.1016\u002Fj.cmet.2019.12.009",{"id":24,"text":4485,"url":24,"identifiers":4486},"Stephens, J., Ravussin, E. & White, U. The expression of adipose tissue-derived cardiotrophin-1 in humans with obesity. Biology 8, 24 (2019).",{"doi":4487},"10.3390\u002Fbiology8020024",{"id":24,"text":4489,"url":24,"identifiers":4490},"Brandt, N. et al. Leukemia inhibitory factor increases glucose uptake in mouse skeletal muscle. Am. J. Physiol. Endocrinol. Metab. 309, E142–E153 (2015).",{"doi":4491},"10.1152\u002Fajpendo.00313.2014",{"id":24,"text":4493,"url":24,"identifiers":4494},"Broholm, C. et al. Deficient leukemia inhibitory factor signaling in muscle precursor cells from patients with type 2 diabetes. Am. J. Physiol. Endocrinol. Metab. 303, E283–E292 (2012).",{"doi":4495},"10.1152\u002Fajpendo.00586.2011",{"id":24,"text":4497,"url":24,"identifiers":4498},"Mahajan, A. et al. Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps. Nat. Genet. 50, 1505–1513 (2018).",{"doi":4499},"10.1038\u002Fs41588-018-0241-6",{"id":24,"text":4501,"url":24,"identifiers":4502},"Tanaka, M. et al. Reconstitution of the functional mouse oncostatin M (OSM) receptor: molecular cloning of the mouse OSM receptor beta subunit. Blood 93, 804–815 (1999).",{"doi":4503},"10.1182\u002Fblood.V93.3.804",{"id":24,"text":4505,"url":24,"identifiers":4506},"Luo, P. et al. Hepatic oncostatin M receptor β regulates obesity-induced steatosis and insulin resistance. Am. J. Pathol. 186, 1278–1292 (2016).",{"doi":4507},"10.1016\u002Fj.ajpath.2015.12.028",{"id":24,"text":4509,"url":24,"identifiers":4510},"Henkel, J. et al. Oncostatin M produced in Kupffer cells in response to PGE2: possible contributor to hepatic insulin resistance and steatosis. Lab. Invest. 91, 1107–1117 (2011).",{"doi":4511},"10.1038\u002Flabinvest.2011.47",{"id":24,"text":4513,"url":24,"identifiers":4514},"Komori, T., Tanaka, M., Senba, E., Miyajima, A. & Morikawa, Y. Deficiency of oncostatin M receptor β (OSMRβ) exacerbates high-fat diet-induced obesity and related metabolic disorders in mice. J. Biol. Chem. 289, 13821–13837 (2014).",{"doi":4515},"10.1074\u002Fjbc.M113.542399",{"id":24,"text":4517,"url":24,"identifiers":4518},"Baumann, H. & Gauldie, J. The acute phase response. Immunol. Today 15, 74–80 (1994).",{"doi":4519},"10.1016\u002F0167-5699(94)90137-6",{"id":24,"text":4521,"url":24,"identifiers":4522},"Espat, N. J. et al. Ciliary neurotrophic factor is catabolic and shares with IL-6 the capacity to induce an acute phase response. Am. J. Physiol. 271, R185–R190 (1996).",{},{"id":24,"text":4524,"url":24,"identifiers":4525},"Baumann, H. & Schendel, P. Interleukin-11 regulates the hepatic expression of the same plasma protein genes as interleukin-6. J. Biol. Chem. 266, 20424–20427 (1991).",{"doi":4526},"10.1016\u002FS0021-9258(18)54940-1",{"id":24,"text":4528,"url":24,"identifiers":4529},"Peters, M., Roeb, E., Pennica, D., Meyer zum Büschenfelde, K. H. & Rose-John, S. A new hepatocyte stimulating factor: cardiotrophin-1 (CT-1). FEBS Lett. 372, 177–180 (1995).",{"doi":4530},"10.1016\u002F0014-5793(95)00972-C",{"id":24,"text":4532,"url":24,"identifiers":4533},"Schooltink, H., Stoyan, T., Roeb, E., Heinrich, P. C. & Rose-John, S. Ciliary neurotrophic factor induces acute-phase protein expression in hepatocytes. FEBS Lett. 314, 280–284 (1992).",{"doi":4534},"10.1016\u002F0014-5793(92)81489-9",{"id":24,"text":4536,"url":24,"identifiers":4537},"Senaldi, G. et al. Novel neurotrophin-1\u002FB cell-stimulating factor-3: a cytokine of the IL-6 family. Proc. Natl Acad. Sci.USA 96, 11458–11463 (1999).",{"doi":4538},"10.1073\u002Fpnas.96.20.11458",{"id":24,"text":4540,"url":24,"identifiers":4541},"Dittrich, F., Thoenen, H. & Sendtner, M. Ciliary neurotrophic factor: pharmacokinetics and acute-phase response in rat. Ann. Neurol. 35, 151–163 (1994).",{"doi":4542},"10.1002\u002Fana.410350206",{"id":24,"text":4544,"url":24,"identifiers":4545},"Geiger, T. et al. Induction of rat acute-phase proteins by interleukin 6 in vivo. Eur. J. Immunol. 18, 717–721 (1988).",{"doi":4546},"10.1002\u002Feji.1830180510",{"id":24,"text":4548,"url":24,"identifiers":4549},"Metcalf, D., Nicola, N. A. & Gearing, D. P. Effects of injected leukemia inhibitory factor on hematopoietic and other tissues in mice. Blood 76, 50–56 (1990).",{"doi":4550},"10.1182\u002Fblood.V76.1.50.50",{"id":24,"text":4552,"url":24,"identifiers":4553},"Wallace, P. M. et al. In vivo properties of oncostatin M. Ann. N. Y. Acad. Sci. 762, 42–54 (1995).",{"doi":4554},"10.1111\u002Fj.1749-6632.1995.tb32313.x",{"id":24,"text":4556,"url":24,"identifiers":4557},"Yonemura, Y., Kawakita, M., Masuda, T., Fujimoto, K. & Takatsuki, K. Effect of recombinant human interleukin-11 on rat megakaryopoiesis and thrombopoiesis in vivo: comparative study with interleukin-6. Br. J. Haematol. 84, 16–23 (1993).",{"doi":4558},"10.1111\u002Fj.1365-2141.1993.tb03020.x",{"id":24,"text":4560,"url":24,"identifiers":4561},"Matthews, V. B. et al. Oncostatin M induces an acute phase response but does not modulate the growth or maturation-status of liver progenitor (oval) cells in culture. Exp. Cell Res. 306, 252–263 (2005).",{"doi":4562},"10.1016\u002Fj.yexcr.2005.02.010",{"id":24,"text":4564,"url":24,"identifiers":4565},"Dierssen, U. et al. Molecular dissection of gp130-dependent pathways in hepatocytes during liver regeneration. J. Biol. Chem. 283, 9886–9895 (2008).",{"doi":4566},"10.1074\u002Fjbc.M705483200",{"id":24,"text":4568,"url":24,"identifiers":4569},"Alonzi, T. et al. Essential role of STAT3 in the control of the acute-phase response as revealed by inducible gene inactivation [correction of activation] in the liver. Mol. Cell Biol. 21, 1621–1632 (2001).",{"doi":4570},"10.1128\u002FMCB.21.5.1621-1632.2001",{"id":24,"text":4572,"url":24,"identifiers":4573},"Kopf, M. et al. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 368, 339–342 (1994).",{"doi":4574},"10.1038\u002F368339a0",{"id":24,"text":4576,"url":24,"identifiers":4577},"McFarland-Mancini, M. M. et al. Differences in wound healing in mice with deficiency of IL-6 versus IL-6 receptor. J. Immunol. 184, 7219–7228 (2010).",{"doi":4578},"10.4049\u002Fjimmunol.0901929",{"id":24,"text":4580,"url":24,"identifiers":4581},"Weber, M. A. et al. Endogenous leukemia inhibitory factor attenuates endotoxin response. Lab. Invest. 85, 276–284 (2005).",{"doi":4582},"10.1038\u002Flabinvest.3700216",{"id":24,"text":4584,"url":24,"identifiers":4585},"Wallace, P. M. et al. Regulation of inflammatory responses by oncostatin M. J. Immunol. 162, 5547–5555 (1999).",{"doi":4586},"10.4049\u002Fjimmunol.162.9.5547",{"id":24,"text":4588,"url":24,"identifiers":4589},"Puel, A. et al. Recurrent staphylococcal cellulitis and subcutaneous abscesses in a child with autoantibodies against IL-6. J. Immunol. 180, 647–654 (2008).",{"doi":4590},"10.4049\u002Fjimmunol.180.1.647",{"id":24,"text":4592,"url":24,"identifiers":4593},"Nanki, T. et al. Suppression of elevations in serum C reactive protein levels by anti-IL-6 autoantibodies in two patients with severe bacterial infections. Ann. Rheum. Dis. 72, 1100–1102 (2013).",{"doi":4594},"10.1136\u002Fannrheumdis-2012-202768",{"id":24,"text":4596,"url":24,"identifiers":4597},"Bloomfield, M. et al. Anti-IL6 autoantibodies in an infant with CRP-less septic shock. Front. Immunol. 10, 2629 (2019).",{"doi":4598},"10.3389\u002Ffimmu.2019.02629",{"id":24,"text":4600,"url":24,"identifiers":4601},"Shafran, I. H., Alasti, F., Smolen, J. S. & Aletaha, D. Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab. Ann. Rheum. Dis. 79, 874–882 (2020).",{"doi":4602},"10.1136\u002Fannrheumdis-2019-215987",{"id":24,"text":4604,"url":24,"identifiers":4605},"Lee, J. Y. et al. Serum amyloid A proteins induce pathogenic Th17 cells and promote inflammatory disease. Cell 180, 79–91.e16 (2020).",{"doi":4606},"10.1016\u002Fj.cell.2019.11.026",{"id":24,"text":4608,"url":24,"identifiers":4609},"Michalopoulos, G. K. & DeFrances, M. C. Liver regeneration. Science 276, 60–66 (1997).",{"doi":4610},"10.1126\u002Fscience.276.5309.60",{"id":24,"text":4612,"url":24,"identifiers":4613},"Michalopoulos, G. K. Liver regeneration. J. Cell Physiol. 213, 286–300 (2007).",{"doi":4614},"10.1002\u002Fjcp.21172",{"id":24,"text":4616,"url":24,"identifiers":4617},"Fazel Modares, N. et al. IL-6 trans-signaling controls liver regeneration after partial hepatectomy. Hepatology 70, 2075–2091 (2019).",{"doi":4618},"10.1002\u002Fhep.30774",{"id":24,"text":4620,"url":24,"identifiers":4621},"Drucker, C., Gewiese, J., Malchow, S., Scheller, J. & Rose-John, S. Impact of interleukin-6 classic- and trans-signaling on liver damage and regeneration. J. Autoimmun. 34, 29–37 (2010).",{"doi":4622},"10.1016\u002Fj.jaut.2009.08.003",{"id":24,"text":4624,"url":24,"identifiers":4625},"Haga, S. et al. Compensatory recovery of liver mass by Akt-mediated hepatocellular hypertrophy in liver-specific STAT3-deficient mice. J. Hepatol. 43, 799–807 (2005).",{"doi":4626},"10.1016\u002Fj.jhep.2005.03.027",{"id":24,"text":4628,"url":24,"identifiers":4629},"Riehle, K. J. et al. Regulation of liver regeneration and hepatocarcinogenesis by suppressor of cytokine signaling 3. J. Exp. Med. 205, 91–103 (2008).",{"doi":4630},"10.1084\u002Fjem.20070820",{"id":24,"text":4632,"url":24,"identifiers":4633},"Cressman, D. E. et al. Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science 274, 1379–1383 (1996).",{"doi":4634},"10.1126\u002Fscience.274.5291.1379",{"id":24,"text":4636,"url":24,"identifiers":4637},"Blindenbacher, A. et al. Interleukin 6 is important for survival after partial hepatectomy in mice. Hepatology 38, 674–682 (2003).",{"doi":4638},"10.1053\u002Fjhep.2003.50378",{"id":24,"text":4640,"url":24,"identifiers":4641},"Fulop, A. K. et al. Hepatic regeneration induces transient acute phase reaction: systemic elevation of acute phase reactants and soluble cytokine receptors. Cell Biol. Int. 25, 585–592 (2001).",{"doi":4642},"10.1006\u002Fcbir.2000.0715",{"id":24,"text":4644,"url":24,"identifiers":4645},"Peters, M. et al. Extramedullary expansion of hematopoietic progenitor cells in interleukin (IL)-6-sIL-6R double transgenic mice. J. Exp. Med. 185, 755–766 (1997).",{"doi":4646},"10.1084\u002Fjem.185.4.755",{"id":24,"text":4648,"url":24,"identifiers":4649},"Maione, D. et al. Coexpression of IL-6 and soluble IL-6R causes nodular regenerative hyperplasia and adenomas of the liver. EMBO J. 17, 5588–5597 (1998).",{"doi":4650},"10.1093\u002Femboj\u002F17.19.5588",{"id":24,"text":4652,"url":24,"identifiers":4653},"Nechemia-Arbely, Y. et al. Early hepatocyte DNA synthetic response posthepatectomy is modulated by IL-6 trans-signaling and PI3K\u002FAKT activation. J. Hepatol. 54, 922–929 (2011).",{"doi":4654},"10.1016\u002Fj.jhep.2010.08.017",{"id":24,"text":4656,"url":24,"identifiers":4657},"Nakamura, K., Nonaka, H., Saito, H., Tanaka, M. & Miyajima, A. Hepatocyte proliferation and tissue remodeling is impaired after liver injury in oncostatin M receptor knockout mice. Hepatology 39, 635–644 (2004).",{"doi":4658},"10.1002\u002Fhep.20086",{"id":24,"text":4660,"url":24,"identifiers":4661},"Okaya, A. et al. Oncostatin M inhibits proliferation of rat oval cells, OC15-5, inducing differentiation into hepatocytes. Am. J. Pathol. 166, 709–719 (2005).",{"doi":4662},"10.1016\u002FS0002-9440(10)62292-4",{"id":24,"text":4664,"url":24,"identifiers":4665},"Hamada, T. et al. Oncostatin M gene therapy attenuates liver damage induced by dimethylnitrosamine in rats. Am. J. Pathol. 171, 872–881 (2007).",{"doi":4666},"10.2353\u002Fajpath.2007.060972",{"id":24,"text":4668,"url":24,"identifiers":4669},"Yang, Z. F. et al. Cardiotrophin-1 enhances regeneration of cirrhotic liver remnant after hepatectomy through promotion of angiogenesis and cell proliferation. Liver Int. 28, 622–631 (2008).",{"doi":4670},"10.1111\u002Fj.1478-3231.2008.01687.x",{"id":24,"text":4672,"url":24,"identifiers":4673},"Omori, N. et al. Expression of leukemia inhibitory factor and its receptor during liver regeneration in the adult rat. Lab. Invest. 75, 15–24 (1996).",{},{"id":24,"text":4675,"url":24,"identifiers":4676},"Rosenberg, D., Ilic, Z., Yin, L. & Sell, S. Proliferation of hepatic lineage cells of normal C57BL and interleukin-6 knockout mice after cocaine-induced periportal injury. Hepatology 31, 948–955 (2000).",{"doi":4677},"10.1053\u002Fhe.2000.5410",{"id":24,"text":4679,"url":24,"identifiers":4680},"Gajalakshmi, P. et al. Interleukin-6 secreted by bipotential murine oval liver stem cells induces apoptosis of activated hepatic stellate cells by activating NF-κB-inducible nitric oxide synthase signaling. Biochem. Cell Biol. 95, 263–272 (2017).",{"doi":4681},"10.1139\u002Fbcb-2016-0011",{"id":24,"text":4683,"url":24,"identifiers":4684},"Fausto, N. & Campbell, J. S. The role of hepatocytes and oval cells in liver regeneration and repopulation. Mech. Dev. 120, 117–130 (2003).",{"doi":4685},"10.1016\u002FS0925-4773(02)00338-6",{"id":24,"text":4687,"url":24,"identifiers":4688},"Tirnitz-Parker, J. E. E., Forbes, S. J., Olynyk, J. K. & Ramm, G. A. Cellular plasticity in liver regeneration: spotlight on cholangiocytes. Hepatology 69, 2286–2289 (2019).",{"doi":4689},"10.1002\u002Fhep.30340",{"id":24,"text":4691,"url":24,"identifiers":4692},"Nishina, T. et al. Interleukin-11 links oxidative stress and compensatory proliferation. Sci. Signal. 5, ra5 (2012).",{"doi":4693},"10.1126\u002Fscisignal.2002056",{"id":24,"text":4695,"url":24,"identifiers":4696},"Wahl, A. F. & Wallace, P. M. Oncostatin M in the anti-inflammatory response. Ann. Rheum. Dis. 60, iii75–iii80 (2001).",{},{"id":24,"text":4698,"url":24,"identifiers":4699},"Zhu, C. et al. Hepatitis B virus enhances interleukin-27 expression both in vivo and in vitro. Clin. Immunol. 131, 92–97 (2009).",{"doi":4700},"10.1016\u002Fj.clim.2008.10.011",{"id":24,"text":4702,"url":24,"identifiers":4703},"Katz, A., Chebath, J., Friedman, J. & Revel, M. Increased sensitivity of IL-6-deficient mice to carbon tetrachloride hepatotoxicity and protection with an IL-6 receptor-IL-6 chimera. Cytokines Cell Mol. Ther. 4, 221–227 (1998).",{},{"id":24,"text":4705,"url":24,"identifiers":4706},"Klein, C. et al. The IL-6-gp130-STAT3 pathway in hepatocytes triggers liver protection in T cell-mediated liver injury. J. Clin. Invest. 115, 860–869 (2005).",{"doi":4707},"10.1172\u002FJCI23640",{"id":24,"text":4709,"url":24,"identifiers":4710},"Camargo, C. A. Jr., Madden, J. F., Gao, W., Selvan, R. S. & Clavien, P. A. Interleukin-6 protects liver against warm ischemia\u002Freperfusion injury and promotes hepatocyte proliferation in the rodent. Hepatology 26, 1513–1520 (1997).",{"doi":4711},"10.1002\u002Fhep.510260619",{"id":24,"text":4713,"url":24,"identifiers":4714},"Hoge, J. et al. IL-6 controls the innate immune response against Listeria monocytogenes via classical IL-6 signaling. J. Immunol. 190, 703–711 (2013).",{"doi":4715},"10.4049\u002Fjimmunol.1201044",{"id":24,"text":4717,"url":24,"identifiers":4718},"Jostock, T. et al. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur. J. Biochem. 268, 160–167 (2001).",{"doi":4719},"10.1046\u002Fj.1432-1327.2001.01867.x",{"id":24,"text":4721,"url":24,"identifiers":4722},"Barkhausen, T. et al. Selective blockade of interleukin-6 trans-signaling improves survival in a murine polymicrobial sepsis model. Crit. Care Med. 39, 1407–1413 (2011).",{"doi":4723},"10.1097\u002FCCM.0b013e318211ff56",{"id":24,"text":4725,"url":24,"identifiers":4726},"Li, S. Q., Zhu, S., Han, H. M., Lu, H. J. & Meng, H. Y. IL-6 trans-signaling plays important protective roles in acute liver injury induced by acetaminophen in mice. J. Biochem. Mol. Toxicol. 29, 288–297 (2015).",{"doi":4727},"10.1002\u002Fjbt.21708",{"id":24,"text":4729,"url":24,"identifiers":4730},"Gewiese-Rabsch, J., Drucker, C., Malchow, S., Scheller, J. & Rose-John, S. Role of IL-6 trans-signaling in CCl4 induced liver damage. Biochim. Biophys. Acta 1802, 1054–1061 (2010).",{"doi":4731},"10.1016\u002Fj.bbadis.2010.07.023",{"id":24,"text":4733,"url":24,"identifiers":4734},"Zhao, J., Qi, Y. F. & Yu, Y. R. STAT3: a key regulator in liver fibrosis. Ann. Hepatol. 21, 100224 (2021).",{"doi":4735},"10.1016\u002Fj.aohep.2020.06.010",{"id":24,"text":4737,"url":24,"identifiers":4738},"Maeshima, K. et al. A protective role of interleukin 11 on hepatic injury in acute endotoxemia. Shock 21, 134–138 (2004).",{"doi":4739},"10.1097\u002F01.shk.0000103386.98235.f6",{"id":24,"text":4741,"url":24,"identifiers":4742},"Kawakami, T. et al. Highly liver-specific heme oxygenase-1 induction by interleukin-11 prevents carbon tetrachloride-induced hepatotoxicity. Int. J. Mol. Med. 18, 537–546 (2006).",{},{"id":24,"text":4744,"url":24,"identifiers":4745},"Widjaja, A. A., Chothani, S. P. & Cook, S. A. Different roles of interleukin 6 and interleukin 11 in the liver: implications for therapy. Hum. Vaccin. Immunother. 16, 2357–2362 (2020).",{"doi":4746},"10.1080\u002F21645515.2020.1761203",{"id":24,"text":4748,"url":24,"identifiers":4749},"Richards, C. D. The enigmatic cytokine oncostatin M and roles in disease. ISRN Inflamm. 2013, 512103 (2013).",{"doi":4750},"10.1155\u002F2013\u002F512103",{"id":24,"text":4752,"url":24,"identifiers":4753},"Jones, G. W., Hill, D. G., Cardus, A. & Jones, S. A. IL-27: a double agent in the IL-6 family. Clin. Exp. Immunol. 193, 37–46 (2018).",{"doi":4754},"10.1111\u002Fcei.13116",{"id":24,"text":4756,"url":24,"identifiers":4757},"Iñiguez, M. et al. Cardiotrophin-1 defends the liver against ischemia-reperfusion injury and mediates the protective effect of ischemic preconditioning. J. Exp. Med. 203, 2809–2815 (2006).",{"doi":4758},"10.1084\u002Fjem.20061421",{"id":24,"text":4760,"url":24,"identifiers":4761},"Tuñon, M. J. et al. Cardiotrophin-1 promotes a high survival rate in rabbits with lethal fulminant hepatitis of viral origin. J. Virol. 85, 13124–13132 (2011).",{"doi":4762},"10.1128\u002FJVI.05725-11",{"id":24,"text":4764,"url":24,"identifiers":4765},"Sheng, T. et al. The relationship between serum interleukin-6 and the recurrence of hepatitis B virus related hepatocellular carcinoma after curative resection. Medicine 94, e941 (2015).",{"doi":4766},"10.1097\u002FMD.0000000000000941",{"id":24,"text":4768,"url":24,"identifiers":4769},"Naugler, W. E. et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 317, 121–124 (2007).",{"doi":4770},"10.1126\u002Fscience.1140485",{"id":24,"text":4772,"url":24,"identifiers":4773},"Bosch, F. X., Ribes, J., Diaz, M. & Cleries, R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 127, S5–S16 (2004).",{"doi":4774},"10.1053\u002Fj.gastro.2004.09.011",{"id":24,"text":4776,"url":24,"identifiers":4777},"Giannitrapani, L. et al. Circulating IL-6 and sIL-6R in patients with hepatocellular carcinoma. Ann. N. Y. Acad. Sci. 963, 46–52 (2002).",{"doi":4778},"10.1111\u002Fj.1749-6632.2002.tb04093.x",{"id":24,"text":4780,"url":24,"identifiers":4781},"Bergmann, J. et al. IL-6 trans-signaling is essential for the development of hepatocellular carcinoma in mice. Hepatology 65, 89–103 (2017).",{"doi":4782},"10.1002\u002Fhep.28874",{"id":24,"text":4784,"url":24,"identifiers":4785},"Rose-John, S. The soluble interleukin 6 receptor: advanced therapeutic options in inflammation. Clin. Pharmacol. Ther. 102, 591–598 (2017).",{"doi":4786},"10.1002\u002Fcpt.782",{"id":24,"text":4788,"url":24,"identifiers":4789},"Xiang, Z. L., Zeng, Z. C., Fan, J., Tang, Z. Y. & Zeng, H. Y. Expression of connective tissue growth factor and interleukin-11 in intratumoral tissue is associated with poor survival after curative resection of hepatocellular carcinoma. Mol. Biol. Rep. 39, 6001–6006 (2012).",{"doi":4790},"10.1007\u002Fs11033-011-1413-y",{"id":24,"text":4792,"url":24,"identifiers":4793},"Zheng, H. et al. TMED3 promotes hepatocellular carcinoma progression via IL-11\u002FSTAT3 signaling. Sci. Rep. 6, 37070 (2016).",{"doi":4794},"10.1038\u002Fsrep37070",{"id":24,"text":4796,"url":24,"identifiers":4797},"Widjaja, A. A. et al. Inhibiting interleukin 11 signaling reduces hepatocyte death and liver fibrosis, inflammation, and steatosis in mouse models of nonalcoholic steatohepatitis. Gastroenterology 157, 777–792.e14 (2019).",{"doi":4798},"10.1053\u002Fj.gastro.2019.05.002",{"id":24,"text":4800,"url":24,"identifiers":4801},"Hisaka, T. et al. Expression of leukemia inhibitory factor (LIF) and its receptor gp190 in human liver and in cultured human liver myofibroblasts. Cloning of new isoforms of LIF mRNA. Comp. Hepatol. 3, 10 (2004).",{"doi":4802},"10.1186\u002F1476-5926-3-10",{"id":24,"text":4804,"url":24,"identifiers":4805},"Santos, G. C. et al. Leukemia inhibitory factor (LIF) overexpression increases the angiogenic potential of bone marrow mesenchymal stem\u002Fstromal cells. Front. Cell Dev. Biol. 8, 778 (2020).",{"doi":4806},"10.3389\u002Ffcell.2020.00778",{"id":24,"text":4808,"url":24,"identifiers":4809},"Ferrara, N., Winer, J. & Henzel, W. J. Pituitary follicular cells secrete an inhibitor of aortic endothelial cell growth: identification as leukemia inhibitory factor. Proc. Natl Acad. Sci. USA 89, 698–702 (1992).",{"doi":4810},"10.1073\u002Fpnas.89.2.698",{"id":24,"text":4812,"url":24,"identifiers":4813},"Shi, Y. et al. Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. Nature 569, 131–135 (2019).",{"doi":4814},"10.1038\u002Fs41586-019-1130-6",{"id":24,"text":4816,"url":24,"identifiers":4817},"Levy, M. T., Trojanowska, M. & Reuben, A. Oncostatin M: a cytokine upregulated in human cirrhosis, increases collagen production by human hepatic stellate cells. J. Hepatol. 32, 218–226 (2000).",{"doi":4818},"10.1016\u002FS0168-8278(00)80066-5",{"id":24,"text":4820,"url":24,"identifiers":4821},"Rebouissou, S. et al. Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature 457, 200–204 (2009).",{"doi":4822},"10.1038\u002Fnature07475",{"id":24,"text":4824,"url":24,"identifiers":4825},"Pilati, C. et al. Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas. J. Exp. Med. 208, 1359–1366 (2011).",{"doi":4826},"10.1084\u002Fjem.20110283",{"id":24,"text":4828,"url":24,"identifiers":4829},"Poussin, K. et al. Biochemical and functional analyses of gp130 mutants unveil JAK1 as a novel therapeutic target in human inflammatory hepatocellular adenoma. Oncoimmunology 2, e27090 (2013).",{"doi":4830},"10.4161\u002Fonci.27090",{"id":24,"text":4832,"url":24,"identifiers":4833},"Okamura, Y. et al. Leukemia inhibitory factor receptor (LIFR) is detected as a novel suppressor gene of hepatocellular carcinoma using double-combination array. Cancer Lett. 289, 170–177 (2010).",{"doi":4834},"10.1016\u002Fj.canlet.2009.08.013",{"id":24,"text":4836,"url":24,"identifiers":4837},"Luo, Q. et al. Leukemia inhibitory factor receptor is a novel immunomarker in distinction of well-differentiated HCC from dysplastic nodules. Oncotarget 6, 6989–6999 (2015).",{"doi":4838},"10.18632\u002Foncotarget.3136",{"id":24,"text":4840,"url":24,"identifiers":4841},"Ernst, M., Thiem, S., Nguyen, P. M., Eissmann, M. & Putoczki, T. L. Epithelial gp130\u002FStat3 functions: an intestinal signaling node in health and disease. Semin. Immunol. 26, 29–37 (2014).",{"doi":4842},"10.1016\u002Fj.smim.2013.12.006",{"id":24,"text":4844,"url":24,"identifiers":4845},"Harris, P. R. et al. Recombinant Helicobacter pylori urease activates primary mucosal macrophages. J. Infect. Dis. 178, 1516–1520 (1998).",{"doi":4846},"10.1086\u002F314426",{"id":24,"text":4848,"url":24,"identifiers":4849},"Sobala, G. M. et al. Acute Helicobacter pylori infection: clinical features, local and systemic immune response, gastric mucosal histology, and gastric juice ascorbic acid concentrations. Gut 32, 1415–1418 (1991).",{"doi":4850},"10.1136\u002Fgut.32.11.1415",{"id":24,"text":4852,"url":24,"identifiers":4853},"Crabtree, J. E. Immune and inflammatory responses to Helicobacter pylori infection. Scand. J. Gastroenterol. Suppl. 215, 3–10 (1996).",{"doi":4854},"10.3109\u002F00365529609094526",{"id":24,"text":4856,"url":24,"identifiers":4857},"Furukawa, K., Takahashi, T., Arai, F., Matsushima, K. & Asakura, H. Enhanced mucosal expression of interleukin-6 mRNA but not of interleukin-8 mRNA at the margin of gastric ulcer in Helicobacter pylori-positive gastritis. J. Gastroenterol. 33, 625–633 (1998).",{"doi":4858},"10.1007\u002Fs005350050148",{"id":24,"text":4860,"url":24,"identifiers":4861},"Nishida, T. et al. Endothelin-1, an ulcer inducer, promotes gastric ulcer healing via mobilizing gastric myofibroblasts and stimulates production of stroma-derived factors. Am. J. Physiol. Gastrointest. Liver Physiol. 290, G1041–G1050 (2006).",{"doi":4862},"10.1152\u002Fajpgi.00462.2005",{"id":24,"text":4864,"url":24,"identifiers":4865},"Pradeepkumar Singh, L., Kundu, P., Ganguly, K., Mishra, A. & Swarnakar, S. Novel role of famotidine in downregulation of matrix metalloproteinase-9 during protection of ethanol-induced acute gastric ulcer. Free Radic. Biol. Med. 43, 289–299 (2007).",{"doi":4866},"10.1016\u002Fj.freeradbiomed.2007.04.027",{"id":24,"text":4868,"url":24,"identifiers":4869},"Wen, C. Y. et al. Mechanism of the antiulcerogenic effect of IL-11 on acetic acid-induced gastric ulcer in rats. Life Sci. 70, 2997–3005 (2002).",{"doi":4870},"10.1016\u002FS0024-3205(02)01552-7",{"id":24,"text":4872,"url":24,"identifiers":4873},"Judd, L. M., Ulaganathan, M., Howlett, M. & Giraud, A. S. Cytokine signalling by gp130 regulates gastric mucosal healing after ulceration and, indirectly, antral tumour progression. J. Pathol. 217, 552–562 (2009).",{"doi":4874},"10.1002\u002Fpath.2479",{"id":24,"text":4876,"url":24,"identifiers":4877},"Gallucci, R. M. et al. Impaired cutaneous wound healing in interleukin-6-deficient and immunosuppressed mice. FASEB J. 14, 2525–2531 (2000).",{"doi":4878},"10.1096\u002Ffj.00-0073com",{"id":24,"text":4880,"url":24,"identifiers":4881},"Ernst, M. et al. Defective gp130-mediated signal transducer and activator of transcription (STAT) signaling results in degenerative joint disease, gastrointestinal ulceration, and failure of uterine implantation. J. Exp. Med. 194, 189–203 (2001).",{"doi":4882},"10.1084\u002Fjem.194.2.189",{"id":24,"text":4884,"url":24,"identifiers":4885},"de Souza, H. S. P., Fiocchi, C. & Iliopoulos, D. The IBD interactome: an integrated view of aetiology, pathogenesis and therapy. Nat. Rev. Gastroenterol. Hepatol. 14, 739–749 (2017).",{"doi":4886},"10.1038\u002Fnrgastro.2017.110",{"id":24,"text":4888,"url":24,"identifiers":4889},"Hosokawa, T. et al. Interleukin-6 and soluble interleukin-6 receptor in the colonic mucosa of inflammatory bowel disease. J. Gastroenterol. Hepatol. 14, 987–996 (1999).",{"doi":4890},"10.1046\u002Fj.1440-1746.1999.01989.x",{"id":24,"text":4892,"url":24,"identifiers":4893},"Ganter, U., Arcone, R., Toniatti, C., Morrone, G. & Ciliberto, G. Dual control of C-reactive protein gene expression by interleukin-1 and interleukin-6. EMBO J. 8, 3773–3779 (1989).",{"doi":4894},"10.1002\u002Fj.1460-2075.1989.tb08554.x",{"id":24,"text":4896,"url":24,"identifiers":4897},"Reinecker, H. C. et al. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1β by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn’s disease. Clin. Exp. Immunol. 94, 174–181 (1993).",{"doi":4898},"10.1111\u002Fj.1365-2249.1993.tb05997.x",{"id":24,"text":4900,"url":24,"identifiers":4901},"Lovato, P. et al. Constitutive STAT3 activation in intestinal T cells from patients with Crohn’s disease. J. Biol. Chem. 278, 16777–16781 (2003).",{"doi":4902},"10.1074\u002Fjbc.M207999200",{"id":24,"text":4904,"url":24,"identifiers":4905},"Mudter, J. et al. Activation pattern of signal transducers and activators of transcription (STAT) factors in inflammatory bowel diseases. Am. J. Gastroenterol. 100, 64–72 (2005).",{"doi":4906},"10.1111\u002Fj.1572-0241.2005.40615.x",{"id":24,"text":4908,"url":24,"identifiers":4909},"Li, Y. et al. Disease-related expression of the IL6\u002FSTAT3\u002FSOCS3 signalling pathway in ulcerative colitis and ulcerative colitis-related carcinogenesis. Gut 59, 227–235 (2010).",{"doi":4910},"10.1136\u002Fgut.2009.184176",{"id":24,"text":4912,"url":24,"identifiers":4913},"Mitsuyama, K. et al. Soluble interleukin-6 receptors in inflammatory bowel disease: relation to circulating interleukin-6. Gut 36, 45–49 (1995).",{"doi":4914},"10.1136\u002Fgut.36.1.45",{"id":24,"text":4916,"url":24,"identifiers":4917},"Gustot, T. et al. Profile of soluble cytokine receptors in Crohn’s disease. Gut 54, 488–495 (2005).",{"doi":4918},"10.1136\u002Fgut.2004.043554",{"id":24,"text":4920,"url":24,"identifiers":4921},"Yamamoto, M., Yoshizaki, K., Kishimoto, T. & Ito, H. IL-6 is required for the development of Th1 cell-mediated murine colitis. J. Immunol. 164, 4878–4882 (2000).",{"doi":4922},"10.4049\u002Fjimmunol.164.9.4878",{"id":24,"text":4924,"url":24,"identifiers":4925},"Parisinos, C. A. et al. Variation in interleukin 6 receptor gene associates with risk of Crohn’s disease and ulcerative colitis. Gastroenterology 155, 303–306.e2 (2018).",{"doi":4926},"10.1053\u002Fj.gastro.2018.05.022",{"id":24,"text":4928,"url":24,"identifiers":4929},"Garbers, C. et al. The interleukin-6 receptor Asp358Ala single nucleotide polymorphism rs2228145 confers increased proteolytic conversion rates by ADAM proteases. Biochim. Biophys. Acta 1842, 1485–1494 (2014).",{"doi":4930},"10.1016\u002Fj.bbadis.2014.05.018",{"id":24,"text":4932,"url":24,"identifiers":4933},"Scheller, J. & Rose-John, S. The interleukin 6 pathway and atherosclerosis. Lancet 380, 338 (2012).",{"doi":4934},"10.1016\u002FS0140-6736(12)61246-X",{"id":24,"text":4936,"url":24,"identifiers":4937},"Smillie, C. S. et al. Intra- and inter-cellular rewiring of the human colon during ulcerative colitis. Cell 178, 714–730.e22 (2019).",{"doi":4938},"10.1016\u002Fj.cell.2019.06.029",{"id":24,"text":4940,"url":24,"identifiers":4941},"Qiu, B. S., Pfeiffer, C. J. & Keith, J. C. Jr. Protection by recombinant human interleukin-11 against experimental TNB-induced colitis in rats. Dig. Dis. Sci. 41, 1625–1630 (1996).",{"doi":4942},"10.1007\u002FBF02087911",{"id":24,"text":4944,"url":24,"identifiers":4945},"Keith, J. C. Jr., Albert, L., Sonis, S. T., Pfeiffer, C. J. & Schaub, R. G. IL-11, a pleiotropic cytokine: exciting new effects of IL-11 on gastrointestinal mucosal biology. Stem Cell 12, 79–89; discussion 89-90 (1994).",{},{"id":24,"text":4947,"url":24,"identifiers":4948},"Greenwood-Van Meerveld, B., Venkova, K. & Keith, J. C. Jr. Recombinant human interleukin-11 restores smooth muscle function in the jejunum and colon of human leukocyte antigen-B27 rats with intestinal inflammation. J. Pharmacol. Exp. Ther. 299, 58–66 (2001).",{},{"id":24,"text":4950,"url":24,"identifiers":4951},"Gibson, D. L. et al. Interleukin-11 reduces TLR4-induced colitis in TLR2-deficient mice and restores intestinal STAT3 signaling. Gastroenterology 139, 1277–1288 (2010).",{"doi":4952},"10.1053\u002Fj.gastro.2010.06.057",{"id":24,"text":4954,"url":24,"identifiers":4955},"Lim, W. W. et al. Transgenic interleukin 11 expression causes cross-tissue fibro-inflammation and an inflammatory bowel phenotype in mice. PLoS ONE 15, e0227505 (2020).",{"doi":4956},"10.1371\u002Fjournal.pone.0227505",{"id":24,"text":4958,"url":24,"identifiers":4959},"Zhang, Y. S. et al. STAT4 activation by leukemia inhibitory factor confers a therapeutic effect on intestinal inflammation. EMBO J. 38, e99595 (2019).",{"doi":4960},"10.15252\u002Fembj.201899595",{"id":24,"text":4962,"url":24,"identifiers":4963},"Guimbaud, R. et al. Leukemia inhibitory factor involvement in human ulcerative colitis and its potential role in malignant course. Eur. Cytokine Netw. 9, 607–612 (1998).",{},{"id":24,"text":4965,"url":24,"identifiers":4966},"Prieto-Vicente, V. et al. Cardiotrophin-1 attenuates experimental colitis in mice. Clin. Sci. 132, 985–1001 (2018).",{"doi":4967},"10.1042\u002FCS20171513",{"id":24,"text":4969,"url":24,"identifiers":4970},"Sanchez-Garrido, A. I. et al. Preventive effect of cardiotrophin-1 administration before DSS-induced ulcerative colitis in mice. J. Clin. Med. 8, 2086 (2019).",{"doi":4971},"10.3390\u002Fjcm8122086",{"id":24,"text":4973,"url":24,"identifiers":4974},"Beigel, F. et al. Oncostatin M mediates STAT3-dependent intestinal epithelial restitution via increased cell proliferation, decreased apoptosis and upregulation of SERPIN family members. PLoS ONE 9, e93498 (2014).",{"doi":4975},"10.1371\u002Fjournal.pone.0093498",{"id":24,"text":4977,"url":24,"identifiers":4978},"Sanchez, A. L. et al. Adenoviral transfer of the murine oncostatin M gene suppresses dextran-sodium sulfate-induced colitis. J. Interferon Cytokine Res. 23, 193–201 (2003).",{"doi":4979},"10.1089\u002F107999003765027393",{"id":24,"text":4981,"url":24,"identifiers":4982},"Jostins, L. et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491, 119–124 (2012).",{"doi":4983},"10.1038\u002Fnature11582",{"id":24,"text":4985,"url":24,"identifiers":4986},"West, N. R. et al. Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. Nat. Med. 23, 579–589 (2017).",{"doi":4987},"10.1038\u002Fnm.4307",{"id":24,"text":4989,"url":24,"identifiers":4990},"Imielinski, M. et al. Common variants at five new loci associated with early-onset inflammatory bowel disease. Nat. Genet. 41, 1335–1340 (2009).",{"doi":4991},"10.1038\u002Fng.489",{"id":24,"text":4993,"url":24,"identifiers":4994},"Wang, Z., Wang, L., Fan, R., Zhou, J. & Zhong, J. Association of IL-27 gene three polymorphisms with Crohn’s disease susceptibility in a Chinese Han population. Int. J. Clin. Exp. Pathol. 7, 8952–8957 (2014).",{},{"id":24,"text":4996,"url":24,"identifiers":4997},"Li, C. S. et al. Interleukin-27 polymorphisms are associated with inflammatory bowel diseases in a Korean population. J. Gastroenterol. Hepatol. 24, 1692–1696 (2009).",{"doi":4998},"10.1111\u002Fj.1440-1746.2009.05901.x",{"id":24,"text":5000,"url":24,"identifiers":5001},"Hanson, M. L. et al. Oral delivery of IL-27 recombinant bacteria attenuates immune colitis in mice. Gastroenterology 146, 210–221.e13 (2014).",{"doi":5002},"10.1053\u002Fj.gastro.2013.09.060",{"id":24,"text":5004,"url":24,"identifiers":5005},"Sasaoka, T. et al. Treatment with IL-27 attenuates experimental colitis through the suppression of the development of IL-17-producing T helper cells. Am. J. Physiol. Gastrointest. Liver Physiol. 300, G568–G576 (2011).",{"doi":5006},"10.1152\u002Fajpgi.00329.2010",{"id":24,"text":5008,"url":24,"identifiers":5009},"Dambacher, J. et al. Interleukin 31 mediates MAP kinase and STAT1\u002F3 activation in intestinal epithelial cells and its expression is upregulated in inflammatory bowel disease. Gut 56, 1257–1265 (2007).",{"doi":5010},"10.1136\u002Fgut.2006.118679",{"id":24,"text":5012,"url":24,"identifiers":5013},"Perrigoue, J. G., Zaph, C., Guild, K., Du, Y. & Artis, D. IL-31-IL-31R interactions limit the magnitude of Th2 cytokine-dependent immunity and inflammation following intestinal helminth infection. J. Immunol. 182, 6088–6094 (2009).",{"doi":5014},"10.4049\u002Fjimmunol.0802459",{"id":24,"text":5016,"url":24,"identifiers":5017},"Nayar, S. et al. A myeloid-stromal niche and gp130 rescue in NOD2-driven Crohn’s disease. Nature 593, 275–281 (2021).",{"doi":5018},"10.1038\u002Fs41586-021-03484-5",{"id":24,"text":5020,"url":24,"identifiers":5021},"Putoczki, T. L. et al. Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically. Cancer Cell 24, 257–271 (2013).",{"doi":5022},"10.1016\u002Fj.ccr.2013.06.017",{"id":24,"text":5024,"url":24,"identifiers":5025},"Yoshizaki, A. et al. Expression of interleukin (IL)-11 and IL-11 receptor in human colorectal adenocarcinoma: IL-11 up-regulation of the invasive and proliferative activity of human colorectal carcinoma cells. Int. J. Oncol. 29, 869–876 (2006).",{},{"id":24,"text":5027,"url":24,"identifiers":5028},"Wei, J. et al. Bazedoxifene as a novel GP130 inhibitor for colon cancer therapy. J. Exp. Clin. Cancer Res. 38, 63 (2019).",{"doi":5029},"10.1186\u002Fs13046-019-1072-8",{"id":24,"text":5031,"url":24,"identifiers":5032},"Thilakasiri, P. et al. Repurposing the selective estrogen receptor modulator bazedoxifene to suppress gastrointestinal cancer growth. EMBO Mol. Med. 11, e9539 (2019).",{"doi":5033},"10.15252\u002Femmm.201809539",{"id":24,"text":5035,"url":24,"identifiers":5036},"Lesina, M. et al. Stat3\u002FSocs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 19, 456–469 (2011).",{"doi":5037},"10.1016\u002Fj.ccr.2011.03.009",{"id":24,"text":5039,"url":24,"identifiers":5040},"Corcoran, R. B. et al. STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. Cancer Res. 71, 5020–5029 (2011).",{"doi":5041},"10.1158\u002F0008-5472.CAN-11-0908",{"id":24,"text":5043,"url":24,"identifiers":5044},"Zhang, Y. et al. Interleukin-6 is required for pancreatic cancer progression by promoting MAPK signaling activation and oxidative stress resistance. Cancer Res. 73, 6359–6374 (2013).",{"doi":5045},"10.1158\u002F0008-5472.CAN-13-1558-T",{"id":24,"text":5047,"url":24,"identifiers":5048},"Goumas, F. A. et al. Inhibition of IL-6 signaling significantly reduces primary tumor growth and recurrencies in orthotopic xenograft models of pancreatic cancer. Int. J. Cancer 137, 1035–1046 (2015).",{"doi":5049},"10.1002\u002Fijc.29445",{"id":24,"text":5051,"url":24,"identifiers":5052},"Wu, X., Cao, Y., Xiao, H., Li, C. & Lin, J. Bazedoxifene as a novel GP130 inhibitor for pancreatic cancer therapy. Mol. Cancer Ther. 15, 2609–2619 (2016).",{"doi":5053},"10.1158\u002F1535-7163.MCT-15-0921",{"id":24,"text":5055,"url":24,"identifiers":5056},"Judd, L. M. et al. Gastric cancer development in mice lacking the SHP2 binding site on the IL-6 family co-receptor gp130. Gastroenterology 126, 196–207 (2004).",{"doi":5057},"10.1053\u002Fj.gastro.2003.10.066",{"id":24,"text":5059,"url":24,"identifiers":5060},"Jenkins, B. J. et al. Hyperactivation of Stat3 in gp130 mutant mice promotes gastric hyperproliferation and desensitizes TGF-β signaling. Nat. Med. 11, 845–852 (2005).",{"doi":5061},"10.1038\u002Fnm1282",{"id":24,"text":5063,"url":24,"identifiers":5064},"Tebbutt, N. C. et al. Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STAT-mediated trefoil gene activation in gp130 mutant mice. Nat. Med. 8, 1089–1097 (2002).",{"doi":5065},"10.1038\u002Fnm763",{"id":24,"text":5067,"url":24,"identifiers":5068},"Hill, D. G. et al. Hyperactive gp130\u002FSTAT3-driven gastric tumourigenesis promotes submucosal tertiary lymphoid structure development. Int. J. Cancer 143, 167–178 (2018).",{"doi":5069},"10.1002\u002Fijc.31298",{"id":24,"text":5071,"url":24,"identifiers":5072},"Ernst, M. et al. STAT3 and STAT1 mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice. J. Clin. Invest. 118, 1727–1738 (2008).",{},{"id":24,"text":5074,"url":24,"identifiers":5075},"Jackson, C. B. et al. Augmented gp130-mediated cytokine signalling accompanies human gastric cancer progression. J. Pathol. 213, 140–151 (2007).",{"doi":5076},"10.1002\u002Fpath.2218",{"id":24,"text":5078,"url":24,"identifiers":5079},"Komoda, H. et al. Interleukin-6 levels in colorectal cancer tissues. World J. Surg. 22, 895–898 (1998).",{"doi":5080},"10.1007\u002Fs002689900489",{"id":24,"text":5082,"url":24,"identifiers":5083},"Heikkila, K., Ebrahim, S. & Lawlor, D. A. Systematic review of the association between circulating interleukin-6 (IL-6) and cancer. Eur. J. Cancer 44, 937–945 (2008).",{"doi":5084},"10.1016\u002Fj.ejca.2008.02.047",{"id":24,"text":5086,"url":24,"identifiers":5087},"Grivennikov, S. et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15, 103–113 (2009).",{"doi":5088},"10.1016\u002Fj.ccr.2009.01.001",{"id":24,"text":5090,"url":24,"identifiers":5091},"Howlett, M. et al. The interleukin-6 family cytokine interleukin-11 regulates homeostatic epithelial cell turnover and promotes gastric tumor development. Gastroenterology 136, 967–977 (2009).",{"doi":5092},"10.1053\u002Fj.gastro.2008.12.003",{"id":24,"text":5094,"url":24,"identifiers":5095},"US National Library of Medicine. ClinicalTrials.gov https:\u002F\u002Fclinicaltrials.gov\u002Fshow\u002FNCT02641522 (2018).",{},{"id":24,"text":5097,"url":24,"identifiers":5098},"US National Library of Medicine. ClinicalTrials.gov https:\u002F\u002Fclinicaltrials.gov\u002Fshow\u002FNCT02293837 (2021).",{},{"id":24,"text":5100,"url":24,"identifiers":5101},"Wedell-Neergaard, A. S. et al. Exercise-induced changes in visceral adipose tissue mass are regulated by IL-6 signaling: a randomized controlled trial. Cell Metab. 29, 844–855.e3 (2019).",{"doi":5102},"10.1016\u002Fj.cmet.2018.12.007",{"id":24,"text":5104,"url":24,"identifiers":5105},"US National Library of Medicine. ClinicalTrials.gov, https:\u002F\u002Fclinicaltrials.gov\u002Fshow\u002FNCT01073826 (2016).",{},{"id":24,"text":5107,"url":24,"identifiers":5108},"[No authors listed]. A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. ALS CNTF Treatment Study Group. Neurology 46, 1244-1249 (1996).",{"doi":5109},"10.1212\u002FWNL.46.5.1244",{"id":24,"text":5111,"url":24,"identifiers":5112},"Ettinger, M. P. et al. Recombinant variant of ciliary neurotrophic factor for weight loss in obese adults: a randomized, dose-ranging study. Jama 289, 1826–1832 (2003).",{"doi":5113},"10.1001\u002Fjama.289.14.1826",{"id":24,"text":5115,"url":24,"identifiers":5116},"Duff, E. & Baile, C. A. Ciliary neurotrophic factor: a role in obesity? Nutr. Rev. 61, 423–426 (2003).",{"doi":5117},"10.1301\u002Fnr.2003.dec.423-426",{"id":24,"text":5119,"url":24,"identifiers":5120},"Ito, H. et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn’s disease. Gastroenterology 126, 989–996; discussion 947 (2004).",{"doi":5121},"10.1053\u002Fj.gastro.2004.01.012",{"id":24,"text":5123,"url":24,"identifiers":5124},"US National Library of Medicine. ClinicalTrials.gov https:\u002F\u002Fclinicaltrials.gov\u002Fshow\u002FNCT01287897 (2016).",{},{"id":24,"text":5126,"url":24,"identifiers":5127},"Danese, S. et al. Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn’s disease (ANDANTE I and II). Gut 68, 40–48 (2019).",{"doi":5128},"10.1136\u002Fgutjnl-2017-314562",{"id":24,"text":5130,"url":24,"identifiers":5131},"US National Library of Medicine. ClinicalTrials.gov https:\u002F\u002Fclinicaltrials.gov\u002Fshow\u002FNCT01545050 (2020).",{},{"id":24,"text":5133,"url":24,"identifiers":5134},"US National Library of Medicine. ClinicalTrials.gov https:\u002F\u002Fclinicaltrials.gov\u002Fshow\u002FNCT01635621 (2012).",{},{"id":24,"text":5136,"url":24,"identifiers":5137},"Mitsuyama, K. et al. STAT3 activation via interleukin 6 trans-signalling contributes to ileitis in SAMP1\u002FYit mice. Gut 55, 1263–1269 (2006).",{"doi":5138},"10.1136\u002Fgut.2005.079343",{"id":24,"text":5140,"url":24,"identifiers":5141},"Atreya, R. et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nat. Med. 6, 583–588 (2000).",{"doi":5142},"10.1038\u002F75068",{"id":24,"text":5144,"url":24,"identifiers":5145},"Schreiber, S. et al. Therapeutic interleukin 6 trans-signaling inhibition by olamkicept (sgp130Fc) in patients with active inflammatory bowel disease. Gastroenterology https:\u002F\u002Fdoi.org\u002F10.1053\u002Fj.gastro.2021.02.062 (2021).",{"doi":5146},"10.1053\u002Fj.gastro.2021.02.062",{"id":24,"text":5148,"url":24,"identifiers":5149},"US National Library of Medicine. ClinicalTrials.gov https:\u002F\u002Fclinicaltrials.gov\u002Fshow\u002FNCT03235752 (2021).",{},{"id":24,"text":5151,"url":24,"identifiers":5152},"Sands, B. E. et al. Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn’s disease. Gastroenterology 117, 58–64 (1999).",{"doi":5153},"10.1016\u002FS0016-5085(99)70550-0",{"id":24,"text":5155,"url":24,"identifiers":5156},"Sands, B. E. et al. Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn’s disease. Aliment. Pharmacol. Ther. 16, 399–406 (2002).",{"doi":5157},"10.1046\u002Fj.1365-2036.2002.01179.x",{"id":24,"text":5159,"url":24,"identifiers":5160},"Herrlinger, K. R. et al. Randomized, double blind controlled trial of subcutaneous recombinant human interleukin-11 versus prednisolone in active Crohn’s disease. Am. J. Gastroenterol. 101, 793–797 (2006).",{"doi":5161},"10.1111\u002Fj.1572-0241.2005.00356.x",{"id":24,"text":5163,"url":24,"identifiers":5164},"Sandborn, W. J. et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N. Engl. J. Med. 367, 616–624 (2012).",{"doi":5165},"10.1056\u002FNEJMoa1112168",{"id":24,"text":5167,"url":24,"identifiers":5168},"Sandborn, W. J. et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 376, 1723–1736 (2017).",{"doi":5169},"10.1056\u002FNEJMoa1606910",{"id":24,"text":5171,"url":24,"identifiers":5172},"US National Library of Medicine. ClinicalTrials.gov https:\u002F\u002Fclinicaltrials.gov\u002Fshow\u002FNCT03281304 (2021).",{},{"id":24,"text":5174,"url":24,"identifiers":5175},"Panes, J. et al. Tofacitinib for induction and maintenance therapy of Crohn’s disease: results of two phase IIb randomised placebo-controlled trials. Gut 66, 1049–1059 (2017).",{"doi":5176},"10.1136\u002Fgutjnl-2016-312735",{"id":24,"text":5178,"url":24,"identifiers":5179},"Sands, B. E. et al. Peficitinib, an oral janus kinase inhibitor, in moderate-to-severe ulcerative colitis: results from a randomised, phase 2 study. J. Crohns Colitis 12, 1158–1169 (2018).",{"doi":5180},"10.1093\u002Fecco-jcc\u002Fjjy085",{"id":24,"text":5182,"url":24,"identifiers":5183},"Vermeire, S. et al. Clinical remission in patients with moderate-to-severe Crohn’s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet 389, 266–275 (2017).",{"doi":5184},"10.1016\u002FS0140-6736(16)32537-5",{"id":24,"text":5186,"url":24,"identifiers":5187},"US National Library of Medicine. ClinicalTrials.gov https:\u002F\u002Fclinicaltrials.gov\u002Fshow\u002FNCT02914600 (2021).",{},{"id":24,"text":5189,"url":24,"identifiers":5190},"US National Library of Medicine. ClinicalTrials.gov https:\u002F\u002Fclinicaltrials.gov\u002Fshow\u002FNCT02914535 (2021).",{},{"id":24,"text":5192,"url":24,"identifiers":5193},"Sandborn, W. J. et al. Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn’s disease. Gastroenterology 158, 2123–2138.e8 (2020).",{"doi":5194},"10.1053\u002Fj.gastro.2020.01.047",{"id":24,"text":5196,"url":24,"identifiers":5197},"US National Library of Medicine. ClinicalTrials.gov https:\u002F\u002Fclinicaltrials.gov\u002Fshow\u002FNCT03006068 (2021).",{},{"id":24,"text":5199,"url":24,"identifiers":5200},"US National Library of Medicine. ClinicalTrials.gov https:\u002F\u002Fclinicaltrials.gov\u002Fshow\u002FNCT03345836 (2021).",{},{"id":24,"text":5202,"url":24,"identifiers":5203},"US National Library of Medicine. ClinicalTrials.gov https:\u002F\u002Fclinicaltrials.gov\u002Fshow\u002FNCT03675477 (2021).",{},{"id":24,"text":5205,"url":24,"identifiers":5206},"US National Library of Medicine. ClinicalTrials.gov https:\u002F\u002Fclinicaltrials.gov\u002Fshow\u002FNCT03677648 (2020).",{},{"id":24,"text":5208,"url":24,"identifiers":5209},"US National Library of Medicine. ClinicalTrials.gov https:\u002F\u002Fclinicaltrials.gov\u002Fshow\u002FNCT03635112 (2021).",{},{"id":24,"text":5211,"url":24,"identifiers":5212},"US National Library of Medicine. ClinicalTrials.gov https:\u002F\u002Fclinicaltrials.gov\u002Fshow\u002FNCT03920254 (2021).",{},{"id":24,"text":5214,"url":24,"identifiers":5215},"US National Library of Medicine. ClinicalTrials.gov https:\u002F\u002Fclinicaltrials.gov\u002Fshow\u002FNCT03395184 (2021).",{},{"id":24,"text":5217,"url":24,"identifiers":5218},"US National Library of Medicine. ClinicalTrials.gov https:\u002F\u002Fclinicaltrials.gov\u002Fshow\u002FNCT02958865 (2021).",{},{"id":24,"text":5220,"url":24,"identifiers":5221},"US National Library of Medicine. ClinicalTrials.gov https:\u002F\u002Fclinicaltrials.gov\u002Fshow\u002FNCT04353791 (2021).",{},{"id":24,"text":5223,"url":24,"identifiers":5224},"Wilde, M. I. & Faulds, D. Oprelvekin: a review of its pharmacology and therapeutic potential in chemotherapy-induced thrombocytopenia. BioDrugs 10, 159–171 (1998).",{"doi":5225},"10.2165\u002F00063030-199810020-00006",{"id":24,"text":5227,"url":24,"identifiers":5228},"US National Library of Medicine. ClinicalTrials.gov https:\u002F\u002Fclinicaltrials.gov\u002Fshow\u002FNCT03490669 (2020).",{},{"id":24,"text":5230,"url":24,"identifiers":5231},"US National Library of Medicine. ClinicalTrials.gov https:\u002F\u002Fclinicaltrials.gov\u002Fshow\u002FNCT04191421 (2020).",{},{"id":24,"text":5233,"url":24,"identifiers":5234},"US National Library of Medicine. ClinicalTrials.gov https:\u002F\u002Fclinicaltrials.gov\u002Fshow\u002FNCT03382340 (2020).",{},{"id":24,"text":5236,"url":24,"identifiers":5237},"US National Library of Medicine. ClinicalTrials.gov https:\u002F\u002Fclinicaltrials.gov\u002Fshow\u002FNCT02119676 (2018).",{},{"id":24,"text":5239,"url":24,"identifiers":5240},"US National Library of Medicine. ClinicalTrials.gov https:\u002F\u002Fclinicaltrials.gov\u002Fshow\u002FNCT02277093 (2017).",{},{"id":24,"text":5242,"url":24,"identifiers":5243},"US National Library of Medicine. ClinicalTrials.gov https:\u002F\u002Fclinicaltrials.gov\u002Fshow\u002FNCT03522649 (2019).",{},{"id":24,"text":5245,"url":24,"identifiers":5246},"Okusaka, T. et al. Phase 1 and pharmacological trial of OPB-31121, a signal transducer and activator of transcription-3 inhibitor, in patients with advanced hepatocellular carcinoma. Hepatol. Res. 45, 1283–1291 (2015).",{"doi":5247},"10.1111\u002Fhepr.12504",{"id":24,"text":5249,"url":24,"identifiers":5250},"US National Library of Medicine. ClinicalTrials.gov https:\u002F\u002Fclinicaltrials.gov\u002Fshow\u002FNCT01839604 (2017).",{},{"id":24,"text":5252,"url":24,"identifiers":5253},"Plimack, E. R. et al. AZD1480: a phase I study of a novel JAK2 inhibitor in solid tumors. Oncologist 18, 819–820 (2013).",{"doi":5254},"10.1634\u002Ftheoncologist.2013-0198",{"id":24,"text":5256,"url":24,"identifiers":5257},"US National Library of Medicine. ClinicalTrials.gov https:\u002F\u002Fclinicaltrials.gov\u002Fshow\u002FNCT01219543 (2013).",{},{"id":24,"text":5259,"url":24,"identifiers":5260},"US National Library of Medicine. ClinicalTrials.gov https:\u002F\u002Fclinicaltrials.gov\u002Fshow\u002FNCT04358185 (2020).",{},{"id":24,"text":5262,"url":24,"identifiers":5263},"US National Library of Medicine. ClinicalTrials.gov https:\u002F\u002Fclinicaltrials.gov\u002Fshow\u002FNCT04374877 (2020).",{},{"id":24,"text":5265,"url":24,"identifiers":5266},"Spencer, S. et al. Loss of the interleukin-6 receptor causes immunodeficiency, atopy, and abnormal inflammatory responses. J. Exp. Med. 216, 1986–1998 (2019).",{"doi":5267},"10.1084\u002Fjem.20190344",{"id":24,"text":5269,"url":24,"identifiers":5270},"Chen, Y. H. et al. Absence of GP130 cytokine receptor signaling causes extended Stüve-Wiedemann syndrome. J. Exp. Med. 217, e20191306 (2020).",{"doi":5271},"10.1084\u002Fjem.20191306",{"id":24,"text":5273,"url":24,"identifiers":5274},"Schwerd, T. et al. A biallelic mutation in IL6ST encoding the GP130 co-receptor causes immunodeficiency and craniosynostosis. J. Exp. Med. 214, 2547–2562 (2017).",{"doi":5275},"10.1084\u002Fjem.20161810",{"id":24,"text":5277,"url":24,"identifiers":5278},"Shahin, T. et al. Selective loss of function variants in IL6ST cause hyper-IgE syndrome with distinct impairments of T-cell phenotype and function. Haematologica 104, 609–621 (2019).",{"doi":5279},"10.3324\u002Fhaematol.2018.194233",{"id":24,"text":5281,"url":24,"identifiers":5282},"Minegishi, Y. et al. Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity 25, 745–755 (2006).",{"doi":5283},"10.1016\u002Fj.immuni.2006.09.009",{"id":24,"text":5285,"url":24,"identifiers":5286},"Boisson-Dupuis, S. et al. Tuberculosis and impaired IL-23-dependent IFN-γ immunity in humans homozygous for a common TYK2 missense variant. Sci. Immunol. 3, eaau8714 (2018).",{"doi":5287},"10.1126\u002Fsciimmunol.aau8714",{"id":24,"text":5289,"url":24,"identifiers":5290},"Minegishi, Y. et al. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature 448, 1058–1062 (2007).",{"doi":5291},"10.1038\u002Fnature06096",{"id":24,"text":5293,"url":24,"identifiers":5294},"Fabre, A. et al. Clinical aspects of STAT3 gain-of-function germline mutations: a systematic review. J. Allergy Clin. Immunol. Pract. 7, 1958–1969.e9 (2019).",{"doi":5295},"10.1016\u002Fj.jaip.2019.02.018",{"id":24,"text":5297,"url":24,"identifiers":5298},"Yang, S. et al. Activating JAK1 mutation may predict the sensitivity of JAK-STAT inhibition in hepatocellular carcinoma. Oncotarget 7, 5461–5469 (2016).",{"doi":5299},"10.18632\u002Foncotarget.6684",{"id":24,"text":5301,"url":24,"identifiers":5302},"Ungureanu, D. et al. The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling. Nat. Struct. Mol. Biol. 18, 971–976 (2011).",{"doi":5303},"10.1038\u002Fnsmb.2099",{"id":24,"text":5305,"url":24,"identifiers":5306},"Keupp, K. et al. Mutations in the interleukin receptor IL11RA cause autosomal recessive Crouzon-like craniosynostosis. Mol. Genet. Genomic Med. 1, 223–237 (2013).",{"doi":5307},"10.1002\u002Fmgg3.28",{"id":24,"text":5309,"url":24,"identifiers":5310},"Brischoux-Boucher, E. et al. IL11RA-related Crouzon-like autosomal recessive craniosynostosis in 10 new patients: resemblances and differences. Clin. Genet. 94, 373–380 (2018).",{"doi":5311},"10.1111\u002Fcge.13409",{"id":24,"text":5313,"url":24,"identifiers":5314},"Arita, K. et al. Oncostatin M receptor-β mutations underlie familial primary localized cutaneous amyloidosis. Am. J. Hum. Genet. 82, 73–80 (2008).",{"doi":5315},"10.1016\u002Fj.ajhg.2007.09.002",{"id":24,"text":5317,"url":24,"identifiers":5318},"Dagoneau, N. et al. Null leukemia inhibitory factor receptor (LIFR) mutations in Stuve-Wiedemann\u002FSchwartz-Jampel type 2 syndrome. Am. J. Hum. Genet. 74, 298–305 (2004).",{"doi":5319},"10.1086\u002F381715",{"id":5321,"createTime":5322,"updateTime":5322,"relativeEntities":5323,"slug":5324,"properties":5325,"entityType":184,"verifyStatus":185,"verifyTime":5322,"verifyNote":186,"syncStatus":23,"languages":5338,"translateLanguages":24,"viewCount":25,"primaryUrl":5339,"fullTextUrl":24,"authors":5340,"publicationType":310,"publisherRelationship":5379,"citationCount":5416,"citationInfo":5417,"publishDate":5424,"publishYear":5425,"citationAnalyzeStatus":23,"lastCitationAnalyze":24,"indexDatabases":24,"openAccess":24,"references":5426,"isForceReanalyzing":595},"bd0f4710-7fc2-4024-85d6-50269a916eb1","2024-09-25T22:21:50.758+00:00",[],"Gut-microbiota-in-colorectal-cancer-mechanisms-of-action-and-clinical-applications",{"mag":5326,"keywords":5328,"openalex":5329,"abstract":5331,"title":5332,"pm":5334,"doi":5336},{"VOID":5327},"2976007626",{},{"VOID":5330},"W2976007626",{},{"EN":5333},"Gut microbiota in colorectal cancer: mechanisms of action and clinical applications",{"VOID":5335},"31554963",{"VOID":5337},"10.1038\u002Fs41575-019-0209-8",[188],"https:\u002F\u002Fwww.nature.com\u002Farticles\u002Fs41575-019-0209-8",[5341,5362],{"id":5342,"sortIndex":25,"researcher":24,"roles":5343,"affiliations":5344,"properties":5355},"c5e19cba-a69b-4157-afb6-b96b57c6c4bf",[],[5345],{"id":5346,"sortIndex":25,"affiliation":5347,"properties":24},"3e88c612-ce24-40ac-b303-7aa02d9d3fa3",{"id":5348,"createTime":5349,"updateTime":5349,"relativeEntities":5350,"slug":5351,"properties":5352,"entityType":53,"verifyStatus":23,"verifyTime":24,"verifyNote":24,"syncStatus":23,"languages":24,"translateLanguages":24,"viewCount":25},"3e1e437c-661f-45b8-935e-7f4668bbf8a0","2024-09-25T22:21:50.782+00:00",[],"Institute-of-Digestive-Disease-and-Department-of-Medicine-and-Therapeutics-State-Key-Laboratory-of-Digestive-Diseases-Li-Ka-Shing-Institute-of-Health-Sciences-The-Chinese-University-of-Hong-Kong-Hong-Kong-People-s-Republic-of-China",{"title":5353},{"EN":5354},"Institute of Digestive Disease and Department of Medicine and Therapeutics, State Key Laboratory of Digestive Diseases, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, People’s Republic of China",{"openalex":5356,"orcid":5358,"title":5360},{"VOID":5357},"A5033997612",{"VOID":5359},"https:\u002F\u002Forcid.org\u002F0000-0002-3354-9310",{"EN":5361},"Sunny H. Wong",{"id":5363,"sortIndex":215,"researcher":24,"roles":5364,"affiliations":5365,"properties":5372},"3ee1ecd5-9865-4731-aa38-91ba3759a817",[],[5366],{"id":5367,"sortIndex":25,"affiliation":5368,"properties":24},"54413f75-9ee4-437e-8267-7be5da2bb338",{"id":5348,"createTime":5349,"updateTime":5349,"relativeEntities":5369,"slug":5351,"properties":5370,"entityType":53,"verifyStatus":23,"verifyTime":24,"verifyNote":24,"syncStatus":23,"languages":24,"translateLanguages":24,"viewCount":25},[],{"title":5371},{"EN":5354},{"openalex":5373,"orcid":5375,"title":5377},{"VOID":5374},"A5033829154",{"VOID":5376},"https:\u002F\u002Forcid.org\u002F0000-0003-3435-6550",{"EN":5378},"Jun Yu",{"url":24,"publisher":5380,"properties":5410},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":5381,"slug":10,"properties":5382,"entityType":22,"verifyStatus":23,"verifyTime":24,"verifyNote":24,"syncStatus":23,"languages":24,"translateLanguages":24,"viewCount":25,"subjectFields":5388,"manageAffiliations":5389,"indexDatabases":5390,"url":106,"thumbnailPath":24,"statistic":5405,"gsStatistic":24,"type":24,"analyzePriority":24},[],{"country":5383,"issn":5384,"introduce":5385,"eissn":5386,"title":5387},{"VOID":13},{"VOID":15},{"EN":17},{"VOID":19},{"EN":21},[],[],[5391,5398],{"id":88,"indexDatabase":5392,"url":103,"indexYears":24,"academicFieldIds":5397,"indexDatabaseRanking":24},{"id":90,"createTime":91,"updateTime":92,"relativeEntities":5393,"label":5394,"description":5395,"key":99,"publicationTags":5396,"standard":24},[],{"EN":95,"VI":95},{"VI":97,"EN":98},[101,102],[105],{"id":68,"indexDatabase":5399,"url":81,"indexYears":82,"academicFieldIds":5404,"indexDatabaseRanking":86},{"id":70,"createTime":71,"updateTime":72,"relativeEntities":5400,"label":5401,"description":5402,"key":78,"publicationTags":5403,"standard":24},[],{"EN":75,"VI":75},{"EN":75,"VI":77},[80],[84,85],{"impactFactor":25,"impactFactorByYear":5406,"i10Index":121,"i10IndexLast5Year":122,"totalPublication":121,"totalPublicationByYear":5407,"totalCitation":129,"totalCitationByYear":5408,"totalCitationPerPublication":145,"totalCitationPerPublicationByYear":5409,"hindexLast5Year":161,"hindex":161},{"2012":109,"2013":110,"2014":111,"2015":112,"2016":113,"2017":114,"2018":115,"2019":116,"2020":117,"2021":118,"2022":119,"2023":120},{"2009":124,"2010":124,"2011":125,"2012":126,"2013":127,"2014":124,"2015":125,"2016":127,"2017":128,"2018":127,"2019":127,"2020":126,"2021":125,"2022":126},{"2009":131,"2010":132,"2011":133,"2012":134,"2013":135,"2014":136,"2015":137,"2016":138,"2017":139,"2018":140,"2019":141,"2020":142,"2021":143,"2022":144},{"2009":147,"2010":148,"2011":149,"2012":150,"2013":151,"2014":152,"2015":153,"2016":154,"2017":155,"2018":156,"2019":157,"2020":158,"2021":159,"2022":160},{"volume":5411,"pages":5413,"issue":5415},{"VOID":5412},"16",{"VOID":5414},"690-704",{"VOID":3092},848,{"total":5416,"publishYear":24,"statisticByYear":5418},{"2019":215,"2020":5419,"2021":5420,"2022":5421,"2023":5422,"2024":5423},93,148,212,215,167,"2019-11-01",2019,[5427,5430,5434,5438,5442,5446,5450,5454,5458,5462,5466,5470,5474,5478,5482,5485,5488,5491,5495,5499,5503,5507,5511,5514,5518,5522,5526,5530,5534,5538,5542,5546,5550,5554,5558,5562,5566,5570,5574,5578,5582,5586,5590,5594,5598,5602,5606,5610,5614,5618,5622,5626,5630,5634,5638,5642,5646,5650,5654,5658,5662,5666,5670,5674,5678,5682,5686,5690,5694,5698,5702,5706,5710,5714,5718,5720,5724,5727,5731,5735,5739,5743,5747,5751,5755,5759,5763,5767,5771,5774,5778,5782,5786,5790,5794,5798,5802,5806,5810,5814,5818,5822,5826,5830,5834,5838,5842,5846,5850,5854,5858,5862,5866,5870,5874,5878,5882,5886,5890,5894,5898,5902,5906,5910,5914,5918,5921,5925,5929,5933,5937,5941,5945,5949,5953,5957,5961,5965,5969,5973,5977,5981,5985,5989,5993,5997,6001,6005,6009,6013,6017,6021,6025,6029,6033,6037,6041,6044,6048,6052,6056,6060,6064,6068,6072,6076,6080,6084,6088,6092,6096,6100,6104,6108,6112,6116,6120,6124,6128,6132,6136,6140,6144,6148,6152,6156,6160,6164,6168,6172,6176,6180,6184,6188,6192,6196,6200,6204,6208,6212,6216,6220,6224,6227,6231,6235,6239,6243,6247,6251,6255,6259,6263,6267,6271,6275,6279,6283,6287,6291,6295,6299,6303,6307,6311,6315,6319,6323,6327,6331,6335,6339,6343,6347,6351,6355,6359,6362,6366,6370,6374,6378,6382,6386,6390,6394,6398,6402,6406,6410,6414,6418,6422,6426,6430,6434,6438,6442,6446,6450,6454,6458,6462,6466,6470,6474],{"id":24,"text":5428,"url":24,"identifiers":5429},"Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424 (2018).",{},{"id":24,"text":5431,"url":24,"identifiers":5432},"Lichtenstein, P. et al. Environmental and heritable factors in the causation of cancer — analyses of cohorts of twins from Sweden, Denmark, and Finland. N. Engl. J. Med. 343, 78–85 (2000).",{"doi":5433},"10.1056\u002FNEJM200007133430201",{"id":24,"text":5435,"url":24,"identifiers":5436},"Foulkes, W. D. Inherited susceptibility to common cancers. N. Engl. J. Med. 359, 2143–2153 (2008).",{"doi":5437},"10.1056\u002FNEJMra0802968",{"id":24,"text":5439,"url":24,"identifiers":5440},"Czene, K., Lichtenstein, P. & Hemminki, K. Environmental and heritable causes of cancer among 9.6 million individuals in the Swedish family-cancer database. Int. J. Cancer 99, 260–266 (2002).",{"doi":5441},"10.1002\u002Fijc.10332",{"id":24,"text":5443,"url":24,"identifiers":5444},"Plummer, M. et al. Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob. Health 4, e609-e616 (2016).",{"doi":5445},"10.1016\u002FS2214-109X(16)30143-7",{"id":24,"text":5447,"url":24,"identifiers":5448},"Helmink, B. A., Khan, M. A. W., Hermann, A., Gopalakrishnan, V. & Wargo, J. A. The microbiome, cancer, and cancer therapy. Nat. Med. 25, 377–388 (2019).",{"doi":5449},"10.1038\u002Fs41591-019-0377-7",{"id":24,"text":5451,"url":24,"identifiers":5452},"Qin, J. et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464, 59–65 (2010).",{"doi":5453},"10.1038\u002Fnature08821",{"id":24,"text":5455,"url":24,"identifiers":5456},"Turnbaugh, P. J. et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444, 1027–1031 (2006).",{"doi":5457},"10.1038\u002Fnature05414",{"id":24,"text":5459,"url":24,"identifiers":5460},"Chung, H. et al. Gut immune maturation depends on colonization with a host-specific microbiota. Cell 149, 1578–1593 (2012).",{"doi":5461},"10.1016\u002Fj.cell.2012.04.037",{"id":24,"text":5463,"url":24,"identifiers":5464},"Brown, J. M. & Hazen, S. L. Microbial modulation of cardiovascular disease. Nat. Rev. Microbiol. 16, 171–181 (2018).",{"doi":5465},"10.1038\u002Fnrmicro.2017.149",{"id":24,"text":5467,"url":24,"identifiers":5468},"Maruvada, P., Leone, V., Kaplan, L. M. & Chang, E. B. The human microbiome and obesity: moving beyond associations. Cell Host Microbe 22, 589–599 (2017).",{"doi":5469},"10.1016\u002Fj.chom.2017.10.005",{"id":24,"text":5471,"url":24,"identifiers":5472},"Sharon, G., Sampson, T. R., Geschwind, D. H. & Mazmanian, S. K. The central nervous system and the gut microbiome. Cell 167, 915–932 (2016).",{"doi":5473},"10.1016\u002Fj.cell.2016.10.027",{"id":24,"text":5475,"url":24,"identifiers":5476},"Kostic, A. D., Xavier, R. J. & Gevers, D. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology 146, 1489–1499 (2014).",{"doi":5477},"10.1053\u002Fj.gastro.2014.02.009",{"id":24,"text":5479,"url":24,"identifiers":5480},"Buffie, C. G. et al. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature 517, 205–208 (2015).",{"doi":5481},"10.1038\u002Fnature13828",{"id":24,"text":5483,"url":24,"identifiers":5484},"Laqueur, G. L., McDaniel, E. G. & Matsumoto, H. Tumor induction in germfree rats with methylazoxymethanol (MAM) and synthetic MAM acetate. J. Natl Cancer Inst. 39, 355–371 (1967).",{},{"id":24,"text":5486,"url":24,"identifiers":5487},"Reddy, B. S., Weisburger, J. H., Narisawa, T. & Wynder, E. L. Colon carcinogenesis in germ-free rats with 1,2-dimethylhydrazine and N-methyl-n’-nitro-N-nitrosoguanidine. Cancer Res. 34, 2368–2372 (1974).",{},{"id":24,"text":5489,"url":24,"identifiers":5490},"Reddy, B. S. et al. Colon carcinogenesis with azoxymethane and dimethylhydrazine in germ-free rats. Cancer Res. 35, 287–290 (1975). This study provides early evidence that gut microbiota can alter the effect of carcinogens in the large intestine.",{},{"id":24,"text":5492,"url":24,"identifiers":5493},"Onoue, M., Kado, S., Sakaitani, Y., Uchida, K. & Morotomi, M. Specific species of intestinal bacteria influence the induction of aberrant crypt foci by 1,2-dimethylhydrazine in rats. Cancer Lett. 113, 179–186 (1997).",{"doi":5494},"10.1016\u002FS0304-3835(97)04698-3",{"id":24,"text":5496,"url":24,"identifiers":5497},"Wong, S. H. et al. Gavage of fecal samples from patients with colorectal cancer promotes intestinal carcinogenesis in germ-free and conventional mice. Gastroenterology 153, 1621–1633 e1626 (2017). Using faecal microbiota transplantation, this study demonstrates the carcinogenic properties of microbial communities obtained from patients with CRC in two mouse models.",{"doi":5498},"10.1053\u002Fj.gastro.2017.08.022",{"id":24,"text":5500,"url":24,"identifiers":5501},"Castellarin, M. et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res. 22, 299–306 (2012). This study reports the association between the abundance of Fusobacterium nucleatum and CRC in humans.",{"doi":5502},"10.1101\u002Fgr.126516.111",{"id":24,"text":5504,"url":24,"identifiers":5505},"Feng, Q. et al. Gut microbiome development along the colorectal adenoma-carcinoma sequence. Nat. Commun. 6, 6528 (2015).",{"doi":5506},"10.1038\u002Fncomms7528",{"id":24,"text":5508,"url":24,"identifiers":5509},"Yu, J. et al. Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer. Gut 66, 70–78 (2017).",{"doi":5510},"10.1136\u002Fgutjnl-2015-309800",{"id":24,"text":5512,"url":24,"identifiers":5513},"Sobhani, I. et al. Microbial dysbiosis in colorectal cancer (CRC) patients. PLoS One 6, (e16393 (2011).",{},{"id":24,"text":5515,"url":24,"identifiers":5516},"Wang, T. et al. Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers. ISME J. 6, 320–329 (2012).",{"doi":5517},"10.1038\u002Fismej.2011.109",{"id":24,"text":5519,"url":24,"identifiers":5520},"Ahn, J. et al. Human gut microbiome and risk for colorectal cancer. J. Natl Cancer Inst. 105, 1907–1911 (2013).",{"doi":5521},"10.1093\u002Fjnci\u002Fdjt300",{"id":24,"text":5523,"url":24,"identifiers":5524},"Zeller, G. et al. Potential of fecal microbiota for early-stage detection of colorectal cancer. Mol. Syst. Biol. 10, 766 (2014).",{"doi":5525},"10.15252\u002Fmsb.20145645",{"id":24,"text":5527,"url":24,"identifiers":5528},"Zackular, J. P., Rogers, M. A., Ruffin, M. Tt & Schloss, P. D. The human gut microbiome as a screening tool for colorectal cancer. Cancer Prev. Res. (Phila) 7, 1112–1121 (2014).",{"doi":5529},"10.1158\u002F1940-6207.CAPR-14-0129",{"id":24,"text":5531,"url":24,"identifiers":5532},"Baxter, N. T., Ruffin, M. Tt, Rogers, M. A. & Schloss, P. D. Microbiota-based model improves the sensitivity of fecal immunochemical test for detecting colonic lesions. Genome Med. 8, 37 (2016).",{"doi":5533},"10.1186\u002Fs13073-016-0290-3",{"id":24,"text":5535,"url":24,"identifiers":5536},"Yazici, C. et al. Race-dependent association of sulfidogenic bacteria with colorectal cancer. Gut 66, 1983–1994 (2017).",{"doi":5537},"10.1136\u002Fgutjnl-2016-313321",{"id":24,"text":5539,"url":24,"identifiers":5540},"Thomas, A. M. et al. Metagenomic analysis of colorectal cancer datasets identifies cross-cohort microbial diagnostic signatures and a link with choline degradation. Nat. Med. 25, 667–678 (2019).",{"doi":5541},"10.1038\u002Fs41591-019-0405-7",{"id":24,"text":5543,"url":24,"identifiers":5544},"Wirbel, J. et al. Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer. Nat. Med. 25, 679–689 (2019).",{"doi":5545},"10.1038\u002Fs41591-019-0406-6",{"id":24,"text":5547,"url":24,"identifiers":5548},"Yachida, S. et al. Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer. Nat. Med. 25, 968–976 (2019).",{"doi":5549},"10.1038\u002Fs41591-019-0458-7",{"id":24,"text":5551,"url":24,"identifiers":5552},"Marchesi, J. R. et al. Towards the human colorectal cancer microbiome. PLoS One 6, e20447 (2011).",{"doi":5553},"10.1371\u002Fjournal.pone.0020447",{"id":24,"text":5555,"url":24,"identifiers":5556},"Chen, W., Liu, F., Ling, Z., Tong, X. & Xiang, C. Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer. PLoS One 7, e39743 (2012).",{"doi":5557},"10.1371\u002Fjournal.pone.0039743",{"id":24,"text":5559,"url":24,"identifiers":5560},"Kostic, A. D. et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe 14, 207–215 (2013). This study evaluates the role of F. nucleatum in CRC, providing support that it could generate a pro-inflammatory microenvironment conducive to the progression of colorectal neoplasma.",{"doi":5561},"10.1016\u002Fj.chom.2013.07.007",{"id":24,"text":5563,"url":24,"identifiers":5564},"Warren, R. L. et al. Co-occurrence of anaerobic bacteria in colorectal carcinomas. Microbiome 1, 16 (2013).",{"doi":5565},"10.1186\u002F2049-2618-1-16",{"id":24,"text":5567,"url":24,"identifiers":5568},"Zhang, Z. et al. Spatial heterogeneity and co-occurrence patterns of human mucosal-associated intestinal microbiota. ISME J. 8, 881–893 (2014).",{"doi":5569},"10.1038\u002Fismej.2013.185",{"id":24,"text":5571,"url":24,"identifiers":5572},"Allali, I. et al. Gut microbiome compositional and functional differences between tumor and non-tumor adjacent tissues from cohorts from the US and Spain. Gut Microbes 6, 161–172 (2015).",{"doi":5573},"10.1080\u002F19490976.2015.1039223",{"id":24,"text":5575,"url":24,"identifiers":5576},"Nakatsu, G. et al. Gut mucosal microbiome across stages of colorectal carcinogenesis. Nat. Commun. 6, 8727 (2015). This study depicts the mucosal microbiota landscape along different stages of colorectal carcinogenesis and reports changes in bacterial abundance and interspecies interactions in patients with colorectal adenoma and CRC.",{"doi":5577},"10.1038\u002Fncomms9727",{"id":24,"text":5579,"url":24,"identifiers":5580},"Flemer, B. et al. Tumour-associated and non-tumour-associated microbiota in colorectal cancer. Gut 66, 633–643 (2017).",{"doi":5581},"10.1136\u002Fgutjnl-2015-309595",{"id":24,"text":5583,"url":24,"identifiers":5584},"Wu, S. et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat. Med. 15, 1016–1022 (2009). This study establishes enterotoxigenic Bacteroides fragilis as a cancer-promoting bacterium via activation of the T H 17 cell response.",{"doi":5585},"10.1038\u002Fnm.2015",{"id":24,"text":5587,"url":24,"identifiers":5588},"Arthur, J. C. et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 338, 120–123 (2012). Using a mouse model of colitis, this landmark study establishes genotoxic E. coli as a cancer-inducing bacterium in CRC.",{"doi":5589},"10.1126\u002Fscience.1224820",{"id":24,"text":5591,"url":24,"identifiers":5592},"Huycke, M. M., Abrams, V. & Moore, D. R. Enterococcus faecalis produces extracellular superoxide and hydrogen peroxide that damages colonic epithelial cell DNA. Carcinogenesis 23, 529–536 (2002).",{"doi":5593},"10.1093\u002Fcarcin\u002F23.3.529",{"id":24,"text":5595,"url":24,"identifiers":5596},"Boleij, A. & Tjalsma, H. The itinerary of Streptococcus gallolyticus infection in patients with colonic malignant disease. Lancet Infect. Dis. 13, 719–724 (2013).",{"doi":5597},"10.1016\u002FS1473-3099(13)70107-5",{"id":24,"text":5599,"url":24,"identifiers":5600},"Zhernakova, A. et al. Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. Science 352, 565–569 (2016).",{"doi":5601},"10.1126\u002Fscience.aad3369",{"id":24,"text":5603,"url":24,"identifiers":5604},"He, Y. et al. Regional variation limits applications of healthy gut microbiome reference ranges and disease models. Nat. Med. 24, 1532–1535 (2018).",{"doi":5605},"10.1038\u002Fs41591-018-0164-x",{"id":24,"text":5607,"url":24,"identifiers":5608},"Drewes, J. L. et al. High-resolution bacterial 16S rRNA gene profile meta-analysis and biofilm status reveal common colorectal cancer consortia. NPJ Biofilms Microbiomes 3, 34 (2017).",{"doi":5609},"10.1038\u002Fs41522-017-0040-3",{"id":24,"text":5611,"url":24,"identifiers":5612},"Dai, Z. et al. Multi-cohort analysis of colorectal cancer metagenome identified altered bacteria across populations and universal bacterial markers. Microbiome 6, 70 (2018).",{"doi":5613},"10.1186\u002Fs40168-018-0451-2",{"id":24,"text":5615,"url":24,"identifiers":5616},"Shah, M. S. et al. Leveraging sequence-based faecal microbial community survey data to identify a composite biomarker for colorectal cancer. Gut 67, 882–891 (2018).",{"doi":5617},"10.1136\u002Fgutjnl-2016-313189",{"id":24,"text":5619,"url":24,"identifiers":5620},"Dai, Z., Wong, S. H., Yu, J. & Wei, Y. Batch effects correction for microbiome data with Dirichlet-multinomial regression. Bioinformatics 35, 2348 (2018).",{"doi":5621},"10.1093\u002Fbioinformatics\u002Fbty874",{"id":24,"text":5623,"url":24,"identifiers":5624},"Sears, C. L., Geis, A. L. & Housseau, F. Bacteroides fragilis subverts mucosal biology: from symbiont to colon carcinogenesis. J. Clin. Invest. 124, 4166–4172 (2014).",{"doi":5625},"10.1172\u002FJCI72334",{"id":24,"text":5627,"url":24,"identifiers":5628},"Chung, L. et al. Bacteroides fragilis toxin coordinates a pro-carcinogenic inflammatory cascade via targeting of colonic epithelial cells. Cell Host Microbe 23, 421 (2018).",{"doi":5629},"10.1016\u002Fj.chom.2018.02.004",{"id":24,"text":5631,"url":24,"identifiers":5632},"Seki, H. et al. Prevention of antibiotic-associated diarrhea in children by Clostridium butyricum MIYAIRI. Pediatr. Int. 45, 86–90 (2003).",{"doi":5633},"10.1046\u002Fj.1442-200X.2003.01671.x",{"id":24,"text":5635,"url":24,"identifiers":5636},"Correa, N. B., Peret Filho, L. A., Penna, F. J., Lima, F. M. & Nicoli, J. R. A randomized formula controlled trial of Bifidobacterium lactis and Streptococcus thermophilus for prevention of antibiotic-associated diarrhea in infants. J. Clin. Gastroenterol. 39, 385–389 (2005).",{"doi":5637},"10.1097\u002F01.mcg.0000159217.47419.5b",{"id":24,"text":5639,"url":24,"identifiers":5640},"Collins, D., Hogan, A. M. & Winter, D. C. Microbial and viral pathogens in colorectal cancer. Lancet Oncol. 12, 504–512 (2011).",{"doi":5641},"10.1016\u002FS1470-2045(10)70186-8",{"id":24,"text":5643,"url":24,"identifiers":5644},"Harkins, L. et al. Specific localisation of human cytomegalovirus nucleic acids and proteins in human colorectal cancer. Lancet 360, 1557–1563 (2002).",{"doi":5645},"10.1016\u002FS0140-6736(02)11524-8",{"id":24,"text":5647,"url":24,"identifiers":5648},"Bender, C. et al. Analysis of colorectal cancers for human cytomegalovirus presence. Infect. Agent Cancer 4, 6 (2009).",{"doi":5649},"10.1186\u002F1750-9378-4-6",{"id":24,"text":5651,"url":24,"identifiers":5652},"Laghi, L. et al. JC virus DNA is present in the mucosa of the human colon and in colorectal cancers. Proc Natl Acad Sci USA 96, 7484–7489 (1999).",{"doi":5653},"10.1073\u002Fpnas.96.13.7484",{"id":24,"text":5655,"url":24,"identifiers":5656},"Cheng, J. Y., Sheu, L. F., Meng, C. L., Lee, W. H. & Lin, J. C. Detection of human papillomavirus DNA in colorectal carcinomas by polymerase chain reaction. Gut 37, 87–90 (1995).",{"doi":5657},"10.1136\u002Fgut.37.1.87",{"id":24,"text":5659,"url":24,"identifiers":5660},"Hart, H., Neill, W. A. & Norval, M. Lack of association of cytomegalovirus with adenocarcinoma of the colon. Gut 23, 21–30 (1982).",{"doi":5661},"10.1136\u002Fgut.23.1.21",{"id":24,"text":5663,"url":24,"identifiers":5664},"Knosel, T., Schewe, C., Dietel, M. & Petersen, I. Cytomegalovirus is not associated with progression and metastasis of colorectal cancer. Cancer Lett. 211, 243–247 (2004).",{"doi":5665},"10.1016\u002Fj.canlet.2004.02.011",{"id":24,"text":5667,"url":24,"identifiers":5668},"Gornick, M. C. et al. Human papillomavirus is not associated with colorectal cancer in a large international study. Cancer Causes Control 21, 737–743 (2010).",{"doi":5669},"10.1007\u002Fs10552-010-9502-0",{"id":24,"text":5671,"url":24,"identifiers":5672},"Nakatsu, G. et al. Alterations in enteric virome are associated with colorectal cancer and survival outcomes. Gastroenterology 155, 529–541.e5 (2018). This study is the first to report the gut virome in patients with CRC and identifies viral markers that could classify cases and controls.",{"doi":5673},"10.1053\u002Fj.gastro.2018.04.018",{"id":24,"text":5675,"url":24,"identifiers":5676},"Hannigan, G. D., Duhaime, M. B., Ruffin, M. Tt, Koumpouras, C. C. & Schloss, P. D. Diagnostic potential and interactive dynamics of the colorectal cancer virome. mBio 9, e02248-18 (2018).",{"doi":5677},"10.1128\u002FmBio.02248-18",{"id":24,"text":5679,"url":24,"identifiers":5680},"Gao, R. et al. Dysbiosis signature of mycobiota in colon polyp and colorectal cancer. Eur. J. Clin. Microbiol Infect. Dis. 36, 2457–2468 (2017).",{"doi":5681},"10.1007\u002Fs10096-017-3085-6",{"id":24,"text":5683,"url":24,"identifiers":5684},"Coker, O. O. et al. Enteric fungal microbiota dysbiosis and ecological alterations in colorectal cancer. Gut 68, 654–662 (2019).",{"doi":5685},"10.1136\u002Fgutjnl-2018-317178",{"id":24,"text":5687,"url":24,"identifiers":5688},"Strum, W. B. Colorectal adenomas. N. Engl. J. Med. 374, 1065–1075 (2016).",{"doi":5689},"10.1056\u002FNEJMra1513581",{"id":24,"text":5691,"url":24,"identifiers":5692},"Shen, X. J. et al. Molecular characterization of mucosal adherent bacteria and associations with colorectal adenomas. Gut Microbes 1, 138–147 (2010).",{"doi":5693},"10.4161\u002Fgmic.1.3.12360",{"id":24,"text":5695,"url":24,"identifiers":5696},"Sanapareddy, N. et al. Increased rectal microbial richness is associated with the presence of colorectal adenomas in humans. ISME J. 6, 1858–1868 (2012).",{"doi":5697},"10.1038\u002Fismej.2012.43",{"id":24,"text":5699,"url":24,"identifiers":5700},"McCoy, A. N. et al. Fusobacterium is associated with colorectal adenomas. PLOS ONE 8, e53653 (2013).",{"doi":5701},"10.1371\u002Fjournal.pone.0053653",{"id":24,"text":5703,"url":24,"identifiers":5704},"Lu, Y. et al. Mucosal adherent bacterial dysbiosis in patients with colorectal adenomas. Sci. Rep. 6, 26337 (2016).",{"doi":5705},"10.1038\u002Fsrep26337",{"id":24,"text":5707,"url":24,"identifiers":5708},"Luan, C. et al. Dysbiosis of fungal microbiota in the intestinal mucosa of patients with colorectal adenomas. Sci. Rep. 5, 7980 (2015).",{"doi":5709},"10.1038\u002Fsrep07980",{"id":24,"text":5711,"url":24,"identifiers":5712},"Tilg, H., Adolph, T. E., Gerner, R. R. & Moschen, A. R. The intestinal microbiota in colorectal cancer. Cancer Cell 33, 954–964 (2018).",{"doi":5713},"10.1016\u002Fj.ccell.2018.03.004",{"id":24,"text":5715,"url":24,"identifiers":5716},"Round, J. L. & Mazmanian, S. K. The gut microbiota shapes intestinal immune responses during health and disease. Nat. Rev. Immunol. 9, 313–323 (2009).",{"doi":5717},"10.1038\u002Fnri2515",{"id":24,"text":1123,"url":24,"identifiers":5719},{"doi":1125},{"id":24,"text":5721,"url":24,"identifiers":5722},"Lasry, A., Zinger, A. & Ben-Neriah, Y. Inflammatory networks underlying colorectal cancer. Nat. Immunol. 17, 230–240 (2016).",{"doi":5723},"10.1038\u002Fni.3384",{"id":24,"text":5725,"url":24,"identifiers":5726},"Beaugerie, L. & Itzkowitz, S. H. Cancers complicating inflammatory bowel disease. N. Engl. J. Med. 373, 195 (2015).",{},{"id":24,"text":5728,"url":24,"identifiers":5729},"Eaden, J. A., Abrams, K. R. & Mayberry, J. F. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 48, 526–535 (2001).",{"doi":5730},"10.1136\u002Fgut.48.4.526",{"id":24,"text":5732,"url":24,"identifiers":5733},"Canavan, C., Abrams, K. R. & Mayberry, J. Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn’s disease. Aliment. Pharmacol. Ther. 23, 1097–1104 (2006).",{"doi":5734},"10.1111\u002Fj.1365-2036.2006.02854.x",{"id":24,"text":5736,"url":24,"identifiers":5737},"Sebastian, S. et al. Colorectal cancer in inflammatory bowel disease: results of the 3rd ECCO pathogenesis scientific workshop (I). J. Crohns Colitis 8, 5–18 (2014).",{"doi":5738},"10.1016\u002Fj.crohns.2013.04.008",{"id":24,"text":5740,"url":24,"identifiers":5741},"Cremonesi, E. et al. Gut microbiota modulate T cell trafficking into human colorectal cancer. Gut 67, 1984–1994 (2018).",{"doi":5742},"10.1136\u002Fgutjnl-2016-313498",{"id":24,"text":5744,"url":24,"identifiers":5745},"Tomkovich, S. et al. Locoregional effects of microbiota in a preclinical model of colon carcinogenesis. Cancer Res. 77, 2620–2632 (2017).",{"doi":5746},"10.1158\u002F0008-5472.CAN-16-3472",{"id":24,"text":5748,"url":24,"identifiers":5749},"Boleij, A. et al. The Bacteroides fragilistoxin gene is prevalent in the colon mucosa of colorectal cancer patients. Clin. Infect. Dis. 60, 208–215 (2015).",{"doi":5750},"10.1093\u002Fcid\u002Fciu787",{"id":24,"text":5752,"url":24,"identifiers":5753},"Arthur, J. C. et al. Microbial genomic analysis reveals the essential role of inflammation in bacteria-induced colorectal cancer. Nat. Commun. 5, 4724 (2014).",{"doi":5754},"10.1038\u002Fncomms5724",{"id":24,"text":5756,"url":24,"identifiers":5757},"Bonnet, M. et al. Colonization of the human gut by E. coli and colorectal cancer risk. Clin. Cancer Res. 20, 859–867 (2014).",{"doi":5758},"10.1158\u002F1078-0432.CCR-13-1343",{"id":24,"text":5760,"url":24,"identifiers":5761},"Wang, X. et al. 4-hydroxy-2-nonenal mediates genotoxicity and bystander effects caused by Enterococcus faecalis-infected macrophages. Gastroenterology 142, 543–551 e547 (2012).",{"doi":5762},"10.1053\u002Fj.gastro.2011.11.020",{"id":24,"text":5764,"url":24,"identifiers":5765},"Moschen, A. R. et al. Lipocalin 2 protects from inflammation and tumorigenesis associated with gut microbiota alterations. Cell Host Microbe 19, 455–469 (2016).",{"doi":5766},"10.1016\u002Fj.chom.2016.03.007",{"id":24,"text":5768,"url":24,"identifiers":5769},"Kesselring, R. et al. IRAK-M expression in tumor cells supports colorectal cancer progression through reduction of antimicrobial defense and stabilization of STAT3. Cancer Cell 29, 684–696 (2016).",{"doi":5770},"10.1016\u002Fj.ccell.2016.03.014",{"id":24,"text":5772,"url":24,"identifiers":5773},"Couturier-Maillard, A. et al. NOD2-mediated dysbiosis predisposes mice to transmissible colitis and colorectal cancer. J. Clin. Invest. 123, 700–711 (2013).",{},{"id":24,"text":5775,"url":24,"identifiers":5776},"Zhu, H. et al. RNA virus receptor Rig-I monitors gut microbiota and inhibits colitis-associated colorectal cancer. J. Exp. Clin. Cancer Res. 36, 2 (2017).",{"doi":5777},"10.1186\u002Fs13046-016-0471-3",{"id":24,"text":5779,"url":24,"identifiers":5780},"Man, S. M. et al. Critical role for the DNA sensor AIM2 in stem cell proliferation and cancer. Cell 162, 45–58 (2015).",{"doi":5781},"10.1016\u002Fj.cell.2015.06.001",{"id":24,"text":5783,"url":24,"identifiers":5784},"Yang, Y. et al. Fusobacterium nucleatum increases proliferation of colorectal cancer cells and tumor development in mice by activating toll-like receptor 4 signaling to nuclear factor-kappab, and up-regulating expression of microRNA-21. Gastroenterology 152, 851–866 e824 (2017).",{"doi":5785},"10.1053\u002Fj.gastro.2016.11.018",{"id":24,"text":5787,"url":24,"identifiers":5788},"Wu, Y. et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis in mice via a toll-like receptor 4\u002Fp21-activated kinase 1 cascade. Dig. Dis. Sci. 63, 1210–1218 (2018).",{"doi":5789},"10.1007\u002Fs10620-018-4999-2",{"id":24,"text":5791,"url":24,"identifiers":5792},"Tsoi, H. et al. Peptostreptococcus anaerobius induces intracellular cholesterol biosynthesis in colon cells to induce proliferation and causes dysplasia in mice. Gastroenterology 152, 1419–1433 e1415 (2017).",{"doi":5793},"10.1053\u002Fj.gastro.2017.01.009",{"id":24,"text":5795,"url":24,"identifiers":5796},"Doll, R. & Peto, R. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J. Natl Cancer Inst. 66, 1191–1308 (1981).",{"doi":5797},"10.1093\u002Fjnci\u002F66.6.1192",{"id":24,"text":5799,"url":24,"identifiers":5800},"Zhang, F. F. et al. Preventable cancer burden associated with poor diet in the United States. JNCI Cancer Spectr. 3, pkz034 (2019).",{"doi":5801},"10.1093\u002Fjncics\u002Fpkz034",{"id":24,"text":5803,"url":24,"identifiers":5804},"Alexander, D. D., Weed, D. L., Cushing, C. A. & Lowe, K. A. Meta-analysis of prospective studies of red meat consumption and colorectal cancer. Eur. J. Cancer Prev. 20, 293–307 (2011).",{"doi":5805},"10.1097\u002FCEJ.0b013e328345f985",{"id":24,"text":5807,"url":24,"identifiers":5808},"O’Keefe, S. J. Diet, microorganisms and their metabolites, and colon cancer. Nat. Rev. Gastroenterol. Hepatol. 13, 691–706 (2016).",{"doi":5809},"10.1038\u002Fnrgastro.2016.165",{"id":24,"text":5811,"url":24,"identifiers":5812},"Louis, P., Hold, G. L. & Flint, H. J. The gut microbiota, bacterial metabolites and colorectal cancer. Nat. Rev. Microbiol. 12, 661–672 (2014).",{"doi":5813},"10.1038\u002Fnrmicro3344",{"id":24,"text":5815,"url":24,"identifiers":5816},"Ijssennagger, N. et al. Gut microbiota facilitates dietary heme-induced epithelial hyperproliferation by opening the mucus barrier in colon. Proc. Natl Acad. Sci. USA 112, 10038–10043 (2015).",{"doi":5817},"10.1073\u002Fpnas.1507645112",{"id":24,"text":5819,"url":24,"identifiers":5820},"Singh, N. et al. Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. Immunity 40, 128–139 (2014).",{"doi":5821},"10.1016\u002Fj.immuni.2013.12.007",{"id":24,"text":5823,"url":24,"identifiers":5824},"Chang, P. V., Hao, L., Offermanns, S. & Medzhitov, R. The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition. Proc. Natl Acad. Sci. USA 111, 2247–2252 (2014).",{"doi":5825},"10.1073\u002Fpnas.1322269111",{"id":24,"text":5827,"url":24,"identifiers":5828},"Buda, A. et al. Butyrate downregulates alpha2beta1 integrin: a possible role in the induction of apoptosis in colorectal cancer cell lines. Gut 52, 729–734 (2003).",{"doi":5829},"10.1136\u002Fgut.52.5.729",{"id":24,"text":5831,"url":24,"identifiers":5832},"Furusawa, Y. et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 504, 446–450 (2013).",{"doi":5833},"10.1038\u002Fnature12721",{"id":24,"text":5835,"url":24,"identifiers":5836},"Smith, P. M. et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 341, 569–573 (2013).",{"doi":5837},"10.1126\u002Fscience.1241165",{"id":24,"text":5839,"url":24,"identifiers":5840},"Ou, J. et al. Diet, microbiota, and microbial metabolites in colon cancer risk in rural Africans and African Americans. Am. J. Clin. Nutr. 98, 111–120 (2013).",{"doi":5841},"10.3945\u002Fajcn.112.056689",{"id":24,"text":5843,"url":24,"identifiers":5844},"Vernia, P., Gnaedinger, A., Hauck, W. & Breuer, R. I. Organic anions and the diarrhea of inflammatory bowel disease. Dig. Dis. Sci. 33, 1353–1358 (1988).",{"doi":5845},"10.1007\u002FBF01536987",{"id":24,"text":5847,"url":24,"identifiers":5848},"Chen, H. M. et al. Decreased dietary fiber intake and structural alteration of gut microbiota in patients with advanced colorectal adenoma. Am. J. Clin. Nutr. 97, 1044–1052 (2013).",{"doi":5849},"10.3945\u002Fajcn.112.046607",{"id":24,"text":5851,"url":24,"identifiers":5852},"Bultman, S. J. Molecular pathways: gene-environment interactions regulating dietary fiber induction of proliferation and apoptosis via butyrate for cancer prevention. Clin. Cancer Res. 20, 799–803 (2014).",{"doi":5853},"10.1158\u002F1078-0432.CCR-13-2483",{"id":24,"text":5855,"url":24,"identifiers":5856},"Belcheva, A. et al. Gut microbial metabolism drives transformation of MSH2-deficient colon epithelial cells. Cell 158, 288–299 (2014).",{"doi":5857},"10.1016\u002Fj.cell.2014.04.051",{"id":24,"text":5859,"url":24,"identifiers":5860},"Bultman, S. J. & Jobin, C. Microbial-derived butyrate: an oncometabolite or tumor-suppressive metabolite? Cell Host Microbe 16, 143–145 (2014).",{"doi":5861},"10.1016\u002Fj.chom.2014.07.011",{"id":24,"text":5863,"url":24,"identifiers":5864},"de Aguiar Vallim, T. Q., Tarling, E. J. & Edwards, P. A. Pleiotropic roles of bile acids in metabolism. Cell Metab. 17, 657–669 (2013).",{"doi":5865},"10.1016\u002Fj.cmet.2013.03.013",{"id":24,"text":5867,"url":24,"identifiers":5868},"Ou, J., DeLany, J. P., Zhang, M., Sharma, S. & O’Keefe, S. J. Association between low colonic short-chain fatty acids and high bile acids in high colon cancer risk populations. Nutr. Cancer 64, 34–40 (2012).",{"doi":5869},"10.1080\u002F01635581.2012.630164",{"id":24,"text":5871,"url":24,"identifiers":5872},"Chomchai, C., Bhadrachari, N. & Nigro, N. D. The effect of bile on the induction of experimental intestinal tumors in rats. Dis. Colon Rectum 17, 310–312 (1974).",{"doi":5873},"10.1007\u002FBF02586971",{"id":24,"text":5875,"url":24,"identifiers":5876},"Bernstein, H., Bernstein, C., Payne, C. M. & Dvorak, K. Bile acids as endogenous etiologic agents in gastrointestinal cancer. World J. Gastroenterol. 15, 3329–3340 (2009).",{"doi":5877},"10.3748\u002Fwjg.15.3329",{"id":24,"text":5879,"url":24,"identifiers":5880},"Bernstein, C. et al. Carcinogenicity of deoxycholate, a secondary bile acid. Arch. Toxicol. 85, 863–871 (2011).",{"doi":5881},"10.1007\u002Fs00204-011-0648-7",{"id":24,"text":5883,"url":24,"identifiers":5884},"Cuevas-Ramos, G. et al. Escherichia coli induces DNA damage in vivo and triggers genomic instability in mammalian cells. Proc. Natl Acad. Sci. USA 107, 11537–11542 (2010).",{"doi":5885},"10.1073\u002Fpnas.1001261107",{"id":24,"text":5887,"url":24,"identifiers":5888},"He, Z. et al. Campylobacter jejuni promotes colorectal tumorigenesis through the action of cytolethal distending toxin. Gut 68, 289–300 (2019).",{"doi":5889},"10.1136\u002Fgutjnl-2018-317200",{"id":24,"text":5891,"url":24,"identifiers":5892},"Shen, Z. et al. Cytolethal distending toxin promotes Helicobacter cinaedi-associated typhlocolitis in interleukin-10-deficient mice. Infect. Immun. 77, 2508–2516 (2009).",{"doi":5893},"10.1128\u002FIAI.00166-09",{"id":24,"text":5895,"url":24,"identifiers":5896},"Buc, E. et al. High prevalence of mucosa-associated E. coli producing cyclomodulin and genotoxin in colon cancer. PLOS ONE 8, e56964 (2013).",{"doi":5897},"10.1371\u002Fjournal.pone.0056964",{"id":24,"text":5899,"url":24,"identifiers":5900},"Goodwin, A. C. et al. Polyamine catabolism contributes to enterotoxigenic Bacteroides fragilis-induced colon tumorigenesis. Proc. Natl Acad. Sci. USA 108, 15354–15359 (2011).",{"doi":5901},"10.1073\u002Fpnas.1010203108",{"id":24,"text":5903,"url":24,"identifiers":5904},"Wang, X. & Huycke, M. M. Extracellular superoxide production by Enterococcus faecalis promotes chromosomal instability in mammalian cells. Gastroenterology 132, 551–561 (2007).",{"doi":5905},"10.1053\u002Fj.gastro.2006.11.040",{"id":24,"text":5907,"url":24,"identifiers":5908},"Cougnoux, A. et al. Small-molecule inhibitors prevent the genotoxic and protumoural effects induced by colibactin-producing bacteria. Gut 65, 278–285 (2016).",{"doi":5909},"10.1136\u002Fgutjnl-2014-307241",{"id":24,"text":5911,"url":24,"identifiers":5912},"Tjalsma, H., Boleij, A., Marchesi, J. R. & Dutilh, B. E. A bacterial driver-passenger model for colorectal cancer: beyond the usual suspects. Nat. Rev. Microbiol. 10, 575–582 (2012). This Perspective proposes the driver–passenger carcinogenesis model in which driver and passenger bacteria have distinct roles in the tissue microenvironment.",{"doi":5913},"10.1038\u002Fnrmicro2819",{"id":24,"text":5915,"url":24,"identifiers":5916},"Lauby-Secretan, B. et al. The IARC perspective on colorectal cancer screening. New Engl. J. Med. 378, 1734–1740 (2018).",{"doi":5917},"10.1056\u002FNEJMsr1714643",{"id":24,"text":5919,"url":24,"identifiers":5920},"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2019. CA Cancer J. Clin. 69, 7–34 (2019).",{},{"id":24,"text":5922,"url":24,"identifiers":5923},"Lee, J. K., Liles, E. G., Bent, S., Levin, T. R. & Corley, D. A. Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta-analysis. Ann. Intern. Med. 160, 171 (2014).",{"doi":5924},"10.7326\u002FM13-1484",{"id":24,"text":5926,"url":24,"identifiers":5927},"Hundt, S., Haug, U. & Brenner, H. Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection. Ann. Intern. Med. 150, 162–169 (2009).",{"doi":5928},"10.7326\u002F0003-4819-150-3-200902030-00005",{"id":24,"text":5930,"url":24,"identifiers":5931},"Imperiale, T. F. et al. Multitarget stool DNA testing for colorectal-cancer screening. N. Engl. J. Med. 370, 1287–1297 (2014).",{"doi":5932},"10.1056\u002FNEJMoa1311194",{"id":24,"text":5934,"url":24,"identifiers":5935},"Wong, S. H. et al. Quantitation of faecal Fusobacterium improves faecal immunochemical test in detecting advanced colorectal neoplasia. Gut 66, 1441–1448 (2017). This study reports that quantifying faecal Fusobacterium could improve the performance of the occult blood test in detecting CRC and advanced adenoma.",{"doi":5936},"10.1136\u002Fgutjnl-2016-312766",{"id":24,"text":5938,"url":24,"identifiers":5939},"Suehiro, Y. et al. Highly sensitive faecal DNA testing of TWIST1 methylation in combination with faecal immunochemical test for haemoglobin is a promising marker for detection of colorectal neoplasia. Ann. Clin. Biochem. 55, 59–68 (2018).",{"doi":5940},"10.1177\u002F0004563217691064",{"id":24,"text":5942,"url":24,"identifiers":5943},"Guo, S. et al. A simple and novel fecal biomarker for colorectal cancer: ratio of Fusobacterium nucleatum to probiotics populations, based on their antagonistic effect. Clin. Chem. 64, 1327–1337 (2018).",{"doi":5944},"10.1373\u002Fclinchem.2018.289728",{"id":24,"text":5946,"url":24,"identifiers":5947},"Xie, Y. H. et al. Fecal clostridium symbiosum for noninvasive detection of early and advanced colorectal cancer: test and validation studies. EBioMedicine 25, 32–40 (2017).",{"doi":5948},"10.1016\u002Fj.ebiom.2017.10.005",{"id":24,"text":5950,"url":24,"identifiers":5951},"Eklof, V. et al. Cancer-associated fecal microbial markers in colorectal cancer detection. Int. J. Cancer 141, 2528–2536 (2017).",{"doi":5952},"10.1002\u002Fijc.31011",{"id":24,"text":5954,"url":24,"identifiers":5955},"Liang, Q. et al. Fecal bacteria act as novel biomarkers for noninvasive diagnosis of colorectal cancer. Clin Cancer Res. 23, 2061–2070 (2017).",{"doi":5956},"10.1158\u002F1078-0432.CCR-16-1599",{"id":24,"text":5958,"url":24,"identifiers":5959},"Fearon, E. R. & Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell 61, 759–767 (1990).",{"doi":5960},"10.1016\u002F0092-8674(90)90186-I",{"id":24,"text":5962,"url":24,"identifiers":5963},"Rezasoltani, S. et al. The association between fecal microbiota and different types of colorectal polyp as precursors of colorectal cancer. Microb. Pathog. 124, 244–249 (2018).",{"doi":5964},"10.1016\u002Fj.micpath.2018.08.035",{"id":24,"text":5966,"url":24,"identifiers":5967},"Flanagan, L. et al. Fusobacterium nucleatum associates with stages of colorectal neoplasia development, colorectal cancer and disease outcome. Eur. J. Clin. Microbiol Infect. Dis. 33, 1381–1390 (2014).",{"doi":5968},"10.1007\u002Fs10096-014-2081-3",{"id":24,"text":5970,"url":24,"identifiers":5971},"Yu, J. et al. Invasive Fusobacterium nucleatum may play a role in the carcinogenesis of proximal colon cancer through the serrated neoplasia pathway. Int. J. Cancer 139, 1318–1326 (2016).",{"doi":5972},"10.1002\u002Fijc.30168",{"id":24,"text":5974,"url":24,"identifiers":5975},"Russo, E. et al. Preliminary comparison of oral and intestinal human microbiota in patients with colorectal cancer: a pilot study. Front. Microbiol. 8, 2699 (2017).",{"doi":5976},"10.3389\u002Ffmicb.2017.02699",{"id":24,"text":5978,"url":24,"identifiers":5979},"Flemer, B. et al. The oral microbiota in colorectal cancer is distinctive and predictive. Gut 67, 1454–1463 (2018).",{"doi":5980},"10.1136\u002Fgutjnl-2017-314814",{"id":24,"text":5982,"url":24,"identifiers":5983},"Corredoira-Sanchez, J. et al. Association between bacteremia due to Streptococcus gallolyticus subsp. gallolyticus (Streptococcus bovis I) and colorectal neoplasia: a case-control study. Clin. Infect. Dis. 55, 491–496 (2012).",{"doi":5984},"10.1093\u002Fcid\u002Fcis434",{"id":24,"text":5986,"url":24,"identifiers":5987},"Kwong, T. N. Y. et al. Association between bacteremia from specific microbes and subsequent diagnosis of colorectal cancer. Gastroenterology 155, 383–390.e8 (2018).",{"doi":5988},"10.1053\u002Fj.gastro.2018.04.028",{"id":24,"text":5990,"url":24,"identifiers":5991},"Butt, J. et al. Prospective evaluation of antibody response to Streptococcus gallolyticus and risk of colorectal cancer. Int. J. Cancer 143, 245–252 (2018).",{"doi":5992},"10.1002\u002Fijc.31283",{"id":24,"text":5994,"url":24,"identifiers":5995},"Butt, J. et al. Antibody responses to Streptococcus gallolyticus subspecies gallolyticusproteins in a large prospective colorectal cancer cohort consortium. Cancer Epidemiol. Biomarkers Prev. 27, 1186–1194 (2018).",{"doi":5996},"10.1158\u002F1055-9965.EPI-18-0249",{"id":24,"text":5998,"url":24,"identifiers":5999},"Wang, H. F. et al. Evaluation of antibody level against Fusobacterium nucleatum in the serological diagnosis of colorectal cancer. Sci. Rep. 6, 33440 (2016).",{"doi":6000},"10.1038\u002Fsrep33440",{"id":24,"text":6002,"url":24,"identifiers":6003},"Weaver, G. A., Krause, J. A., Miller, T. L. & Wolin, M. J. Short chain fatty acid distributions of enema samples from a sigmoidoscopy population: an association of high acetate and low butyrate ratios with adenomatous polyps and colon cancer. Gut 29, 1539–1543 (1988).",{"doi":6004},"10.1136\u002Fgut.29.11.1539",{"id":24,"text":6006,"url":24,"identifiers":6007},"Weir, T. L. et al. Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults. PLOS ONE 8, e70803 (2013).",{"doi":6008},"10.1371\u002Fjournal.pone.0070803",{"id":24,"text":6010,"url":24,"identifiers":6011},"Wang, X., Wang, J., Rao, B. & Deng, L. Gut flora profiling and fecal metabolite composition of colorectal cancer patients and healthy individuals. Exp. Ther. Med. 13, 2848–2854 (2017).",{"doi":6012},"10.3892\u002Fetm.2017.4367",{"id":24,"text":6014,"url":24,"identifiers":6015},"Mima, K. et al. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Gut 65, 1973–1980 (2016).",{"doi":6016},"10.1136\u002Fgutjnl-2015-310101",{"id":24,"text":6018,"url":24,"identifiers":6019},"Wei, Z. et al. Could gut microbiota serve as prognostic biomarker associated with colorectal cancer patients’ survival? A pilot study on relevant mechanism. Oncotarget 7, 46158–46172 (2016).",{"doi":6020},"10.18632\u002Foncotarget.10064",{"id":24,"text":6022,"url":24,"identifiers":6023},"Tahara, T. et al. Fusobacterium in colonic flora and molecular features of colorectal carcinoma. Cancer Res. 74, 1311–1318 (2014).",{"doi":6024},"10.1158\u002F0008-5472.CAN-13-1865",{"id":24,"text":6026,"url":24,"identifiers":6027},"Ito, M. et al. Association of Fusobacterium nucleatum with clinical and molecular features in colorectal serrated pathway. Int. J. Cancer 137, 1258–1268 (2015).",{"doi":6028},"10.1002\u002Fijc.29488",{"id":24,"text":6030,"url":24,"identifiers":6031},"Mima, K. et al. Fusobacterium nucleatum in colorectal carcinoma tissue according to tumor location. Clin. Transl Gastroenterol. 7, e200 (2016).",{"doi":6032},"10.1038\u002Fctg.2016.53",{"id":24,"text":6034,"url":24,"identifiers":6035},"Kerr, J., Anderson, C. & Lippman, S. M. Physical activity, sedentary behaviour, diet, and cancer: an update and emerging new evidence. Lancet Oncol. 18, e457–e471 (2017).",{"doi":6036},"10.1016\u002FS1470-2045(17)30411-4",{"id":24,"text":6038,"url":24,"identifiers":6039},"Song, M. & Giovannucci, E. Preventable incidence and mortality of carcinoma associated with lifestyle factors among white adults in the United States. JAMA Oncol. 2, 1154–1161 (2016).",{"doi":6040},"10.1001\u002Fjamaoncol.2016.0843",{"id":24,"text":6042,"url":24,"identifiers":6043},"Islami, F. et al. Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States. CA Cancer J. Clin. 68, 31–54 (2018).",{},{"id":24,"text":6045,"url":24,"identifiers":6046},"Carmody, R. N. et al. Diet dominates host genotype in shaping the murine gut microbiota. Cell Host Microbe 17, 72–84 (2015).",{"doi":6047},"10.1016\u002Fj.chom.2014.11.010",{"id":24,"text":6049,"url":24,"identifiers":6050},"Rothschild, D. et al. Environment dominates over host genetics in shaping human gut microbiota. Nature 555, 210–215 (2018).",{"doi":6051},"10.1038\u002Fnature25973",{"id":24,"text":6053,"url":24,"identifiers":6054},"David, L. A. et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 505, 559–563 (2014).",{"doi":6055},"10.1038\u002Fnature12820",{"id":24,"text":6057,"url":24,"identifiers":6058},"O’Keefe, S. J. et al. Fat, fibre and cancer risk in African Americans and rural Africans. Nat. Commun. 6, 6342 (2015). This study shows that dietary change alone is sufficient to shift the microbiota, affect intestinal inflammation and alter cell proliferation markers that could reflect carcinogenesis.",{"doi":6059},"10.1038\u002Fncomms7342",{"id":24,"text":6061,"url":24,"identifiers":6062},"De Filippo, C. et al. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc. Natl Acad. Sci. USA 107, 14691–14696 (2010).",{"doi":6063},"10.1073\u002Fpnas.1005963107",{"id":24,"text":6065,"url":24,"identifiers":6066},"Makki, K., Deehan, E. C., Walter, J. & Backhed, F. The impact of dietary fiber on gut microbiota in host health and disease. Cell Host Microbe 23, 705–715 (2018).",{"doi":6067},"10.1016\u002Fj.chom.2018.05.012",{"id":24,"text":6069,"url":24,"identifiers":6070},"Gibson, G. R. et al. Expert consensus document: the International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat. Rev. Gastroenterol. Hepatol. 14, 491–502 (2017).",{"doi":6071},"10.1038\u002Fnrgastro.2017.75",{"id":24,"text":6073,"url":24,"identifiers":6074},"So, D. et al. Dietary fiber intervention on gut microbiota composition in healthy adults: a systematic review and meta-analysis. Am. J. Clin. Nutr. 107, 965–983 (2018).",{"doi":6075},"10.1093\u002Fajcn\u002Fnqy041",{"id":24,"text":6077,"url":24,"identifiers":6078},"Donohoe, D. R. et al. A gnotobiotic mouse model demonstrates that dietary fiber protects against colorectal tumorigenesis in a microbiota- and butyrate-dependent manner. Cancer Discov. 4, 1387–1397 (2014).",{"doi":6079},"10.1158\u002F2159-8290.CD-14-0501",{"id":24,"text":6081,"url":24,"identifiers":6082},"Alberts, D. S. et al. Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. Phoenix Colon Cancer Prevention Physicians’ Network. N. Engl. J. Med. 342, 1156–1162 (2000).",{"doi":6083},"10.1056\u002FNEJM200004203421602",{"id":24,"text":6085,"url":24,"identifiers":6086},"Schatzkin, A. et al. Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas. Polyp Prevention Trial Study Group. N. Engl. J. Med. 342, 1149–1155 (2000).",{"doi":6087},"10.1056\u002FNEJM200004203421601",{"id":24,"text":6089,"url":24,"identifiers":6090},"Lanza, E. et al. The Polyp Prevention trial continued follow-up study: no effect of a low-fat, high-fiber, high-fruit, and -vegetable diet on adenoma recurrence eight years after randomization. Cancer Epidemiol. Biomarkers Prev. 16, 1745–1752 (2007).",{"doi":6091},"10.1158\u002F1055-9965.EPI-07-0127",{"id":24,"text":6093,"url":24,"identifiers":6094},"Chan, D. S. et al. Red and processed meat and colorectal cancer incidence: meta-analysis of prospective studies. PLOS ONE 6, e20456 (2011).",{"doi":6095},"10.1371\u002Fjournal.pone.0020456",{"id":24,"text":6097,"url":24,"identifiers":6098},"Bouvard, V. et al. Carcinogenicity of consumption of red and processed meat. Lancet Oncol. 16, 1599–1600 (2015).",{"doi":6099},"10.1016\u002FS1470-2045(15)00444-1",{"id":24,"text":6101,"url":24,"identifiers":6102},"Orlich, M. J. et al. Vegetarian dietary patterns and the risk of colorectal cancers. JAMA Intern. Med. 175, 767–776 (2015).",{"doi":6103},"10.1001\u002Fjamainternmed.2015.59",{"id":24,"text":6105,"url":24,"identifiers":6106},"Hildebrandt, M. A. et al. High-fat diet determines the composition of the murine gut microbiome independently of obesity. Gastroenterology 137, 1716–1724.e1-2 (2009).",{"doi":6107},"10.1053\u002Fj.gastro.2009.08.042",{"id":24,"text":6109,"url":24,"identifiers":6110},"Devkota, S. et al. Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10-\u002F- mice. Nature 487, 104–108 (2012).",{"doi":6111},"10.1038\u002Fnature11225",{"id":24,"text":6113,"url":24,"identifiers":6114},"Zhang, C. et al. Structural resilience of the gut microbiota in adult mice under high-fat dietary perturbations. ISME J. 6, 1848–1857 (2012).",{"doi":6115},"10.1038\u002Fismej.2012.27",{"id":24,"text":6117,"url":24,"identifiers":6118},"Cao, H. et al. The secondary bile acid, deoxycholate accelerates intestinal adenoma-adenocarcinoma sequence in Apcmin\u002F+ mice through enhancing Wnt signaling. Fam. Cancer 13, 563–571 (2014).",{"doi":6119},"10.1007\u002Fs10689-014-9742-3",{"id":24,"text":6121,"url":24,"identifiers":6122},"Drasar, B. S. & Irving, D. Environmental factors and cancer of the colon and breast. Br. J. Cancer 27, 167–172 (1973).",{"doi":6123},"10.1038\u002Fbjc.1973.20",{"id":24,"text":6125,"url":24,"identifiers":6126},"Oba, S. et al. The relationship between the consumption of meat, fat, and coffee and the risk of colon cancer: a prospective study in Japan. Cancer Lett. 244, 260–267 (2006).",{"doi":6127},"10.1016\u002Fj.canlet.2005.12.037",{"id":24,"text":6129,"url":24,"identifiers":6130},"Liu, L. et al. Is dietary fat associated with the risk of colorectal cancer? A meta-analysis of 13 prospective cohort studies. Eur. J. Nutr. 50, 173–184 (2011).",{"doi":6131},"10.1007\u002Fs00394-010-0128-5",{"id":24,"text":6133,"url":24,"identifiers":6134},"MacLennan, R. et al. Randomized trial of intake of fat, fiber, and beta carotene to prevent colorectal adenomas. J. Natl Cancer Inst. 87, 1760–1766 (1995).",{"doi":6135},"10.1093\u002Fjnci\u002F87.23.1760",{"id":24,"text":6137,"url":24,"identifiers":6138},"Thomson, C. A. et al. Cancer incidence and mortality during the intervention and postintervention periods of the Women’s Health Initiative dietary modification trial. Cancer Epidemiol. Biomarkers Prev. 23, 2924–2935 (2014).",{"doi":6139},"10.1158\u002F1055-9965.EPI-14-0922",{"id":24,"text":6141,"url":24,"identifiers":6142},"Le Chatelier, E. et al. Richness of human gut microbiome correlates with metabolic markers. Nature 500, 541–546 (2013).",{"doi":6143},"10.1038\u002Fnature12506",{"id":24,"text":6145,"url":24,"identifiers":6146},"Ley, R. E. et al. Obesity alters gut microbial ecology. Proc. Natl Acad. Sci. USA 102, 11070–11075 (2005).",{"doi":6147},"10.1073\u002Fpnas.0504978102",{"id":24,"text":6149,"url":24,"identifiers":6150},"Ley, R. E., Turnbaugh, P. J., Klein, S. & Gordon, J. I. Microbial ecology: human gut microbes associated with obesity. Nature 444, 1022–1023 (2006).",{"doi":6151},"10.1038\u002F4441022a",{"id":24,"text":6153,"url":24,"identifiers":6154},"Li, R. et al. Obesity, rather than diet, drives epigenomic alterations in colonic epithelium resembling cancer progression. Cell Metab. 19, 702–711 (2014).",{"doi":6155},"10.1016\u002Fj.cmet.2014.03.012",{"id":24,"text":6157,"url":24,"identifiers":6158},"Qin, Y. et al. An obesity-associated gut microbiome reprograms the intestinal epigenome and leads to altered colonic gene expression. Genome Biol. 19, 7 (2018).",{"doi":6159},"10.1186\u002Fs13059-018-1389-1",{"id":24,"text":6161,"url":24,"identifiers":6162},"Liu, R. et al. Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention. Nat. Med. 23, 859–868 (2017).",{"doi":6163},"10.1038\u002Fnm.4358",{"id":24,"text":6165,"url":24,"identifiers":6166},"Seganfredo, F. B. et al. Weight-loss interventions and gut microbiota changes in overweight and obese patients: a systematic review. Obes. Rev. 18, 832–851 (2017).",{"doi":6167},"10.1111\u002Fobr.12541",{"id":24,"text":6169,"url":24,"identifiers":6170},"Keum, N. et al. Adult weight gain and adiposity-related cancers: a dose-response meta-analysis of prospective observational studies. J. Natl Cancer Inst. 107, djv088 (2015).",{"doi":6171},"10.1093\u002Fjnci\u002Fdjv088",{"id":24,"text":6173,"url":24,"identifiers":6174},"Sjostrom, L. et al. Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial. Lancet Oncol. 10, 653–662 (2009).",{"doi":6175},"10.1016\u002FS1470-2045(09)70159-7",{"id":24,"text":6177,"url":24,"identifiers":6178},"Derogar, M. et al. Increased risk of colorectal cancer after obesity surgery. Ann. Surg. 258, 983–988 (2013).",{"doi":6179},"10.1097\u002FSLA.0b013e318288463a",{"id":24,"text":6181,"url":24,"identifiers":6182},"Aravani, A. et al. Obesity surgery and risk of colorectal and other obesity-related cancers: an English population-based cohort study. Cancer Epidemiol. 53, 99–104 (2018).",{"doi":6183},"10.1016\u002Fj.canep.2018.01.002",{"id":24,"text":6185,"url":24,"identifiers":6186},"Schauer, D. P. et al. Bariatric surgery and the risk of cancer in a large multisite cohort. Ann. Surg. 269, 95–101 (2019).",{"doi":6187},"10.1097\u002FSLA.0000000000002525",{"id":24,"text":6189,"url":24,"identifiers":6190},"Hull, M. A., Markar, S. R. & Morris, E. J. A. Cancer risk after bariatric surgery — is colorectal cancer a special case? Nat. Rev. Gastroenterol. Hepatol. 15, 653–654 (2018).",{"doi":6191},"10.1038\u002Fs41575-018-0070-1",{"id":24,"text":6193,"url":24,"identifiers":6194},"Hill, C. et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat. Rev. Gastroenterol. Hepatol. 11, 506–514 (2014).",{"doi":6195},"10.1038\u002Fnrgastro.2014.66",{"id":24,"text":6197,"url":24,"identifiers":6198},"Zitvogel, L., Daillere, R., Roberti, M. P., Routy, B. & Kroemer, G. Anticancer effects of the microbiome and its products. Nat. Rev. Microbiol. 15, 465–478 (2017).",{"doi":6199},"10.1038\u002Fnrmicro.2017.44",{"id":24,"text":6201,"url":24,"identifiers":6202},"Dos Reis, S. A. et al. Review of the mechanisms of probiotic actions in the prevention of colorectal cancer. Nutr. Res. 37, 1–19 (2017).",{"doi":6203},"10.1016\u002Fj.nutres.2016.11.009",{"id":24,"text":6205,"url":24,"identifiers":6206},"Thirabunyanon, M., Boonprasom, P. & Niamsup, P. Probiotic potential of lactic acid bacteria isolated from fermented dairy milks on antiproliferation of colon cancer cells. Biotechnol. Lett. 31, 571–576 (2009).",{"doi":6207},"10.1007\u002Fs10529-008-9902-3",{"id":24,"text":6209,"url":24,"identifiers":6210},"Chen, C. C. et al. Oral inoculation of probiotics Lactobacillus acidophilus NCFM suppresses tumour growth both in segmental orthotopic colon cancer and extra-intestinal tissue. Br. J. Nutr. 107, 1623–1634 (2012).",{"doi":6211},"10.1017\u002FS0007114511004934",{"id":24,"text":6213,"url":24,"identifiers":6214},"Wan, Y. et al. Fermentation supernatants of Lactobacillus delbrueckii inhibit growth of human colon cancer cells and induce apoptosis through a caspase 3-dependent pathway. Oncol. Lett. 7, 1738–1742 (2014).",{"doi":6215},"10.3892\u002Fol.2014.1959",{"id":24,"text":6217,"url":24,"identifiers":6218},"Konishi, H. et al. Probiotic-derived ferrichrome inhibits colon cancer progression via JNK-mediated apoptosis. Nat. Commun. 7, 12365 (2016).",{"doi":6219},"10.1038\u002Fncomms12365",{"id":24,"text":6221,"url":24,"identifiers":6222},"Corthesy, B., Gaskins, H. R. & Mercenier, A. Cross-talk between probiotic bacteria and the host immune system. J. Nutr. 137, 781S–790S (2007).",{"doi":6223},"10.1093\u002Fjn\u002F137.3.781S",{"id":24,"text":6225,"url":24,"identifiers":6226},"Delcenserie, V. et al. Immunomodulatory effects of probiotics in the intestinal tract. Curr. Issues Mol. Biol. 10, 37–54 (2008).",{},{"id":24,"text":6228,"url":24,"identifiers":6229},"Burns, A. J. & Rowland, I. R. Antigenotoxicity of probiotics and prebiotics on faecal water-induced DNA damage in human colon adenocarcinoma cells. Mutat. Res. 551, 233–243 (2004).",{"doi":6230},"10.1016\u002Fj.mrfmmm.2004.03.010",{"id":24,"text":6232,"url":24,"identifiers":6233},"Nowak, A. & Libudzisz, Z. Ability of probiotic Lactobacillus casei DN 114001 to bind or\u002Fand metabolise heterocyclic aromatic amines in vitro. Eur. J. Nutr. 48, 419–427 (2009).",{"doi":6234},"10.1007\u002Fs00394-009-0030-1",{"id":24,"text":6236,"url":24,"identifiers":6237},"Zhu, J. et al. Lactobacillus salivarius Ren prevent the early colorectal carcinogenesis in 1,2-dimethylhydrazine-induced rat model. J. Appl. Microbiol. 117, 208–216 (2014).",{"doi":6238},"10.1111\u002Fjam.12499",{"id":24,"text":6240,"url":24,"identifiers":6241},"Ishikawa, H. et al. Randomized trial of dietary fiber and Lactobacillus caseiadministration for prevention of colorectal tumors. Int. J. Cancer 116, 762–767 (2005).",{"doi":6242},"10.1002\u002Fijc.21115",{"id":24,"text":6244,"url":24,"identifiers":6245},"Rafter, J. et al. Dietary synbiotics reduce cancer risk factors in polypectomized and colon cancer patients. Am. J. Clin. Nutr. 85, 488–496 (2007).",{"doi":6246},"10.1093\u002Fajcn\u002F85.2.488",{"id":24,"text":6248,"url":24,"identifiers":6249},"Worthley, D. L. et al. A human, double-blind, placebo-controlled, crossover trial of prebiotic, probiotic, and synbiotic supplementation: effects on luminal, inflammatory, epigenetic, and epithelial biomarkers of colorectal cancer. Am. J. Clin. Nutr. 90, 578–586 (2009).",{"doi":6250},"10.3945\u002Fajcn.2009.28106",{"id":24,"text":6252,"url":24,"identifiers":6253},"Zitvogel, L., Ma, Y., Raoult, D., Kroemer, G. & Gajewski, T. F. The microbiome in cancer immunotherapy: diagnostic tools and therapeutic strategies. Science 359, 1366–1370 (2018). This review discusses how gut microbiota can affect cancer immunotherapy and how this interaction could be utilized to enhance treatment efficacy and reduce adverse effects.",{"doi":6254},"10.1126\u002Fscience.aar6918",{"id":24,"text":6256,"url":24,"identifiers":6257},"Garcia-Gonzalez, A. P. et al. Bacterial metabolism affects the C. elegansresponse to cancer chemotherapeutics. Cell 169, 431–441.e8 (2017).",{"doi":6258},"10.1016\u002Fj.cell.2017.03.046",{"id":24,"text":6260,"url":24,"identifiers":6261},"Viaud, S. et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 342, 971–976 (2013).",{"doi":6262},"10.1126\u002Fscience.1240537",{"id":24,"text":6264,"url":24,"identifiers":6265},"Daillere, R. et al. Enterococcus hiraeand Barnesiella intestinihominis facilitate cyclophosphamide-induced therapeutic immunomodulatory effects. Immunity 45, 931–943 (2016).",{"doi":6266},"10.1016\u002Fj.immuni.2016.09.009",{"id":24,"text":6268,"url":24,"identifiers":6269},"Vande Voorde, J. et al. Nucleoside-catabolizing enzymes in mycoplasma-infected tumor cell cultures compromise the cytostatic activity of the anticancer drug gemcitabine. J. Biol. Chem. 289, 13054–13065 (2014).",{"doi":6270},"10.1074\u002Fjbc.M114.558924",{"id":24,"text":6272,"url":24,"identifiers":6273},"Iida, N. et al. Commensal bacteria control Cancer Res.ponse to therapy by modulating the tumor microenvironment. Science 342, 967–970 (2013).",{"doi":6274},"10.1126\u002Fscience.1240527",{"id":24,"text":6276,"url":24,"identifiers":6277},"Alexander, J. L. et al. Gut microbiota modulation of chemotherapy efficacy and toxicity. Nat. Rev. Gastroenterol. Hepatol. 14, 356–365 (2017).",{"doi":6278},"10.1038\u002Fnrgastro.2017.20",{"id":24,"text":6280,"url":24,"identifiers":6281},"Yu, T. et al. Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy. Cell 170, 548–563 e516 (2017).",{"doi":6282},"10.1016\u002Fj.cell.2017.07.008",{"id":24,"text":6284,"url":24,"identifiers":6285},"Wallace, B. D. et al. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science 330, 831–835 (2010).",{"doi":6286},"10.1126\u002Fscience.1191175",{"id":24,"text":6288,"url":24,"identifiers":6289},"Wallace, B. D. et al. Structure and inhibition of microbiome beta-glucuronidases essential to the alleviation of cancer drug toxicity. Chem. Biol. 22, 1238–1249 (2015).",{"doi":6290},"10.1016\u002Fj.chembiol.2015.08.005",{"id":24,"text":6292,"url":24,"identifiers":6293},"Yeung, C. Y. et al. Amelioration of chemotherapy-induced intestinal mucositis by orally administered probiotics in a mouse model. PLOS ONE 10, e0138746 (2015).",{"doi":6294},"10.1371\u002Fjournal.pone.0138746",{"id":24,"text":6296,"url":24,"identifiers":6297},"Kato, S. et al. Probiotic Bifidobacterium bifidum G9-1 attenuates 5-fluorouracil-induced intestinal mucositis in mice via suppression of dysbiosis-related secondary inflammatory responses. Clin. Exp. Pharmacol. Physiol. 44, 1017–1025 (2017).",{"doi":6298},"10.1111\u002F1440-1681.12792",{"id":24,"text":6300,"url":24,"identifiers":6301},"Chang, C. W. et al. Lactobacillus casei variety rhamnosus probiotic preventively attenuates 5-fluorouracil\u002Foxaliplatin-induced intestinal injury in a syngeneic colorectal cancer model. Front. Microbiol. 9, 983 (2018).",{"doi":6302},"10.3389\u002Ffmicb.2018.00983",{"id":24,"text":6304,"url":24,"identifiers":6305},"Wei, S. C., Duffy, C. R. & Allison, J. P. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 8, 1069–1086 (2018).",{"doi":6306},"10.1158\u002F2159-8290.CD-18-0367",{"id":24,"text":6308,"url":24,"identifiers":6309},"Routy, B. et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359, 91–97 (2018).",{"doi":6310},"10.1126\u002Fscience.aan3706",{"id":24,"text":6312,"url":24,"identifiers":6313},"Sivan, A. et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 350, 1084–1089 (2015).",{"doi":6314},"10.1126\u002Fscience.aac4255",{"id":24,"text":6316,"url":24,"identifiers":6317},"Gopalakrishnan, V. et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359, 97–103 (2018).",{"doi":6318},"10.1126\u002Fscience.aan4236",{"id":24,"text":6320,"url":24,"identifiers":6321},"Matson, V. et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science 359, 104–108 (2018).",{"doi":6322},"10.1126\u002Fscience.aao3290",{"id":24,"text":6324,"url":24,"identifiers":6325},"Vetizou, M. et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 350, 1079–1084 (2015).",{"doi":6326},"10.1126\u002Fscience.aad1329",{"id":24,"text":6328,"url":24,"identifiers":6329},"Peled, J. U. et al. Intestinal microbiota and relapse after hematopoietic-cell transplantation. J. Clin. Oncol. 35, 1650–1659 (2017).",{"doi":6330},"10.1200\u002FJCO.2016.70.3348",{"id":24,"text":6332,"url":24,"identifiers":6333},"Chaput, N. et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann. Oncol. 28, 1368–1379 (2017).",{"doi":6334},"10.1093\u002Fannonc\u002Fmdx108",{"id":24,"text":6336,"url":24,"identifiers":6337},"Gharaibeh, R. Z. & Jobin, C. Microbiota and cancer immunotherapy: in search of microbial signals. Gut https:\u002F\u002Fdoi.org\u002F10.1136\u002Fgutjnl-2018-317220 (2018).",{"doi":6338},"10.1136\u002Fgutjnl-2018-317220",{"id":24,"text":6340,"url":24,"identifiers":6341},"Tanoue, T. et al. A defined commensal consortium elicits CD8 T cells and anti-cancer immunity. Nature 565, 600–605 (2019).",{"doi":6342},"10.1038\u002Fs41586-019-0878-z",{"id":24,"text":6344,"url":24,"identifiers":6345},"Dubin, K. et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat. Commun. 7, 10391 (2016).",{"doi":6346},"10.1038\u002Fncomms10391",{"id":24,"text":6348,"url":24,"identifiers":6349},"Wang, Y. et al. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat. Med. 24, 1804–1808 (2018). This study reports for the first time that modifying gut microbiota by faecal transplantation can ameliorate refractory colitis as an adverse effect of immunotherapy.",{"doi":6350},"10.1038\u002Fs41591-018-0238-9",{"id":24,"text":6352,"url":24,"identifiers":6353},"Brahmer, J. R. et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28, 3167–3175 (2010).",{"doi":6354},"10.1200\u002FJCO.2009.26.7609",{"id":24,"text":6356,"url":24,"identifiers":6357},"Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443–2454 (2012).",{"doi":6358},"10.1056\u002FNEJMoa1200690",{"id":24,"text":6360,"url":24,"identifiers":6361},"Overman, M. J. et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 18, 1182–1191 (2017).",{"doi":1280},{"id":24,"text":6363,"url":24,"identifiers":6364},"Overman, M. J. et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient\u002Fmicrosatellite instability-high metastatic colorectal cancer. J. Clin. Oncol. 36, 773–779 (2018).",{"doi":6365},"10.1200\u002FJCO.2017.76.9901",{"id":24,"text":6367,"url":24,"identifiers":6368},"Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509–2520 (2015).",{"doi":6369},"10.1056\u002FNEJMoa1500596",{"id":24,"text":6371,"url":24,"identifiers":6372},"Le, D. T. et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357, 409–413 (2017).",{"doi":6373},"10.1126\u002Fscience.aan6733",{"id":24,"text":6375,"url":24,"identifiers":6376},"Bullman, S. et al. Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer. Science 358, 1443–1448 (2017). This landmark study identifies the presence of Fusobacterium in metastatic CRC lesions and shows that oral metronidazole can shrink tumours in mice bearing a cancer xenograft.",{"doi":6377},"10.1126\u002Fscience.aal5240",{"id":24,"text":6379,"url":24,"identifiers":6380},"D’Haens, G. R. & Jobin, C. Fecal microbial transplantation for diseases beyond recurrent Clostridium difficile infection. Gastroenterology 157, 624–636 (2019).",{"doi":6381},"10.1053\u002Fj.gastro.2019.04.053",{"id":24,"text":6383,"url":24,"identifiers":6384},"McQuade, J. L., Daniel, C. R., Helmink, B. A. & Wargo, J. A. Modulating the microbiome to improve therapeutic response in cancer. Lancet Oncol. 20, e77–e91 (2019).",{"doi":6385},"10.1016\u002FS1470-2045(18)30952-5",{"id":24,"text":6387,"url":24,"identifiers":6388},"Suez, J. & Elinav, E. The path towards microbiome-based metabolite treatment. Nat. Microbiol. 2, 17075 (2017).",{"doi":6389},"10.1038\u002Fnmicrobiol.2017.75",{"id":24,"text":6391,"url":24,"identifiers":6392},"Hu, Y. et al. Manipulation of the gut microbiota using resistant starch is associated with protection against colitis-associated colorectal cancer in rats. Carcinogenesis 37, 366–375 (2016).",{"doi":6393},"10.1093\u002Fcarcin\u002Fbgw019",{"id":24,"text":6395,"url":24,"identifiers":6396},"Kaiko, G. E. et al. The colonic crypt protects stem cells from microbiota-derived metabolites. Cell 167, 1137 (2016).",{"doi":6397},"10.1016\u002Fj.cell.2016.10.034",{"id":24,"text":6399,"url":24,"identifiers":6400},"Mimee, M., Citorik, R. J. & Lu, T. K. Microbiome therapeutics — advances and challenges. Adv. Drug Deliv. Rev. 105, 44–54 (2016).",{"doi":6401},"10.1016\u002Fj.addr.2016.04.032",{"id":24,"text":6403,"url":24,"identifiers":6404},"Duan, F. & March, J. C. Engineered bacterial communication prevents Vibrio cholerae virulence in an infant mouse model. Proc. Natl Acad. Sci. USA 107, 11260–11264 (2010).",{"doi":6405},"10.1073\u002Fpnas.1001294107",{"id":24,"text":6407,"url":24,"identifiers":6408},"Steidler, L. et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 289, 1352–1355 (2000).",{"doi":6409},"10.1126\u002Fscience.289.5483.1352",{"id":24,"text":6411,"url":24,"identifiers":6412},"Kommineni, S. et al. Bacteriocin production augments niche competition by enterococci in the mammalian gastrointestinal tract. Nature 526, 719–722 (2015).",{"doi":6413},"10.1038\u002Fnature15524",{"id":24,"text":6415,"url":24,"identifiers":6416},"Reardon, S. Phage therapy gets revitalized. Nature 510, 15–16 (2014).",{"doi":6417},"10.1038\u002F510015a",{"id":24,"text":6419,"url":24,"identifiers":6420},"Kingwell, K. Bacteriophage therapies re-enter clinical trials. Nat. Rev. Drug Discov. 14, 515–516 (2015).",{"doi":6421},"10.1038\u002Fnrd4695",{"id":24,"text":6423,"url":24,"identifiers":6424},"Suez, J. et al. Post-antibiotic gut mucosal microbiome reconstitution is impaired by probiotics and improved by autologous FMT. Cell 174, 1406–1423 e1416 (2018).",{"doi":6425},"10.1016\u002Fj.cell.2018.08.047",{"id":24,"text":6427,"url":24,"identifiers":6428},"Zmora, N. et al. Personalized gut mucosal colonization resistance to empiric probiotics is associated with unique host and microbiome features. Cell 174, 1388–1405 e1321 (2018).",{"doi":6429},"10.1016\u002Fj.cell.2018.08.041",{"id":24,"text":6431,"url":24,"identifiers":6432},"van Nood, E. et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N. Engl. J. Med. 368, 407–415 (2013).",{"doi":6433},"10.1056\u002FNEJMoa1205037",{"id":24,"text":6435,"url":24,"identifiers":6436},"Smith, M. B., Kelly, C. & Alm, E. J. Policy: how to regulate faecal transplants. Nature 506, 290–291 (2014).",{"doi":6437},"10.1038\u002F506290a",{"id":24,"text":6439,"url":24,"identifiers":6440},"Sullivan, A., Edlund, C. & Nord, C. E. Effect of antimicrobial agents on the ecological balance of human microflora. Lancet Infect. Dis. 1, 101–114 (2001).",{"doi":6441},"10.1016\u002FS1473-3099(01)00066-4",{"id":24,"text":6443,"url":24,"identifiers":6444},"Dethlefsen, L. & Relman, D. A. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc. Natl Acad. Sci. USA 108, 4554–4561 (2011).",{"doi":6445},"10.1073\u002Fpnas.1000087107",{"id":24,"text":6447,"url":24,"identifiers":6448},"Koliaraki, V., Pallangyo, C. K., Greten, F. R. & Kollias, G. Mesenchymal cells in colon cancer. Gastroenterology 152, 964–979 (2017).",{"doi":6449},"10.1053\u002Fj.gastro.2016.11.049",{"id":24,"text":6451,"url":24,"identifiers":6452},"Manson McGuire, A. et al. Evolution of invasion in a diverse set of Fusobacteriumspecies. mBio 5, e01864 (2014).",{"doi":6453},"10.1128\u002FmBio.01864-14",{"id":24,"text":6455,"url":24,"identifiers":6456},"Strauss, J. et al. Invasive potential of gut mucosa-derived Fusobacterium nucleatum positively correlates with IBD status of the host. Inflamm. Bowel Dis. 17, 1971–1978 (2011).",{"doi":6457},"10.1002\u002Fibd.21606",{"id":24,"text":6459,"url":24,"identifiers":6460},"Brennan, C. A. & Garrett, W. S. Fusobacterium nucleatum – symbiont, opportunist and oncobacterium. Nat. Rev. Microbiol. 17, 156–166 (2019).",{"doi":6461},"10.1038\u002Fs41579-018-0129-6",{"id":24,"text":6463,"url":24,"identifiers":6464},"Flynn, K. J., Baxter, N. T. & Schloss, P. D. Metabolic and community synergy of oral bacteria in colorectal cancer. mSphere 1, e00102–e00116 (2016).",{"doi":6465},"10.1128\u002FmSphere.00102-16",{"id":24,"text":6467,"url":24,"identifiers":6468},"Scott, A. J. et al. International Cancer Microbiome Consortium consensus statement on the role of the human microbiome in carcinogenesis. Gut 68, 1624–1632 (2019).",{"doi":6469},"10.1136\u002Fgutjnl-2019-318556",{"id":24,"text":6471,"url":24,"identifiers":6472},"Baxter, N. T., Koumpouras, C. C., Rogers, M. A., Ruffin, M. Tt & Schloss, P. D. DNA from fecal immunochemical test can replace stool for detection of colonic lesions using a microbiota-based model. Microbiome 4, 59 (2016).",{"doi":6473},"10.1186\u002Fs40168-016-0205-y",{"id":24,"text":6475,"url":24,"identifiers":6476},"Cammarota, G., Ianiro, G., Gasbarrini, A. & European, F. M. T. W. G. Faecal microbiota transplantation in clinical practice. Gut 67, 196–197 (2018).",{"doi":6477},"10.1136\u002Fgutjnl-2017-314049",{"id":6479,"createTime":6480,"updateTime":6480,"relativeEntities":6481,"slug":6482,"properties":6483,"entityType":184,"verifyStatus":185,"verifyTime":6480,"verifyNote":186,"syncStatus":23,"languages":6496,"translateLanguages":24,"viewCount":25,"primaryUrl":6497,"fullTextUrl":24,"authors":6498,"publicationType":310,"publisherRelationship":6589,"citationCount":3103,"citationInfo":6626,"publishDate":6629,"publishYear":6630,"citationAnalyzeStatus":23,"lastCitationAnalyze":24,"indexDatabases":24,"openAccess":24,"references":6631,"isForceReanalyzing":595},"6e908655-119b-4da6-99fe-07ffb8cc6347","2024-09-25T22:20:34.066+00:00",[],"A-clinician-s-guide-to-microbiome-analysis",{"mag":6484,"keywords":6486,"openalex":6487,"abstract":6489,"title":6490,"pm":6492,"doi":6494},{"VOID":6485},"2743544008",{},{"VOID":6488},"W2743544008",{},{"EN":6491},"A clinician's guide to microbiome analysis",{"VOID":6493},"28790452",{"VOID":6495},"10.1038\u002Fnrgastro.2017.97",[188],"https:\u002F\u002Fwww.nature.com\u002Farticles\u002Fnrgastro.2017.97",[6499,6543,6566],{"id":6500,"sortIndex":215,"researcher":24,"roles":6501,"affiliations":6502,"properties":6536},"5ea818dd-b037-4ac8-9372-ce244e623614",[],[6503,6514,6525],{"id":6504,"sortIndex":126,"affiliation":6505,"properties":24},"fad003b9-7b92-4099-804d-b7f736c03790",{"id":6506,"createTime":6507,"updateTime":6508,"relativeEntities":6509,"slug":6510,"properties":6511,"entityType":53,"verifyStatus":23,"verifyTime":24,"verifyNote":24,"syncStatus":23,"languages":24,"translateLanguages":24,"viewCount":25},"988525a8-97ca-4ae4-b178-b5b17be96452","2024-01-28T01:04:08.917+00:00","2024-10-10T01:09:07.741+00:00",[],"School-of-Microbiology-University-College-Cork-Cork-Ireland",{"title":6512},{"VI":6513},"School of Microbiology, University College Cork, Cork, Ireland",{"id":6515,"sortIndex":215,"affiliation":6516,"properties":24},"ae7058e3-e1ef-403e-be12-85cdaa2cdc0c",{"id":6517,"createTime":6518,"updateTime":6519,"relativeEntities":6520,"slug":6521,"properties":6522,"entityType":53,"verifyStatus":23,"verifyTime":24,"verifyNote":24,"syncStatus":23,"languages":24,"translateLanguages":24,"viewCount":25},"075725d7-f033-4fca-a53c-2ba8f16bcd99","2024-02-23T03:42:58.429+00:00","2025-06-11T20:23:00.429+00:00",[],"Department-of-Biological-Sciences-Cork-Institute-of-Technology-Cork-Ireland",{"title":6523},{"VI":6524},"Department of Biological Sciences, Cork Institute of Technology, Cork, Ireland",{"id":6526,"sortIndex":25,"affiliation":6527,"properties":24},"a689ece0-02ac-4c14-9d0e-54c5c1f35b6c",{"id":6528,"createTime":6529,"updateTime":6530,"relativeEntities":6531,"slug":6532,"properties":6533,"entityType":53,"verifyStatus":23,"verifyTime":24,"verifyNote":24,"syncStatus":23,"languages":24,"translateLanguages":24,"viewCount":25},"c131f477-e508-4f05-93bd-8dae5b285f20","2024-01-14T23:20:36.363+00:00","2025-02-06T12:54:08.681+00:00",[],"APC-Microbiome-Institute-University-College-Cork-Cork-Ireland",{"title":6534},{"VI":6535},"APC Microbiome Institute, University College Cork, Cork, Ireland",{"openalex":6537,"orcid":6539,"title":6541},{"VOID":6538},"A5021685996",{"VOID":6540},"https:\u002F\u002Forcid.org\u002F0000-0003-4881-9544",{"EN":6542},"Adam G. Clooney",{"id":6544,"sortIndex":25,"researcher":24,"roles":6545,"affiliations":6546,"properties":6559},"b939fc9c-f9b7-4f44-8815-0b30a15cad00",[],[6547,6553],{"id":6548,"sortIndex":215,"affiliation":6549,"properties":24},"7b65b726-5d2e-4a31-9c47-59d2ff8b05d8",{"id":6506,"createTime":6507,"updateTime":6508,"relativeEntities":6550,"slug":6510,"properties":6551,"entityType":53,"verifyStatus":23,"verifyTime":24,"verifyNote":24,"syncStatus":23,"languages":24,"translateLanguages":24,"viewCount":25},[],{"title":6552},{"VI":6513},{"id":6554,"sortIndex":25,"affiliation":6555,"properties":24},"42528833-bb5d-47e8-adf0-8f2a949d560a",{"id":6528,"createTime":6529,"updateTime":6530,"relativeEntities":6556,"slug":6532,"properties":6557,"entityType":53,"verifyStatus":23,"verifyTime":24,"verifyNote":24,"syncStatus":23,"languages":24,"translateLanguages":24,"viewCount":25},[],{"title":6558},{"VI":6535},{"openalex":6560,"orcid":6562,"title":6564},{"VOID":6561},"A5061467408",{"VOID":6563},"https:\u002F\u002Forcid.org\u002F0000-0002-5712-0623",{"EN":6565},"Marcus J. Claesson",{"id":6567,"sortIndex":126,"researcher":24,"roles":6568,"affiliations":6569,"properties":6582},"351a5c73-069c-4f6d-9c79-91472cfb7fa8",[],[6570,6576],{"id":6571,"sortIndex":215,"affiliation":6572,"properties":24},"4c087e94-7b54-4f2f-945d-ee3d3b7b3dd2",{"id":6506,"createTime":6507,"updateTime":6508,"relativeEntities":6573,"slug":6510,"properties":6574,"entityType":53,"verifyStatus":23,"verifyTime":24,"verifyNote":24,"syncStatus":23,"languages":24,"translateLanguages":24,"viewCount":25},[],{"title":6575},{"VI":6513},{"id":6577,"sortIndex":25,"affiliation":6578,"properties":24},"80c9b951-ea8d-43f3-b597-487fbade2bfc",{"id":6528,"createTime":6529,"updateTime":6530,"relativeEntities":6579,"slug":6532,"properties":6580,"entityType":53,"verifyStatus":23,"verifyTime":24,"verifyNote":24,"syncStatus":23,"languages":24,"translateLanguages":24,"viewCount":25},[],{"title":6581},{"VI":6535},{"openalex":6583,"orcid":6585,"title":6587},{"VOID":6584},"A5015909472",{"VOID":6586},"https:\u002F\u002Forcid.org\u002F0000-0001-5377-0824",{"EN":6588},"Paul W. O’Toole",{"url":24,"publisher":6590,"properties":6620},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":6591,"slug":10,"properties":6592,"entityType":22,"verifyStatus":23,"verifyTime":24,"verifyNote":24,"syncStatus":23,"languages":24,"translateLanguages":24,"viewCount":25,"subjectFields":6598,"manageAffiliations":6599,"indexDatabases":6600,"url":106,"thumbnailPath":24,"statistic":6615,"gsStatistic":24,"type":24,"analyzePriority":24},[],{"country":6593,"issn":6594,"introduce":6595,"eissn":6596,"title":6597},{"VOID":13},{"VOID":15},{"EN":17},{"VOID":19},{"EN":21},[],[],[6601,6608],{"id":88,"indexDatabase":6602,"url":103,"indexYears":24,"academicFieldIds":6607,"indexDatabaseRanking":24},{"id":90,"createTime":91,"updateTime":92,"relativeEntities":6603,"label":6604,"description":6605,"key":99,"publicationTags":6606,"standard":24},[],{"EN":95,"VI":95},{"VI":97,"EN":98},[101,102],[105],{"id":68,"indexDatabase":6609,"url":81,"indexYears":82,"academicFieldIds":6614,"indexDatabaseRanking":86},{"id":70,"createTime":71,"updateTime":72,"relativeEntities":6610,"label":6611,"description":6612,"key":78,"publicationTags":6613,"standard":24},[],{"EN":75,"VI":75},{"EN":75,"VI":77},[80],[84,85],{"impactFactor":25,"impactFactorByYear":6616,"i10Index":121,"i10IndexLast5Year":122,"totalPublication":121,"totalPublicationByYear":6617,"totalCitation":129,"totalCitationByYear":6618,"totalCitationPerPublication":145,"totalCitationPerPublicationByYear":6619,"hindexLast5Year":161,"hindex":161},{"2012":109,"2013":110,"2014":111,"2015":112,"2016":113,"2017":114,"2018":115,"2019":116,"2020":117,"2021":118,"2022":119,"2023":120},{"2009":124,"2010":124,"2011":125,"2012":126,"2013":127,"2014":124,"2015":125,"2016":127,"2017":128,"2018":127,"2019":127,"2020":126,"2021":125,"2022":126},{"2009":131,"2010":132,"2011":133,"2012":134,"2013":135,"2014":136,"2015":137,"2016":138,"2017":139,"2018":140,"2019":141,"2020":142,"2021":143,"2022":144},{"2009":147,"2010":148,"2011":149,"2012":150,"2013":151,"2014":152,"2015":153,"2016":154,"2017":155,"2018":156,"2019":157,"2020":158,"2021":159,"2022":160},{"volume":6621,"pages":6623,"issue":6625},{"VOID":6622},"14",{"VOID":6624},"585-595",{"VOID":1507},{"total":3103,"publishYear":24,"statisticByYear":6627},{"2017":126,"2018":2216,"2019":6628,"2020":2217,"2021":6628,"2022":353,"2023":1516,"2024":1514},22,"2017-10-01",2017,[6632,6636,6640,6644,6648,6652,6656,6660,6664,6668,6672,6676,6680,6684,6688,6692,6696,6700,6704,6708,6712,6716,6720,6723,6727,6731,6735,6739,6743,6747,6751,6755,6759,6763,6767,6771,6775,6779,6783,6787,6791,6795,6799,6803,6807,6811,6815,6819,6822,6826,6830,6834,6838,6842,6846,6850,6854,6858,6862,6866,6870,6874,6878,6882,6886,6890,6894,6898,6902,6906,6910,6914,6918,6922,6926,6930,6934,6938,6942,6946,6950,6954,6958,6962,6966,6970,6974,6978,6982,6986,6990,6994,6998,7002,7006,7010,7014,7018,7022,7026,7030,7034,7038,7041,7044,7048,7052,7055,7059,7063,7067,7071,7075,7078,7081,7085,7089,7093,7097,7101,7105,7109,7113,7117,7121,7124,7128,7132,7136,7140,7144,7148,7152,7156,7160,7164,7168,7172,7176,7180,7184,7188,7192,7196,7200,7204,7208,7212,7216,7220,7224,7228,7232,7236,7240,7244,7248,7252,7256,7260,7264,7268,7272,7276,7279,7283,7287,7291,7295,7299,7303,7307,7311,7315,7319,7323,7327,7331,7335,7339,7343,7347,7351,7355,7359,7363,7367,7371,7375,7379,7383,7387,7391,7395,7399,7403,7407,7411,7415,7419,7423,7427,7431,7435,7439,7443,7447,7451,7455,7459,7463],{"id":24,"text":6633,"url":24,"identifiers":6634},"Manichanh, C., Borruel, N., Casellas, F. & Guarner, F. The gut microbiota in IBD. Nat. Rev. Gastroenterol. Hepatol. 9, 599–608 (2012).",{"doi":6635},"10.1038\u002Fnrgastro.2012.152",{"id":24,"text":6637,"url":24,"identifiers":6638},"Salonen, A., de Vos, W. M. & Palva, A. Gastrointestinal microbiota in irritable bowel syndrome: present state and perspectives. Microbiology 156, 3205–3215 (2010).",{"doi":6639},"10.1099\u002Fmic.0.043257-0",{"id":24,"text":6641,"url":24,"identifiers":6642},"Tang, W. H.  et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N. Engl. J. Med. 368, 1575–1584 (2013).",{"doi":6643},"10.1056\u002FNEJMoa1109400",{"id":24,"text":6645,"url":24,"identifiers":6646},"Pedersen, H. K.  et al. Human gut microbes impact host serum metabolome and insulin sensitivity. Nature 535, 376–381 (2016).",{"doi":6647},"10.1038\u002Fnature18646",{"id":24,"text":6649,"url":24,"identifiers":6650},"Sears, C. L. & Garrett, W. S. Microbes, microbiota, and colon cancer. Cell Host Microbe 15, 317–328 (2014).",{"doi":6651},"10.1016\u002Fj.chom.2014.02.007",{"id":24,"text":6653,"url":24,"identifiers":6654},"Marchesi, J. R. & Ravel, J. The vocabulary of microbiome research: a proposal. Microbiome 3, 31 (2015).",{"doi":6655},"10.1186\u002Fs40168-015-0094-5",{"id":24,"text":6657,"url":24,"identifiers":6658},"Costello, E. K., Stagaman, K., Dethlefsen, L., Bohannan, B. J. & Relman, D. A. The application of ecological theory toward an understanding of the human microbiome. Science 336, 1255–1262 (2012).",{"doi":6659},"10.1126\u002Fscience.1224203",{"id":24,"text":6661,"url":24,"identifiers":6662},"Cho, I.  et al. Antibiotics in early life alter the murine colonic microbiome and adiposity. Nature 488, 621–626 (2012).",{"doi":6663},"10.1038\u002Fnature11400",{"id":24,"text":6665,"url":24,"identifiers":6666},"Dethlefsen, L., Huse, S., Sogin, M. L. & Relman, D. A. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol. 6, e280 (2008).",{"doi":6667},"10.1371\u002Fjournal.pbio.0060280",{"id":24,"text":6669,"url":24,"identifiers":6670},"Petrosino, J. F., Highlander, S., Luna, R. A., Gibbs, R. A. & Versalovic, J. Metagenomic pyrosequencing and microbial identification. Clin. Chem. 55, 856–866 (2009).",{"doi":6671},"10.1373\u002Fclinchem.2008.107565",{"id":24,"text":6673,"url":24,"identifiers":6674},"Acinas, S. G., Marcelino, L. A., Klepac-Ceraj, V. & Polz, M. F. Divergence and redundancy of 16S rRNA sequences in genomes with multiple rrn operons. J. Bacteriol. 186, 2629–2635 (2004).",{"doi":6675},"10.1128\u002FJB.186.9.2629-2635.2004",{"id":24,"text":6677,"url":24,"identifiers":6678},"Neefs, J. M., Van de Peer, Y., De Rijk, P., Chapelle, S. & De Wachter, R. Compilation of small ribosomal subunit RNA structures. Nucleic Acids Res. 21, 3025–3049 (1993).",{"doi":6679},"10.1093\u002Fnar\u002F21.13.3025",{"id":24,"text":6681,"url":24,"identifiers":6682},"Claesson, M. J.  et al. Comparison of two next-generation sequencing technologies for resolving highly complex microbiota composition using tandem variable 16S rRNA gene regions. Nucleic Acids Res. 38, e200 (2010).",{"doi":6683},"10.1093\u002Fnar\u002Fgkq873",{"id":24,"text":6685,"url":24,"identifiers":6686},"Clooney, A. G.  et al. Comparing apples and oranges?: Next generation sequencing and its impact on microbiome analysis. PLoS ONE 11, e0148028 (2016).",{"doi":6687},"10.1371\u002Fjournal.pone.0148028",{"id":24,"text":6689,"url":24,"identifiers":6690},"Findley, K.  et al. Topographic diversity of fungal and bacterial communities in human skin. Nature 498, 367–370 (2013).",{"doi":6691},"10.1038\u002Fnature12171",{"id":24,"text":6693,"url":24,"identifiers":6694},"Lavelle, A.  et al. Spatial variation of the colonic microbiota in patients with ulcerative colitis and control volunteers. Gut 64, 1553–1561 (2015).",{"doi":6695},"10.1136\u002Fgutjnl-2014-307873",{"id":24,"text":6697,"url":24,"identifiers":6698},"Huse, S. M.  et al. Comparison of brush and biopsy sampling methods of the ileal pouch for assessment of mucosa-associated microbiota of human subjects. Microbiome 2, 5 (2014).",{"doi":6699},"10.1186\u002F2049-2618-2-5",{"id":24,"text":6701,"url":24,"identifiers":6702},"Chiodini, R. J.  et al. Microbial population differentials between mucosal and submucosal intestinal tissues in advanced crohn's disease of the ileum. PLoS ONE 10, e0134382 (2015).",{"doi":6703},"10.1371\u002Fjournal.pone.0134382",{"id":24,"text":6705,"url":24,"identifiers":6706},"Watt, E.  et al. Extending colonic mucosal microbiome analysis-assessment of colonic lavage as a proxy for endoscopic colonic biopsies. Microbiome 4, 61 (2016).",{"doi":6707},"10.1186\u002Fs40168-016-0207-9",{"id":24,"text":6709,"url":24,"identifiers":6710},"Budding, A. E.  et al. Rectal swabs for analysis of the intestinal microbiota. PLoS ONE 9, e101344 (2014).",{"doi":6711},"10.1371\u002Fjournal.pone.0101344",{"id":24,"text":6713,"url":24,"identifiers":6714},"Shobar, R. M.  et al. The effects of bowel preparation on microbiota-related metrics differ in health and in inflammatory bowel disease and for the mucosal and luminal microbiota compartments. Clin. Transl Gastroenterol. 7, e143 (2016).",{"doi":6715},"10.1038\u002Fctg.2015.54",{"id":24,"text":6717,"url":24,"identifiers":6718},"Gevers, D.  et al. The treatment-naive microbiome in new-onset Crohn's disease. Cell Host Microbe 15, 382–392 (2014).",{"doi":6719},"10.1016\u002Fj.chom.2014.02.005",{"id":24,"text":6721,"url":24,"identifiers":6722},"Flemer, B.  et al. Tumour-associated and non-tumour-associated microbiota in colorectal cancer. Gut \n                    http:\u002F\u002Fdx.doi.org\u002F10.1136\u002Fgutjnl-2015-309595\n                    \n                   (2016).",{"doi":5581},{"id":24,"text":6724,"url":24,"identifiers":6725},"Gorzelak, M. A.  et al. Methods for improving human gut microbiome data by reducing variability through sample processing and storage of stool. PLoS ONE 10, e0134802 (2015).",{"doi":6726},"10.1371\u002Fjournal.pone.0134802",{"id":24,"text":6728,"url":24,"identifiers":6729},"Cardona, S.  et al. Storage conditions of intestinal microbiota matter in metagenomic analysis. BMC Microbiol. 12, 158 (2012).",{"doi":6730},"10.1186\u002F1471-2180-12-158",{"id":24,"text":6732,"url":24,"identifiers":6733},"Bahl, M. I., Bergstrom, A. & Licht, T. R. Freezing fecal samples prior to DNA extraction affects the Firmicutes to Bacteroidetes ratio determined by downstream quantitative PCR analysis. FEMS Microbiol. Lett. 329, 193–197 (2012).",{"doi":6734},"10.1111\u002Fj.1574-6968.2012.02523.x",{"id":24,"text":6736,"url":24,"identifiers":6737},"Shaw, A. G.  et al. Latitude in sample handling and storage for infant faecal microbiota studies: the elephant in the room? Microbiome 4, 40 \n                    http:\u002F\u002Fdx.doi.org\u002F10.1186\u002Fs40168-016-0186-x\n                    \n                   (2016).",{"doi":6738},"10.1186\u002Fs40168-016-0186-x",{"id":24,"text":6740,"url":24,"identifiers":6741},"Vogtmann, E.  et al. Comparison of collection methods for fecal samples in microbiome studies. Am. J. Epidemiol. 185, 115–123 (2017).",{"doi":6742},"10.1093\u002Faje\u002Fkww177",{"id":24,"text":6744,"url":24,"identifiers":6745},"Hill, C. J.  et al. Effect of room temperature transport vials on DNA quality and phylogenetic composition of faecal microbiota of elderly adults and infants. Microbiome 4, 19 (2016).",{"doi":6746},"10.1186\u002Fs40168-016-0164-3",{"id":24,"text":6748,"url":24,"identifiers":6749},"Anderson, E. L.  et al. A robust ambient temperature collection and stabilization strategy: enabling worldwide functional studies of the human microbiome. Sci. Rep. 6, 31731 (2016).",{"doi":6750},"10.1038\u002Fsrep31731",{"id":24,"text":6752,"url":24,"identifiers":6753},"Flores, R.  et al. Collection media and delayed freezing effects on microbial composition of human stool. Microbiome 3, 33 (2015).",{"doi":6754},"10.1186\u002Fs40168-015-0092-7",{"id":24,"text":6756,"url":24,"identifiers":6757},"Choo, J. M., Leong, L. E. & Rogers, G. B. Sample storage conditions significantly influence faecal microbiome profiles. Scientif. Rep. 5, 16350 (2015).",{"doi":6758},"10.1038\u002Fsrep16350",{"id":24,"text":6760,"url":24,"identifiers":6761},"Sherker, A. R., Cherepanov, V., Alvandi, Z., Ramos, R. & Feld, J. J. Optimal preservation of liver biopsy samples for downstream translational applications. Hepatol. Int. 7, 758–766 (2013).",{"doi":6762},"10.1007\u002Fs12072-013-9423-6",{"id":24,"text":6764,"url":24,"identifiers":6765},"Persson, S., de Boer, R. F., Kooistra-Smid, A. M. & Olsen, K. E. Five commercial DNA extraction systems tested and compared on a stool sample collection. Diagnost. Microbiol. Infecti. Dis. 69, 240–244 (2011).",{"doi":6766},"10.1016\u002Fj.diagmicrobio.2010.09.023",{"id":24,"text":6768,"url":24,"identifiers":6769},"Yuan, S., Cohen, D. B., Ravel, J., Abdo, Z. & Forney, L. J. Evaluation of methods for the extraction and purification of DNA from the human microbiome. PLoS ONE 7, e33865 (2012).",{"doi":6770},"10.1371\u002Fjournal.pone.0033865",{"id":24,"text":6772,"url":24,"identifiers":6773},"Li, F., Hullar, M. A. & Lampe, J. W. Optimization of terminal restriction fragment polymorphism (TRFLP) analysis of human gut microbiota. J. Microbiol. Methods 68, 303–311 (2007).",{"doi":6774},"10.1016\u002Fj.mimet.2006.09.006",{"id":24,"text":6776,"url":24,"identifiers":6777},"Ariefdjohan, M. W., Savaiano, D. A. & Nakatsu, C. H. Comparison of DNA extraction kits for PCR-DGGE analysis of human intestinal microbial communities from fecal specimens. Nutr. J. 9, 23 (2010).",{"doi":6778},"10.1186\u002F1475-2891-9-23",{"id":24,"text":6780,"url":24,"identifiers":6781},"Becker, L., Steglich, M., Fuchs, S., Werner, G. & Nubel, U. Comparison of six commercial kits to extract bacterial chromosome and plasmid DNA for MiSeq sequencing. Scientif. Rep. 6, 28063 (2016).",{"doi":6782},"10.1038\u002Fsrep28063",{"id":24,"text":6784,"url":24,"identifiers":6785},"Mirsepasi, H.  et al. Microbial diversity in fecal samples depends on DNA extraction method: easyMag DNA extraction compared to QIAamp DNA stool mini kit extraction. BMC Res. Notes 7, 50 (2014).",{"doi":6786},"10.1186\u002F1756-0500-7-50",{"id":24,"text":6788,"url":24,"identifiers":6789},"Wesolowska-Andersen, A.  et al. Choice of bacterial DNA extraction method from fecal material influences community structure as evaluated by metagenomic analysis. Microbiome 2, 19 (2014).",{"doi":6790},"10.1186\u002F2049-2618-2-19",{"id":24,"text":6792,"url":24,"identifiers":6793},"Gerasimidis, K.  et al. The effect of DNA extraction methodology on gut microbiota research applications. BMC Res. Notes 9, 365 (2016).",{"doi":6794},"10.1186\u002Fs13104-016-2171-7",{"id":24,"text":6796,"url":24,"identifiers":6797},"Hart, M. L., Meyer, A., Johnson, P. J. & Ericsson, A. C. Comparative evaluation of DNA extraction methods from feces of multiple host species for downstream next-generation sequencing. PLoS ONE 10, e0143334 (2015).",{"doi":6798},"10.1371\u002Fjournal.pone.0143334",{"id":24,"text":6800,"url":24,"identifiers":6801},"Kennedy, N. A.  et al. The impact of different DNA extraction kits and laboratories upon the assessment of human gut microbiota composition by 16S rRNA gene sequencing. PLoS ONE 9, e88982 (2014).",{"doi":6802},"10.1371\u002Fjournal.pone.0088982",{"id":24,"text":6804,"url":24,"identifiers":6805},"Salter, S. J.  et al. Reagent and laboratory contamination can critically impact sequence-based microbiome analyses. BMC Biol. 12, 87 \n                    http:\u002F\u002Fdx.doi.org\u002F10.1186\u002Fs12915-014-0087-z\n                    \n                   (2014).",{"doi":6806},"10.1186\u002Fs12915-014-0087-z",{"id":24,"text":6808,"url":24,"identifiers":6809},"Lauder, A. P.  et al. Comparison of placenta samples with contamination controls does not provide evidence for a distinct placenta microbiota. Microbiome 4, 29 (2016).",{"doi":6810},"10.1186\u002Fs40168-016-0172-3",{"id":24,"text":6812,"url":24,"identifiers":6813},"Perez-Munoz, M. E., Arrieta, M. C., Ramer-Tait, A. E. & Walter, J. A critical assessment of the “sterile womb” and “in utero colonization” hypotheses: implications for research on the pioneer infant microbiome. Microbiome 5, 48 (2017).",{"doi":6814},"10.1186\u002Fs40168-017-0268-4",{"id":24,"text":6816,"url":24,"identifiers":6817},"Edri, S. & Tuller, T. Quantifying the effect of ribosomal density on mRNA stability. PLoS ONE 9, e102308 (2014).",{"doi":6818},"10.1371\u002Fjournal.pone.0102308",{"id":24,"text":6820,"url":24,"identifiers":6821},"Goodwin, S., McPherson, J. D. & McCombie, W. R. Coming of age: ten years of next-generation sequencing technologies. Nature reviews. Genetics 17, 333–351 (2016).",{},{"id":24,"text":6823,"url":24,"identifiers":6824},"Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30, 2114–2120 (2014).",{"doi":6825},"10.1093\u002Fbioinformatics\u002Fbtu170",{"id":24,"text":6827,"url":24,"identifiers":6828},"Treangen, T. J.  et al. MetAMOS: a modular and open source metagenomic assembly and analysis pipeline. Genome Biol. 14, R2 (2013).",{"doi":6829},"10.1186\u002Fgb-2013-14-1-r2",{"id":24,"text":6831,"url":24,"identifiers":6832},"Namiki, T., Hachiya, T., Tanaka, H. & Sakakibara, Y. MetaVelvet: an extension of Velvet assembler to de novo metagenome assembly from short sequence reads. Nucleic Acids Res. 40, e155 (2012).",{"doi":6833},"10.1093\u002Fnar\u002Fgks678",{"id":24,"text":6835,"url":24,"identifiers":6836},"Luo, R.  et al. SOAPdenovo2: an empirically improved memory-efficient short-read de novo assembler. GigaScience 1, 18 (2012).",{"doi":6837},"10.1186\u002F2047-217X-1-18",{"id":24,"text":6839,"url":24,"identifiers":6840},"Compeau, P. E. C., Pevzner, P. A. & Tesla, G. How to apply de Bruijn graphs to genome assembly. Nat. Biotechnol. 29, 987–991 (2011).",{"doi":6841},"10.1038\u002Fnbt.2023",{"id":24,"text":6843,"url":24,"identifiers":6844},"Simpson, J. T.  et al. ABySS: a parallel assembler for short read sequence data. Genome Res. 19, 1117–1123 (2009).",{"doi":6845},"10.1101\u002Fgr.089532.108",{"id":24,"text":6847,"url":24,"identifiers":6848},"Peng, Y., Leung, H. C., Yiu, S. M. & Chin, F. Y. IDBA-UD: a de novo assembler for single-cell and metagenomic sequencing data with highly uneven depth. Bioinformatics 28, 1420–1428 (2012).",{"doi":6849},"10.1093\u002Fbioinformatics\u002Fbts174",{"id":24,"text":6851,"url":24,"identifiers":6852},"Afiahayati, Sato, K. & Sakakibara, Y. MetaVelvet-SL: an extension of the Velvet assembler to a de novo metagenomic assembler utilizing supervised learning. DNA Res.: Int. J. Rapid Publ. Rep. Genes Genomes 22, 69–77 (2015).",{"doi":6853},"10.1093\u002Fdnares\u002Fdsu041",{"id":24,"text":6855,"url":24,"identifiers":6856},"Teeling, H., Waldmann, J., Lombardot, T., Bauer, M. & Glockner, F. O. TETRA: a web-service and a stand-alone program for the analysis and comparison of tetranucleotide usage patterns in DNA sequences. BMC Bioinformat. 5, 163 (2004).",{"doi":6857},"10.1186\u002F1471-2105-5-163",{"id":24,"text":6859,"url":24,"identifiers":6860},"Patil, K. R., Roune, L. & McHardy, A. C. The PhyloPythiaS web server for taxonomic assignment of metagenome sequences. PLoS ONE 7, e38581 (2012).",{"doi":6861},"10.1371\u002Fjournal.pone.0038581",{"id":24,"text":6863,"url":24,"identifiers":6864},"Wood, D. E. & Salzberg, S. L. Kraken: ultrafast metagenomic sequence classification using exact alignments. Genome Biol. 15, R46 (2014).",{"doi":6865},"10.1186\u002Fgb-2014-15-3-r46",{"id":24,"text":6867,"url":24,"identifiers":6868},"Truong, D. T.  et al. MetaPhlAn2 for enhanced metagenomic taxonomic profiling. Nature Methods 12, 902–903 (2015).",{"doi":6869},"10.1038\u002Fnmeth.3589",{"id":24,"text":6871,"url":24,"identifiers":6872},"Brady, A. & Salzberg, S. L. Phymm and PhymmBL: metagenomic phylogenetic classification with interpolated Markov models. Nature Methods 6, 673–676 (2009).",{"doi":6873},"10.1038\u002Fnmeth.1358",{"id":24,"text":6875,"url":24,"identifiers":6876},"Wang, Y., Leung, H., Yiu, S. & Chin, F. MetaCluster-TA: taxonomic annotation for metagenomic data based on assembly-assisted binning. BMC Genom. 15 (Suppl. 1), S12 (2014).",{"doi":6877},"10.1186\u002F1471-2164-15-S1-S12",{"id":24,"text":6879,"url":24,"identifiers":6880},"Wu, M. & Scott, A. J. Phylogenomic analysis of bacterial and archaeal sequences with AMPHORA2. Bioinformatics 28, 1033–1034 (2012).",{"doi":6881},"10.1093\u002Fbioinformatics\u002Fbts079",{"id":24,"text":6883,"url":24,"identifiers":6884},"Lin, H. H. & Liao, Y. C. Accurate binning of metagenomic contigs via automated clustering sequences using information of genomic signatures and marker genes. Scientif. Rep. 6, 24175 (2016).",{"doi":6885},"10.1038\u002Fsrep24175",{"id":24,"text":6887,"url":24,"identifiers":6888},"Peabody, M. A., Van Rossum, T., Lo, R. & Brinkman, F. S. Evaluation of shotgun metagenomics sequence classification methods using in silico and in vitro simulated communities. BMC Bioinformat. 16, 363 (2015).",{"doi":6889},"10.1186\u002Fs12859-015-0788-5",{"id":24,"text":6891,"url":24,"identifiers":6892},"Ounit, R., Wanamaker, S., Close, T. J. & Lonardi, S. CLARK: fast and accurate classification of metagenomic and genomic sequences using discriminative k-mers. BMC Genom. 16, 236 (2015).",{"doi":6893},"10.1186\u002Fs12864-015-1419-2",{"id":24,"text":6895,"url":24,"identifiers":6896},"Lindgreen, S., Adair, K. L. & Gardner, P. P. An evaluation of the accuracy and speed of metagenome analysis tools. Scientif. Rep. 6, 19233 (2016).",{"doi":6897},"10.1038\u002Fsrep19233",{"id":24,"text":6899,"url":24,"identifiers":6900},"Zhu, W., Lomsadze, A. & Borodovsky, M. Ab initio gene identification in metagenomic sequences. Nucleic Acids Res. 38, e132 (2010).",{"doi":6901},"10.1093\u002Fnar\u002Fgkq275",{"id":24,"text":6903,"url":24,"identifiers":6904},"Rho, M., Tang, H. & Ye, Y. FragGeneScan: predicting genes in short and error-prone reads. Nucleic Acids Res. 38, e191 (2010).",{"doi":6905},"10.1093\u002Fnar\u002Fgkq747",{"id":24,"text":6907,"url":24,"identifiers":6908},"Hyatt, D., LoCascio, P. F., Hauser, L. J. & Uberbacher, E. C. Gene and translation initiation site prediction in metagenomic sequences. Bioinformatics 28, 2223–2230 (2012).",{"doi":6909},"10.1093\u002Fbioinformatics\u002Fbts429",{"id":24,"text":6911,"url":24,"identifiers":6912},"Altschul, S. F., Gish, W., Miller, W., Myers, E. W. & Lipman, D. J. Basic local alignment search tool. J. Mol. Biol. 215, 403–410 (1990).",{"doi":6913},"10.1016\u002FS0022-2836(05)80360-2",{"id":24,"text":6915,"url":24,"identifiers":6916},"Huerta-Cepas, J.  et al. eggNOG 4.5: a hierarchical orthology framework with improved functional annotations for eukaryotic, prokaryotic and viral sequences. Nucleic Acids Res. 44, D286–D293 (2016).",{"doi":6917},"10.1093\u002Fnar\u002Fgkv1248",{"id":24,"text":6919,"url":24,"identifiers":6920},"Tatusov, R. L.  et al. The COG database: an updated version includes eukaryotes. BMC Bioinformatics 4, 41 (2003).",{"doi":6921},"10.1186\u002F1471-2105-4-41",{"id":24,"text":6923,"url":24,"identifiers":6924},"Kanehisa, M. & Goto, S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27–30 (2000).",{"doi":6925},"10.1093\u002Fnar\u002F28.1.27",{"id":24,"text":6927,"url":24,"identifiers":6928},"Finn, R. D.  et al. Pfam: the protein families database. Nucleic Acids Res. 42, D222–230 (2014).",{"doi":6929},"10.1093\u002Fnar\u002Fgkt1223",{"id":24,"text":6931,"url":24,"identifiers":6932},"Haft, D. H., Selengut, J. D. & White, O. The TIGRFAMs database of protein families. Nucleic Acids Res. 31, 371–373 (2003).",{"doi":6933},"10.1093\u002Fnar\u002Fgkg128",{"id":24,"text":6935,"url":24,"identifiers":6936},"Hunter, S.  et al. InterPro: the integrative protein signature database. Nucleic Acids Res. 37, D211–D215 (2009).",{"doi":6937},"10.1093\u002Fnar\u002Fgkn785",{"id":24,"text":6939,"url":24,"identifiers":6940},"Meyer, F.  et al. The metagenomics RAST server - a public resource for the automatic phylogenetic and functional analysis of metagenomes. BMC Bioinformat. 9, 386 (2008).",{"doi":6941},"10.1186\u002F1471-2105-9-386",{"id":24,"text":6943,"url":24,"identifiers":6944},"Seshadri, R., Kravitz, S. A., Smarr, L., Gilna, P. & Frazier, M. CAMERA: a community resource for metagenomics. PLoS Biol. 5, e75 (2007).",{"doi":6945},"10.1371\u002Fjournal.pbio.0050075",{"id":24,"text":6947,"url":24,"identifiers":6948},"Hunter, S.  et al. EBI metagenomics—a new resource for the analysis and archiving of metagenomic data. Nucleic Acids Res. 42, D600–606 (2014).",{"doi":6949},"10.1093\u002Fnar\u002Fgkt961",{"id":24,"text":6951,"url":24,"identifiers":6952},"Caporaso, J. G.  et al. QIIME allows analysis of high-throughput community sequencing data. Nature Methods 7, 335–336 (2010).",{"doi":6953},"10.1038\u002Fnmeth.f.303",{"id":24,"text":6955,"url":24,"identifiers":6956},"Schloss, P. D.  et al. Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities. Appl. Environ. Microbiol. 75, 7537–7541 (2009).",{"doi":6957},"10.1128\u002FAEM.01541-09",{"id":24,"text":6959,"url":24,"identifiers":6960},"Edgar, R. C. UPARSE: highly accurate OTU sequences from microbial amplicon reads. Nature Methods 10, 996–998 (2013).",{"doi":6961},"10.1038\u002Fnmeth.2604",{"id":24,"text":6963,"url":24,"identifiers":6964},"Plummer, E., Twin, J., Bulach, D. M., Garland, S. M. & Tabrizi, S. N. A comparison of three bioinformatics pipelines for the analysis of preterm gut microbiota using 16S rRNA gene sequencing data. J. Proteomics Bioinform, 8, 283–291 (2015).",{"doi":6965},"10.4172\u002Fjpb.1000381",{"id":24,"text":6967,"url":24,"identifiers":6968},"Westcott, S. L. & Schloss, P. D. de novo clustering methods outperform reference-based methods for assigning 16S rRNA gene sequences to operational taxonomic units. PeerJ 3, e1487 (2015).",{"doi":6969},"10.7717\u002Fpeerj.1487",{"id":24,"text":6971,"url":24,"identifiers":6972},"Jervis-Bardy, J.  et al. Deriving accurate microbiota profiles from human samples with low bacterial content through post-sequencing processing of Illumina MiSeq data. Microbiome 3, 19 (2015).",{"doi":6973},"10.1186\u002Fs40168-015-0083-8",{"id":24,"text":6975,"url":24,"identifiers":6976},"Kopylova, E.  et al. Open-source sequence clustering methods improve the state of the art. mSystems 1, e00003–00015 (2016).",{"doi":6977},"10.1128\u002FmSystems.00003-15",{"id":24,"text":6979,"url":24,"identifiers":6980},"Edgar, R. C., Haas, B. J., Clemente, J. C., Quince, C. & Knight, R. UCHIME improves sensitivity and speed of chimera detection. Bioinformatics 27, 2194–2200 (2011).",{"doi":6981},"10.1093\u002Fbioinformatics\u002Fbtr381",{"id":24,"text":6983,"url":24,"identifiers":6984},"Haas, B. J.  et al. Chimeric 16S rRNA sequence formation and detection in Sanger and 454-pyrosequenced PCR amplicons. Genome Res. 21, 494–504 (2011).",{"doi":6985},"10.1101\u002Fgr.112730.110",{"id":24,"text":6987,"url":24,"identifiers":6988},"Wang, Q., Garrity, G. M., Tiedje, J. M. & Cole, J. R. Naive Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. Appl. Environ. Microbiol. 73, 5261–5267 (2007).",{"doi":6989},"10.1128\u002FAEM.00062-07",{"id":24,"text":6991,"url":24,"identifiers":6992},"Quast, C.  et al. The SILVA ribosomal RNA gene database project: improved data processing and web-based tools. Nucleic Acids Res. 41, D590–D596 (2013).",{"doi":6993},"10.1093\u002Fnar\u002Fgks1219",{"id":24,"text":6995,"url":24,"identifiers":6996},"DeSantis, T. Z.  et al. Greengenes, a chimera-checked 16S rRNA gene database and workbench compatible with ARB. Appl. Environ. Microbiol. 72, 5069–5072 (2006).",{"doi":6997},"10.1128\u002FAEM.03006-05",{"id":24,"text":6999,"url":24,"identifiers":7000},"Maidak, B. L.  et al. The RDP-II (Ribosomal Database Project). Nucleic Acids Res. 29, 173–174 (2001).",{"doi":7001},"10.1093\u002Fnar\u002F29.1.173",{"id":24,"text":7003,"url":24,"identifiers":7004},"Koljalg, U.  et al. UNITE: a database providing web-based methods for the molecular identification of ectomycorrhizal fungi. New Phytol. 166, 1063–1068 (2005).",{"doi":7005},"10.1111\u002Fj.1469-8137.2005.01376.x",{"id":24,"text":7007,"url":24,"identifiers":7008},"Allard, G., Ryan, F. J., Jeffery, I. B. & Claesson, M. J. SPINGO: a rapid species-classifier for microbial amplicon sequences. BMC Bioinformat. 16, 324 (2015).",{"doi":7009},"10.1186\u002Fs12859-015-0747-1",{"id":24,"text":7011,"url":24,"identifiers":7012},"Edgar, R. C. Search and clustering orders of magnitude faster than BLAST. Bioinformatics 26, 2460–2461 (2010).",{"doi":7013},"10.1093\u002Fbioinformatics\u002Fbtq461",{"id":24,"text":7015,"url":24,"identifiers":7016},"Chen, W., Zhang, C. K., Cheng, Y., Zhang, S. & Zhao, H. A comparison of methods for clustering 16S rRNA sequences into OTUs. PLoS ONE 8, e70837 (2013).",{"doi":7017},"10.1371\u002Fjournal.pone.0070837",{"id":24,"text":7019,"url":24,"identifiers":7020},"Callahan, B. J.  et al. DADA2: high-resolution sample inference from Illumina amplicon data. Nature Methods 13, 581–583 (2016).",{"doi":7021},"10.1038\u002Fnmeth.3869",{"id":24,"text":7023,"url":24,"identifiers":7024},"Huson, D. H.  et al. MEGAN Community Edition — Interactive exploration and analysis of large-scale microbiome sequencing data. PLoS Computat. Biol. 12, e1004957 (2016).",{"doi":7025},"10.1371\u002Fjournal.pcbi.1004957",{"id":24,"text":7027,"url":24,"identifiers":7028},"McMurdie, P. J. & Holmes, S. phyloseq: an R package for reproducible interactive analysis and graphics of microbiome census data. PLoS ONE 8, e61217 (2013).",{"doi":7029},"10.1371\u002Fjournal.pone.0061217",{"id":24,"text":7031,"url":24,"identifiers":7032},"Langille, M. G.  et al. Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. Nature Biotechnol. 31, 814–821 (2013).",{"doi":7033},"10.1038\u002Fnbt.2676",{"id":24,"text":7035,"url":24,"identifiers":7036},"Asshauer, K. P., Wemheuer, B., Daniel, R. & Meinicke, P. Tax4Fun: predicting functional profiles from metagenomic 16S rRNA data. Bioinformatics 31, 2882–2884 (2015).",{"doi":7037},"10.1093\u002Fbioinformatics\u002Fbtv287",{"id":24,"text":7039,"url":24,"identifiers":7040},"van Nood, E.  et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N. Engl. J. Med. 368, 407–415 (2013).",{"doi":6433},{"id":24,"text":7042,"url":24,"identifiers":7043},"Le Chatelier, E.  et al. Richness of human gut microbiome correlates with metabolic markers. Nature 500, 541–546 (2013).",{"doi":6143},{"id":24,"text":7045,"url":24,"identifiers":7046},"Claesson, M. J.  et al. Gut microbiota composition correlates with diet and health in the elderly. Nature 488, 178–184 (2012).",{"doi":7047},"10.1038\u002Fnature11319",{"id":24,"text":7049,"url":24,"identifiers":7050},"Olle, B. Medicines from microbiota. Nat. Biotechnol. 31, 309–315 (2013).",{"doi":7051},"10.1038\u002Fnbt.2548",{"id":24,"text":7053,"url":24,"identifiers":7054},"US Food and Drug Administration. Early Clinical Trials With Live Biotherapeutic Products: Chemistry, Manufacturing, and Control Information; Guidance for Industry (FDA, 2016).",{},{"id":24,"text":7056,"url":24,"identifiers":7057},"Goldberg, B., Sichtig, H., Geyer, C., Ledeboer, N. & Weinstock, G. M. Making the leap from research laboratory to clinic: challenges and opportunities for next-generation sequencing in infectious disease diagnostics. mBio 6, e01888–e01815 (2015).",{"doi":7058},"10.1128\u002FmBio.01888-15",{"id":24,"text":7060,"url":24,"identifiers":7061},"Wilson, M. R.  et al. Acute west nile virus meningoencephalitis diagnosed via metagenomic deep sequencing of cerebrospinal fluid in a renal transplant patient. Am. J. Transplant. \n                    http:\u002F\u002Fdx.doi.org\u002F10.1111\u002Fajt.14058\n                    \n                   (2016).",{"doi":7062},"10.1111\u002Fajt.14058",{"id":24,"text":7064,"url":24,"identifiers":7065},"Zeevi, D.  et al. Personalized nutrition by prediction of glycemic responses. Cell 163, 1079–1094 (2015).",{"doi":7066},"10.1016\u002Fj.cell.2015.11.001",{"id":24,"text":7068,"url":24,"identifiers":7069},"Bauer, E., Laczny, C. C., Magnusdottir, S., Wilmes, P. & Thiele, I. Phenotypic differentiation of gastrointestinal microbes is reflected in their encoded metabolic repertoires. Microbiome 3, 55 (2015).",{"doi":7070},"10.1186\u002Fs40168-015-0121-6",{"id":24,"text":7072,"url":24,"identifiers":7073},"Heinken, A. & Thiele, I. Systems biology of host-microbe metabolomics. Wiley Interdiscip. Rev. Syst. Biol. Med. 7, 195–219 (2015).",{"doi":7074},"10.1002\u002Fwsbm.1301",{"id":24,"text":7076,"url":24,"identifiers":7077},"[No authors listed.] Babraham Bioinformatics \n                    http:\u002F\u002Fwww.bioinformatics.babraham.ac.uk\u002Fprojects\u002Ffastqc\u002F",{},{"id":24,"text":7079,"url":24,"identifiers":7080},"[No authors listed.] Hannonlab \n                    http:\u002F\u002Fhannonlab.cshl.edu\u002Ffastx_toolkit\u002Findex.html",{},{"id":24,"text":7082,"url":24,"identifiers":7083},"Schmieder, R. & Edwards, R. Quality control and preprocessing of metagenomic datasets. Bioinformatics 27, 863–864 (2011).",{"doi":7084},"10.1093\u002Fbioinformatics\u002Fbtr026",{"id":24,"text":7086,"url":24,"identifiers":7087},"Patel, R. K. & Jain, M. NGS QC Toolkit: a toolkit for quality control of next generation sequencing data. PLoS ONE 7, e30619 (2012).",{"doi":7088},"10.1371\u002Fjournal.pone.0030619",{"id":24,"text":7090,"url":24,"identifiers":7091},"Zhou, Q., Su, X., Jing, G. & Ning, K. Meta-QC-Chain: comprehensive and fast quality control method for metagenomic data. Genom. Proteom. Bioinformat. 12, 52–56 (2014).",{"doi":7092},"10.1016\u002Fj.gpb.2014.01.002",{"id":24,"text":7094,"url":24,"identifiers":7095},"Peng, Y., Leung, H. C., Yiu, S. M. & Chin, F. Y. Meta-IDBA: a de novo assembler for metagenomic data. Bioinformatics 27, i94–i101 (2011).",{"doi":7096},"10.1093\u002Fbioinformatics\u002Fbtr216",{"id":24,"text":7098,"url":24,"identifiers":7099},"Zerbino, D. R. & Birney, E. Velvet: algorithms for de novo short read assembly using de Bruijn graphs. Genome Res. 18, 821–829 (2008).",{"doi":7100},"10.1101\u002Fgr.074492.107",{"id":24,"text":7102,"url":24,"identifiers":7103},"Boisvert, S., Raymond, F., Godzaridis, E., Laviolette, F. & Corbeil, J. Ray Meta: scalable de novo metagenome assembly and profiling. Genome Biol. 13, R122 (2012).",{"doi":7104},"10.1186\u002Fgb-2012-13-12-r122",{"id":24,"text":7106,"url":24,"identifiers":7107},"Li, D., Liu, C. M., Luo, R., Sadakane, K. & Lam, T. W. MEGAHIT: an ultra-fast single-node solution for large and complex metagenomics assembly via succinct de Bruijn graph. Bioinformatics 31, 1674–1676 (2015).",{"doi":7108},"10.1093\u002Fbioinformatics\u002Fbtv033",{"id":24,"text":7110,"url":24,"identifiers":7111},"Kang, D. D., Froula, J., Egan, R. & Wang, Z. MetaBAT, an efficient tool for accurately reconstructing single genomes from complex microbial communities. PeerJ 3, e1165 (2015).",{"doi":7112},"10.7717\u002Fpeerj.1165",{"id":24,"text":7114,"url":24,"identifiers":7115},"Haider, B.  et al. Omega: an overlap-graph de novo assembler for metagenomics. Bioinformatics 30, 2717–2722 (2014).",{"doi":7116},"10.1093\u002Fbioinformatics\u002Fbtu395",{"id":24,"text":7118,"url":24,"identifiers":7119},"Reddy, R. M., Mohammed, M. H. & Mande, S. S. MetaCAA: a clustering-aided methodology for efficient assembly of metagenomic datasets. Genomics 103, 161–168 (2014).",{"doi":7120},"10.1016\u002Fj.ygeno.2014.02.007",{"id":24,"text":7122,"url":24,"identifiers":7123},"Nurk, S., Meleshko, D., Korobeynikov, A. & Pevzner, P. metaSPAdes: a new versatile de novo metagenomics assembler. arXiv 1604.03071 (2016).",{},{"id":24,"text":7125,"url":24,"identifiers":7126},"Ye, Y. & Tang, H. An ORFome assembly approach to metagenomics sequences analysis. J. Bioinformat. Computat. Biol. 7, 455–471 (2009).",{"doi":7127},"10.1142\u002FS0219720009004151",{"id":24,"text":7129,"url":24,"identifiers":7130},"Yu, F., Sun, Y., Liu, L. & Farmerie, W. GSTaxClassifier: a genomic signature based taxonomic classifier for metagenomic data analysis. Bioinformation 4, 46–49 (2010).",{"doi":7131},"10.6026\u002F97320630004046",{"id":24,"text":7133,"url":24,"identifiers":7134},"Sunagawa, S.  et al. Metagenomic species profiling using universal phylogenetic marker genes. Nature Methods 10, 1196–1199 (2013).",{"doi":7135},"10.1038\u002Fnmeth.2693",{"id":24,"text":7137,"url":24,"identifiers":7138},"Ounit, R. & Lonardi, S. Higher classification sensitivity of short metagenomic reads with CLARK-S. Bioinformatics \n                    http:\u002F\u002Fdx.doi.org\u002F10.1093\u002Fbioinformatics\u002Fbtw542\n                    \n                   (2016).",{"doi":7139},"10.1093\u002Fbioinformatics\u002Fbtw542",{"id":24,"text":7141,"url":24,"identifiers":7142},"Diaz, N. N., Krause, L., Goesmann, A., Niehaus, K. & Nattkemper, T. W. TACOA: taxonomic classification of environmental genomic fragments using a kernelized nearest neighbor approach. BMC Bioinformat. 10, 56 (2009).",{"doi":7143},"10.1186\u002F1471-2105-10-56",{"id":24,"text":7145,"url":24,"identifiers":7146},"Rosen, G. L., Reichenberger, E. R. & Rosenfeld, A. M. NBC: the Naive Bayes Classification tool webserver for taxonomic classification of metagenomic reads. Bioinformatics 27, 127–129 (2011).",{"doi":7147},"10.1093\u002Fbioinformatics\u002Fbtq619",{"id":24,"text":7149,"url":24,"identifiers":7150},"Stark, M., Berger, S. A., Stamatakis, A. & von Mering, C. MLTreeMap—accurate Maximum Likelihood placement of environmental DNA sequences into taxonomic and functional reference phylogenies. BMC Genom. 11, 461 (2010).",{"doi":7151},"10.1186\u002F1471-2164-11-461",{"id":24,"text":7153,"url":24,"identifiers":7154},"Freitas, T. A., Li, P. E., Scholz, M. B. & Chain, P. S. Accurate read-based metagenome characterization using a hierarchical suite of unique signatures. Nucleic Acids Res. 43, e69 (2015).",{"doi":7155},"10.1093\u002Fnar\u002Fgkv180",{"id":24,"text":7157,"url":24,"identifiers":7158},"Gerlach, W. & Stoye, J. Taxonomic classification of metagenomic shotgun sequences with CARMA3. Nucleic Acids Res. 39, e91 (2011).",{"doi":7159},"10.1093\u002Fnar\u002Fgkr225",{"id":24,"text":7161,"url":24,"identifiers":7162},"Ames, S. K.  et al. Scalable metagenomic taxonomy classification using a reference genome database. Bioinformatics 29, 2253–2260 (2013).",{"doi":7163},"10.1093\u002Fbioinformatics\u002Fbtt389",{"id":24,"text":7165,"url":24,"identifiers":7166},"Droge, J., Gregor, I. & McHardy, A. C. Taxator-tk: precise taxonomic assignment of metagenomes by fast approximation of evolutionary neighborhoods. Bioinformatics 31, 817–824 (2015).",{"doi":7167},"10.1093\u002Fbioinformatics\u002Fbtu745",{"id":24,"text":7169,"url":24,"identifiers":7170},"MacDonald, N. J., Parks, D. H. & Beiko, R. G. Rapid identification of high-confidence taxonomic assignments for metagenomic data. Nucleic Acids Res. 40, e111 (2012).",{"doi":7171},"10.1093\u002Fnar\u002Fgks335",{"id":24,"text":7173,"url":24,"identifiers":7174},"Monzoorul Haque, M., Ghosh, T. S., Komanduri, D. & Mande, S. S. SOrt-ITEMS: sequence orthology based approach for improved taxonomic estimation of metagenomic sequences. Bioinformatics 25, 1722–1730 (2009).",{"doi":7175},"10.1093\u002Fbioinformatics\u002Fbtp317",{"id":24,"text":7177,"url":24,"identifiers":7178},"Mohammed, M. H., Ghosh, T. S., Singh, N. K. & Mande, S. S. SPHINX—an algorithm for taxonomic binning of metagenomic sequences. Bioinformatics 27, 22–30 (2011).",{"doi":7179},"10.1093\u002Fbioinformatics\u002Fbtq608",{"id":24,"text":7181,"url":24,"identifiers":7182},"Nalbantoglu, O. U., Way, S. F., Hinrichs, S. H. & Sayood, K. RAIphy: phylogenetic classification of metagenomics samples using iterative refinement of relative abundance index profiles. BMC Bioinformat. 12, 41 (2011).",{"doi":7183},"10.1186\u002F1471-2105-12-41",{"id":24,"text":7185,"url":24,"identifiers":7186},"Koslicki, D., Foucart, S. & Rosen, G. WGSQuikr: fast whole-genome shotgun metagenomic classification. PLoS ONE 9, e91784 (2014).",{"doi":7187},"10.1371\u002Fjournal.pone.0091784",{"id":24,"text":7189,"url":24,"identifiers":7190},"Chan, C. K., Hsu, A. L., Halgamuge, S. K. & Tang, S. L. Binning sequences using very sparse labels within a metagenome. BMC Bioinformat. 9, 215 (2008).",{"doi":7191},"10.1186\u002F1471-2105-9-215",{"id":24,"text":7193,"url":24,"identifiers":7194},"Schreiber, F., Gumrich, P., Daniel, R. & Meinicke, P. Treephyler: fast taxonomic profiling of metagenomes. Bioinformatics 26, 960–961 (2010).",{"doi":7195},"10.1093\u002Fbioinformatics\u002Fbtq070",{"id":24,"text":7197,"url":24,"identifiers":7198},"Weber, M.  et al. Practical application of self-organizing maps to interrelate biodiversity and functional data in NGS-based metagenomics. ISME J. 5, 918–928 (2011).",{"doi":7199},"10.1038\u002Fismej.2010.180",{"id":24,"text":7201,"url":24,"identifiers":7202},"Pati, A., Heath, L. S., Kyrpides, N. C. & Ivanova, N. ClaMS: a classifier for metagenomic sequences. Standards Genom. Sci. 5, 248–253 (2011).",{"doi":7203},"10.4056\u002Fsigs.2075298",{"id":24,"text":7205,"url":24,"identifiers":7206},"Davenport, C. F.  et al. Genometa—a fast and accurate classifier for short metagenomic shotgun reads. PLoS ONE 7, e41224 (2012).",{"doi":7207},"10.1371\u002Fjournal.pone.0041224",{"id":24,"text":7209,"url":24,"identifiers":7210},"Sharma, A. K., Gupta, A., Kumar, S., Dhakan, D. B. & Sharma, V. K. Woods: a fast and accurate functional annotator and classifier of genomic and metagenomic sequences. Genomics 106, 1–6 (2015).",{"doi":7211},"10.1016\u002Fj.ygeno.2015.04.001",{"id":24,"text":7213,"url":24,"identifiers":7214},"Ghosh, T. S., Monzoorul Haque, M. & Mande, S. S. DiScRIBinATE: a rapid method for accurate taxonomic classification of metagenomic sequences. BMC Bioinformat. 11 (Suppl. 7), S14 (2010).",{"doi":7215},"10.1186\u002F1471-2105-11-S7-S14",{"id":24,"text":7217,"url":24,"identifiers":7218},"Liu, J.  et al. Composition-based classification of short metagenomic sequences elucidates the landscapes of taxonomic and functional enrichment of microorganisms. Nucleic Acids Res. 41, e3 (2013).",{"doi":7219},"10.1093\u002Fnar\u002Fgks828",{"id":24,"text":7221,"url":24,"identifiers":7222},"Mohammed, M. H.  et al. INDUS - a composition-based approach for rapid and accurate taxonomic classification of metagenomic sequences. BMC Genom. 12 (Suppl. 3), S4 (2011).",{"doi":7223},"10.1186\u002F1471-2164-12-S3-S4",{"id":24,"text":7225,"url":24,"identifiers":7226},"Sharma, V. K., Kumar, N., Prakash, T. & Taylor, T. D. Fast and accurate taxonomic assignments of metagenomic sequences using MetaBin. PLoS ONE 7, e34030 (2012).",{"doi":7227},"10.1371\u002Fjournal.pone.0034030",{"id":24,"text":7229,"url":24,"identifiers":7230},"Liu, B., Gibbons, T., Ghodsi, M., Treangen, T. & Pop, M. Accurate and fast estimation of taxonomic profiles from metagenomic shotgun sequences. BMC Genom. 12 (Suppl. 2), S4 (2011).",{"doi":7231},"10.1186\u002F1471-2164-12-S2-S4",{"id":24,"text":7233,"url":24,"identifiers":7234},"Rasheed, Z. & Rangwala, H. Metagenomic taxonomic classification using extreme learning machines. J. Bioinformat. Computat. Biol. 10, 1250015 (2012).",{"doi":7235},"10.1142\u002FS0219720012500151",{"id":24,"text":7237,"url":24,"identifiers":7238},"Ander, C., Schulz-Trieglaff, O. B., Stoye, J. & Cox, A. J. metaBEETL: high-throughput analysis of heterogeneous microbial populations from shotgun DNA sequences. BMC Bioinformat. 14 (Suppl. 5), S2 (2013).",{"doi":7239},"10.1186\u002F1471-2105-14-S5-S2",{"id":24,"text":7241,"url":24,"identifiers":7242},"Porter, M. S. & Beiko, R. G. SPANNER: taxonomic assignment of sequences using pyramid matching of similarity profiles. Bioinformatics 29, 1858–1864 (2013).",{"doi":7243},"10.1093\u002Fbioinformatics\u002Fbtt313",{"id":24,"text":7245,"url":24,"identifiers":7246},"Piro, V. C., Lindner, M. S. & Renard, B. Y. DUDes: a top-down taxonomic profiler for metagenomics. Bioinformatics 32, 2272–2280 (2016).",{"doi":7247},"10.1093\u002Fbioinformatics\u002Fbtw150",{"id":24,"text":7249,"url":24,"identifiers":7250},"Menzel, P., Ng, K. L. & Krogh, A. Fast and sensitive taxonomic classification for metagenomics with Kaiju. Nature Commun. 7, 11257 (2016).",{"doi":7251},"10.1038\u002Fncomms11257",{"id":24,"text":7253,"url":24,"identifiers":7254},"Wu, Y. W., Tang, Y. H., Tringe, S. G., Simmons, B. A. & Singer, S. W. MaxBin: an automated binning method to recover individual genomes from metagenomes using an expectation-maximization algorithm. Microbiome 2, 26 (2014).",{"doi":7255},"10.1186\u002F2049-2618-2-26",{"id":24,"text":7257,"url":24,"identifiers":7258},"Petrenko, P., Lobb, B., Kurtz, D. A., Neufeld, J. D. & Doxey, A. C. MetAnnotate: function-specific taxonomic profiling and comparison of metagenomes. BMC Biol. 13, 92 (2015).",{"doi":7259},"10.1186\u002Fs12915-015-0195-4",{"id":24,"text":7261,"url":24,"identifiers":7262},"Luo, C., Rodriguez, R. L. & Konstantinidis, K. T. MyTaxa: an advanced taxonomic classifier for genomic and metagenomic sequences. Nucleic Acids Res. 42, e73 (2014).",{"doi":7263},"10.1093\u002Fnar\u002Fgku169",{"id":24,"text":7265,"url":24,"identifiers":7266},"Jiang, H., An, L., Lin, S. M., Feng, G. & Qiu, Y. A statistical framework for accurate taxonomic assignment of metagenomic sequencing reads. PLoS ONE 7, e46450 (2012).",{"doi":7267},"10.1371\u002Fjournal.pone.0046450",{"id":24,"text":7269,"url":24,"identifiers":7270},"Klingenberg, H., Asshauer, K. P., Lingner, T. & Meinicke, P. Protein signature-based estimation of metagenomic abundances including all domains of life and viruses. Bioinformatics 29, 973–980 (2013).",{"doi":7271},"10.1093\u002Fbioinformatics\u002Fbtt077",{"id":24,"text":7273,"url":24,"identifiers":7274},"Reddy, R. M., Mohammed, M. H. & Mande, S. S. TWARIT: an extremely rapid and efficient approach for phylogenetic classification of metagenomic sequences. Gene 505, 259–265 (2012).",{"doi":7275},"10.1016\u002Fj.gene.2012.06.014",{"id":24,"text":7277,"url":24,"identifiers":7278},"Hou, T.  et al. Classification of metagenomics data at lower taxonomic level using a robust supervised classifier. Evol. Bioinformat. Online 11, 3–10 S20523 (2015).",{},{"id":24,"text":7280,"url":24,"identifiers":7281},"Kristiansson, E., Hugenholtz, P. & Dalevi, D. ShotgunFunctionalizeR: an R-package for functional comparison of metagenomes. Bioinformatics 25, 2737–2738 (2009).",{"doi":7282},"10.1093\u002Fbioinformatics\u002Fbtp508",{"id":24,"text":7284,"url":24,"identifiers":7285},"Li, W. Analysis and comparison of very large metagenomes with fast clustering and functional annotation. BMC Bioinformat. 10, 359 (2009).",{"doi":7286},"10.1186\u002F1471-2105-10-359",{"id":24,"text":7288,"url":24,"identifiers":7289},"Kelley, D. R., Liu, B., Delcher, A. L., Pop, M. & Salzberg, S. L. Gene prediction with Glimmer for metagenomic sequences augmented by classification and clustering. Nucleic Acids Res. 40, e9 (2012).",{"doi":7290},"10.1093\u002Fnar\u002Fgkr1067",{"id":24,"text":7292,"url":24,"identifiers":7293},"Hoff, K. J., Lingner, T., Meinicke, P. & Tech, M. Orphelia: predicting genes in metagenomic sequencing reads. Nucleic Acids Res. 37, W101–W105 (2009).",{"doi":7294},"10.1093\u002Fnar\u002Fgkp327",{"id":24,"text":7296,"url":24,"identifiers":7297},"Liu, Y., Guo, J., Hu, G. & Zhu, H. Gene prediction in metagenomic fragments based on the SVM algorithm. BMC Bioinformat. 14 (Suppl. 5), S12 (2013).",{"doi":7298},"10.1186\u002F1471-2105-14-S5-S12",{"id":24,"text":7300,"url":24,"identifiers":7301},"van der Veen, B. E., Harris, H. M., O'Toole, P. W. & Claesson, M. J. Metaphor: finding bi-directional best hit homology relationships in (meta)genomic datasets. Genomics 104, 459–463 (2014).",{"doi":7302},"10.1016\u002Fj.ygeno.2014.10.008",{"id":24,"text":7304,"url":24,"identifiers":7305},"Liu, B. & Pop, M. MetaPath: identifying differentially abundant metabolic pathways in metagenomic datasets. BMC Proc. 5 (Suppl. 2), S9 (2011).",{"doi":7306},"10.1186\u002F1753-6561-5-S2-S9",{"id":24,"text":7308,"url":24,"identifiers":7309},"Overbeek, R.  et al. The SEED and the Rapid Annotation of microbial genomes using Subsystems Technology (RAST). Nucleic Acids Res. 42, D206–D214 (2014).",{"doi":7310},"10.1093\u002Fnar\u002Fgkt1226",{"id":24,"text":7312,"url":24,"identifiers":7313},"Powell, S.  et al. eggNOG v4.0: nested orthology inference across 3686 organisms. Nucleic Acids Res. 42, D231–D239 (2014).",{"doi":7314},"10.1093\u002Fnar\u002Fgkt1253",{"id":24,"text":7316,"url":24,"identifiers":7317},"Abubucker, S.  et al. Metabolic reconstruction for metagenomic data and its application to the human microbiome. PLoS Computat. Biol. 8, e1002358 (2012).",{"doi":7318},"10.1371\u002Fjournal.pcbi.1002358",{"id":24,"text":7320,"url":24,"identifiers":7321},"Segata, N.  et al. Metagenomic biomarker discovery and explanation. Genome Biol. 12, R60 (2011).",{"doi":7322},"10.1186\u002Fgb-2011-12-6-r60",{"id":24,"text":7324,"url":24,"identifiers":7325},"Markowitz, V. M.  et al. IMG\u002FM 4 version of the integrated metagenome comparative analysis system. Nucleic Acids Res. 42, D568–573 (2014).",{"doi":7326},"10.1093\u002Fnar\u002Fgkt919",{"id":24,"text":7328,"url":24,"identifiers":7329},"Wu, S., Zhu, Z., Fu, L., Niu, B. & Li, W. WebMGA: a customizable web server for fast metagenomic sequence analysis. BMC Genom. 12, 444 (2011).",{"doi":7330},"10.1186\u002F1471-2164-12-444",{"id":24,"text":7332,"url":24,"identifiers":7333},"Goll, J.  et al. METAREP: JCVI metagenomics reports—an open source tool for high-performance comparative metagenomics. Bioinformatics 26, 2631–2632 (2010).",{"doi":7334},"10.1093\u002Fbioinformatics\u002Fbtq455",{"id":24,"text":7336,"url":24,"identifiers":7337},"Su, X., Pan, W., Song, B., Xu, J. & Ning, K. Parallel-META 2.0: enhanced metagenomic data analysis with functional annotation, high performance computing and advanced visualization. PloS one 9, e89323 (2014).",{"doi":7338},"10.1371\u002Fjournal.pone.0089323",{"id":24,"text":7340,"url":24,"identifiers":7341},"Kultima, J. R.  et al. MOCAT: a metagenomics assembly and gene prediction toolkit. PLoS ONE 7, e47656 (2012).",{"doi":7342},"10.1371\u002Fjournal.pone.0047656",{"id":24,"text":7344,"url":24,"identifiers":7345},"Afgan, E.  et al. The Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2016 update. Nucleic Acids Res. 44, W3–W10 (2016).",{"doi":7346},"10.1093\u002Fnar\u002Fgkw343",{"id":24,"text":7348,"url":24,"identifiers":7349},"Fosso, B.  et al. BioMaS: a modular pipeline for Bioinformatic analysis of Metagenomic AmpliconS. BMC Bioinformat. 16, 203 (2015).",{"doi":7350},"10.1186\u002Fs12859-015-0595-z",{"id":24,"text":7352,"url":24,"identifiers":7353},"Angly, F.  et al. PHACCS, an online tool for estimating the structure and diversity of uncultured viral communities using metagenomic information. BMC Bioinformat. 6, 41 (2005).",{"doi":7354},"10.1186\u002F1471-2105-6-41",{"id":24,"text":7356,"url":24,"identifiers":7357},"Arumugam, M., Harrington, E. D., Foerstner, K. U., Raes, J. & Bork, P. SmashCommunity: a metagenomic annotation and analysis tool. Bioinformatics 26, 2977–2978 (2010).",{"doi":7358},"10.1093\u002Fbioinformatics\u002Fbtq536",{"id":24,"text":7360,"url":24,"identifiers":7361},"Schloss, P. D. & Handelsman, J. Introducing DOTUR, a computer program for defining operational taxonomic units and estimating species richness. Appl. Environ. Microbiol. 71, 1501–1506 (2005).",{"doi":7362},"10.1128\u002FAEM.71.3.1501-1506.2005",{"id":24,"text":7364,"url":24,"identifiers":7365},"Li, W. & Godzik, A. Cd-hit: a fast program for clustering and comparing large sets of protein or nucleotide sequences. Bioinformatics 22, 1658–1659 (2006).",{"doi":7366},"10.1093\u002Fbioinformatics\u002Fbtl158",{"id":24,"text":7368,"url":24,"identifiers":7369},"Hao, X., Jiang, R. & Chen, T. Clustering 16S rRNA for OTU prediction: a method of unsupervised Bayesian clustering. Bioinformatics 27, 611–618 (2011).",{"doi":7370},"10.1093\u002Fbioinformatics\u002Fbtq725",{"id":24,"text":7372,"url":24,"identifiers":7373},"Cai, Y. & Sun, Y. ESPRIT-Tree: hierarchical clustering analysis of millions of 16S rRNA pyrosequences in quasilinear computational time. Nucleic Acids Res. 39, e95 (2011).",{"doi":7374},"10.1093\u002Fnar\u002Fgkr349",{"id":24,"text":7376,"url":24,"identifiers":7377},"Ghodsi, M., Liu, B. & Pop, M. DNACLUST: accurate and efficient clustering of phylogenetic marker genes. BMC Bioinformat. 12, 271 (2011).",{"doi":7378},"10.1186\u002F1471-2105-12-271",{"id":24,"text":7380,"url":24,"identifiers":7381},"Russell, D. J., Way, S. F., Benson, A. K. & Sayood, K. A grammar-based distance metric enables fast and accurate clustering of large sets of 16S sequences. BMC Bioinformat. 11, 601 (2010).",{"doi":7382},"10.1186\u002F1471-2105-11-601",{"id":24,"text":7384,"url":24,"identifiers":7385},"Wang, X., Yao, J., Sun, Y. & Mai, V. M-Pick, a modularity-based method for OTU picking of 16S rRNA sequences. BMC Bioinformat. 14, 43 (2013).",{"doi":7386},"10.1186\u002F1471-2105-14-43",{"id":24,"text":7388,"url":24,"identifiers":7389},"Mahe, F., Rognes, T., Quince, C., de Vargas, C. & Dunthorn, M. Swarm v2: highly-scalable and high-resolution amplicon clustering. PeerJ 3, e1420 (2015).",{"doi":7390},"10.7717\u002Fpeerj.1420",{"id":24,"text":7392,"url":24,"identifiers":7393},"Franzen, O.  et al. Improved OTU-picking using long-read 16S rRNA gene amplicon sequencing and generic hierarchical clustering. Microbiome 3, 43 (2015).",{"doi":7394},"10.1186\u002Fs40168-015-0105-6",{"id":24,"text":7396,"url":24,"identifiers":7397},"Wei, Z. G. & Zhang, S. W. MtHc: a motif-based hierarchical method for clustering massive 16S rRNA sequences into OTUs. Mol. bioSystems 11, 1907–1913 (2015).",{"doi":7398},"10.1039\u002FC5MB00089K",{"id":24,"text":7400,"url":24,"identifiers":7401},"Mysara, M., Saeys, Y., Leys, N., Raes, J. & Monsieurs, P. CATCh, an ensemble classifier for chimera detection in 16S rRNA sequencing studies. Appl. Environ. Microbiol. 81, 1573–1584 (2015).",{"doi":7402},"10.1128\u002FAEM.02896-14",{"id":24,"text":7404,"url":24,"identifiers":7405},"Soergel, D. A., Dey, N., Knight, R. & Brenner, S. E. Selection of primers for optimal taxonomic classification of environmental 16S rRNA gene sequences. ISME J. 6, 1440–1444 (2012).",{"doi":7406},"10.1038\u002Fismej.2011.208",{"id":24,"text":7408,"url":24,"identifiers":7409},"Chaudhary, N., Sharma, A. K., Agarwal, P., Gupta, A. & Sharma, V. K. 16S classifier: a tool for fast and accurate taxonomic classification of 16S rRNA hypervariable regions in metagenomic datasets. PLoS ONE 10, e0116106 (2015).",{"doi":7410},"10.1371\u002Fjournal.pone.0116106",{"id":24,"text":7412,"url":24,"identifiers":7413},"Stoddard, S. F., Smith, B. J., Hein, R., Roller, B. R. & Schmidt, T. M. rrnDB: improved tools for interpreting rRNA gene abundance in bacteria and archaea and a new foundation for future development. Nucleic Acids Res. 43, D593–D598 (2015).",{"doi":7414},"10.1093\u002Fnar\u002Fgku1201",{"id":24,"text":7416,"url":24,"identifiers":7417},"Jaziri, F.  et al. PhylOPDb: a 16S rRNA oligonucleotide probe database for prokaryotic identification. Database (Oxford) \n                    http:\u002F\u002Fdx.doi.org\u002F10.1093\u002Fdatabase\u002Fbau036\n                    \n                   (2014).",{"doi":7418},"10.1093\u002Fdatabase\u002Fbau036",{"id":24,"text":7420,"url":24,"identifiers":7421},"Ritari, J., Salojarvi, J., Lahti, L. & de Vos, W. M. Improved taxonomic assignment of human intestinal 16S rRNA sequences by a dedicated reference database. BMC Genom. 16, 1056 (2015).",{"doi":7422},"10.1186\u002Fs12864-015-2265-y",{"id":24,"text":7424,"url":24,"identifiers":7425},"Lozupone, C., Hamady, M. & Knight, R. UniFrac—an online tool for comparing microbial community diversity in a phylogenetic context. BMC Bioinformat. 7, 371 (2006).",{"doi":7426},"10.1186\u002F1471-2105-7-371",{"id":24,"text":7428,"url":24,"identifiers":7429},"Gilmore, R. D., Cieplak, W., Policastro, P. F. & Hackstadt, T. The 120 kilodalton outer membrane (rOmpB) of Rickettsia rickettsii is encoded by an unusually long open reading frame: evidence for protein processing from a large precursor. Mol. Microbiol. 5, 2361–2370 (1991).",{"doi":7430},"10.1111\u002Fj.1365-2958.1991.tb02082.x",{"id":24,"text":7432,"url":24,"identifiers":7433},"Paulson, J. N., Stine, O. C., Bravo, H. C. & Pop, M. Differential abundance analysis for microbial marker-gene surveys. Nature Methods 10, 1200–1202 (2013).",{"doi":7434},"10.1038\u002Fnmeth.2658",{"id":24,"text":7436,"url":24,"identifiers":7437},"Angly, F. E.  et al. CopyRighter: a rapid tool for improving the accuracy of microbial community profiles through lineage-specific gene copy number correction. Microbiome 2, 11 (2014).",{"doi":7438},"10.1186\u002F2049-2618-2-11",{"id":24,"text":7440,"url":24,"identifiers":7441},"Beck, D., Settles, M. & Foster, J. A. OTUbase: an R infrastructure package for operational taxonomic unit data. Bioinformatics 27, 1700–1701 (2011).",{"doi":7442},"10.1093\u002Fbioinformatics\u002Fbtr196",{"id":24,"text":7444,"url":24,"identifiers":7445},"Seguritan, V. & Rohwer, F. FastGroup: a program to dereplicate libraries of 16S rDNA sequences. BMC Bioinformat. 2, 9 (2001).",{"doi":7446},"10.1186\u002F1471-2105-2-9",{"id":24,"text":7448,"url":24,"identifiers":7449},"Giongo, A.  et al. PANGEA: pipeline for analysis of next generation amplicons. ISME J. 4, 852–861 (2010).",{"doi":7450},"10.1038\u002Fismej.2010.16",{"id":24,"text":7452,"url":24,"identifiers":7453},"Kumar, S.  et al. CLOTU: an online pipeline for processing and clustering of 454 amplicon reads into OTUs followed by taxonomic annotation. BMC Bioinformat. 12, 182 (2011).",{"doi":7454},"10.1186\u002F1471-2105-12-182",{"id":24,"text":7456,"url":24,"identifiers":7457},"Nebel, M. E.  et al. JAGUC—a software package for environmental diversity analyses. J. Bioinformat. Computat. Biol. 9, 749–773 (2011).",{"doi":7458},"10.1142\u002FS0219720011005781",{"id":24,"text":7460,"url":24,"identifiers":7461},"Albanese, D., Fontana, P., De Filippo, C., Cavalieri, D. & Donati, C. MICCA: a complete and accurate software for taxonomic profiling of metagenomic data. Scientif. Rep. 5, 9743 (2015).",{"doi":7462},"10.1038\u002Fsrep09743",{"id":24,"text":7464,"url":24,"identifiers":7465},"Weisman, D., Yasuda, M. & Bowen, J. L. FunFrame: functional gene ecological analysis pipeline. Bioinformatics 29, 1212–1214 (2013).",{"doi":7466},"10.1093\u002Fbioinformatics\u002Fbtt123",{"id":7468,"createTime":7469,"updateTime":7469,"relativeEntities":7470,"slug":7471,"properties":7472,"entityType":184,"verifyStatus":185,"verifyTime":7484,"verifyNote":186,"syncStatus":23,"languages":7485,"translateLanguages":24,"viewCount":25,"primaryUrl":7486,"fullTextUrl":24,"authors":7487,"publicationType":310,"publisherRelationship":7544,"citationCount":7580,"citationInfo":7581,"publishDate":7589,"publishYear":6630,"citationAnalyzeStatus":23,"lastCitationAnalyze":24,"indexDatabases":24,"openAccess":24,"references":7590,"isForceReanalyzing":595},"dea7d314-45c5-4cd7-9f02-8d5411fcd36d","2024-11-26T22:01:40.192+00:00",[],"NAFLD-and-diabetes-mellitus",{"mag":7473,"keywords":7475,"openalex":7476,"abstract":7478,"title":7479,"pm":7481,"doi":7483},{"VOID":7474},"2531626219",{},{"VOID":7477},"W2531626219",{},{"EN":7480},"NAFLD and diabetes mellitus",{"VOID":7482},"27729660",{"VOID":3472},"2024-11-26T22:01:40.191+00:00",[188],"https:\u002F\u002Fwww.nature.com\u002Farticles\u002Fnrgastro.2016.147",[7488,7506,7523],{"id":7489,"sortIndex":25,"researcher":24,"roles":7490,"affiliations":7491,"properties":7502},"94d00ef2-6217-43c2-9080-531d198aefa9",[],[7492],{"id":7493,"sortIndex":25,"affiliation":7494,"properties":24},"1c63ff3c-176e-443a-add4-1511a1b31de4",{"id":7495,"createTime":7496,"updateTime":7496,"relativeEntities":7497,"slug":7498,"properties":7499,"entityType":53,"verifyStatus":23,"verifyTime":24,"verifyNote":24,"syncStatus":23,"languages":24,"translateLanguages":24,"viewCount":25},"2ddffc93-e406-4561-ad55-7d4c7a823a38","2024-11-26T22:01:40.267+00:00",[],"Department-of-Internal-Medicine-I-Gastroenterology-Endocrinology-Metabolism-Medical-University-Innsbruck-Anichstrasse-35-Innsbruck-6020-Austria",{"title":7500},{"EN":7501},"Department of Internal Medicine I, Gastroenterology, Endocrinology & Metabolism, Medical University Innsbruck, Anichstrasse 35, Innsbruck, 6020, Austria",{"openalex":7503,"orcid":7504,"title":7505},{"VOID":3368},{"VOID":3370},{"EN":3372},{"id":7507,"sortIndex":215,"researcher":24,"roles":7508,"affiliations":7509,"properties":7516},"1dcd3bcb-a0c8-4387-802a-c76e37f68477",[],[7510],{"id":7511,"sortIndex":25,"affiliation":7512,"properties":24},"245739e1-de65-48cc-8c60-c170e03f5be9",{"id":7495,"createTime":7496,"updateTime":7496,"relativeEntities":7513,"slug":7498,"properties":7514,"entityType":53,"verifyStatus":23,"verifyTime":24,"verifyNote":24,"syncStatus":23,"languages":24,"translateLanguages":24,"viewCount":25},[],{"title":7515},{"EN":7501},{"openalex":7517,"orcid":7519,"title":7521},{"VOID":7518},"A5043344995",{"VOID":7520},"https:\u002F\u002Forcid.org\u002F0000-0003-3598-7848",{"EN":7522},"Alexander R. Moschen",{"id":7524,"sortIndex":126,"researcher":24,"roles":7525,"affiliations":7526,"properties":7537},"aeb67898-6298-431f-bb19-b37efa52beb5",[],[7527],{"id":7528,"sortIndex":25,"affiliation":7529,"properties":24},"5483a1fd-7f25-4b9e-badc-895a47479954",{"id":7530,"createTime":7531,"updateTime":7531,"relativeEntities":7532,"slug":7533,"properties":7534,"entityType":53,"verifyStatus":23,"verifyTime":24,"verifyNote":24,"syncStatus":23,"languages":24,"translateLanguages":24,"viewCount":25},"c2c1c5df-f6fe-4015-9936-7f5a5445a7f7","2024-11-26T22:01:40.316+00:00",[],"Department-of-Endocrinology-and-Diabetology-Medical-Faculty-Heinrich-Heine-University-c-o-Auf-m-Hennekamp-65-D%C3%BCsseldorf-40225-Germany",{"title":7535},{"EN":7536},"Department of Endocrinology and Diabetology, Medical Faculty, Heinrich-Heine University, c\u002Fo Auf'm Hennekamp 65, Düsseldorf, 40225, Germany",{"openalex":7538,"orcid":7540,"title":7542},{"VOID":7539},"A5022032933",{"VOID":7541},"https:\u002F\u002Forcid.org\u002F0000-0001-8200-6382",{"EN":7543},"Michael Roden",{"url":24,"publisher":7545,"properties":7575},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":7546,"slug":10,"properties":7547,"entityType":22,"verifyStatus":23,"verifyTime":24,"verifyNote":24,"syncStatus":23,"languages":24,"translateLanguages":24,"viewCount":25,"subjectFields":7553,"manageAffiliations":7554,"indexDatabases":7555,"url":106,"thumbnailPath":24,"statistic":7570,"gsStatistic":24,"type":24,"analyzePriority":24},[],{"country":7548,"issn":7549,"introduce":7550,"eissn":7551,"title":7552},{"VOID":13},{"VOID":15},{"EN":17},{"VOID":19},{"EN":21},[],[],[7556,7563],{"id":88,"indexDatabase":7557,"url":103,"indexYears":24,"academicFieldIds":7562,"indexDatabaseRanking":24},{"id":90,"createTime":91,"updateTime":92,"relativeEntities":7558,"label":7559,"description":7560,"key":99,"publicationTags":7561,"standard":24},[],{"EN":95,"VI":95},{"VI":97,"EN":98},[101,102],[105],{"id":68,"indexDatabase":7564,"url":81,"indexYears":82,"academicFieldIds":7569,"indexDatabaseRanking":86},{"id":70,"createTime":71,"updateTime":72,"relativeEntities":7565,"label":7566,"description":7567,"key":78,"publicationTags":7568,"standard":24},[],{"EN":75,"VI":75},{"EN":75,"VI":77},[80],[84,85],{"impactFactor":25,"impactFactorByYear":7571,"i10Index":121,"i10IndexLast5Year":122,"totalPublication":121,"totalPublicationByYear":7572,"totalCitation":129,"totalCitationByYear":7573,"totalCitationPerPublication":145,"totalCitationPerPublicationByYear":7574,"hindexLast5Year":161,"hindex":161},{"2012":109,"2013":110,"2014":111,"2015":112,"2016":113,"2017":114,"2018":115,"2019":116,"2020":117,"2021":118,"2022":119,"2023":120},{"2009":124,"2010":124,"2011":125,"2012":126,"2013":127,"2014":124,"2015":125,"2016":127,"2017":128,"2018":127,"2019":127,"2020":126,"2021":125,"2022":126},{"2009":131,"2010":132,"2011":133,"2012":134,"2013":135,"2014":136,"2015":137,"2016":138,"2017":139,"2018":140,"2019":141,"2020":142,"2021":143,"2022":144},{"2009":147,"2010":148,"2011":149,"2012":150,"2013":151,"2014":152,"2015":153,"2016":154,"2017":155,"2018":156,"2019":157,"2020":158,"2021":159,"2022":160},{"volume":7576,"pages":7577,"issue":7579},{"VOID":6622},{"VOID":7578},"32-42",{"VOID":348},801,{"total":7580,"publishYear":24,"statisticByYear":7582},{"2016":126,"2017":355,"2018":7583,"2019":7584,"2020":7585,"2021":7586,"2022":7587,"2023":7588,"2024":7584},67,75,111,153,141,131,"2017-01-01",[7591,7595,7599,7603,7607,7611,7615,7618,7621,7625,7629,7631,7634,7637,7639,7643,7647,7651,7655,7659,7663,7667,7671,7675,7679,7683,7687,7691,7695,7699,7703,7707,7711,7715,7719,7723,7727,7731,7735,7739,7743,7747,7751,7755,7759,7763,7767,7771,7775,7779,7783,7787,7791,7795,7799,7803,7807,7811,7815,7818,7821,7825,7829,7833,7837,7841,7845,7849,7853,7857,7861,7865,7869,7873,7877,7881,7884,7887,7890,7894,7898,7902,7905,7909,7913,7915,7919,7923,7927,7931,7935,7939,7943,7947,7951,7955,7959,7963,7966,7970,7974,7978,7982,7986,7990,7994,7998,8002,8006,8010,8013,8017,8021,8025,8029,8033,8036,8040,8044,8048,8052,8056,8060,8064,8068,8072,8076,8080,8084,8088,8092,8096,8100,8104,8108,8112,8116,8120,8123,8127,8131,8135,8139,8143,8147,8151,8154,8158,8162,8166],{"id":24,"text":7592,"url":24,"identifiers":7593},"Ratziu, V., Goodman, Z. & Sanyal, A. Current efforts and trends in the treatment of NASH. J. Hepatol. 62, S65–75 (2015).",{"doi":7594},"10.1016\u002Fj.jhep.2015.02.041",{"id":24,"text":7596,"url":24,"identifiers":7597},"Ahmed, A., Wong, R. J. & Harrison, S. A. Nonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and Outcomes. Clin. Gastroenterol. Hepatol. 13, 2062–2070 (2015).",{"doi":7598},"10.1016\u002Fj.cgh.2015.07.029",{"id":24,"text":7600,"url":24,"identifiers":7601},"Castera, L., Vilgrain, V. & Angulo, P. Noninvasive evaluation of NAFLD. Nat. Rev. Gastroenterol. Hepatol. 10, 666–675 (2013).",{"doi":7602},"10.1038\u002Fnrgastro.2013.175",{"id":24,"text":7604,"url":24,"identifiers":7605},"Hyysalo, J.  et al. A population-based study on the prevalence of NASH using scores validated against liver histology. J. Hepatol. 60, 839–846 (2014).",{"doi":7606},"10.1016\u002Fj.jhep.2013.12.009",{"id":24,"text":7608,"url":24,"identifiers":7609},"Yeh, M. M. & Brunt, E. M. Pathological features of fatty liver disease. Gastroenterology 147, 754–764 (2014).",{"doi":7610},"10.1053\u002Fj.gastro.2014.07.056",{"id":24,"text":7612,"url":24,"identifiers":7613},"Wree, A., Broderick, L., Canbay, A., Hoffman, H. M. & Feldstein, A. E. From NAFLD to NASH to cirrhosis-new insights into disease mechanisms. Nat. Rev. Gastroenterol. Hepatol. 10, 627–636 (2013).",{"doi":7614},"10.1038\u002Fnrgastro.2013.149",{"id":24,"text":7616,"url":24,"identifiers":7617},"Sanyal, A. J.  et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med. 362, 1675–1685 (2010).",{"doi":4077},{"id":24,"text":7619,"url":24,"identifiers":7620},"Armstrong, M. J.  et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 387, 679–690 (2016).",{"doi":4085},{"id":24,"text":7622,"url":24,"identifiers":7623},"Marchesini, G.  et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am. J. Med. 107, 450–455 (1999).",{"doi":7624},"10.1016\u002FS0002-9343(99)00271-5",{"id":24,"text":7626,"url":24,"identifiers":7627},"Haas, J. T., Francque, S. & Staels, B. Pathophysiology and mechanisms of nonalcoholic fatty liver disease. Annu. Rev. Physiol. 78, 181–205 (2016).",{"doi":7628},"10.1146\u002Fannurev-physiol-021115-105331",{"id":24,"text":3837,"url":24,"identifiers":7630},{"doi":3839},{"id":24,"text":7632,"url":24,"identifiers":7633},"Williams, C. D.  et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 140, 124–131 (2011).",{"doi":3134},{"id":24,"text":7635,"url":24,"identifiers":7636},"Loomba, R.  et al. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology 56, 943–951 (2012).",{"doi":3138},{"id":24,"text":3216,"url":24,"identifiers":7638},{"doi":3218},{"id":24,"text":7640,"url":24,"identifiers":7641},"Kwok, R.  et al. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. Gut 65, 1359–1368 (2015).",{"doi":7642},"10.1136\u002Fgutjnl-2015-309265",{"id":24,"text":7644,"url":24,"identifiers":7645},"Koehler, E. M.  et al. Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: the Rotterdam study. Hepatology 63, 138–147 (2016).",{"doi":7646},"10.1002\u002Fhep.27981",{"id":24,"text":7648,"url":24,"identifiers":7649},"Collaboration, N. C. D. R. F. Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet 387, 1513–1530 (2016).",{"doi":7650},"10.1016\u002FS0140-6736(16)00618-8",{"id":24,"text":7652,"url":24,"identifiers":7653},"Yki-Jarvinen, H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol. 2, 901–910 (2014).",{"doi":7654},"10.1016\u002FS2213-8587(14)70032-4",{"id":24,"text":7656,"url":24,"identifiers":7657},"Anstee, Q. M., Targher, G. & Day, C. P. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat. Rev. Gastroenterol. Hepatol. 10, 330–344 (2013).",{"doi":7658},"10.1038\u002Fnrgastro.2013.41",{"id":24,"text":7660,"url":24,"identifiers":7661},"Lonardo, A., Ballestri, S., Marchesini, G., Angulo, P. & Loria, P. Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. Dig. Liver Dis. 47, 181–190 (2015).",{"doi":7662},"10.1016\u002Fj.dld.2014.09.020",{"id":24,"text":7664,"url":24,"identifiers":7665},"Roden, M. Mechanisms of disease: hepatic steatosis in type 2 diabetes—pathogenesis and clinical relevance. Nat. Clin. Pract. Endocrinol. Metab. 2, 335–348 (2006).",{"doi":7666},"10.1038\u002Fncpendmet0190",{"id":24,"text":7668,"url":24,"identifiers":7669},"Kotronen, A., Westerbacka, J., Bergholm, R., Pietilainen, K. H. & Yki-Jarvinen, H. Liver fat in the metabolic syndrome. J. Clin. Endocrinol. Metab. 92, 3490–3497 (2007).",{"doi":7670},"10.1210\u002Fjc.2007-0482",{"id":24,"text":7672,"url":24,"identifiers":7673},"Gaggini, M.  et al. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients 5, 1544–1560 (2013).",{"doi":7674},"10.3390\u002Fnu5051544",{"id":24,"text":7676,"url":24,"identifiers":7677},"McPherson, S.  et al. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J. Hepatol. 62, 1148–1155 (2015).",{"doi":7678},"10.1016\u002Fj.jhep.2014.11.034",{"id":24,"text":7680,"url":24,"identifiers":7681},"Krssak, M.  et al. Alterations in postprandial hepatic glycogen metabolism in type 2 diabetes. Diabetes 53, 3048–3056 (2004).",{"doi":7682},"10.2337\u002Fdiabetes.53.12.3048",{"id":24,"text":7684,"url":24,"identifiers":7685},"Lomonaco, R.  et al. Metabolic impact of nonalcoholic steatohepatitis in obese patients with type 2 diabetes. Diabetes Care 39, 632–638 (2016).",{"doi":7686},"10.2337\u002Fdc15-1876",{"id":24,"text":7688,"url":24,"identifiers":7689},"Marchesini, G.  et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50, 1844–1850 (2001).",{"doi":7690},"10.2337\u002Fdiabetes.50.8.1844",{"id":24,"text":7692,"url":24,"identifiers":7693},"Utzschneider, K. M.  et al. Insulin resistance is the best predictor of the metabolic syndrome in subjects with a first-degree relative with type 2 diabetes. Obesity (Silver Spring) 18, 1781–1787 (2010).",{"doi":7694},"10.1038\u002Foby.2010.77",{"id":24,"text":7696,"url":24,"identifiers":7697},"Iozzo, P.  et al. Defective liver disposal of free fatty acids in patients with impaired glucose tolerance. J. Clin. Endocrinol. Metab. 89, 3496–3502 (2004).",{"doi":7698},"10.1210\u002Fjc.2003-031142",{"id":24,"text":7700,"url":24,"identifiers":7701},"Nielsen, S., Guo, Z., Johnson, C. M., Hensrud, D. D. & Jensen, M. D. Splanchnic lipolysis in human obesity. J. Clin. Invest. 113, 1582–1588 (2004).",{"doi":7702},"10.1172\u002FJCI21047",{"id":24,"text":7704,"url":24,"identifiers":7705},"Donnelly, K. L.  et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Invest. 115, 1343–1351 (2005).",{"doi":7706},"10.1172\u002FJCI23621",{"id":24,"text":7708,"url":24,"identifiers":7709},"Sanyal, A. J.  et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 120, 1183–1192 (2001).",{"doi":7710},"10.1053\u002Fgast.2001.23256",{"id":24,"text":7712,"url":24,"identifiers":7713},"Lomonaco, R.  et al. Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease. Hepatology 55, 1389–1397 (2012).",{"doi":7714},"10.1002\u002Fhep.25539",{"id":24,"text":7716,"url":24,"identifiers":7717},"Fabbrini, E.  et al. Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Gastroenterology 134, 424–431 (2008).",{"doi":7718},"10.1053\u002Fj.gastro.2007.11.038",{"id":24,"text":7720,"url":24,"identifiers":7721},"Lambert, J. E., Ramos-Roman, M. A., Browning, J. D. & Parks, E. J. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology 146, 726–735 (2014).",{"doi":7722},"10.1053\u002Fj.gastro.2013.11.049",{"id":24,"text":7724,"url":24,"identifiers":7725},"Petersen, K. F.  et al. The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proc. Natl. Acad. Sci. USA 104, 12587–12594 (2007).",{"doi":7726},"10.1073\u002Fpnas.0705408104",{"id":24,"text":7728,"url":24,"identifiers":7729},"Roden, M.  et al. Effects of free fatty acid elevation on postabsorptive endogenous glucose production and gluconeogenesis in humans. Diabetes 49, 701–707 (2000).",{"doi":7730},"10.2337\u002Fdiabetes.49.5.701",{"id":24,"text":7732,"url":24,"identifiers":7733},"Shulman, G. I. Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. N. Engl. J. Med. 371, 2237–2238 (2014).",{"doi":7734},"10.1056\u002FNEJMra1011035",{"id":24,"text":7736,"url":24,"identifiers":7737},"Szendroedi, J.  et al. Role of diacylglycerol activation of PKCθ in lipid-induced muscle insulin resistance in humans. Proc. Natl. Acad. Sci. USA 111, 9597–9602 (2014).",{"doi":7738},"10.1073\u002Fpnas.1409229111",{"id":24,"text":7740,"url":24,"identifiers":7741},"Samuel, V. T.  et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J. Biol. Chem. 279, 32345–32353 (2004).",{"doi":7742},"10.1074\u002Fjbc.M313478200",{"id":24,"text":7744,"url":24,"identifiers":7745},"Kumashiro, N.  et al. Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. Proc. Natl. Acad. Sci. USA 108, 16381–16385 (2011).",{"doi":7746},"10.1073\u002Fpnas.1113359108",{"id":24,"text":7748,"url":24,"identifiers":7749},"Magkos, F.  et al. Intrahepatic diacylglycerol content is associated with hepatic insulin resistance in obese subjects. Gastroenterology 142, 1444–1446.e2 (2012).",{"doi":7750},"10.1053\u002Fj.gastro.2012.03.003",{"id":24,"text":7752,"url":24,"identifiers":7753},"Unger, R. H. Lipid overload and overflow: metabolic trauma and the metabolic syndrome. Trends Endocrinol. Metab. 14, 398–403 (2003).",{"doi":7754},"10.1016\u002Fj.tem.2003.09.008",{"id":24,"text":7756,"url":24,"identifiers":7757},"Szendroedi, J.  et al. Lower fasting muscle mitochondrial activity relates to hepatic steatosis in humans. Diabetes Care 37, 468–474 (2014).",{"doi":7758},"10.2337\u002Fdc13-1359",{"id":24,"text":7760,"url":24,"identifiers":7761},"Szendroedi, J.  et al. Abnormal hepatic energy homeostasis in type 2 diabetes. Hepatology 50, 1079–1086 (2009).",{"doi":7762},"10.1002\u002Fhep.23093",{"id":24,"text":7764,"url":24,"identifiers":7765},"Schmid, A. I.  et al. Liver ATP synthesis is lower and relates to insulin sensitivity in patients with type 2 diabetes. Diabetes Care 34, 448–453 (2011).",{"doi":7766},"10.2337\u002Fdc10-1076",{"id":24,"text":7768,"url":24,"identifiers":7769},"Schmid, A. I.  et al. Quantitative ATP synthesis in human liver measured by localized 31P spectroscopy using the magnetization transfer experiment. NMR Biomed. 21, 437–443 (2008).",{"doi":7770},"10.1002\u002Fnbm.1207",{"id":24,"text":7772,"url":24,"identifiers":7773},"Koliaki, C.  et al. Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis. Cell Metab. 21, 739–746 (2015).",{"doi":7774},"10.1016\u002Fj.cmet.2015.04.004",{"id":24,"text":7776,"url":24,"identifiers":7777},"Fritsch, M.  et al. Time course of postprandial hepatic phosphorus metabolites in lean, obese, and type 2 diabetes patients. Am. J. Clin. Nutr. 102, 1051–1058 (2015).",{"doi":7778},"10.3945\u002Fajcn.115.107599",{"id":24,"text":7780,"url":24,"identifiers":7781},"Cortez-Pinto, H.  et al. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. JAMA 282, 1659–1664 (1999).",{"doi":7782},"10.1001\u002Fjama.282.17.1659",{"id":24,"text":7784,"url":24,"identifiers":7785},"Satapati, S.  et al. Mitochondrial metabolism mediates oxidative stress and inflammation in fatty liver. J. Clin. Invest. 125, 4447–4462 (2015).",{"doi":7786},"10.1172\u002FJCI82204",{"id":24,"text":7788,"url":24,"identifiers":7789},"Perez-Carreras, M.  et al. Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology 38, 999–1007 (2003).",{"doi":7790},"10.1002\u002Fhep.1840380426",{"id":24,"text":7792,"url":24,"identifiers":7793},"Serviddio, G.  et al. Uncoupling protein-2 (UCP2) induces mitochondrial proton leak and increases susceptibility of non-alcoholic steatohepatitis (NASH) liver to ischaemia-reperfusion injury. Gut 57, 957–965 (2008).",{"doi":7794},"10.1136\u002Fgut.2007.147496",{"id":24,"text":7796,"url":24,"identifiers":7797},"Morris, E. M., Rector, R. S., Thyfault, J. P. & Ibdah, J. A. Mitochondria and redox signaling in steatohepatitis. Antioxid. Redox Signal. 15, 485–504 (2011).",{"doi":7798},"10.1089\u002Fars.2010.3795",{"id":24,"text":7800,"url":24,"identifiers":7801},"Romestaing, C.  et al. Mitochondrial adaptations to steatohepatitis induced by a methionine- and choline-deficient diet. Am. J. Physiol. Endocrinol. Metab. 294, E110–E119 (2008).",{"doi":7802},"10.1152\u002Fajpendo.00407.2007",{"id":24,"text":7804,"url":24,"identifiers":7805},"Titchenell, P. M., Chu, Q., Monks, B. R. & Birnbaum, M. J. Hepatic insulin signalling is dispensable for suppression of glucose output by insulin in vivo. Nat. Commun. 6, 7078 (2015).",{"doi":7806},"10.1038\u002Fncomms8078",{"id":24,"text":7808,"url":24,"identifiers":7809},"Haeusler, R. A.  et al. Integrated control of hepatic lipogenesis versus glucose production requires FoxO transcription factors. Nat. Commun. 5, 5190 (2014).",{"doi":7810},"10.1038\u002Fncomms6190",{"id":24,"text":7812,"url":24,"identifiers":7813},"Lu, M.  et al. Insulin regulates liver metabolism in vivo in the absence of hepatic Akt and Foxo1. Nat. Med. 18, 388–395 (2012).",{"doi":7814},"10.1038\u002Fnm.2686",{"id":24,"text":7816,"url":24,"identifiers":7817},"Perry, R. J.  et al. Hepatic acetyl CoA links adipose tissue inflammation to hepatic insulin resistance and type 2 diabetes. Cell 160, 745–758 (2015).",{"doi":4415},{"id":24,"text":7819,"url":24,"identifiers":7820},"Romeo, S.  et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 40, 1461–1465 (2008).",{"doi":3240},{"id":24,"text":7822,"url":24,"identifiers":7823},"He, S.  et al. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J. Biol. Chem. 285, 6706–6715 (2010).",{"doi":7824},"10.1074\u002Fjbc.M109.064501",{"id":24,"text":7826,"url":24,"identifiers":7827},"Donati, B.  et al. The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage. Hepatology 63, 787–798 (2016).",{"doi":7828},"10.1002\u002Fhep.28370",{"id":24,"text":7830,"url":24,"identifiers":7831},"Kozlitina, J.  et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 46, 352–356 (2014).",{"doi":7832},"10.1038\u002Fng.2901",{"id":24,"text":7834,"url":24,"identifiers":7835},"Zhou, Y.  et al. Circulating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E167K variant in TM6SF2. J. Hepatol. 62, 657–663 (2015).",{"doi":7836},"10.1016\u002Fj.jhep.2014.10.010",{"id":24,"text":7838,"url":24,"identifiers":7839},"Lee, H. Y.  et al. Apolipoprotein CIII overexpressing mice are predisposed to diet-induced hepatic steatosis and hepatic insulin resistance. Hepatology 54, 1650–1660 (2011).",{"doi":7840},"10.1002\u002Fhep.24571",{"id":24,"text":7842,"url":24,"identifiers":7843},"Amaro, A.  et al. Dissociation between intrahepatic triglyceride content and insulin resistance in familial hypobetalipoproteinemia. Gastroenterology 139, 149–153 (2010).",{"doi":7844},"10.1053\u002Fj.gastro.2010.03.039",{"id":24,"text":7846,"url":24,"identifiers":7847},"Tilg, H. & Moschen, A. R. Inflammatory mechanisms in the regulation of insulin resistance. Mol. Med. 14, 222–231 (2008).",{"doi":7848},"10.2119\u002F2007-00119.Tilg",{"id":24,"text":7850,"url":24,"identifiers":7851},"Johnson, A. M. & Olefsky, J. M. The origins and drivers of insulin resistance. Cell 152, 673–684 (2013).",{"doi":7852},"10.1016\u002Fj.cell.2013.01.041",{"id":24,"text":7854,"url":24,"identifiers":7855},"Moller, D. E. & Kaufman, K. D. Metabolic syndrome: a clinical and molecular perspective. Annu. Rev. Med. 56, 45–62 (2005).",{"doi":7856},"10.1146\u002Fannurev.med.56.082103.104751",{"id":24,"text":7858,"url":24,"identifiers":7859},"Morris, E. M., Rector, R. S., Thyfault, J. P. & Ibdah, J. A. Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha. J. Clin Invest. 94, 1543–1549 (1994).",{"doi":7860},"10.1172\u002FJCI117423",{"id":24,"text":7862,"url":24,"identifiers":7863},"Samuel, V. T. & Shulman, G. I. Mechanisms for insulin resistance: common threads and missing links. Cell 148, 852–871 (2012).",{"doi":7864},"10.1016\u002Fj.cell.2012.02.017",{"id":24,"text":7866,"url":24,"identifiers":7867},"Wieser, V., Moschen, A. R. & Tilg, H. Inflammation, cytokines and insulin resistance: a clinical perspective. Arch. Immunol. Ther. Exp. (Warsz) 61, 119–125 (2013).",{"doi":7868},"10.1007\u002Fs00005-012-0210-1",{"id":24,"text":7870,"url":24,"identifiers":7871},"Tilg, H. & Diehl, A. M. Cytokines in alcoholic and nonalcoholic steatohepatitis. N. Engl. J. Med. 343, 1467–1476 (2000).",{"doi":7872},"10.1056\u002FNEJM200011163432007",{"id":24,"text":7874,"url":24,"identifiers":7875},"Le, K. A.  et al. Subcutaneous adipose tissue macrophage infiltration is associated with hepatic and visceral fat deposition, hyperinsulinemia, and stimulation of NF-κB stress pathway. Diabetes 60, 2802–2809 (2011).",{"doi":7876},"10.2337\u002Fdb10-1263",{"id":24,"text":7878,"url":24,"identifiers":7879},"Yuan, M.  et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkβ. Science 293, 1673–1677 (2001).",{"doi":7880},"10.1126\u002Fscience.1061620",{"id":24,"text":7882,"url":24,"identifiers":7883},"Cai, D.  et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB. Nat. Med. 11, 183–190 (2005).",{"doi":3784},{"id":24,"text":7885,"url":24,"identifiers":7886},"Arkan, M. C.  et al. IKK-β links inflammation to obesity-induced insulin resistance. Nat. Med. 11, 191–198 (2005).",{"doi":3788},{"id":24,"text":7888,"url":24,"identifiers":7889},"Kiechl, S.  et al. Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus. Nat. Med. 19, 358–363 (2013).",{"doi":3792},{"id":24,"text":7891,"url":24,"identifiers":7892},"Kong, Y. Y.  et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402, 304–309 (1999).",{"doi":7893},"10.1038\u002F46303",{"id":24,"text":7895,"url":24,"identifiers":7896},"Goto, H.  et al. Primary human bone marrow adipocytes support TNF-α-induced osteoclast differentiation and function through RANKL expression. Cytokine 56, 662–668 (2011).",{"doi":7897},"10.1016\u002Fj.cyto.2011.09.005",{"id":24,"text":7899,"url":24,"identifiers":7900},"Lee, N. K.  et al. Endocrine regulation of energy metabolism by the skeleton. Cell 130, 456–469 (2007).",{"doi":7901},"10.1016\u002Fj.cell.2007.05.047",{"id":24,"text":7903,"url":24,"identifiers":7904},"Moschen, A. R.  et al. Anti-inflammatory effects of excessive weight loss: potent suppression of adipose interleukin 6 and tumour necrosis factor α expression. Gut 59, 1259–1264 (2010).",{"doi":3799},{"id":24,"text":7906,"url":24,"identifiers":7907},"Moschen, A. R.  et al. Adipose and liver expression of interleukin (IL)-1 family members in morbid obesity and effects of weight loss. Mol. Med. 17, 840–845 (2011).",{"doi":7908},"10.2119\u002Fmolmed.2010.00108",{"id":24,"text":7910,"url":24,"identifiers":7911},"Cao, H.  et al. Adipocyte lipid chaperone AP2 is a secreted adipokine regulating hepatic glucose production. Cell Metab. 17, 768–778 (2013).",{"doi":7912},"10.1016\u002Fj.cmet.2013.04.012",{"id":24,"text":3758,"url":24,"identifiers":7914},{"doi":3760},{"id":24,"text":7916,"url":24,"identifiers":7917},"Mathis, D. Immunological goings-on in visceral adipose tissue. Cell Metab. 17, 851–859 (2013).",{"doi":7918},"10.1016\u002Fj.cmet.2013.05.008",{"id":24,"text":7920,"url":24,"identifiers":7921},"Okada-Iwabu, M.  et al. A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity. Nature 503, 493–499 (2013).",{"doi":7922},"10.1038\u002Fnature12656",{"id":24,"text":7924,"url":24,"identifiers":7925},"Angulo, P. Nonalcoholic fatty liver disease. N. Engl. J. Med. 346, 1221–1231 (2002).",{"doi":7926},"10.1056\u002FNEJMra011775",{"id":24,"text":7928,"url":24,"identifiers":7929},"Matthews, D. R.  et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412–419 (1985).",{"doi":7930},"10.1007\u002FBF00280883",{"id":24,"text":7932,"url":24,"identifiers":7933},"Lee, D. H.  et al. Gamma-glutamyltransferase and diabetes—a 4 year follow-up study. Diabetologia 46, 359–364 (2003).",{"doi":7934},"10.1007\u002Fs00125-003-1036-5",{"id":24,"text":7936,"url":24,"identifiers":7937},"Hanley, A. J.  et al. Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study. Diabetes 54, 3140–3147 (2005).",{"doi":7938},"10.2337\u002Fdiabetes.54.11.3140",{"id":24,"text":7940,"url":24,"identifiers":7941},"Goessling, W.  et al. Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease. Gastroenterology 135, 1935–1944.e1 (2008).",{"doi":7942},"10.1053\u002Fj.gastro.2008.09.018",{"id":24,"text":7944,"url":24,"identifiers":7945},"Fraser, A.  et al. Alanine aminotransferase, γ-glutamyltransferase, and incident diabetes: the British Women's Heart and Health Study and meta-analysis. Diabetes Care 32, 741–750 (2009).",{"doi":7946},"10.2337\u002Fdc08-1870",{"id":24,"text":7948,"url":24,"identifiers":7949},"Fracanzani, A. L.  et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology 48, 792–798 (2008).",{"doi":7950},"10.1002\u002Fhep.22429",{"id":24,"text":7952,"url":24,"identifiers":7953},"Armstrong, M. J., Adams, L. A., Canbay, A. & Syn, W. K. Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology 59, 1174–1197 (2014).",{"doi":7954},"10.1002\u002Fhep.26717",{"id":24,"text":7956,"url":24,"identifiers":7957},"Sung, K. C., Wild, S. H. & Byrne, C. D. Resolution of fatty liver and risk of incident diabetes. J. Clin. Endocrinol. Metab. 98, 3637–3643 (2013).",{"doi":7958},"10.1210\u002Fjc.2013-1519",{"id":24,"text":7960,"url":24,"identifiers":7961},"Pais, R.  et al. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J. Hepatol. 59, 550–556 (2013).",{"doi":7962},"10.1016\u002Fj.jhep.2013.04.027",{"id":24,"text":7964,"url":24,"identifiers":7965},"Ekstedt, M.  et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44, 865–873 (2006).",{"doi":3272},{"id":24,"text":7967,"url":24,"identifiers":7968},"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) & European Association for the Study of Obesity (EASO) EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 64, 1388–1402 (2016).",{"doi":7969},"10.1016\u002Fj.jhep.2015.11.004",{"id":24,"text":7971,"url":24,"identifiers":7972},"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) & European Association for the Study of Obesity (EASO) EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. Diabetologia 59, 1121–1240 (2016).",{"doi":7973},"10.1007\u002Fs00125-016-3902-y",{"id":24,"text":7975,"url":24,"identifiers":7976},"Portillo-Sanchez, P.  et al. High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels. J. Clin. Endocrinol. Metab. 100, 2231–2238 (2015).",{"doi":7977},"10.1210\u002Fjc.2015-1966",{"id":24,"text":7979,"url":24,"identifiers":7980},"Poonawala, A., Nair, S. P. & Thuluvath, P. J. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology 32, 689–692 (2000).",{"doi":7981},"10.1053\u002Fjhep.2000.17894",{"id":24,"text":7983,"url":24,"identifiers":7984},"Ghouri, N., Preiss, D. & Sattar, N. Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data. Hepatology 52, 1156–1161 (2010).",{"doi":7985},"10.1002\u002Fhep.23789",{"id":24,"text":7987,"url":24,"identifiers":7988},"Leite, N. C., Salles, G. F., Araujo, A. L., Villela-Nogueira, C. A. & Cardoso, C. R. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int. 29, 113–119 (2009).",{"doi":7989},"10.1111\u002Fj.1478-3231.2008.01718.x",{"id":24,"text":7991,"url":24,"identifiers":7992},"Doycheva, I.  et al. Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE. Aliment. Pharmacol. Ther. 43, 83–95 (2016).",{"doi":7993},"10.1111\u002Fapt.13405",{"id":24,"text":7995,"url":24,"identifiers":7996},"Abrams, G. A., Kunde, S. S., Lazenby, A. J. & Clements, R. H. Portal fibrosis and hepatic steatosis in morbidly obese subjects: a spectrum of nonalcoholic fatty liver disease. Hepatology 40, 475–483 (2004).",{"doi":7997},"10.1002\u002Fhep.20323",{"id":24,"text":7999,"url":24,"identifiers":8000},"Goh, G. B.  et al. Clinical spectrum of non-alcoholic fatty liver disease in diabetic and non-diabetic patients. BBA Clin. 3, 141–145 (2015).",{"doi":8001},"10.1016\u002Fj.bbacli.2014.09.001",{"id":24,"text":8003,"url":24,"identifiers":8004},"Bazick, J.  et al. Clinical model for NASH and advanced fibrosis in adult patients with diabetes and NAFLD: guidelines for referral in NAFLD. Diabetes Care 38, 1347–1355 (2015).",{"doi":8005},"10.2337\u002Fdc14-1239",{"id":24,"text":8007,"url":24,"identifiers":8008},"Morling, J. R.  et al. Using non-invasive biomarkers to identify hepatic fibrosis in people with type 2 diabetes mellitus: the Edinburgh type 2 diabetes study. J. Hepatol. 60, 384–391 (2014).",{"doi":8009},"10.1016\u002Fj.jhep.2013.10.017",{"id":24,"text":8011,"url":24,"identifiers":8012},"Angulo, P.  et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 149, 389–397.e10 (2015).",{"doi":3994},{"id":24,"text":8014,"url":24,"identifiers":8015},"Angulo, P., Keach, J. C., Batts, K. P. & Lindor, K. D. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 30, 1356–1362 (1999).",{"doi":8016},"10.1002\u002Fhep.510300604",{"id":24,"text":8018,"url":24,"identifiers":8019},"Hossain, N.  et al. Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 7, 1224–1229, 1229.e1–1229.e2 (2009).",{"doi":8020},"10.1016\u002Fj.cgh.2009.06.007",{"id":24,"text":8022,"url":24,"identifiers":8023},"Adams, L. A.  et al. Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study. Am. J. Gastroenterol. 105, 1567–1573 (2010).",{"doi":8024},"10.1038\u002Fajg.2010.18",{"id":24,"text":8026,"url":24,"identifiers":8027},"Targher, G.  et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 30, 1212–1218 (2007).",{"doi":8028},"10.2337\u002Fdc06-2247",{"id":24,"text":8030,"url":24,"identifiers":8031},"Targher, G.  et al. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative\u002Flaser-treated retinopathy in type 2 diabetic patients. Diabetologia 51, 444–450 (2008).",{"doi":8032},"10.1007\u002Fs00125-007-0897-4",{"id":24,"text":8034,"url":24,"identifiers":8035},"Byrne, C. D. & Targher, G. NAFLD: a multisystem disease. J. Hepatol. 62 (Suppl. 1), S47–S64 (2015).",{"doi":3480},{"id":24,"text":8037,"url":24,"identifiers":8038},"Marengo, A., Rosso, C. & Bugianesi, E. Liver cancer: connections with obesity, fatty liver, and cirrhosis. Annu. Rev. Med. 67, 103–117 (2016).",{"doi":8039},"10.1146\u002Fannurev-med-090514-013832",{"id":24,"text":8041,"url":24,"identifiers":8042},"Bugianesi, E.  et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 123, 134–140 (2002).",{"doi":8043},"10.1053\u002Fgast.2002.34168",{"id":24,"text":8045,"url":24,"identifiers":8046},"Oberaigner, W.  et al. Increased cancer incidence risk in type 2 diabetes mellitus: results from a cohort study in Tyrol\u002FAustria. BMC Public Health 14, 1058 (2014).",{"doi":8047},"10.1186\u002F1471-2458-14-1058",{"id":24,"text":8049,"url":24,"identifiers":8050},"Dyson, J.  et al. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. J. Hepatol. 60, 110–117 (2014).",{"doi":8051},"10.1016\u002Fj.jhep.2013.08.011",{"id":24,"text":8053,"url":24,"identifiers":8054},"Zheng, Z.  et al. Diabetes mellitus is associated with hepatocellular carcinoma: a retrospective case-control study in hepatitis endemic area. PLoS ONE 8, e84776 (2013).",{"doi":8055},"10.1371\u002Fjournal.pone.0084776",{"id":24,"text":8057,"url":24,"identifiers":8058},"Yasui, K.  et al. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin. Gastroenterol. Hepatol. 9, 428–433 (2011).",{"doi":8059},"10.1016\u002Fj.cgh.2011.01.023",{"id":24,"text":8061,"url":24,"identifiers":8062},"Welzel, T. M.  et al. Population-attributable fractions of risk factors for hepatocellular carcinoma in the United States. Am. J. Gastroenterol. 108, 1314–1321 (2013).",{"doi":8063},"10.1038\u002Fajg.2013.160",{"id":24,"text":8065,"url":24,"identifiers":8066},"Aleksandrova, K.  et al. Inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer. Hepatology 60, 858–871 (2014).",{"doi":8067},"10.1002\u002Fhep.27016",{"id":24,"text":8069,"url":24,"identifiers":8070},"Chiang, C. H.  et al. The relationship of diabetes and smoking status to hepatocellular carcinoma mortality. Medicine (Baltimore) 95, e2699 (2016).",{"doi":8071},"10.1097\u002FMD.0000000000002699",{"id":24,"text":8073,"url":24,"identifiers":8074},"Raff, E. J.  et al. Diabetes mellitus predicts occurrence of cirrhosis and hepatocellular cancer in alcoholic liver and non-alcoholic fatty liver diseases. J. Clin. Transl Hepatol. 3, 9–16 (2015).",{"doi":8075},"10.14218\u002FJCTH.2015.00001",{"id":24,"text":8077,"url":24,"identifiers":8078},"Musso, G., Cassader, M., Rosina, F. & Gambino, R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia 55, 885–904 (2012).",{"doi":8079},"10.1007\u002Fs00125-011-2446-4",{"id":24,"text":8081,"url":24,"identifiers":8082},"Phielix, E., Szendroedi, J. & Roden, M. The role of metformin and thiazolidinediones in the regulation of hepatic glucose metabolism and its clinical impact. Trends Pharmacol. Sci. 32, 607–616 (2011).",{"doi":8083},"10.1016\u002Fj.tips.2011.06.006",{"id":24,"text":8085,"url":24,"identifiers":8086},"Bugianesi, E.  et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am. J. Gastroenterol. 100, 1082–1090 (2005).",{"doi":8087},"10.1111\u002Fj.1572-0241.2005.41583.x",{"id":24,"text":8089,"url":24,"identifiers":8090},"Haukeland, J. W.  et al. Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. Scand. J. Gastroenterol. 44, 853–860 (2009).",{"doi":8091},"10.1080\u002F00365520902845268",{"id":24,"text":8093,"url":24,"identifiers":8094},"Shields, W. W., Thompson, K. E., Grice, G. A., Harrison, S. A. & Coyle, W. J. The effect of metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and nonalcoholic steatohepatitis (NASH): a pilot trial. Therap. Adv. Gastroenterol. 2, 157–163 (2009).",{"doi":8095},"10.1177\u002F1756283X09105462",{"id":24,"text":8097,"url":24,"identifiers":8098},"Lavine, J. E.  et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 305, 1659–1668 (2011).",{"doi":8099},"10.1001\u002Fjama.2011.520",{"id":24,"text":8101,"url":24,"identifiers":8102},"Torres, D. M.  et al. Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open- label trial. Hepatology 54, 1631–1639 (2011).",{"doi":8103},"10.1002\u002Fhep.24558",{"id":24,"text":8105,"url":24,"identifiers":8106},"Franciosi, M.  et al. Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS ONE 8, e71583 (2013).",{"doi":8107},"10.1371\u002Fjournal.pone.0071583",{"id":24,"text":8109,"url":24,"identifiers":8110},"Phielix, E.  et al. Effects of pioglitazone versus glimepiride exposure on hepatocellular fat content in type 2 diabetes. Diabetes Obes. Metab. 15, 915–922 (2013).",{"doi":8111},"10.1111\u002Fdom.12112",{"id":24,"text":8113,"url":24,"identifiers":8114},"Belfort, R.  et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N. Engl. J. Med. 355, 2297–2307 (2006).",{"doi":8115},"10.1056\u002FNEJMoa060326",{"id":24,"text":8117,"url":24,"identifiers":8118},"Aithal, G. P.  et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 135, 1176–1184 (2008).",{"doi":8119},"10.1053\u002Fj.gastro.2008.06.047",{"id":24,"text":8121,"url":24,"identifiers":8122},"Cusi, K.  et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann. Intern. Med. 165, 305–315 (2016).",{"doi":4081},{"id":24,"text":8124,"url":24,"identifiers":8125},"Ratziu, V.  et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 135, 100–110 (2008).",{"doi":8126},"10.1053\u002Fj.gastro.2008.03.078",{"id":24,"text":8128,"url":24,"identifiers":8129},"Ratziu, V.  et al. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology 51, 445–453 (2010).",{"doi":8130},"10.1002\u002Fhep.23270",{"id":24,"text":8132,"url":24,"identifiers":8133},"Fruci, B., Giuliano, S., Mazza, A., Malaguarnera, R. & Belfiore, A. Nonalcoholic fatty liver: a possible new target for type 2 diabetes prevention and treatment. Int. J. Mol. Sci. 14, 22933–22966 (2013).",{"doi":8134},"10.3390\u002Fijms141122933",{"id":24,"text":8136,"url":24,"identifiers":8137},"Cui, J.  et al. Sitagliptin versus placebo for nonalcoholic fatty liver disease: a randomized controlled trial. J. Hepatol. 65, 369–376 (2016).",{"doi":8138},"10.1016\u002Fj.jhep.2016.04.021",{"id":24,"text":8140,"url":24,"identifiers":8141},"Singh, S., Khera, R., Allen, A. M., Murad, M. H. & Loomba, R. Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: a systematic review and network meta-analysis. Hepatology 62, 1417–1432 (2015).",{"doi":8142},"10.1002\u002Fhep.27999",{"id":24,"text":8144,"url":24,"identifiers":8145},"Stefan, N.  et al. Inhibition of 11β-HSD1 with RO5093151 for non-alcoholic fatty liver disease: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2, 406–416 (2014).",{"doi":8146},"10.1016\u002FS2213-8587(13)70170-0",{"id":24,"text":8148,"url":24,"identifiers":8149},"Cariou, B. & Staels, B. GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes. Expert Opin. Investig. Drugs 23, 1441–1448 (2014).",{"doi":8150},"10.1517\u002F13543784.2014.954034",{"id":24,"text":8152,"url":24,"identifiers":8153},"Ratziu, V.  et al. Elafibranor, an agonist of the peroxisome proliferator-activated receptor-α and -δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology 150, 1147–1159 (2016).",{"doi":4101},{"id":24,"text":8155,"url":24,"identifiers":8156},"Perry, R. J., Zhang, D., Zhang, X. M., Boyer, J. L. & Shulman, G. I. Controlled-release mitochondrial protonophore reverses diabetes and steatohepatitis in rats. Science 347, 1253–1256 (2015).",{"doi":8157},"10.1126\u002Fscience.aaa0672",{"id":24,"text":8159,"url":24,"identifiers":8160},"Caiazzo, R.  et al. Roux-en-Y gastric bypass versus adjustable gastric banding to reduce nonalcoholic fatty liver disease: a 5-year controlled longitudinal study. Ann. Surg. 260, 893–898; discussion 898–899 (2014).",{"doi":8161},"10.1097\u002FSLA.0000000000000945",{"id":24,"text":8163,"url":24,"identifiers":8164},"Lassailly, G.  et al. Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients. Gastroenterology 149, 379–388; quiz e15–e16 (2015).",{"doi":8165},"10.1053\u002Fj.gastro.2015.04.014",{"id":24,"text":8167,"url":24,"identifiers":8168},"Thaler, H. [Fatty liver, its causes and concomitant diseases]. Dtsch Med. Wochenschr. 87, 1049–1055 (in German) (1962).",{"doi":8169},"10.1055\u002Fs-0028-1111865"]